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ABSTRACT 
Urothelial carcinoma of the bladder (UCB) is one of the most common cancer types 
in the developed world, especially in men. Established risk factors for UCB are tobacco 
smoking, occupational and exposure to aromatic amines. Recently, 12 genetic variants have 
been reported to be associated with UCB, among them those in NAT2 and GSTM1; these 
genes modify the risk conferred by smoking. DNA methylation plays an important role in 
cellular differentiation and growth, and altered methylation levels in cancer tissues are a 
hallmark of the disease. Both regional and global DNA methylation changes have been 
observed in UCB tissue. DNA methylation levels may be influenced by genetic and 
environmental factors but are poorly characterized. Thus, the objectives of this thesis are to 
identify predictors of genomic DNA methylation (measured at LINE-1 and D4Z4 repeat 
sequences in granulocyte DNA); to investigate the association between genomic DNA 
methylation and the risk and progression of UCB, and; to identify modifiers of these 
associations.  
In this thesis, methylation levels in bisulfite-treated granulocyte DNA were 
determined by pyrosequencing at LINE-1 (952 cases and 892 controls) and D4Z4 (707 
cases and 718 controls) repeats from subjects of the Spanish Bladder Cancer/EPICURO 
Study. Data on sociodemographic characteristics, smoking, trace elements, single 
nucleotide polymorphisms (SNPs) in 24 one-carbon metabolism pathway genes, 
clinicopathological, and follow-up data were included in the analyses. Multivariable robust 
linear regression, logistic regression and Cox proportional hazards regression were used to 
identify potential predictors of genomic DNA methylation, assess its association with risk, 
and determine its prognostic potential in UCB, respectively. Likelihood ratio test was used 
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to compare the models with and without the multiplicative interaction term and estimate the 
interaction p-value.  
LINE-1 methylation levels were associated with gender, tobacco type, arsenic, iron, 
and nickel, and seven genetic variants in one-carbon metabolism pathway genes (DNMT3A-
rs7581217, AS3MT-rs7085104, MTHFS-rs1380642, SLC19A1-rs914238, and rs9621049, 
rs9606756, rs4820887 in TCN2). D4Z4 methylation levels were associated with gender, 
tobacco type, and selenium. LINE-1 methylation showed a U-shaped association with risk 
of UCB. Both the lowest and highest tertiles were associated with increased risk of UCB 
when compared to the middle tertile. This association was modified by five SNPs in the 
PEMT gene. Individuals with D4Z4 methylation levels above or equal to the median had a 
slightly increased risk of UCB. D4Z4 hypermethylation was associated with significantly 
increased risk of low-grade non-muscle-invasive bladder cancer overexpressing FGFR3. 
The overall risk conferred by D4Z4 hypermethylation was significantly modified by iron, 
manganese, and zinc, and FOLH1-rs11040387. LINE-1 methylation and D4Z4 methylation 
levels were not associated with individual outcomes of UCB. 
In summary, personal characteristics, environmental and common genetic 
polymorphisms in one-carbon metabolism pathway genes were associated with genomic 
DNA methylation. Genomic DNA methylation was associated with increased risk of UCB, 
and this risk was modified by trace elements and genetic polymorphisms. These results 
show the potential of genomic DNA methylation as a biomarker of susceptibility to UCB. 
Further studies in larger populations are required to confirm these findings. 
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RESUMEN 
El carcinoma urotelial de vejiga (CUV) es uno de los tipos de cánceres más 
comunes en el mundo desarrollado, principalmente en hombres. Los factores de riesgo 
establecidos para el CUV son fumar, exposición ocupacional a las aminas aromáticas. 
Recientemente, se ha visto que 12 variantes genéticas están asociadas con el CUV, entre 
ellas las que se encuentran en NAT2 y GSTM1; estos genes modifican el riesgo que confiere 
el tabaco. La metilación del ADN juega un importante papel en la diferenciación y 
crecimiento celular y la alteración de los niveles de metilación en los tejidos tumorales son 
marcadores de la enfermedad. Se han observado cambios en la metilación del ADN, tanto 
global como regional en tejido del CUV. Los niveles de metilación del ADN pueden verse 
influenciados por factores genéticos y ambientales, pero éstos están poco caracterizados por 
el momento. Por lo tanto, los objetivos de esta tesis son identificar los predictores de la 
metilación del ADN genómico (medida en las secuencias repetidas de LINE-1 y D4Z4 del 
ADN de granulocitos), para estudiar la asociación entre la metilación del ADN genómico y 
el riesgo y progresión del CUV, así como identificar modificadores de esta asociación. 
Para realizar la tesis, los niveles de metilación en el ADN de granulocitos tratado 
con bisulfito fueron determinados por pirosecuenciación en LINE-1 (952 casos y 892 
controles) y D4Z4 (707 casos y 718 controles) elementos repetitivos de sujetos del Estudio 
Español de Cáncer de Vejiga/EPICURO. El análisis se incluyeron datos sociodemográficos, 
consumo de tabaco, elementos traza, polimorfismos de un solo nucleótido (SNPs) en 24 
genes de la via del metabolismo del monocarbono, clínico-patológicos y de seguimiento. Se 
realizó un análisis multivariante de regresión lineal robusta, regresión logística y regresión 
de Cox de riesgos proporcionales para identificar potenciales predictores de la metilación 
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del ADN, evaluar su asociación con el riesgo, y determinar su potencial pronóstico del 
CUV, respectivamente. Se utilizó el “likelihood ratio test, LRT” para comparar los modelos 
en presencia o ausencia del término de interacción multiplicativa y estimar el p-valor de la 
interacción. 
Los niveles de metilación de LINE-1 se asociaron con género, tipo de tabaco, 
arsénico, hierro, y níquel, y siete variantes genéticas en genes de la via del metabolismo del 
monocarbono (DNMT3A-rs7581217, AS3MT-rs7085104, MTHFS-rs1380642, SLC19A1-
rs914238, y rs9621049, rs9606756, rs4820887 en TCN2). Los niveles de metilación de 
D4Z4 se asociaron con género, tipo de tabaco y selenio. La metilación de LINE-1 mostró 
una asociación en forma de U con el riesgo del CUV. Tanto el tertil más bajo como el más 
alto se asociaron con un aumento del riesgo de CUV cuando se comparó con el tertil del 
medio. Esta asociación estaba modificada por cinco SNPs en el gen PEMT. Individuos con 
niveles de metilación igual o superiores a la media tenían un ligero aumento del riesgo de 
CUV. La hipermetilación de D4Z4 se asoció con un aumento significativo del riesgo de 
cáncer de vejiga no músculo invasivo de bajo grado con sobreexpresión de FGFR3. El 
riesgo global que supone la hipermetilación de D4Z4 estaba modificado de manera 
significativa por el hierro, manganeso, y zinc y FOLH1-rs11040387.  La metilación de 
LINE-1 y los niveles de metilación de D4Z4 no estaban asociados con el pronóstico del 
CUV. 
En resumen, características personales, ambientales y polimorfismos genéticos 
comunes en genes de la vía del metabolismo del monocarbono se asociaron con metilación 
del ADN genómico. La metilación del ADN genómico se asoció con un aumento del riesgo 
de CUV, y ese riesgo estaba modificado por elementos traza y polimorfismos genéticos. 
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Estos resultados muestran el potencial de la metilación del ADN genómico como un 
biomarcador de susceptibilidad al CUV. Se precisan estudios adicionales en poblaciones 
más amplias para confirmar estos hallazgos. 
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CHAPTER I. GENERAL INTRODUCTION 
1. Epidemiology of urothelial carcinoma of the bladder  
Bladder cancer was the ninth most frequent cancer type worldwide with an estimated 
382,660 new cases and 150,282 deaths, for both sexes combined, in 2008. It ranks second among 
urogenital malignancies (Ferlay et al. 2010). Bladder cancer is histologically classified into major 
categories as urothelial (transitional cell) carcinoma, squamous cell carcinoma, adenocarcinoma, 
and others. Urothelial carcinoma of the bladder (UCB) is the most frequent type of bladder 
cancer, accounting for about 90% of all cases in the Western world, followed by squamous cell 
carcinoma and adenocarcinoma. It predominantly affects men, with the male to female ratio 
ranging from 3 to 5 (Parkin 2008). In Europe, the highest incidence rates are observed in 
Denmark, Spain and FYR Macedonia with age-standardized incidence rates (world) of 14.5, 14.1, 
and 14.1 per 100,000, respectively (Ferlay et al. 2010). In Spain, the past three decades have seen 
an increase in the incidence rate of bladder cancer while mortality rate decreased in both sexes 
(Izarzugaza et al. 2010). Yet Spanish men have one of the highest mortality rates in Europe (age-
standardized mortality rate of 8.3 per 100,000) (Ferlay et al. 2010). In Spain, the male to female 
ratio for this cancer is the highest with 7:1(Izarzugaza et al. 2010). 
At initial presentation, the majority of UCB patients (75-85%) are diagnosed with non-
muscle-invasive bladder cancer (NMIBC), and the rest with muscle-invasive bladder cancer 
(MIBC) (Falke & Witjes 2011). Depending on their tendency to recur and progress to advanced 
disease, NMIBC is further divided into low- and high-risk subgroups. Low-risk NMIBC tumors 
have a higher tendency for recurrence, whereas high-risk NMIBC tumors are prone to 
progression to muscle-invasive disease and metastasis (Donat 2003). Low-risk NMIBC are 
comprised of TaG1 and TaG2 tumors, while high-risk NMIBC includes carcinoma in situ (CIS, 
Tis), TaG3 and T1 tumors. Tumors with stages T2, T3 and T4 constitute the MIBC group. The 
risk of recurrence in non-muscle invasive tumors is 15-70% while approximately 7-40% progress 
to muscle-invasive disease, although these rates may vary because of tumor heterogeneity 
(Kaufman et al. 2009, Prasad et al. 2011). On the other hand, muscle-invasive disease is a life-
threatening condition with 25-80% of tumors eventually developing into metastatic disease and 
5-year survival being between 27-67% (Prasad et al. 2011).   
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Current molecular evidence indicates that UCB generally develops along two distinct 
pathways with genetic alterations in known tumor suppressor genes and oncogenes. Non-invasive 
tumors are characterized by gain-of-function mutations in FGFR3 (50-60% of tumors), PIK3CA 
and HRAS, whereas high grade invasive tumors are characterized by loss-of-function mutations in 
TP53 and RB genes (Knowles 2008, Wu 2005, Falke & Witjes 2011). Apart from specific gene 
mutation, deletion and genomic instability have been identified that are thought to be early events 
in bladder tumor development. The most frequent genomic alteration is seen in chromosome 9 
where more than 50% of tumors, regardless of tumor stage and grade, display loss-of-
heterozygosity at chromosome 9 (Knowles 2008). Additional frequent cytogenetic alterations 
include deletion at chromosomes 8p, 10p, 10q, 11p and gain at 1q, 17q and 20q (Knowles 2008).  
1.1. Risk factors for urothelial carcinoma of the bladder 
 Incidence rates of UCB peak at age of 75 years and above, and its development is 
multifactorial in origin, mainly related to exposure to environmental carcinogens (Ferlay et al. 
2010). Established risk factors include tobacco smoking, occupational exposure to aromatic 
amines and exposure to arsenic in drinking water (Delclos & Lerner 2008, Murta-Nascimento et 
al. 2007, Burger et al. 2013, Volanis et al. 2010).   
Tobacco smoking is the most important risk factor for UCB. Tobacco smoke contains a 
multitude of carcinogens such as aromatic amines (β-naphthylamine, nitrosamines) and oxygen 
free radicals. The risk estimates for current smokers is between three and four relative to never 
smokers (Freedman et al. 2011), with smoking accounting for approximately 50-65% of the cases 
in men and 20-52% in women. The relative risk for former smokers is close to two compared to 
never smokers (Murta-Nascimento et al. 2007, Freedman et al. 2011). With changes over the past 
decades in the prevalence of tobacco smoking in both men and women, a recent study showed the 
proportion of UCB cases attributable to tobacco smoking to be approximately 50% in both sexes 
(Freedman et al. 2011) suggesting factors other than smoking may explain the elevated male-to-
female ratio of developing the disease. Additionally, the type of tobacco smoked has been shown 
to have a differential effect on the risk of UCB, during and after cessation of smoking. The risk of 
developing the disease for smokers of black tobacco has been shown to be higher than that of 
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smokers of blond tobacco. Moreover, it has been shown that for smokers of blond tobacco an 
inverse association between risk and time since quitting might exist (Samanic et al. 2006).  
Another risk factor for UCB is occupational exposure to carcinogens such as polycyclic 
aromatic hydrocarbons and aromatic amines (4-aminobiphenyl, benzo[ɑ]pyrene, benzidine, β-
naphthylamine, N,N-bis(2-chloroethyl)-2-naphthylamine (chlornaphazine), 4,4´-methylene bis(2-
chloroaniline) (MOCA), and ortho-toluidine) (Delclos & Lerner 2008). It is estimated that about 
30% of UCB cases are attributable to occupational exposures (Delclos & Lerner 2008).  
Arsenic is a known carcinogen to humans causing cancer at different sites, including 
urinary bladder when exposure to arsenic is through drinking water. Inorganic arsenic is 
metabolized through a series of methylation reactions to monomethylarsonic and dimethylarsinic 
acids, themselves carcinogens, before being excreted through urine (Murta-Nascimento et al. 
2007, Straif et al. 2009). Other potential risk factors include reduced fluid intake, and exposure to 
trihalomethanes in water (Murta-Nascimento et al. 2007, Burger et al. 2013). Individuals with 
lower serum vitamin D levels were found to have significantly increased risk of aggressive types 
of UCB and of tumors that express low levels of FGFR3 (Amaral et al. 2012a).       
Medical conditions such as diabetes mellitus, chronic cystitis, bladder calculi, and 
treatments such as use of phenacetin-containing analgesics, cyclophosphamide, chlornaphazine, 
pioglitazone and pelvic irradiation have been found to be associated with UCB development 
(Murta-Nascimento et al. 2007, Burger et al. 2013). On the other hand, use of aspirin is 
inconsistently associated with decreased risk of UCB (Bosetti et al. 2012). 
So far, the protective effect of fruit and vegetable consumption against UCB has been 
inconsistent and a recent large prospective study has found no clear association (Murta-
Nascimento et al. 2007, Burger et al. 2013). Selenium intake has been shown to be inversely 
associated with UCB risk (Amaral et al. 2010, Rayman 2012).  
Family history of UCB in first-degree relatives is associated with a two-fold increase in 
risk of developing the disease (Burger et al. 2013). Germline variations in NAT2 resulting in a 
slow-acetylator phenotype and loss of both copies of GSTM1 gene are the two best established 
genetic risk factors for UCB. In addition, multiplicative interactions between these genetic 
variations and smoking have been shown (Rothman et al. 2010, Garcia-Closas et al. 2005). More 
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recently, a series of genome-wide association studies and fine mapping studies on UCB identified 
additional genetic susceptibility variants in the following genes: APOBEC3A, CCNE1, 
CLPTM1L, MYC, NAT2, PSCA, SLC14A1, TACC3/FGFR3, TERT, TP63 and UGT1A6 (Tang et 
al. 2012, Garcia-Closas et al. 2011, Rothman et al. 2010, Wu et al. 2009, Rafnar et al. 2009, 
Kiemeney et al. 2008). Further, risk-difference modifications between smoking status and 
susceptibility variants in NAT2, MYC, PSCA, CBX6/APOBEC3A, UGT1A6, and GSTM1 copy 
number variation have been reported (Garcia-Closas et al. 2013).  
1.2. Diagnosis, staging, grading and treatment of urothelial carcinoma of the bladder 
UCB is a heterogeneous disease with diverse morphologic and clinical manifestations. 
The most salient presentation of UCB is painless, intermittent hematuria. More than three-
quarters of patients present with gross hematuria. The rest present as nonspecific irritating 
voiding symptoms, including urgency, frequency of urination and dysuria; symptoms frequently 
misinterpreted as urinary tract infection but that may signify either trigone involvement with 
tumor or the presence of CIS (Lopez-Beltran 2008, Prasad et al. 2011). Initial evaluation and 
management of patients with suspected bladder cancer involves invasive procedures such as 
cystoscopic evaluation of the bladder, transurethral resection of visible tumor for staging and 
grading, and assessment of the appearance of the uninvolved bladder and prostatic urethra 
(Lopez-Beltran 2008). In addition, urine cytology has an important role in detecting high risk 
UCB (Prasad et al. 2011).  
Staging and grading are the most important determinants of patient outcome and decision 
on treatment and follow-up regimens, therefore accurate staging and grading is critical (Prasad et 
al. 2011, Lopez-Beltran 2008). Staging is often challenging, and substantial interobserver and 
intraobserver variability has been observed. Similarly, grading and classification of UCB has 
been controversial, with the grading of papillary urothelial carcinomas being the most debated 
(Lopez-Beltran 2008). In a bid to improve the classification system and reflective of this lack of 
consensus, several grading schemes for bladder cancer have been developed. These are the World 
Health Organization (WHO) 1973 classification (grading as: papilloma, grades 1 to 3), the 1998 
WHO/ISUP classification [papilloma, papillary urothelial neoplasm of low malignant potential 
(PUNLMP), low grade, high grade], the 1999 WHO classification (papilloma, PUNLMP, grades 
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1 to 3), and the 2004 WHO classification systems (papilloma, PUNLMP, low grade, high grade), 
which is identical to the 1998 system. Grading with both the WHO 1973 and 2004 classification 
systems is recommended, although the 2004 system has less interobserver variability than the 
former (Liedberg et al. 2012, Cheng et al. 2012).  On the other hand, clinical and emerging data 
from whole-genome gene expression, chromosomal aberrations, and mutation analyses support 
the use of the 1999 WHO classification system, particularly the separation of grade 3 from grade 
2 in high grade tumors (Liedberg et al. 2012). There are ongoing efforts to replace the existing 
bladder tumor grading and classification system. Recently, Cheng et al. proposed a new four tier 
numerical grading system (as papilloma, grades 1 to 4) that incorporates the strengths of both the 
1973 and the 2004 grading systems and abandons the terminology “PUNLMP” (Cheng et al. 
2012). Incorporation of molecular grading, based on biomarker expression profiles, in the grading 
process may provide highly objective assessment of the tumors’ biologic potential and help 
differentiate patients at risk of adverse clinical outcome (Cheng et al. 2012).  
Treatment of UCB is dictated by the tumor stage, grade, size and number of tumors 
detected as well as the patient’s performance status. Although treatment is individualized and can 
differ from patient to patient, generally, CIS is treated with transurethral resection of bladder 
tumor (TURBT) and intravesical immunotherapy by bacille Calmette-Guérin (BCG), which is an 
attenuated strain of Mycobacterium bovis used for immunization against tuberculosis. Low grade 
tumors Ta and T1 are treated by TURBT and/or subsequent intravesical instillation of BCG or 
single dose immediate chemotherapy with one of mitomycin C, epirubicin, or doxorubicin. High 
grade T1 tumors are managed either by radical cystectomy or TURBT and intravesical BCG or 
chemotherapy. Because of the risk of recurrence and progression, follow-up by periodic 
cystoscopy and urinary cytology for secondary tumors is required for both low- and high-risk 
NMIBC patients (Babjuk et al. 2011). MIBC can be treated by one of the following treatment 
options: radical cystectomy only; neoadjuvant chemotherapy and radical cystectomy; radical 
cystectomy followed by adjuvant chemotherapy; neoadjuvant chemotherapy, chemotherapy and 
irradiation when bladder preservation is indicated. Metastatic disease is managed by cisplatin-
containing combined systemic chemotherapy, followed by selective surgery or irradiation (Stenzl 
et al. 2011). 
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1.3. Prognostic factors for urothelial carcinoma of the bladder 
 Both NMIBC and MIBC show different clinical outcomes. Low-risk NMIBCs are prone 
to recurrence, while high-risk NMIBCs are usually associated with increased rate of progression 
(Hernandez et al. 2006). Unlike other cancer types, mortality rate from UCB has changed very 
little over the past 20 years (Malmstrom 2011). Besides, the increased rate of recurrence and 
progression associated with NMIBC requires repeated cystoscopy, and long-term follow-ups for 
continued treatment, surveillance and monitoring. This creates a burden on the health care system 
and, in fact, UCB is the most expensive cancer to treat per patient (Botteman et al. 2003). 
Although there is no available data, indirect costs in the form of potential loss of work and 
productivity, decreased quality of life are also associated with the disease. Currently, established 
prognostic factors in NMIBC include grade, stage, presence of associated CIS (dysplasia), 
multifocality, tumor size, frequency of recurrence, and depth of lamina propria invasion. 
Prognostic factors for MIBC are stage, presence of lymphovascular invasion and presence of 
divergent histology (Netto 2012). Although these conventional prognostic factors are widely 
used, they fail to clearly evaluate each individual tumor’s malignant potential (Lopez-Beltran 
2008). These shortcomings indicate a need for the development of additional molecular 
prognostic markers to improve the accuracy of the existing clinicopathology-based prognostic 
scoring system in identifying patients who might benefit from aggressive and more intensive 
treatment (Netto 2012). 
Apart from the abovementioned clinicopathological parameters, a growing number of 
potential molecular prognostic markers are being identified for both NMIBC and MIBC. 
Emerging molecular prognostic markers in NMIBC include FGFR3 mutation and 
overexpression, HRAS alteration, proliferation indices, loss of E-cadherin, overexpression of 
angiogenesis markers, and markers for MIBC include TP53 inactivation, alteration of RB, p16 
expression, loss of E-cadherin, overexpression of angiogenesis markers (Netto 2012). Mutations 
in FGFR3 are associated with increased risk of recurrence and decreased rate of progression 
(Hernandez et al. 2006), while HRAS is overexpressed in tumors with low progression potential. 
On the other hand, tumors with altered TP53 exhibit the worst prognosis (Mitra & Cote 2009). In 
addition to somatic prognostic markers, germline polymorphisms have been identified through 
candidate-gene and genome-wide prognostic studies. Polymorphisms in genes involved in critical 
cellular processes such as cell cycle (TP53, MDM2), DNA repair, inflammation and oxidative 
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stress have been associated with various end points of the disease (Chang et al. 2012). A recent 
multi-stage genome-wide prognostic study has identified common germline polymorphisms 
associated with recurrence, progression and relapse of NMIBC (Malats et al. 2013).  
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2. Epigenetics 
Epigenetics refers to the study of “a stably heritable phenotype resulting from changes in 
a chromosome without alterations in the DNA sequence” and passed on through cell division - 
either mitosis or meiosis (Berger et al. 2009). The epigenome refers to the epigenetic overall state 
of the cell. Epigenetic changes include DNA modifications [5-methylcytosine, 5-
hydroxymethylcytosine, 5-formylcytosine, 5-carboxylcytosine (Ito et al. 2011, Bhutani et al. 
2011)], post-translational modifications of histone proteins [methylation, acetylation, and several 
other modifications of the N-terminal of amino acids of histones (Tan et al. 2011)], chromatin 
remodeling (nucleosome positioning), and non-coding RNAs. The combination of these 
epigenetic modifications impact transcription factors or other chromatin binding proteins, thereby 
regulating gene expression and maintaining genomic stability (Berger et al. 2009).  
2.1. DNA methylation  
DNA methylation is the most studied and fundamental epigenetic modification. It 
corresponds to the covalent addition of a methyl group to DNA at the 5´position of the cytosine 
pyrimidine ring. DNA methylation is dynamic over time and is established and continually 
maintained by DNA methyltransferases (DNMT1, DNMT3A and DNMT3B). DNMT3A and 
DNMT3B are primarily de novo methyltransferases, while DNMT1 maintains the methylation 
marks after DNA replication in cooperation with the de novo methyltransferases (Fernandez et al. 
2012, Jones & Liang 2009, Bird 2002). Cytosine methylation predominantly occurs in the context 
of CpG dinucleotides that are asymmetrically distributed over the human genome. Although rare, 
non-CpG methylation has recently been described in humans at CHG and CHH sites where H can 
be any of the three other nucleobases (A, C, T) (Portela & Esteller 2010). CpG dinucleotides 
constitute approximately 1% of the genome and are mostly found in CpG islands -located close 
to most gene promoters, CpG islands are genomic regions with more than 200 bases with a G+C 
content of at least 50% and a ratio of observed to statistically expected CpG frequencies of at 
least 0.6,  CpG island shores -located up to 2 kb upstream of the CpG island,  gene bodies, 
repetitive genomic sequences -long interspersed nucleotide element-1 (LINE-1), Alu and sort 
interspersed nucleotide element (SINE), and tandem repeats -such as D4Z4 (subtelomeric 
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regions), NBL2, pericentromeric satellite 2 and 3 repeats, alpha satellite sequences (Satα) (Portela 
& Esteller 2010, Sandoval et al. 2011).  
The function of DNA methylation is dependent on the context of the genome, and when 
disrupted it leads to altered gene expression and phenotypic consequences. DNA methylation 
plays a fundamental role in long-term silencing of retrotransposons, germline and tissue-specific 
genes, imprinting, and X-chromosome inactivation thereby ensuring normal cellular 
differentiation, growth and development (Jones 2012). CpG islands at transcription start sites are 
usually unmethylated in normal cells and methylation in these regions is associated with 
repression of gene expression (Portela & Esteller 2010, Jones 2012). This repression of gene 
expression is achieved by mechanisms such as recruitment of methyl-CpG-binding domain 
proteins, histone-modifying and chromatin-remodeling complexes, and directly by precluding the 
recruitment of DNA binding proteins. DNA methylation in repetitive and transposable DNA 
elements is a mechanism that protects chromosomal integrity by preventing the expression of 
endoparasitic sequences, which can cause chromosomal instability, translocation and gene 
disruption. Most gene bodies contain multiple repetitive and transposable elements that are 
extensively methylated. However, here methylation is positively correlated with gene expression 
instead of repression, i.e. transcriptional elongation efficiency and suppression of spurious 
initiation of transcription (Jones 2012, Portela & Esteller 2010). This indicates that the effect of 
methylation is dependent on genomic and cellular context (Jones 2012).  
2.2. LINE-1 and D4Z4 repeat sequences 
The human genome contains millions of copies of transposable elements and other 
repetitive sequences. These non-coding repeat sequences constitute two-thirds of the human 
genome (de Koning et al. 2011). Non-coding DNA, once thought to be ‘junk DNA’, was recently 
assigned some sort of biochemical function, without clear specification (Dunham et al. 2012). 
Transposons, also known as mobile DNAs or ‘jumping genes’ fall into two different classes: 
DNA transposons which move by a cut-and-paste mechanism, and retrotransposons which move 
by a copy-and-paste mechanism through an RNA intermediate. Retrotransposons are subdivided 
into those sequences that contain Long Terminal Repeats (LTR) and those that do not (non-LTR). 
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Non-LTR subclass, the only element thought to be currently active in humans, is further divided 
into LINE-1, Alu and SINE (Hancks & Kazazian 2012).  
2.2.1. LINE-1 retrotransposons 
A substantial fraction of the human genome, more than 30%, is derived directly or 
indirectly from LINE-1 retrotransposon activity (Hancks & Kazazian 2012). LINE-1 elements 
with more than half-a-million copies comprise approximately 17% of the human genome (Lander 
et al. 2001). Only 80-100 active full-length LINE-1s are retrotranspositionally and 
transcriptionally competent while most are inactive due to truncation at 5’ ends, point mutations 
or rearrangements (Hancks & Kazazian 2012). A full-length LINE-1 is approximately 6 kb long 
and contains a promoter located in the 5’untranslated region, two open reading frames and a 
poly(A) tail necessary for retrotransposition (Beck et al. 2011). LINE-1 mediated 
retrotransposition has been associated with various human diseases including cancer of different 
sites (Belancio et al. 2008). LINE-1s contribute to cancer and other diseases by causing 
mutations, insertions, double strand breaks and genome instability. Additionally, LINE-1 
insertional mutagenesis can also affect the genome globally by altering the epigenetic landscape 
and creating genomic structural variants (Beck et al. 2011, Belancio et al. 2008). For these 
reasons, the host genome developed a mechanism to defend itself from retrotransposon activity 
primarily by DNA methylation for repression of LINE-1 expression. The internal promoter used 
by LINE-1 elements encompasses a CpG island, and they are typically highly methylated 
(Belancio et al. 2008). Malignant cells and cancer tissues containing LINE-1 retrotransposition 
events exhibit hypomethylation of the LINE-1 5’untranslated region and global patterns of 
hypomethylation, providing a correlative link between epigenetic changes and increased LINE-1 
retrotransposition in tumors (Beck et al. 2011). Because they reflect the global patterns of 
methylation, LINE-1 and other non-LTR repetitive sequences have been used as surrogate 
measure of cellular global DNA methylation (Estecio et al. 2007, Yang et al. 2004). LINE-1 
methylation can be quantified using simple assays with small amount of DNA making it suitable 
for large-scale global DNA methylation profiling in epigenetic epidemiology and integrated 
molecular pathological epidemiology studies (Terry et al. 2011, Ogino et al. 2013). 
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2.2.2. D4Z4 tandem repeats 
The tandem DNA repeat D4Z4 is a subtelomeric macrosatellite repeat array located 
approximately 40-60 kb proximal to the telomere repeats in chromosomes 4q, 10q and all 
acrocentric chromosomes. The D4Z4 repeat unit is 3.3 kb long and multiple units are ordered 
head-to-tail to form the D4Z4 tandem repeat array (Lyle et al. 1995, van der Maarel et al. 2011). 
The D4Z4 repeat on chromosome 4, almost identical to that of chromosome 10, contains between 
11 and over 100 copies of D4Z4 units (van der Maarel et al. 2011). Every repeat unit contains a 
retrotransposed gene called double homeobox 4 (DUX4), a transcription factor that has been 
shown to regulate several genes involved in various cellular processes, including oncogenesis, 
immune function, and apoptosis (Geng et al. 2012). D4Z4 repeats have high CpG content, and 
aberrant methylation changes have been observed in different human diseases in addition to 
cancer (Choi et al. 2009, Ehrlich et al. 2007, Fraga et al. 2005b, van der Maarel et al. 2012). 
2.3. Methods and techniques to study DNA methylation  
Measuring the pattern and distribution of genomic DNA methylation is important to 
understand its function and explore its association with disease. DNA methylation can be 
quantified at different levels of the genome, by means of global DNA methylation, locus specific 
DNA methylation, and genome-wide methylation studies. The details of currently available 
techniques and methods with their advantages and disadvantages have been recently revised 
(Lara et al. 2011). One relatively novel method used for quantification of DNA methylation is 
pyrosequencing. Pyrosequencing is a sequencing-by-synthesis method that measures the degree 
of methylated cytosine by using bisulfite-modified DNA. In this method, nucleotides 
complementary to the template DNA are sequentially added and incorporated by a DNA 
polymerase. This process releases pyrophosphate molecules that are quantitatively converted into 
bioluminometric signal characteristic to each nucleotide incorporated. Bisulfite treatment 
converts unmethylated cytosine to uracil (thymine after PCR amplification) while methylated 
cytosine are refractory to the treatment. The level of methylation at each CpG position is then 
expressed (%) as the ratio of methylated cytosine over the sum of total thymine and methylated 
cytosine. Methylation values for any CpG position analyzed are given in a pyrosequencing out 
called pyrogram. Examples of a typical pyrogram for LINE-1 and D4Z4 sequences are shown in 
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Figure 1-1 and Figure 1-2, respectively. Pyrosequencing, which is being widely used in 
molecular epidemiology studies, offers the ability of direct quantitative sequencing, accurate and 
reproducible measurements, speed and ease of use (Tost & Gut 2007, Laird 2010, Lara et al. 
2011). 
 
Figure 1-1 A typical pyrogram analyzing four CpG sites of LINE-1 sequences and their 
respective methylation level. The y-axis represents the relative light signal intensity while the x-
axis shows the nucleotide dispensation order. Blue columns indicate the measured CpG sites 
while yellow columns indicate controls of bisulfite treatment. 
 
 
 
 
Figure 1-2 A typical pyrogram analyzing six CpG sites of D4Z4 sequences and their respective 
methylation level. The y-axis represents the relative light signal intensity while the x-axis shows 
the nucleotide dispensation order. Blue columns indicate the measured CpG sites while yellow 
columns indicate controls of bisulfite treatment. 
 
78% 43% 55% 44%
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2.4. Predictors of genomic DNA methylation 
DNA methylation changes over time in response to cellular and environmental cues. 
These are broadly classified as extrinsic (environmental), intrinsic (genetic), and stochastic 
factors (Fraga 2009). Altered DNA methylation has been implicated as mechanism through 
which these factors contribute in the pathogenesis and development of common complex 
diseases. Intrinsic factors such as sex have been linked to DNA methylation. External factors 
include life-style behaviors (smoking, physical activity), nutritional factors, and chemical 
pollutants (arsenic, particulate matters, benzene) (Terry et al. 2011). Many dietary components 
including folate, B vitamins, methionine and choline have been associated with DNA 
methylation. These nutrients are essential cofactors in the one-carbon metabolism pathway that 
generate S-adenosylmethionine, which is the methyl group donor for the DNA methylation 
reaction (Feil & Fraga 2011). Genetic factors are also known to modulate DNA methylation. 
Common genetic variants in one of the one-carbon metabolism genes (MTHFR) have been 
reported to be predictors of genomic DNA methylation (Friso et al. 2002, Castro et al. 2004). 
Factors associated with DNA methylation (global and at specific repetitive elements other than 
LINE-1) have been reviewed elsewhere (Terry et al. 2011). Table 1-1 summarizes factors that 
have been studied so far in relation to LINE-1 methylation levels in peripheral blood cells 
(Alegria-Torres et al. 2013, Baccarelli et al. 2009, Bollati et al. 2007, Bollati et al. 2009, Cash et 
al. 2011, Cash et al. 2012, Chalitchagorn et al. 2004, El-Maarri et al. 2007, El-Maarri et al. 2011, 
Figueiredo et al. 2009, Flom et al. 2011, Fryer et al. 2009, Hsiung et al. 2007, Hubner et al. 
2013, Kim et al. 2010, Li et al. 2013, Lumey et al. 2012, Madrigano et al. 2011, Peluso et al. 
2012, Pilsner et al. 2009, Piyathilake et al. 2013, Rusiecki et al. 2008, Seow et al. 2012, Sordillo 
et al. 2012, Subramanyam et al. 2013, Tarantini et al. 2009, Tehranifar et al. 2013, Wilhelm et al. 
2010, Wright et al. 2010, Wu et al. 2011b, Zhang et al. 2011, Zhu et al. 2012).  
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Table 1-1 Predictors of LINE-1 methylation in leukocyte DNA reported in the literature   
Parameters 
Direction of association 
Positive/Direct Negative/Inverse Null 
Demographic/Intrinsic       
Age Subramanyam et al. 2013 Bollati et al. 2009 
Chalitchagorn et al. 2004; El-
Maarri et al. 2011; Hsiung et 
al. 2007; Kim et al. 2010; 
Wilhelm et al. 2010; Zhang et 
al 2011; Zhu et al. 2012 
Sex (female vs. male)   
Cash et al. 2011; Cash et al. 2012; 
El-Maarri et al. 2007; El-Maarri et 
al. 2011; Hsiung et al. 2007; 
Subramanyam et al. 2013; Wilhelm 
et al. 2010; Zhang et al. 2011; Zhu et 
al. 2012 
Kim et al. 2010 
Socioeconomic status (wealth)   Subramanyam et al. 2013  Tehranifar et al. 2013 
Life-style behaviors        
Body mass index   Piyathilake et al. 2013  Kim et al. 2010;Zhang et al. 2011; Zhu et al. 2012  
Physical activity Zhang et al. 2011     
Cigarette smoking     
Figueiredo et al. 2009; Hsiung 
et al. 2007; Kim et al. 2010; 
Rusieki et al. 2008; Wilhelm 
et al. 2010; Zhu et al. 2012 
Prenatal tobacco smoking     Flom et al. 2011 
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Table 1-1 (cont.) Predictors of LINE-1 methylation in leukocyte DNA reported in the literature  
Parameters 
Direction of association 
Positive/Direct Negative/Inverse Null 
Alcohol consumption     Hsiung et al. 2007; Kim et al. 2010; Zhang et al. 2011; Zhu et al. 2010 
Dietary factors       
Prenatal famine exposure     Lumey et al. 2012  
Folate     Fryer et al. 2009; Hübner et al. 2013; Hsiung et al. 2007; Zhang et al. 2011 
Vitamin B12     Hübner et al. 2013 
Vitamin D     Hübner et al. 2013 
Homocysteine   Fryer et al. 2009   
Environmental factors       
Trace elements       
Arsenic   Wilhelm et al. 2010   
Lead   Li et al. 2013; Pilsner et al. 2009; Wright et al. 2010   
Air pollutants       
Air pollutants (PM2.5, PM10)   
Baccarelli et al. 2009; Madrigano et 
al. 2011; Tarantini et al. 2009   
Black carbon   
Baccarelli et al. 2009; Madrigano et 
al. 2011 
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Table 1-1 (cont.) Predictors of LINE-1 methylation in leukocyte DNA reported in the literature  
Parameters 
Direction of association 
Positive/Direct Negative/Inverse Null 
Sulfate   Madrigano et al. 2011   
Benzene   Bollati et al. 2007   
S-phenylmercapturic acid*   Seow et al. 2012   
Trans,trans-muconic acid*     Seow et al. 2012 
Persistent organic pollutants   Rusieki et al. 2008 Kim et al. 2010 
Polycyclic aromatic hydrocarbons   Peluso et al. 2012 Alegría-Torres et al. 2013 
Genetic factors       
DNA adduct - M1dG   Peluso et al. 2012   
Medical conditions       
Family history of cancer   Wu et al. 2011   
Allergen sensitization     Sordillo et al. 2012 
Abbreviations: PM, particulate matter (number indicate aerodynamic diameter); M1dG, 3-(2-deoxy-b-D-
erythropentafuranosyl)pyrimido[1,2-a]purin-10(3H)-one deoxyguanosine 
*Urinary biomarkers of benzene metabolism       
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2.5. DNA methylation in health and disease 
Perturbations in DNA methylation have been shown to play a role in pathogenesis and 
progression of common complex diseases such as cancer, diabetes, hypertension, autoimmune 
diseases, and neuropsychiatric disorders (Heyn & Esteller 2012, Baylin & Jones 2011, Portela & 
Esteller 2010, Robertson 2005, Feinberg & Tycko 2004). However, it is in cancer where altered 
DNA methylation has been extensively studied and is considered a typical hallmark of the 
disease (Fernandez et al. 2012). Aberrant DNA methylation, an early event in cancer 
development, is thought to provide the second hit for cancer initiation, postulated by the two-hit 
model, by inactivating the remaining active allele (Rodriguez-Paredes & Esteller 2011). Over the 
last several decades, accumulating evidence shows that cancer cells display decreased DNA 
methylation globally and at promoters of oncogenes, and regional hypermethylation at promoters 
of tumor suppressor genes (Heyn & Esteller 2012, Taby & Issa 2010, Esteller 2008). Global loss 
of DNA methylation in cancer tissues is usually found in repetitive elements (LINE-1, Alu) and 
usually contributes to tumor development through promotion of genomic instability and 
reactivation of transposable elements (Taby & Issa 2010, Esteller 2008). In an effort to find a 
susceptibility biomarker for cancer that could potentially be used for cancer screening and 
diagnosis, DNA methylation at peripheral blood cells has been used in epigenetic epidemiology 
studies. Recent reviews by Woo et al. and Brennan et al. have shown that global 
hypomethylation in peripheral blood cells might be associated with increased risk of cancer at 
several sites (Brennan & Flanagan 2012, Woo & Kim 2012). However, this association seems to 
be inconsistent when the association between cancer risk and surrogate measures of global DNA 
methylation is used. This inconsistency was attributed to heterogeneity of the techniques used to 
quantify DNA methylation (Brennan & Flanagan 2012, Woo & Kim 2012).  
2.6. DNA methylation and risk of urothelial carcinoma of the bladder  
Studies conducted so far were able to identify important risk factors that can lead to the 
development of UCB. However, these studies have not fully elucidated its etiology. 
Accumulating evidence suggests that epigenetic alterations may provide an additional 
explanation of UCB etiology and pathophysiology. Studies conducted in bladder tumor tissues 
and cell lines have shown alterations in DNA methylation patterns. These altered DNA 
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methylation patterns include promoter hypermethylation of specific genes such as APC, DAPK1, 
CDH1, RASSF1A and hypomethylation of repetitive DNA sequences (Kim & Kim 2012, Heyn & 
Esteller 2012). Furthermore, using DNA methylation analyses of thousands of CpG sites in 
urothelial carcinoma, Lauss et al. were able to define distinct epigenetic subtypes of UCB. 
Interestingly, non-Island CpGs were overrepresented among the CpG sites that defined these 
epigenetic subtypes (Lauss et al. 2012). An earlier study by Jurgens et al. and a follow-up study 
by Florl et al. showed that LINE-1 retrotransposon in tumor tissue, compared to normal bladder 
tissue, presents low levels of methylation (Jurgens et al. 1996, Florl et al. 1999).  
Similar to what has been observed in UCB tissue, decreased global DNA methylation 
level in peripheral blood cell DNA has been associated with increased risk of developing the 
disease (Moore et al. 2008, Wilhelm et al. 2010, Cash et al. 2012). The latter two studies used 
pyrosequencing of LINE-1 methylation as a surrogate marker of genomic DNA methylation, 
while the first study by Moore et al. measured the total 5-methylcytosine content in the genome 
by high-performance capillary electrophoresis. The summary results of these studies are shown in 
Table 1-2.   
 
31 
 
Table 1-2 Association between peripheral blood DNA methylation and risk of urothelial carcinoma of the bladder 
First author, Year Study design Sample size Assay type Odds ratio P Remark 
              
Moore et al. 2008 Case-control 775 cases and 
397 controls 
HpaII/HPCE & 
densitometry of 
global 5-
methylcytosine 
2.67 (lowest 
versus highest 
quartile) 
─ DNA methylation- 
smoking interaction  
              
Wilhelm et al. 2010 Case-control 285 cases and 
465 controls 
Pyrosequencing of 
LINE-1 
1.80 (lowest decile 
versus the rest) 
0.02 no interaction was 
observed 
              
Cash et al. 2012 Case-control 510 cases and 
528 controls 
Pyrosequencing of 
LINE-1 
1.91 (lowest 
versus highest 
tertile among 
never smokers) 
0.03 DNA methylation-
GSTM1/GSTT1 
interaction 
HPCE, high-performance capillary electrophoresis         
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2.7. DNA methylation and prognosis of urothelial carcinoma of the bladder 
It has been suggested that a molecular-guided approach would supplement and improve 
the current prognostic scoring system. One interesting area to identify novel molecular 
biomarkers is the study of DNA methylation in different genomic regions. Studies conducted in 
tumor tissue have reported altered DNA methylation in gene promoters as potential prognostic 
markers for both NMIBC and MIBC. These include promoter hypermethylation of RASSAF1, 
DAPK, APC and EDNRB in NMIBC and RASSF1, CDH1 and EDNRB in MIBC (Netto 2012). 
Alterations in promoter methylation levels have been associated with tumor stage and grade, 
increased recurrence, progression and mortality (Mitra & Cote 2009, Kim & Kim 2012). On the 
other hand global hypomethylation in tumor tissue has been shown to associate with significantly 
shorter time to recurrence and disease-specific survival time (Neuhausen et al. 2006). So far, no 
study has assessed the association between peripheral blood cell DNA methylation and UCB 
outcomes. 
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3. Case for action  
Urothelial carcinoma of the bladder is one of the commonest cancers and is 
associated with increased morbidity and mortality. Because surveillance and frequent 
follow-ups are needed, often using expensive and invasive tests and imaging techniques, 
UCB is one of the most costly cancers to treat. Biomarkers contribute to cancer control and 
prevention by identifying high-risk pre-cancerous lesions and detection of cancer at its 
early stage. Epigenetic modifications such as DNA methylation can provide a link between 
genetic and environmental factors and phenotypic changes and disease risk. Research on 
DNA methylation promises to reveal many of the causes of diseases that remain 
undiscovered after extensive investigation of common genetic variations (Ng et al. 2012). 
Increasing studies report the potential of DNA methylation markers in various biofluids in 
improving diagnostic and therapeutic efficiency in multiple cancer types (Issa 2012, 
Nogueira da Costa & Herceg 2012). Hence, studying DNA methylation in leukocyte DNA 
and its association with UCB risk and prognosis may help identify susceptibility and 
prognostic biomarkers, which could eventually be used for early detection and risk 
stratification for individualized and improved patient care. Moreover, results from such 
study might shade light on the underlying etiology of the disease that could be a potential 
target for chemoprevention and treatment. Finally, these findings may contribute towards 
devising evidence-based public health preventive interventions to UCB by identifying a 
specific group of susceptible subjects who may benefit most from these preventive 
interventions, thus reducing morbidity and mortality.  
Therefore, by using and integrating data from the Spanish Bladder 
Cancer/EPIdemiology of Cancer of the URO
4. The SBC/EPICURO study 
thelium (SBC/EPICURO) study, with this PhD 
thesis I aimed to study the role of DNA methylation at LINE-1 and D4Z4 repetitive 
elements on the risk and survival of UCB, and its interaction with environmental and 
genetic factors. 
The SBC/EPICURO study is a multicenter hospital-based case-control study 
conducted in Spain from 1998 to 2001. The study recruited 1219 cases that are newly 
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diagnosed with urothelial carcinoma of the bladder and 1271 controls from 18 hospitals 
located in Asturias, Barcelona, Elche, Tenerife, and Valles. Diagnosis of UCB was 
confirmed by a panel of expert pathologists based on the 1998 World Health 
Organization/International Society of Urological Pathology classification system. Controls 
were patients admitted to the same hospital as cases for reasons unrelated to the exposure of 
interest. Cases were individually matched to controls based on age at interview (five-year 
interval), gender, geographic region, and smoking status. The age range of study 
participants was between 19 and 81 years. Data on demographic, known and potential risk 
factors for UCB, clinicopathological characteristics were collected using computer-assisted 
personal interviews. The study also collected blood for DNA extraction, and toenail 
clippings to measure trace elements. Cases were followed yearly for almost 10 years, and 
data on recurrence, progression and mortality were recorded. In the present thesis, data 
from 952 cases and 892 controls with LINE-1 methylation measurements, and 707 cases 
and 718 controls with D4Z4 methylation measurements were included in the analyses. 
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CHAPTER II. HYPOTHESES AND OBJECTIVES  
1. Hypotheses 
Some genetic and non-genetic factors are predictors of DNA methylation. Altered 
genomic DNA methylation level is associated risk of UCB and its clinical outcomes.     
2. Objectives 
The general objective of this work was to identify predictors of granulocyte DNA 
methylation and evaluate the role of methylation in UCB risk and outcomes.   
The specific objectives were:  
1. To identify genetic and non-genetic predictors of LINE-1 and  D4Z4 methylation   
2. To assess the association between LINE-1 methylation and UCB risk, and its 
modification by known and potential risk factors 
3. To investigate the association between D4Z4 methylation and UCB risk, and its 
modification by known and potential risk factors 
4. To determine the prognostic significance of LINE-1 and D4Z4 methylation in both 
NMIBC and MIBC outcomes  
Each of the following chapters is structured as a scientific manuscript (abstract, 
introduction, methods, results, discussion, and conclusions) in an attempt to address each of 
the specific objectives listed above. Chapter III addresses the predictors of LINE-1 
methylation in leukocyte DNA; Chapter IV discusses the association between LINE-1 
methylation and UCB risk, and its modification by known and potential risk factors; 
Chapter V addresses the potential predictors of D4Z4 methylation and its role in UCB risk; 
Chapter VI describes an assessment of UCB and the prognostic role of LINE-1 and D4Z4 
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methylation; Chapter VII presents further integrated discussion of the main results, and 
lists recommendations for future research to build upon this work in particular; and 
Chapter VIII provides the main conclusions drawn from this work. 
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Abstract 
Altered DNA methylation has been associated with various diseases. To evaluate the 
association between levels of methylation in leukocyte DNA at long interspersed nuclear element 
1 (LINE-1) and genetic and non-genetic characteristics of 892 control participants from the 
Spanish Bladder Cancer/EPICURO Study. We determined LINE-1 methylation levels by 
pyrosequencing. Individual data included demographics, smoking status, nutrient intake, toenail 
concentrations of 12 trace elements, xenobiotic metabolism gene variants, and 515 
polymorphisms among 24 genes in the one-carbon metabolism pathway. To assess the 
association between LINE-1 methylation levels (percentage of methylated cytosines) and 
potential determinants, we estimated beta coefficients (β) by robust linear regression. Females 
had lower levels of LINE-1 methylation than males (β=-0.7, p-value=0.02). Blond tobacco 
smokers showed lower methylation than non-smokers (β=-0.7, p-value=0.03). Arsenic toenail 
concentration was inversely associated with LINE-1 methylation (β=-3.6, p-value=0.003). By 
contrast, iron (β=0.002, p-value=0.009) and nickel (β=0.02, p-value=0.004) were positively 
associated with LINE-1 methylation. SNPs in DNMT3A (rs7581217-per allele, β=0.3, p-
value=0.002), TCN2 (rs9606756-GG, β=1.9, p-value=0.008; rs4820887-AA, β=4.0, p-
value=4.8x10-7; rs9621049-TT, β=4.2, p-value=4.7x10-9), AS3MT (rs7085104-GG, β=0.7, p-
value=0.001), SLC19A1 (rs914238, TC vs TT: β=0.5 and CC vs TT: β=-0.3, global p-
value=0.0007) and MTHFS (rs1380642, CT vs CC: β=0.3 and TT vs CC; β=-0.8, global p-
value=0.05) were associated with LINE-1 methylation. We identified several characteristics, 
environmental factors, and common genetic variants that predicted DNA methylation among 
study participants. 
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Introduction 
DNA methylation plays a fundamental role in regulation of gene expression, genomic 
imprinting, X-chromosome inactivation, and repression of transposable elements (Jones & Liang 
2009). Aberrant DNA methylation has been associated with various cancers, and with 
developmental, autoimmune, and other chronic diseases (Robertson 2005). Global DNA 
methylation can be directly quantified by measuring 5-methylcytosine content of the genome, or 
can be estimated based on methylation of repetitive sequences such as Alu elements or long 
interspersed nuclear element 1 (LINE-1) (Yang et al. 2004). Age, sex, smoking, and arsenic and 
lead exposures have been associated with DNA methylation, but findings have been inconsistent 
among studies (Fuke et al. 2004, El-Maarri et al. 2007, Terry et al. 2011, Breitling et al. 2011, 
Fraga et al. 2005a).  The folate and methionine-dependent one-carbon metabolism pathway 
could modulate DNA methylation by altering the level of S-adenosylmethionine (SAM), the 
principal source of methyl groups (Ulrey et al. 2005). Genetic variants might also influence the 
methylation of CpG loci locally, or might have a global influence on methylation throughout the 
genome. For example, a single nucleotide polymorphism (SNP) in TRPC3-isoform 2 has been 
reported to regulate the methylation status of its own promoter (Martin-Trujillo et al. 2011), and 
variants of the methylenetetrahydrofolate reductase gene (MTHFR) have been associated with 
global DNA hypomethylation (Friso et al. 2002, Castro et al. 2004). However, although the 
determinants of global and site-specific methylation are widely assumed to be likely contributors 
to health and disease, they are poorly defined at this time. 
Assessing the impact of both genetic and non-genetic factors on global DNA methylation 
may improve our understanding of the molecular pathogenesis of many common diseases. 
Therefore, we investigated associations of global DNA methylation in LINE-1 from bisulfite-
modified granulocyte DNA with genetic variants and personal, demographic, lifestyle, and 
environmental characteristics.  
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Methods 
Study population: The study population, design, and data collection have been 
previously described (Garcia-Closas et al. 2005). Briefly, participating individuals were controls 
from the Spanish Bladder Cancer/EPICURO Study who were admitted to hospitals in five 
regions of Spain for a range of conditions including hernia, fractures, and other non-cancer 
diseases, and were 20–81 years of age. We collected demographic and exposure information at 
the hospitals using computer-assisted personal interviews. From a total of 1,271 controls that 
agreed to participate in the study and were interviewed, 1,056 provided blood for DNA 
extraction. We excluded twenty-three subjects because of inadequate or poor quality DNA 
(N=15) or missing smoking status data (N=8). Three subjects with missing data on smoking 
status were included because they had data on other variables including age, gender, region, and 
body mass index (BMI). To ensure homogeneity, we also excluded one non-Caucasian 
individual, leaving 925 individuals with granulocyte DNA for bisulfite modification and 
pyrosequencing. Pyrosequencing failed in 33 individuals; thus, the final study population for the 
present analysis included 892 participants. We obtained written informed consent from all 
participants, and the study was approved by the local Spanish institutional review boards and US 
National Cancer Institute. 
 
Quantification of LINE-1 methylation: We extracted granulocyte DNA using standard 
methods (Garcia-Closas et al. 2005). We carried out bisulfite conversion of DNA using the EZ-
96 DNA METHYLATION-GOLDTM KIT (Zymo Research, Irvine, CA, USA) according to the 
manufacturer’s recommendations. We carried out PCR amplification of bisulfite-modified DNA 
using a set of forward and reverse primers reported previously (Estecio et al. 2007). To quantify 
the methylation level of each of the first four CpG sites next to the pyrosequencing primer, we 
performed sequencing of the PCR product by pyrosequencing, using the PyroMarkTM Q24 
System (QIAGEN, Valencia, CA, USA) as recommended by the manufacturer. The first four 
were the CpGs from which we could obtain methylation values of all samples. We extracted the 
methylation level at each CpG site using the PyroMarkTM Application Software version 2.0.6 
(QIAGEN, Valencia, CA, USA), and we expressed the value as the percentage of methylated 
cytosines over the sum of methylated and unmethylated cytosines. We used the average 
methylation level of the first four LINE-1 CpG sites as a surrogate marker of the global DNA 
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methylation level. To determine whether changes in blood cell populations affect LINE-1 
methylation levels, we analyzed LINE-1 methylation in independently purified granulocyte and 
lymphocyte samples. The results showed no significant difference in LINE-1 methylation 
between granulocyte and lymphocyte samples, thus suggesting that variation in the distribution 
of peripheral blood cell populations among participants would not contribute to variation in 
global DNA methylation (data not shown). For the present study, we used DNA extracted from 
granulocyte to quantify DNA methylation. As a quality control measure, we measured LINE-1 
methylation in 129 randomly selected duplicate samples and the within-sample coefficient of 
variation (CV) was 4.0%. In the analysis, we used the average of the duplicates for those 
samples. 
 
Nutritional assessment: We estimated the usual intake of vitamins B1, B2, B3, B6, and 
B12, folate, protein, alcohol, fruit and vegetable over the five years before interview using a 
validated food frequency questionnaire of 127 items (Garcia-Closas et al. 2007b). Micronutrients 
and macronutrients included in the present analysis have been suggested as important co-factors 
and methyl donors in one-carbon metabolism (Stover 2009). We calculated nutrient density 
variables by dividing the total estimated mass of daily food consumed by the total estimated 
daily energy intake (μg/day/kcal).  
 
Trace elements: We collected toenail clippings to estimate chronic exposure to trace 
elements. Sample collection and experimental methods used to measure trace elements level 
have been reported (Amaral et al. 2012c). Briefly, after cleaning and washing the toenails to 
remove external contaminants, we quantified elements at the Trace Element Analysis Core 
(Dartmouth College, NH, USA), using inductively coupled plasma-mass spectrometry (Hopkins 
et al. 2004). We digested the samples with Optima HNO3 (Fisher Scientific, St. Louis, MO) at 
105 °C followed by addition of H2O2 and further heating the dilution with deionized water. We 
recorded gravimetrically all sample preparation steps. As a quality control, each batch of 
analyses included six standard reference material samples with known trace element content 
(SRM; GBW 07601, powdered human hair) and six analytic blanks, along with the study 
samples. In total, we determined concentrations (μg/g) of 12 trace elements (aluminum, arsenic, 
cadmium, chromium, copper, iron, lead, manganese, nickel, selenium, vanadium, and zinc). 
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Genotyping: For genotype assays, we extracted DNA from leukocytes as described 
previously (Garcia-Closas et al. 2005). We determined genotypes at the Core Genotyping 
Facility of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, 
USA. We selected for the analysis a total of 515 SNPs in 24 genes involved in the one-carbon 
metabolism pathway, including DNA methylation and arsenic metabolism (see Supplementary 
Table S3-1 for a list of the 24 genes evaluated). We selected these genes because they are critical 
for the one-carbon metabolism pathway (Ulrey et al. 2005, Lee et al. 2009). Previously, we 
described in detail methods of the genotyping process (Garcia-Closas et al. 2005, Garcia-Closas 
et al. 2007a, Rothman et al. 2010). We genotyped SNPs using Illumina Infinium® Human1M-
Duo, Illumina GoldenGate® and TaqMan® assays (see Supplementary Table S3-2 for a 
complete list of SNPs according to assay). In addition, we estimated associations between LINE-
1 methylation and GSTM1, GSTT1, and NAT2 variants because of their relevance to bladder 
cancer (Cash et al. 2012). These variants were determined as described in (Garcia-Closas et al. 
2005). All genotypes included in the study were in Hardy-Weinberg Equilibrium in the study 
population (p-value > 0.05) (data not shown). 
 
Statistical analysis: The distribution of LINE-1 methylation levels was slightly bimodal 
and positively skewed (see Supplementary Figure S3-1). To estimate associations between 
LINE-1 methylation levels and each of the variables considered, we fitted bivariate robust linear 
regression models and calculated the corresponding beta coefficients and 95% confidence 
intervals (95%CI). Characteristics analyzed as continuous variables were age, micronutrient 
intakes, fruit and vegetable intakes, and toenail concentrations of trace elements. Characteristics 
analyzed as categorical variables were BMI (<25.0, 25.0-26.99, 27.0-29.99, ≥30.0), smoking 
status (non-, occasional, former, current smoker), and tobacco type (non-smoker, blond only, 
black only, blond and black, unknown).  
To identify SNPs for detailed assessment we first used the Fisher’s exact test to screen SNPs that 
were significantly associated (p<0.05) with LINE-1 methylation categorized according to tertiles 
(<56.7%, 56.7–58.6%, and >58.6%) according to codominant mode of inheritance. The 22 SNPs 
identified for further analyses (listed in Supplementary Table S3-3) were subsequently modeled 
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according to all modes of inheritance (additive, codominant, dominant and recessive). The mode 
of inheritance that best predicted LINE-1 methylation is reported in Table 3-2.  
In addition to age and gender, adjusted robust linear regression models for each potential 
predictor included region, which may be related to diet, micronutrients (Gabriel et al. 2006), and 
environmental pollution, and smoking status, which may be related to trace elements (Moerman 
& Potts 2011). We also did a sensitivity analysis without adjusting for smoking status to see if 
there was a change in the beta estimates. We included all the 515 SNPs in the analysis regardless 
of linkage disequilibrium. The association between LINE-1 methylation and potential predictors 
was assessed in the multivariable adjusted model stratifying by gender. Because arsenic and 
rs7085104 in arsenic (+3 oxidation state) methyltransferase (AS3MT), which is involved in 
arsenic metabolism, were individually associated with LINE-1 methylation, we assessed the 
presence of effect modification by including a multiplicative interaction term in a model adjusted 
for age, gender, region and smoking status. Wald test was used to calculate the interaction p-
value. We corrected for multiple testing using the Bonferroni’s method. We conducted a 
sensitivity analysis, excluding 42 individuals with CV >4% for LINE-1 methylation in duplicate 
samples. This exclusion did not result in substantial differences in the beta coefficients; therefore 
these individuals remained in the analyses (data not shown). All statistical tests were two-sided, 
and a p-value ≤ 0.05 was considered significant. We carried all data analyses ou t using 
STATA/SE version 10.1 (StataCorp, College Station, TX, USA). 
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Results 
The characteristics of the 892 participants in the present study and median and mean 
LINE-1 methylation levels according to each variable of interest are provided in Supplementary 
Table S3-4. The majority of the study participants were males (89%) and regular smokers 
(63.9%), with median age of 66 years [interquartile range (IQR)=13]. The mean LINE-1 
methylation level was 58.9% (SD=5.3%) with minimum and maximum value of 37.9% and 
85.7%, respectively. Table 3-1 shows the association between LINE-1 methylation levels and 
characteristics of study subjects. In the bivariable robust linear regression analysis, only toenail 
arsenic and nickel concentrations were significantly associated with LINE-1 methylation. 
However, in multivariable robust linear regression models adjusted for age, gender, region, and 
smoking status, the levels of LINE-1 methylation were significantly lower in females than in 
males (adjusted β = -0.7; 95%CI: -1.2, -0.1, p-value=0.02) and in smokers of blond tobacco only 
(adjusted β = -0.7; 95%CI: -1.3, -0.08, p-value=0.03) and of both blond and black tobacco 
(adjusted β = -0.6; 95%CI: -1.1, -0.07, p-value=0.03) compared with nonsmokers. Toenail 
arsenic concentration also was negatively associated with LINE-1 methylation (adjusted β for a 
1-µg/g increase = -3.6; 95%CI: -5.9, -1.2, p-value=0.003). In contrast, LINE-1 levels were 
positively associated with 1-µg/g increases in toenail concentrations of iron (adjusted β = 0.002; 
95%CI: 0.001, 0.004, p-value=0.009) and nickel (adjusted β = 0.02; 95%CI: 0.005, 0.03, p-
value=0.004). BMI, B vitamins, folate, total protein, alcohol, fruit and vegetable intake were not 
significantly associated with LINE-1 methylation regardless of adjustment for covariates (Table 
3-1). Results from the multivariable analyses without adjusting for smoking status done as a 
sensitivity analysis were not different from the associations above (see Supplementary Table S3-
5). If we were to correct for multiple comparisons by Bonferroni’s method none of the above 
would be significant.  
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Table 3-1 Association between LINE-1 methylation level and individual characteristics of study subjects in the SBC/EPICURO Study 
Variables N LINE-1 methylation Unadjusted β (95% CI) P-value N Adjusted β(95% CI)*† P-value Mean (95% CI) 
Age (years) 892 ─ -0.004 (-0.02, 0.01) 0.6 889 -0.006 (-0.02, 0.01) 0.5 
Gender               
Male 792 59.0 (58.6, 59.4) Reference   789 Reference   
Female 100 58.0 (57.1, 58.8) -0.4 (-0.9, 0.05) 0.08 100 -0.7 (-1.2, -0.1) 0.02 
Region               
Barcelona 168 59.3 (58.5, 60.2) Reference   168 Reference   
Valles 135 58.3 (57.5, 59.0) -0.2 (-0.7, 0.4) 0.5 135 -0.2 (-0.7, 0.3) 0.5 
Elche 73 58.2 (57.1, 59.3) -0.4 (-1.1, 0.2) 0.2 73 -0.5 (-1.1, 0.2) 0.1 
Tenerife 145 58.6 (57.8, 59.4) -0.1 (-0.7, 0.4) 0.7 144 -0.1 (-0.6, 0.4) 0.7 
Asturias 371 59.2 (58.6, 59.8) 0.2 (-0.3, 0.6) 0.5 369 0.1 (-0.3, 0.6) 0.6 
Body mass index (kg/m²)               
<25.0 372 58.8 (58.3, 59.3) Reference   370 Reference   
25.0-26.99 148 58.9 (57.9, 59.9) -0.2 (-0.6, 0.3) 0.5 148 -0.2 (-0.6, 0.3) 0.4 
27.0-29.99 120 59.0 (58.1, 59.8) 0.1 (-0.3, 0.6) 0.6 120 0.2 (-0.3, 0.7) 0.4 
≥30.0 57 58.8 (57.5, 60.2) -0.08 (-0.7, 0.6) 0.8 57 -0.03 (-0.7, 0.6) 0.9 
Missing data 195             
Smoking status               
Non-smoker 255 58.2 (57.7, 58.7) Reference   255 Reference   
Occasional smoker 66 60.0 (58.4, 61.5) 0.4 (-0.2, 1.1) 0.2 66 0.3 (-0.3, 1.0) 0.3 
Former smoker 329 58.9 (58.3, 59.5) -0.2 (-0.5, 0.3) 0.6 329 -0.3 (-0.7, 0.1) 0.2 
Current smoker 239 59.4 (58.6, 60.2) -0.2 (-0.6, 0.2) 0.4 239 -0.4 (-0.9, 0.07) 0.1 
Missing data 3             
Tobacco type               
Non-smoker 255 58.2 (57.7, 58.7) Reference   255 Reference   
Blond tobacco only 99 58.5 (57.6, 59.5) -0.5 (-1.0, 0.09) 0.1 99 -0.7 (-1.3, -0.08) 0.03 
Black tobacco only 219 59.6 (58.8, 60.4) 0.06 (-0.4, 0.5) 0.8 218 -0.2 (-0.6, 0.3) 0.5 
Blond and black 154 58.7 (57.8, 59.6) -0.3 (-0.8, 0.2) 0.2 154 -0.6 (-1.1, -0.07) 0.03 
Unknown 97 59.3 (58.2, 60.5) -0.01 (-0.6, 0.6) 0.9 97 -0.12 (-0.7, 0.5) 0.7 
Missing data 68             
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Table 3-1 (cont.) Association between LINE-1 methylation level and individual characteristics of study subjects in the SBC/EPICURO 
Study 
Variables N LINE-1 methylation Unadjusted β (95% CI) P-value N Adjusted β(95% CI)*† P-value Mean (95% CI) 
Controls' diagnosis               
Hernia 332 58.8 (58.2, 59.4) Reference   330 Reference   
Fracture & Trauma 263 59.3 (58.6, 60.0) -0.2 (-0.5, 0.2) 0.4 262 -0.02 (-0.4, 0.4) 0.9 
Hydrocele 122 58.7 (57.8, 59.6) 0.2 (-0.3, 0.7) 0.4 122 0.2 (-0.3, 0.7) 0.5 
Other Abdominal Surgery 99 58.3 (57.4, 59.2) -0.2 (-0.7, 0.3) 0.4 99 -0.09 (-0.6, 0.5) 0.7 
Other Diseases 76 59.2 (57.9, 60.5) 0.01 (-0.9, 0.6) 0.9 76 0.2 (-0.4, 0.8) 0.5 
Dietary intake‡               
Vitamin B1 (µg/day/kcal) 645 ─ 0.5 (-0.6, 1.6) 0.3 644 0.6 (-0.6, 1.7) 0.3 
Vitamin B2 (µg/day/kcal) 645 ─ 0.1 (-0.5, 0.8) 0.7 644 0.2 (-0.5, 0.8) 0.6 
Vitamin B3 (µg/day/kcal) 645 ─ 0.01 (-0.05, 0.08) 0.7 644 0.02 (-0.05, 0.09) 0.5 
Vitamin B6 (µg/day/kcal) 645 ─ 0.6 (-0.2, 1.4) 0.1 644 0.8 (-0.05, 1.6) 0.07 
Vitamin B12 (µg/day/kcal) 645 ─ -0.04 (-0.09, 0.01) 0.1 644 -0.03 (-0.08, 0.02) 0.3 
Folate (µg/day/kcal) 645 ─ 0.001 (-0.002, 0.004) 0.4 644 0.003 (-0.001, 0.01) 0.1 
Protein (µg/day/kcal) 645 ─ 0.01 (-0.01, 0.03) 0.4 644 0.01 (-0.01, 0.03) 0.4 
Alcohol (µg/day/kcal) 645 ─ -0.002 (-0.02, 0.02) 0.8 644 -0.01 (-0.03, 0.02) 0.5 
Fruit (g/day/kcal) 639 ─ 0.0001 (-0.001, 0.002) 0.9 638 0.0001 (-0.001, 0.002) 0.9 
Vegetable (g/day/kcal) 640 ─ 0.001 (-0.001, 0.003) 0.3 639 0.002 (-0.001, 0.004) 0.1 
Fruit and vegetable (g/day/kcal) 639 ─ 0.0003 (-0.0008, 0.001) 0.6 638 0.0005 (-0.0007, 0.002) 0.4 
Toenail trace elements§               
Aluminum (µg/g) 658 ─ -0.003 (-0.008, 0.002) 0.2 658 -0.003 (-0.008, 0.002) 0.2 
Arsenic (µg/g) 659 ─ -2.9 (-5.2, -0.6) 0.02 659 -3.6 (-5.9, -1.2) 0.003 
Cadmium (µg/g) 659 ─ 0.08 (-0.4, 0.5) 0.7 659 0.1 (-0.3, 0.6) 0.6 
Chromium (µg/g) 658 ─ 0.06 (-0.01, 0.1) 0.09 659 -0.01 (-0.05, 0.03) 0.6 
Copper (µg/g) 659 ─ -0.002 (-0.06, 0.05) 0.95 659 -0.01 (-0.07, 0.04) 0.6 
Iron (µg/g) 657 ─ -0.002 (-0.006, 0.002) 0.4 658 0.002 (0.001, 0.004) 0.009 
Lead (µg/g) 659 ─ -0.05 (-0.1, 0.03) 0.2 659 -0.06 (-0.1, 0.02) 0.2 
Manganese (µg/g) 659 ─ -0.03 (-0.1, 0.09) 0.7 659 -0.05 (-0.2, 0.06) 0.4 
Nickel (µg/g) 659 ─ 0.02 (0.006, 0.03) 0.002 659 0.02 (0.005, 0.03) 0.004 
Selenium (µg/g) 659 ─ 0.1 (-0.8, 1.0) 0.8 659 0.2 (-0.7 1.2) 0.6 
Vanadium (µg/g) 651 ─ -0.7 (-2.7, 1.3) 0.5 651 -0.9 (-2.8, 1.2) 0.4 
Zinc (µg/g) 659 ─ -0.002 (-0.004, 0.001) 0.2 659 -0.001 (-0.004, 0.002) 0.4 
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Table 3-1 (cont.) Association between LINE-1 methylation level and individual characteristics of study subjects in the SBC/EPICURO 
Study 
Variables N LINE-1 methylation Unadjusted β (95% CI) P-value N Adjusted β(95% CI)*† P-value Mean (95% CI) 
NAT2 phenotype               
Rapid/Intermediate acetylator 389 59.0 (58.4, 59.6) Reference   388 Reference   
Slow acetylator 498 58.8 (58.4, 59.2) 0.2 (-0.1, 0.5) 0.3 496 0.2 (-0.1, 0.5) 0.2 
Missing data 5             
GSTM1 genotype               
(+/+, +/-) 421 58.9 (58.3, 59.4) Reference   419 Reference   
(-/-) 462 59.0 (58.5, 59.4) 0.04 (-0.3, 0.4) 0.8 461 0.01 (-0.3, 0.3) 0.9 
Missing data 9             
GSTT1 genotype               
(+/+, +/-) 688 59.0 (58.6, 59.4) Reference   685 Reference   
(-/-) 198 58.5 (57.9, 59.2) -0.2 (-0.6, 0.2) 0.3 198 -0.2 (-0.6, 0.2) 0.4 
Missing data 6             
*Adjusted for age, gender, region, and smoking status (non-, occasional, former, current smoker). Tobacco type's β is not adjusted for 
smoking status. 
†The number of observations are reduced by three because of missing data on smoking status. 
‡Data available for those who completed food frequency questionnaire. 
§Data available for those who provided toenail for trace element assessment. 
Note: the exposure contrast for trace elements is 1-μg/g and for dietary variables is 1-μg/day/kcal. 
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Out of the 515 genetic variants assessed, 22 passed a first screening using Fisher’s exact 
test (p-value≤0.05 according to codominant mode of inheritance) (see Supplementary Table S3-
3). Of these, seven SNPs in five genes were significantly associated with LINE-1 methylation 
based on multivariable models adjusted for age, gender, region, and smoking status (Table 3-2; 
model-based estimates for the 15 SNPs that were not significantly associated with LINE-1 
methylation are reported in Supplementary Table S3-6.) Significant positive associations were 
estimated for DNMT3A-rs7581217 (per allele: adjusted β = 0.3; 95%CI: 0.1, 0.6, p-
value=0.002); TCN2-rs9621049 (recessive: adjusted β = 4.2; 95%CI: 2.8, 5.7, p-value=4.7x10-9), 
TCN2-rs4820887 (recessive: adjusted β = 4.0; 95%CI: 2.5, 5.6, p-value=4.8x10-7) and TCN2-
rs9606756 (recessive: adjusted β = 1.9; 95%CI: 0.5, 3.3, p-value=0.008); and AS3MT-rs7085104 
(recessive: adjusted β = 0.7; 95%CI: 0.3, 1.2, p-value=0.001). In addition, significant 
associations under the codominant mode of inheritance (based on global p-values) were 
estimated for SLC19A1-rs914238 (TC vs TT, β = 0.5; 95%CI: 0.08, 0.8; CC vs TT, β = -0.3; 
95%CI:  -0.7, 0.2; global p-value=0.0007) and MTHFS-rs1380642 (CT vs CC, β = 0.3; 95%CI: -
0.08, 0.6; TT vs CC, β = -0.8; 95%CI: -1.6, 0.09; global p-value=0.05). After correcting for 
multiple testing using the Bonferroni’s method, TCN2-rs9621049 and TCN2-rs4820887 
remained significant (p<0.05). 
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Table 3-2 Association between LINE-1 methylation levels and single nucleotide polymorphisms in genes involved in the one-carbon 
metabolism pathway 
Gene dbSNP [Chromosome,  MAF N MOI Genotype Unadjusted β P-value Adjusted β P-value position in the gene, location*] (95% CI) (95% CI)† 
DNMT3A rs7581217 [2, intron, 25378448] 0.39 875 Additive per allele T 0.3 (0.1, 0.6) 0.003 0.3 (0.1, 0.6) 0.002 
AS3MT rs7085104 [10, flanking 5'UTR, 0.38 751 Recessive AA/AG Reference   Reference   
   104618863]   124   GG 0.8 (0.3, 1.2) 0.0008 0.7 (0.3, 1.2) 0.001 
MTHFS‡ rs1380642 [15, flanking 3'UTR, 0.18 585 Codominant CC Reference 0.03 Reference 0.05 
   77883926]   258   CT 0.3 (-0.05, 0.6)   0.3 (-0.08, 0.6)   
      32   TT -0.8 (-1.6, 0.07)   -0.8 (-1.6, 0.09)   
SLC19A1‡ rs914238 [21, flanking 5'UTR, 0.49 231 Codominant TT Reference 0.0008 Reference 0.0007 
   45840089]   435   TC 0.5 (0.09, 0.8)   0.5 (0.08, 0.8)   
      209   CC -0.2 (-0.7, 0.2)   -0.3 (-0.7, 0.2)   
TCN2§ rs9621049 [22, exon, 0.11 864 Recessive CC/CT Reference   Reference   
   29343419]   11   TT 4.5 (3.1, 5.9) 4.3 x 10-10 4.2 (2.8, 5.7) 4.7 x 10-9 
  rs9606756 [22, exon, 0.12 864 Recessive AA/AG Reference   Reference   
   29336860]   11   GG 2.2 (0.8, 3.6) 0.003 1.9 (0.5, 3.3) 0.008 
  rs4820887 [22, intron, 0.1 866 Recessive GG/GA Reference   Reference   
   29346914]   9   AA 4.6 (3.0, 6.2) 9.3 x 10-9 4.0 (2.5, 5.6) 4.8 x 10-7 
MAF, minor allele frequency; MOI, mode of inheritance. 
*Human Genome Build 36.3 location. 
†Adjusted for age, gender, region, and smoking status. 
‡Global p-value for rs1380642 and rs914238 was estimated by using a two-degrees of freedom likelihood-ratio test. 
§Linkage disequilibrium (rs4820887 vs. rs9621049) r2 = 0.8. 
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A significant interaction (p-value=0.01) was observed between arsenic and AS3MT-
rs7085104 on LINE-1 methylation (adjusted β for 1-μg/g increase in As = -4.1; 95%CI: -6.6, -
1.7, p-value=0.001 for genotype AA/AG; and adjusted β for 1-μg/g increase in As = 10.2; 
95%CI: -3.2, 23.7, p-value=0.1 for genotype GG). 
After simultaneously adjusting for age, geographic region, and all factors that were significant 
predictors of LINE-1 methylation (sex; tobacco type; toenail arsenic, iron and nickel; and the 5 
SNPs noted above), associations with sex, arsenic, nickel, iron, DNMT3A-rs7581217, TCN2-
rs9621049, and MTHFS-rs1380642 remained significant. The association with blond tobacco was 
nonsignificant although the direction of the point estimate remained unchanged. The association 
between rs9606756, rs4820887 and LINE-1 methylation become nonsignifcant (see 
Supplementary Table S3-7). This might be due to reduced sample size in the simultaneously 
adjusted model due to missing data. 
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Discussion and conclusions 
In the present study, we took a comprehensive approach to assess associations of genetic 
and non-genetic factors with LINE-1 methylation in a group of individuals aged 20-81 years. 
Lower levels of LINE-1 methylation were found among females compared with males, and 
among smokers of blond tobacco compared with non-smokers. In addition, toenail concentrations 
of arsenic were also negatively associated with LINE-1 methylation. On the other hand, LINE-1 
methylation levels were positively associated with toenail concentrations of iron and nickel, and 
with seven variants in DNMT3A, TCN2, AS3MT, SLC19A1, and MTHFS genes.  
Our findings support previous results showing that females have significantly lower levels of 
LINE-1 methylation (El-Maarri et al. 2007, Zhu et al. 2012, Wilhelm et al. 2010, El-Maarri et al. 
2011). DNA methylation is important for X-chromosome inactivation in females (Jones & Liang 
2009), and although LINE-1 sequences do not seem to be the major mechanism involved in this 
process, they may be involved in spreading the X-inactivation signal across the chromosome 
(Bailey et al. 2000). In support of this, a recent study showed that LINE-1 sequences were 
hypomethylated in the inactive X-chromosome (Singer et al. 2012). A small study of 33 men and 
33 women reported lower levels of blood SAM in women (Poirier et al. 2001). Hormonal factors 
may also contribute to the difference in methylation levels between genders. However, a recent in 
vitro study assessing the role of estrogen, progesterone and dihydrotestosterone on DNA 
methylation in four cell lines found no detectable effect of these hormones on methylation levels 
at the LINE-1 and Alu repeats (El-Maarri et al. 2011). Further studies are needed to decipher the 
relationship between gender and LINE-1 methylation.  
Because tobacco smoking is an important contributor to disease and is a modifiable 
behavioral factor, there has been much interest in the relationship between smoking and DNA 
methylation. Our findings are in line with other studies that reported no association between 
LINE-1 methylation and smoking status (Terry et al. 2011). In the present study, we found that 
subjects who smoked blond tobacco had lower levels of global DNA methylation than 
nonsmokers. An experimental study has shown that cigarette smoke condensates can induce 
DNA demethylation in repeat elements, such as LINE-1 and D4Z4 (Liu et al. 2010). Both black 
and blond tobacco cause disease although the former is more mutagenic, reflective of the higher 
levels of N-nitrosamines and aromatic amines in smoke produced by black tobacco (Malaveille et 
al. 1989). Our findings suggest that the toxic effects of blond tobacco could be mediated by 
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modulating the epigenetic landscape. This may have a public health implication given epigenetic 
alterations are reversible. 
We also provide evidence that arsenic levels were inversely associated with LINE-1 
methylation, and that arsenic may have a strong effect on LINE-1 methylation. For each μg/g 
increase in arsenic there was a 3.6% decrease in DNA methylation level. This inverse association 
is in agreement with that from a population-based study that used a similar assay to assess LINE-
1 methylation levels and toenail concentrations of arsenic (Wilhelm et al. 2010), as well as with 
several other experimental studies (Ren et al. 2011, Reichard & Puga 2010). The mechanisms 
through which arsenic exposure influences DNA methylation are not fully understood. Studies in 
cell lines and mouse models exposed to arsenic for up to 22 and 48 weeks, respectively have 
shown that prolonged exposure to sodium arsenite resulted in decreased global DNA 
methylation, and inhibition of DNMT1, DNMT3A, and DNMT3B gene expression (Ren et al. 
2011, Reichard & Puga 2010). It is likely that through the combined effect of depleting the 
cellular pool of SAM and inhibiting the activity of DNMTs, both inorganic and organic arsenic 
may lead to decreased global DNA methylation.  
We are not aware of any human studies associating iron and nickel levels and global DNA 
methylation. In the present study, iron and nickel showed a small but significant positive 
association with LINE-1 methylation level. Genes involved in hepatocellular carcinoma (HCC) 
have been found to be hypermethylated in hereditary hemochromatosis, a disease characterized 
by chronic iron overload that is a risk factor for HCC (Lehmann et al. 2007). Iron, together with 
2-oxoglutarate and oxygen, is an essential cofactor for the ten-eleven translocation (TET) family 
of proteins that hydroxylate 5-methylcytosine to 5-hydroxymethylcytosine and further oxidize to 
5-carboxylcytosine and 5-formylcytosine, which have all been suggested to be precursors for 
both active and passive DNA demethylation (Bhutani et al. 2011). Experimental studies 
conducted in Chinese hamster cell lines (G12) treated with nickel chloride for up to 3 weeks have 
shown that nickel chloride leads to both promoter hypermethylation and elevated total genomic 
DNA methylation (Lee et al. 1998, Lee et al. 1995). How nickel induces DNA methylation is not 
yet understood, but it has been proposed that nickel first induces chromatin condensation 
followed by de novo methylation of heterochromatic DNA (Lee et al. 1995). 
The three SNPs with the strongest associations with LINE-1 methylation were all in 
TCN2, including two exonic SNPs that result in missense substitutions (rs9606756 and 
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rs9621049) and one intronic SNP (rs4820887). SNPs rs9621049 and rs4820887 have a linkage 
disequilibrium r2 value of 0.8 implying that the observed effect in LINE-1 methylation may 
eventually be attributed to either of them. TCN2 encodes for transcobalamin II which binds and 
transports vitamin B12 into the cell (Regec et al. 1995), which suggests that variations in TCN2 
could potentially impair the one-carbon metabolism pathway by altering the cytoplasmic 
concentration of vitamin B12. TCN2-rs9606756 leads to an I23V substitution located at a 
NAGNAG tandem acceptor site that is a target of alternative splicing (Hiller et al. 2006). TCN2-
rs9621049 leads to a S348F and may also play a role in the availability of vitamin B12 in the cell 
thereby affecting LINE-1 methylation levels.  
Four SNPs in other genes (DNMT3A-rs7581217; AS3MT-rs7085104; MTHFS-rs1380642; 
SLC19A1-rs914238) involved in the one-carbon metabolism were also associated with global 
DNA methylation in our study population. DNMT3A, a de novo DNA methyltransferase, 
establishes the patterns of methylation in early embryonic development, along with DNMT3B, 
and cooperates with DNMT1 to maintain the methylation of repetitive sequences, such as LINE-1 
and Alu elements (Jones & Liang 2009). Recurrent mutations in DNMT3A have been associated 
with adult hematologic malignancies (Ley et al. 2010, Yan et al. 2011), and mice lacking 
Dnmt3a die in the first weeks of postnatal life (Robertson 2005). The product of AS3MT 
catalyzes the conversion of trivalent arsenic by addition of a methyl group to monomethylarsonic 
acid and dimethylarsonic acid (Ren et al. 2011); monomethylarsonic acid being the most toxic 
metabolite (Engstrom et al. 2011). rs7085104, located in the promoter region of AS3MT, has been 
associated with arsenic metabolism, as evidenced by differences in urinary concentration of 
arsenic metabolites (Engstrom et al. 2011, Valenzuela et al. 2009). We also observed a 
significant interaction of this SNP with levels of arsenic on LINE-1 methylation levels. While 
subjects with at least one copy of the major allele had a 4.1% decrease in methylation level for 1-
μg/g increase in arsenic, which is comparable to the overall population (-3.6%), those 
homozygous for the variant allele had a 10% increase in LINE-1 methylation. These findings 
support the putative functionality of the association. The product of MTHFS catalyzes the 
conversion of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate and a genome-wide 
association study reported an association between a variant in this gene and chronic kidney 
disease (Kottgen et al. 2008). SLC19A1 is a ubiquitously expressed major transporter of folate 
and antifolates and regulator of the intracellular concentrations of folate (Matherly et al. 2007). 
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Common variants in this gene have been associated with plasma folate levels, various types of 
cancer (esophageal, gastric and acute lymphoblastic leukemia), and altered methotrexate 
transport and adverse effects of methotrexate (Matherly et al. 2007).  
Among the limitations of the study is the majority of individuals were of advanced age 
(mean age 64 years, SD=10 years) and men. This may explain the lack of association between 
DNA methylation and age in our study population, in contrast with other studies that included 
subjects with a broader age range (Fraga et al. 2005a). Thus, our findings refer to an adult 
population of mostly men. Results were consistent with estimates for the population as a whole 
when stratified by gender, with the exception of nickel, tobacco type, and MTHFS-rs1380642 
which become nonsignificant while the point estimates were in the same direction (data not 
shown). These differences may reflect reduced power to estimate associations among women due 
to the small sample size. The presence of missing data for some of the variables might have 
resulted in decreased power but even with the available sample size we were able to reproduce 
previous results and identify novel predictors of LINE-1 methylation. Furthermore, while the 
study subjects were recruited from hospitals, none of reasons for hospitalization were 
significantly associated with LINE-1 methylation.  
Strengths of the study include its size, the availability and quality of individual data on 
demographics, lifestyle, environmental exposures, and genetics. Additionally, we assessed LINE-
1 methylation levels, which are considered a good marker of global DNA methylation (Yang et 
al. 2004), using pyrosequencing, which gives accurate and reproducible measurements (Laird 
2010, Estecio et al. 2007, Tost & Gut 2007). Furthermore, this assessment was made using DNA 
from granulocytes, avoiding a possible effect of cell blood count in our study. 
To the best of our knowledge, this is the first study to identify seven SNPs in association to 
changes in LINE-1 methylation and to integrate different types of information to assess the 
determinants of global methylation in blood DNA. Integration of both internal and external 
exposure data in this study is a step forward in understanding how the exposome modulates DNA 
methylation patterns. 
In conclusion, the current study provides further evidence that DNA methylation levels 
are influenced by variants in genes involved in the one-carbon metabolism pathway, and 
exposure to trace elements and tobacco smoke. Given the fact that smoking and some of the 
genetic variants and trace elements associated with LINE-1 methylation in the present study have 
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also been associated with adverse health outcomes including cancer, our results provide 
additional insight into the potential mechanism through which these agents participate in the 
development of those diseases. Furthermore, these factors should be considered as potential 
confounders in etiologic and interventional studies analyzing the role of DNA methylation in 
disease. Nevertheless, future studies are required to replicate and extend our findings in different 
populations. 
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Abstract 
Aberrant global DNA methylation is shown to increase cancer risk. LINE-1 has been 
proven a measure of global DNA methylation. The objectives of this study were to assess the 
association between LINE-1 methylation level and risk of urothelial carcinoma of the bladder 
(UCB), and to further explore effect modification by environmental and genetic factors. Bisulfite-
treated leukocyte DNA from 952 cases and 892 controls of the Spanish Bladder 
Cancer/EPICURO Study was used to measure LINE-1 methylation level at four randomly 
selected CpG sites by pyrosequencing. Logistic regression models, adjusted for age, gender, 
region, and smoking, were fitted to estimate odds ratios (ORs) and 95% confidence intervals 
(95%CIs). Interactions between LINE-1 methylation level and environmental and genetic factors 
were assessed. The risk of UCB followed a non-linear association with LINE-1 methylation. 
Compared to subjects in the middle tertile, the adjusted OR for subjects in the lower and the 
higher tertiles were 1.26 (95%CI 0.99-1.60, P = 0.06) and 1.33 (95%CI 1.05-1.69, P = 0.02), 
respectively. This association significantly increased among individuals homozygous for the 
major allele of five single nucleotide polymorphisms located in the phosphatidylethanolamine N-
methyltransferase (PEMT) gene (corrected P-interaction < 0.05). This is the first large-scale 
study showing that both low and high levels of global DNA methylation levels are associated 
with risk of UCB. Moreover, variants in PEMT seemed to markedly modify this risk. Our results 
may provide additional insights into the etiological mechanisms of DNA methylation in UCB 
development, and therefore deserve further exploration in independent populations. 
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Introduction 
Urothelial carcinoma of the bladder (UCB) is one of the most common cancers in 
developed countries mainly affecting men (Parkin 2008). In Spain, the incidence rate of UCB has 
been increasing in the past three decades and the ratio of men to women developing the disease is 
7:1 (Izarzugaza et al. 2010). Recurrence is a major problem in the management of UCB 
necessitating frequent follow-ups thus, making it one of the most expensive cancer types to treat 
(Lotan et al. 2008). Established risk factors for UCB include tobacco smoking, occupational 
exposures to aromatic amines, arsenic in drinking water (Murta-Nascimento et al. 2007, Volanis 
et al. 2010), and genetic variants of NAT2 and GSTM1; the latter two have been shown to 
significantly modify the risk conferred by tobacco smoking (Garcia-Closas et al. 2005, Rothman 
et al. 2010). Recently, additional common genetic variants on CBX6-APOBEC3A, CCNE1, MYC, 
PSCA, SLC14A1, TERT-CLPTM1L, TMEM129-TACC-FGFR3, TP63 and UGT1A6 cluster have 
been associated with risk of UCB (Rothman et al. 2010, Garcia-Closas et al. 2011, Tang et al. 
2012). 
Genome-wide altered epigenetic states are common findings in several malignancies 
including bladder tumors. These epigenetic states include global DNA hypomethylation and gene 
promoter methylation, post-translational histone modifications and deregulation of microRNAs 
(Esteller 2008, Taby & Issa 2010). Global DNA hypomethylation in cancer is mostly found in 
repetitive sequences of the genome such as long interspersed nuclear element 1 (LINE-1) and Alu 
elements (Esteller 2008). It has been suggested that methylation represses the transcription of 
these repetitive regions to maintain genomic stability, and prevent mutations, deletions and 
insertions (Esteller 2008). In UCB, genomic instability has been observed at different stages of 
the disease (Florl & Schulz 2008). There is evidence that LINE-1 hypomethylation could also 
induce the expression of the MET oncogene in UCB and normal tissues (Wolff et al. 2010). 
Global DNA methylation measured in peripheral blood cells has been used to investigate its 
relationship with cancer risk, although results have been inconclusive (Woo & Kim 2012). 
Studies investigating the role of genomic DNA methylation (measured by direct quantification of 
5-methylcytosine as well as at CpG sites in LINE-1 sequences) and UCB have inconclusively 
shown an inverse association between genomic DNA methylation and risk of UCB (Moore et al. 
2008, Wilhelm et al. 2010, Cash et al. 2012). Whether environmental and genetic factors modify 
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the association between global DNA methylation and UCB risk is not known, although it has 
been suggested that smoking, B vitamins, arsenic, and genes involved in the one-carbon 
metabolism pathway may play a modifier role (Volanis et al. 2010, Moore et al. 2007). Hence, 
understanding the role of global DNA methylation in UCB development and its interaction with 
other known and potential risk factors may provide further insight on the etiology and 
susceptibility of this tumor. 
The objectives of this study were to assess the risk of UCB associated with LINE-1 
methylation levels, as a measure of global DNA methylation in peripheral blood, as well as to 
explore whether personal, lifestyle, environmental and genetic factors modify this association.  
Methods 
Study population: The Spanish Bladder Cancer/EPICURO Study is a multi-center, 
hospital-based case-control study conducted in five regions of Spain (Barcelona, Valles, Elche, 
Tenerife, and Asturias) between 1998 and 2001. The design of the study has been previously 
described elsewhere in detail (Garcia-Closas et al. 2005, Samanic et al. 2006). Briefly, cases and 
controls were recruited to the study from 18 hospitals. Cases were newly diagnosed subjects with 
histologically confirmed UCB. Controls were patients admitted to the same hospital as cases for 
reasons not related to exposures of interest and individually matched for age (± five years), 
gender and geographic region to cases. From the initial study population of 1219 cases and 1271 
controls, 1107 cases and 1032 controls provided blood sample (before treatment was instituted). 
Of these, 995 cases and 925 controls, all Caucasians and without missing demographic data, had 
enough leukocyte DNA for sodium bisulfite treatment and subsequent measurement of DNA 
methylation. Because in 43 cases and 33 controls, quantification of DNA methylation failed, the 
final study population for the current analysis was 952 cases and 892 controls aged from 20 to 81 
years. Written informed consent was obtained from each study subject before interview, and the 
study was approved by the US National Cancer Institute and local institutional review boards. 
Data on demographic and personal characteristics, smoking and other known and potential risk 
factors for UCB were collected by means of a computer assisted personal interview. Food 
frequency questionnaires were used to collect data on fruit, vegetable, B vitamins, and protein 
and alcohol intake over the five years before interview (Garcia-Closas et al. 2007b). 
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Analysis of LINE-1 methylation: Bisulfite modification of genomic DNA extracted 
from leukocytes using standard techniques was performed using EZ-96 DNA METHYLATION-
GOLDTM KIT (Zymo Research, Irvin, CA, USA) following the recommendations of the 
manufacturer. PCR amplification of bisulfite-modified DNA was carried out using a set of 
forward and reverse primers reported previously (Estecio et al. 2007). To quantify the 
methylation level of each of the four CpG sites immediately after the sequencing primer, 
sequencing of the PCR product was performed by pyrosequencing using PyroMarkTM Q24 
System (QIAGEN, Valencia, CA, USA) as recommended by the manufacturer. Methylation level 
at each CpG site was extracted using PyroMarkTM Application Software version 2.0.6 (QIAGEN, 
Valencia, CA, USA) and the value was expressed as the percentage of methylated cytosines over 
the sum of methylated and unmethylated cytosines. The average methylation level of the four 
LINE-1 CpG sites was used in the analysis as a marker of the global DNA methylation level. As 
a quality control measure, 307 randomly selected samples from cases and controls were run in 
duplicate and the within-sample coefficient of variation was 4.53%. The mean methylation level 
of the duplicates was used in the analysis. 
Genotyping: Genotyping was carried out using DNA isolated form leukocytes as 
described previously (Garcia-Closas et al. 2005). All genotype assays used in this analysis were 
done at the Core Genotyping Facility of the Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, MD, USA. Methods of the SNP genotyping process were 
described previously (Garcia-Closas et al. 2005, Rothman et al. 2010, Garcia-Closas et al. 
2007a). SNP genotyping was done using Illumina Infinium® Human1M-Duo (480 SNPs), 
Illumina GoldenGate® (36 SNPs) and TaqMan® (8 SNPs) assays. All genotypes included in the 
study were in Hardy-Weinberg equilibrium in the control population (P > 0.05). A total of 524 
SNPs and copy number variation in GSTM1 and GSTT1 were assessed in the present study. Of 
these SNPs, 515 SNPs were located in 24 candidate genes involved in one-carbon metabolism 
pathway, including DNA methylation and arsenic metabolism (see Supplementary Table S4-1). 
These pathways are known to influence DNA methylation by altering the cellular concentration 
of the methyl group donor S-adenosylmethionine (SAM) (Ulrey et al. 2005, Lee et al. 2009, 
Moore et al. 2007). Additionally, eight SNPs identified in a recent multi-stage genome-wide 
association study of UCB, and a SNP rs1495741 tagging NAT2 acetylator phenotype were also 
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included in the analysis (Rothman et al. 2010). SNPs and variants were investigated for their 
modifier effect on the association between LINE-1 methylation and UCB risk. 
Quantification of trace elements: Methods of quantification of toenail trace elements 
level included in the current study have been previously described (Amaral et al. 2011). Briefly, 
after cleaning and washing the toenails to remove external contaminants, trace elements were 
quantified at the Trace Element Analysis Core (Dartmouth College, NH, USA), using inductively 
coupled plasma-mass spectrometry (Hopkins et al. 2004). Toenails were digested with Optima 
nitric acid (Fisher Scientific, St. Louis, MO), at 105 °C, then hydrogen peroxide and further 
heating the dilution with deionized water. All sample preparation steps were recorded 
gravimetrically. For quality control, each batch of analyses accommodated six standard reference 
material samples with known trace element content (SRM; GBW 07601, powdered human hair) 
and six analytic blanks, together with the study samples. Overall, concentrations (μg/g) of 12 
trace elements (aluminum, arsenic, cadmium, chromium, copper, iron, lead, manganese, nickel, 
selenium, vanadium, and zinc) were determined. 
Statistical methods: Pearson chi-square test was used to evaluate the association between 
case-control status and categorical variables. Normality of LINE-1 methylation distribution was 
assessed graphically by plotting histograms and formally tested by using Shapiro-Wilk test for 
normality. The non-parametric Mann-Whitney U test was used to compare medians of 
continuous variables in different strata. 
To estimate the risk associated with global DNA methylation, LINE-1 methylation level 
was modeled using restricted cubic splines in a logistic regression model adjusting for age 
(continuous), gender, region, and smoking status (never, occasional, former and current smoker). 
Upon the visualization of a non-linear “U-shape” risk pattern from the cubic spline regression 
(Supplementary Figure 4-1), LINE-1 methylation levels were categorized into three categories by 
using tertile cut-points (56.68% and 58.65%) based on its distribution among the control 
population. For subsequent analyses, this variable was used by assigning the middle tertile as the 
referent category. Unadjusted and adjusted logistic regression models were fitted to estimate odds 
ratios (ORs) and the corresponding 95% confidence intervals (95%CI). In addition to LINE-1 
methylation, variables included in the basic multivariable adjusted model were age, gender, 
region and smoking status. Association between LINE-1 methylation, in tertiles, at each of the 
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four LINE-1 CpG sites and risk of UCB was evaluated. Also, and in order to mimic the 
distribution of LINE-1 methylation levels in tertiles using a continuous variable, the association 
between the absolute deviation (continuous) from the median LINE-1 methylation level was 
modeled by logistic regression unadjusted and adjusted for age, gender, region, and smoking 
status. Moreover, the association between LINE-1 methylation and UCB subphenotypes (low-, 
high-grade non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer 
(MIBC)) was modeled using multinomial logistic regression. Likelihood ratio test for 
heterogeneity was used to test whether the ORs for low-, high-grade NMIBC and MIBC are 
different from each other.  
Interaction between LINE-1 methylation and individual covariates [age (<60, 60-69, and 
≥ 70 years), gender, smoking status (never and ever smoker), diet factors, trace elements 
(continuous) and SNPs (four modes of inheritance)] was tested by including a multiplicative 
interaction term into the logistic regression model. For the interaction between LINE-1 
methylation and smoking, additional analyses included adjustment among regular smokers for 
each of the following, as a continuous variable: pack-years, duration of cigarette smoking, and 
number of cigarettes smoked per day. Significance of the interaction term was tested by 
comparing the models with and without the interaction term using the likelihood ratio test. A 
permutation test done by randomly sampling 10,000 times and assigning case/control status in a 
proportion similar to the current study was applied to estimate interaction P for each SNP, 
corrected for multiple testing. All statistical tests were two-sided, and a P less than 0.05 was 
considered significant. Statistical analyses were carried out by using STATA/SE, version 10.1 
(StataCorp, College Station, Texas, USA). 
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Results 
The characteristics of cases and controls are shown in Table 4-1. Subjects were mostly 
men and smokers. A large proportion of cases (78%) were diagnosed with a NMIBC. The 
distribution of global DNA methylation was bimodal. The median (interquartile range) LINE-1 
methylation levels among cases and controls were 57.60% (4.06%) and 57.44% (3.36%), 
respectively (P = 0.3). The minimum and maximum values of LINE-1 methylation were 28.81% 
and 85.44% among cases and 37.91% and 85.68% among controls.  
Compared to subjects in the middle tertile of LINE-1 methylation, the adjusted ORs were 
1.26 (95% CI 0.99-1.60, P = 0.06) and 1.33 (95% CI 1.05-1.69, P = 0.02) for the lowest and 
highest tertiles, respectively. These ORs were very similar to the crude ones (Table 4-2). The 
associations between methylation level at each of the four CpG positions of LINE-1 and risk of 
UCB were similar to the results using the average of LINE-1 methylation level (Supplementary 
Table S4-2). The association for the absolute deviation from the median LINE-1 methylation 
level, modeled as a continuous variable and adjusted for age, gender, region and smoking status, 
was similarly significant (adjusted OR = 1.03, 95%CI 1.01-1.05, P = 0.008). When further 
analysis was carried out separately for low-, high-grade NMIBC and MIBC, ORs for LINE-1 
methylation levels were similar to the overall OR and no heterogeneity was found between the 
three UCB subphenotypes (P > 0.05) (Supplementary Table S4-3). 
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Table 4-1 Distribution of characteristics of cases and controls with LINE-1 methylation data in 
the SBC/EPICURO study 
Variables Cases, n (%), N=952 Controls, n (%), N=892 P-value 
Age in years, median (IQR) 68 (13) 66 (13) <0.00001* 
Gender       
Male 826 (86.8) 792 (88.8) 0.2 
Female 126 (13.2) 100 (11.2)   
Region       
Barcelona 162 (17.0) 168 (18.8) 0.7 
Valles 148 (15.5) 135 (15.1)   
Elche 72 (7.6) 73 (8.2)   
Tenerife 173 (18.2) 145 (16.3)   
Asturias 397 (41.7) 371 (41.6)   
Smoking status       
Never 137 (14.5) 255 (28.7) <0.00001 
Occasional 34 (3.6) 66 (7.4)   
Former 376 (39.7) 329 (37.0)   
Current  399 (42.2) 239 (26.9)   
Missing 6 3   
Sub-phenotypes       
Non-muscle invasive 708 (77.6) ─   
Muscle invasive  204 (22.4) ─   
Missing 40 ─   
*Mann–Whitney U test p-value. 
IQR, interquartile range.       
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Table 4-2 Association between LINE-1 methylation and urothelial carcinoma of the bladder risk 
in the SBC/EPICURO study 
 Cases Controls Crude OR 95% CI P-value LINE-1 methylation (tertiles)      T1 (< 56.68%) 337 298 1.29 1.02 1.62 0.03 
T2 (56.68 -< 58.65%) 261 297 1 Referent       
T3 (≥ 58.65%) 354 297 1.36 1.08 1.70 0.008 
              
 Cases Controls OR* 95% CI P-value LINE-1 methylation (tertiles)       T1 (< 56.68%) 335 296 1.26 0.99 1.60 0.06 
T2 (56.68 -< 58.65%) 260 297 1 Referent       
T3 (≥ 58.65%) 351 296 1.33 1.05 1.69 0.02 
*Adjusted for age, gender, region (Barcelona, Valles, Elche, Tenerife and Asturias) and smoking 
status (never, occasional, former and current smoker) 
The effect of LINE-1 on UCB risk was not modified by age, gender, tobacco type, 
nutrient intakes, or trace elements (Supplementary Tables S4-4 and S4-5). Although the risk of 
UCB associated with low and high levels of LINE-1 methylation was significant among never 
smokers, the interaction between LINE-1 methylation and smoking status was not significant (P 
= 0.2; Supplementary Table S4-4). This interaction was not significant even when comparing 
never smokers with regular smokers, after adjusting the models for duration of cigarette smoking, 
cigarettes smoked per day or pack-years among smokers (data not shown). There was no 
interaction between variation in GSTM1 or GSTT1 or SNPs previously associated with UCB risk 
and LINE-1 methylation levels. The same is true for most of the SNPs in genes from the one-
carbon metabolism pathway (Supplementary Tables S4-5 and S4-6). However, the increased risk 
of UCB among subjects in the lowest and highest tertiles was significantly modified by five 
SNPs (rs2124344, rs7215833, rs4646340, rs4646350, and rs4646341) in the 
phosphatidylethanolamine N-methyltransferase (PEMT) gene. Under the dominant mode of 
inheritance, the risk of UCB being in the lowest or highest tertile of LINE-1 methylation was 
significantly increased only among individuals homozygous for the major allele (P-interaction < 
4.9x10-5; P-interaction < 0.03 corrected for multiple testing; Table 4-3). 
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Table 4-3 Interaction between LINE-1 methylation and single nucleotide polymorphisms in phosphatidylethanolamine N-methyltransferase (PEMT) in the SBC/EPICURO study 
rs2124344[CC], PEMT, intron           rs2124344 [CT-TT], PEMT, intron               
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
P-value 
interaction* 
Corrected 
P-value 
interaction†   
T1 (<56.68%) 148 112 2.26 1.52 3.36 5.2x10-5   T1 (<56.68%) 179 177 0.89 0.65 1.21 0.4   1.5x10-5 0.01 
T2 (56.68-<58.65%) 76 132 1 (Ref.)         T2 (56.68-<58.65%) 181 160 1 (Ref.)             
T3 (≥58.65%) 158 107 2.69 1.80 4.00 1.2x10-6   T3 (≥58.65%) 184 183 0.86 0.63 1.18 0.4       
                                    
rs7215833[CC], PEMT, flanking 5'UTR           rs7215833[CT-TT], PEMT, flanking 5'UTR             
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
P-value 
interaction* 
Corrected 
P-value 
interaction†   
T1 (<56.68%) 155 119 2.13 1.44 3.14 0.0002   T1 (<56.68%) 172 171 0.89 0.65 1.23 0.5   3.6x10-5 0.02 
T2 (56.68-<58.65%) 77 131 1 (Ref.)         T2 (56.68-<58.65%) 180 161 1 (Ref.)             
T3 (≥58.65%) 155 101 2.62 1.76 3.91 2.4x10-6   T3 (≥58.65%) 187 189 0.87 0.64 1.19 0.4       
                                    
rs4646340[AA], PEMT, intron‡           rs4646340 [AG-GG], PEMT, intron               
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
P-value 
interaction* 
Corrected 
P-value 
interaction†   
T1 (<56.68%) 153 116 2.13 1.43 3.16 0.0002   T1 (<56.68%) 174 174 0.92 0.67 1.25 0.6   3.8x10-5 0.02 
T2 (56.68-<58.65%) 75 126 1 (Ref.)         T2 (56.68-<58.65%) 182 166 1 (Ref.)             
T3 (≥58.65%) 156 99 2.69 1.79 4.04 1.8x10-6   T3 (≥58.65%) 186 191 0.88 0.65 1.19 0.4       
                                    
rs4646350[CC], PEMT, intron           rs4646350[CT-TT], PEMT, intron               
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
LINE-1 methylation 
(tertiles) Cases Controls OR 95% CI P-value   
P-value 
interaction* 
Corrected 
P-value 
interaction†   
T1 (<56.68%) 148 115 2.16 1.45 3.20 0.0001   T1 (<56.68%) 179 175 0.91 0.66 1.24 0.5   4.9x10-5 0.03 
T2 (56.68-<58.65%) 76 130 1 (Ref.)         T2 (56.68-<58.65%) 181 162 1 (Ref.)             
T3 (≥58.65%) 156 106 2.64 1.77 3.94 2.1x10-6   T3 (≥58.65%) 186 184 0.88 0.65 1.20 0.4       
All models are adjusted for age, gender, region and smoking status (never, occasional, former and current smoker).               
*Uncorrected likelihood ratio test p-value.                               
†Likelihood ratio test p-value corrected for multiple testing using permutation test.                   
‡rs4646341 was in perfect LD with rs4646340 (r2=1.0, D'=1.0) and the corrected p-value for interaction of this SNP was 0.037.           
MAF - rs2124344=0.36, rs7215833=0.36, rs4646340=0.37, rs4646350=0.36 and rs46341=0.37.                   
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Figure 4-1 Linkage disequilibrium plot for SNPs in phosphatidylethanolamine N-methyltransferase 
(PEMT) including the five SNPs analyzed in the current study 
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Discussion and conclusions 
The current study shows that both low and high levels of LINE-1 methylation are 
associated with increased risk of UCB. This association was significantly modified by five SNPs 
in the PEMT gene. The results show, for the first time, a non-linear - “U-shaped” - association 
between global genomic DNA methylation level and UCB risk, which was elevated among 
subjects having specific genotypes of PEMT. Altogether, points to the complex etiological 
mechanisms of DNA methylation in UCB development. 
The finding of increased risk of UCB among individuals with low level of methylation is 
in agreement with previous reports (Moore et al. 2008, Wilhelm et al. 2010, Cash et al. 2012). 
Moore et al., by analyzing global 5-methylcytosine content of the genome using HpaII, high-
performance capillary electrophoresis and densitometry, showed that low level of global DNA 
methylation was associated with increased risk of UCB in a subsample of the same study (Moore 
et al. 2008). Additionally, two studies also using sodium bisulfite modification of leukocyte 
DNA, followed by pyrosequencing to quantify methylation levels of four LINE-1 CpG sites 
reported a similar inverse association between LINE-1 methylation level and risk of UCB in 
independent populations (Wilhelm et al. 2010, Cash et al. 2012). An experimental study 
demonstrated hypomethylation of LINE-1 sequences in urothelial carcinoma cell lines and 
tumors compared to normal bladder tissue (Jurgens et al. 1996). Another study also showed that 
hypomethylation of LINE-1 promoter can induce the expression of the MET oncogene in bladder 
tumors and normal urothelial tissues (Wolff et al. 2010). Interestingly, the current study also 
shows that higher methylation level was associated with increased risk of UCB. In support of this 
finding, a recent case-control study that investigated the association between LINE-1 methylation 
and renal cell carcinoma showed a direct association between methylation and risk of renal cell 
carcinoma (Liao et al. 2011), while another study that evaluated LINE-1 methylation status in 
normal and cancerous cells found out sporadic hypermethylation of LINE-1 loci in cancer cells 
(Phokaew et al. 2008). Recent studies have demonstrated that methylation blocks the initiation of 
transcription of repetitive DNA sequences such as LINE-1 and Alu elements, while at the same 
time allowing transcriptional elongation of the host gene suggesting that methylation at repetitive 
sequences might have dual functions in addition to silencing repetitive sequences depending on 
the location and context of these regions (Jones 2012). 
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To our knowledge, the present study is the first to show a significant interaction between 
LINE-1 methylation and SNPs in PEMT gene on the risk of UCB. There is no available data on 
UCB risk and PEMT polymorphisms. However, a population-based study identified a SNP in a 
promoter region of PEMT to be associated with increased risk of breast cancer (Xu et al. 2008). 
PEMT is located within the Smith-Magenis syndrome region on chromosome 17, and encodes for 
a transmembrane protein involved in important cellular processes including choline and lipid 
metabolism, insulin sensitivity and homocysteine levels (Vance et al. 2007). PEMT methylates, 
using SAM as a substrate, phosphatidylethanolamine to phosphatidylcholine, which accounts for 
95% of total choline pool in tissues (Ueland 2011, Vance et al. 2007). Evidence suggest that 
phosphatidylcholine metabolism could be involved in malignant transformations (Glunde et al. 
2011). Experimental studies have demonstrated altered choline metabolism in tumors, mediated 
by transcription factors (signaling pathways) associated with oncogenesis such as hypoxia-
inducible factors 1, and by the RAS and PI3K/AKT pathways (Glunde et al. 2011). It has been 
known that these pathways are constitutively activated in the majority of bladder tumors, namely 
low-grade non-muscle-invasive papillary tumors, which account for 70-80% of UCB cases (Wu 
2005, Lopez-Knowles et al. 2006). On the other hand, upon oxidation choline gives rise to 
betaine which promotes remethylation of homocysteine to methionine affecting the concentration 
of SAM (Ueland 2011). Therefore, polymorphisms in PEMT could directly affect the one-carbon 
metabolism pathway and impair DNA methylation. The five SNPs are located in flanking 5'UTR 
and intron of PEMT (Figure 4-1). Alternatively, we cannot rule out these associations could be 
due to chance. 
Unlike the previous studies where linear associations were observed between LINE-1 
methylation and cancer risk, in this study increased risk of UCB at both extremes of LINE-1 
methylation was observed. The risk pattern differences with the other studies could be explained 
by the larger sample size in the present that enables to further characterize the risk patterns as 
well as differences in methods used to quantify DNA methylation. A recent meta-analysis of 
LINE-1 methylation and UCB risk found a significant heterogeneity between assays used to 
quantify methylation (Woo & Kim 2012). That same analysis also identified significant 
heterogeneity among studies. It should be noted that LINE-1 methylation level in the current 
study population (mean = 59.2%) were substantially different from those in the previous two 
studies on UCB risk and LINE-1 methylation that reported mean methylation level of 79.6% 
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(Wilhelm et al. 2010), and 81.9% (Cash et al. 2012). This difference is not surprising and 
probably results from the fact that distinct CpG sites were analyzed. On the other hand, the 
differences could perhaps be explained by geographic dissimilarities resulting in differential 
exposure to environmental factors, including diet, or genetic background and stochastic factors 
present in these populations. 
The limitations of this study include the fact that blood samples were collected at the time 
of interviews, before initiation of treatment. Some individuals were not included in the present 
analyses due to the lack of LINE-1 methylation data, however there was no relevant difference in 
selected characteristics except age (among controls) and gender (among cases and controls) 
between those with and without that data (Supplementary Table S4-7). To minimize the potential 
bias, all the models were adjusted for age, gender as well as region and smoking status. DNA 
methylation is tissue specific and it could be affected by cell type. To evaluate if there is a 
difference in methylation level among blood cell types, LINE-1 methylation level was quantified 
in DNA separately isolated from granulocytes and lymphocytes, the most abundant white blood 
cell types. There was no difference in LINE-1 methylation level between these cell types, which 
is in agreement with studies that found significant correlations between LINE-1 methylation 
assays of different blood cell types among healthy individuals (Wu et al. 2011a) as well as UCB 
patients (van Bemmel et al. 2012). However, the study on UCB patients also showed lack of 
correlation between global DNA methylation in blood and bladder tissue (van Bemmel et al. 
2012), while another study showed LINE-1 methylation to be consistent from tissue to tissue 
indicating that tissue heterogeneity might not be associated with LINE-1 methylation levels (Choi 
et al. 2009).  
The study has also important strengths. First is sample size: to the best of our knowledge 
this is the first large study to investigate the association between LINE-1 methylation and UCB 
risk (and any other cancer type). Second, the study integrates a wide range of information, 
including epidemiologic, clinical, environmental, and genetic data. Third, the method used to 
quantify LINE-1 methylation has been shown to be a good surrogate marker of global DNA 
methylation (Yang et al. 2004). Determining DNA methylation levels by pyrosequencing 
provides reproducible and accurate results (Tost & Gut 2007, Laird 2010). 
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In conclusion, this study showed that both low and high levels of global DNA 
methylation may be associated with increased risk of UCB, and that this risk can be markedly 
modified by PEMT. Taken together, the results suggest that DNA methylation and the one-
carbon metabolism pathway play a relevant role in the development of UCB. Global DNA 
methylation may have a more complex association with UCB than previously thought. In 
addition, the findings suggest that DNA methylation measured in peripheral blood cells could be 
further explored to be used as a susceptibility marker for UCB risk. Nevertheless, further studies 
in large and independent populations are required. 
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Abstract 
Epigenetic alterations are a hallmark of carcinogenesis. While methylation of the 
subtelomeric macrosatellite repeat D4Z4 has been implicated in disease, little is known about its 
genetic and non-genetic predictors and whether it is associated with urothelial carcinoma of the 
bladder (UCB) risk. The objectives of this study were to identify the predictors of D4Z4 
methylation and to assess the association between D4Z4 methylation and risk of UCB. Levels of 
D4Z4 methylation were measured by pyrosequencing in bisulfite-modified DNA from 
granulocytes of 707 cases and 718 controls included in the Spanish Bladder Cancer/EPICURO 
Study. Robust linear regression models including non-genetic and genetic characteristics of 
controls were fitted to identify predictors of D4Z4 methylation. The association between D4Z4 
methylation and UCB risk was analyzed using multivariable adjusted logistic regression, and 
odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Interaction between D4Z4 
methylation and both established and potential risk factors for UCB was tested by including 
interaction terms in the models. In analyses limited to the controls, being female (β = -3.3; 
95%CI -6.0 to -0.6, p-value = 0.02) or smoker of blond tobacco (β = -3.7; 95%CI -6.5 to -0.9, p-
value = 0.01) was associated with decreased levels of D4Z4 methylation. Selenium was strongly 
inversely associated with D4Z4 methylation (β for 1-μg/g increase = -8.1; 95%CI -12.7 to -3.5, p-
value = 0.0006). Individuals with D4Z4 methylation levels above or equal to the median (≥ 64.4) 
had a slightly increased risk of UCB (OR = 1.23; 95%CI 0.99 - 1.53, p-value = 0.06). This 
association was modified by iron (p-interaction = 0.003), manganese (p-interaction = 0.04), and 
zinc (p-interaction = 0.01). Additionally, carriers of the minor allele of FOLH1-rs11040387 had a 
3.5-fold increased risk of UCB (95%CI 1.94 - 6.44, p-value = 5.1x10-5, corrected p-interaction = 
0.02). In an analysis by UCB subtypes, D4Z4 hypermethylation was significantly associated with 
increased risk of developing low-risk tumors with FGFR3 overexpression (OR = 1.63; 95%CI 
1.08 - 2.47, p-value = 0.02), but not with the other subtypes (p heterogeneity = 0.01). This is the first 
study showing D4Z4 hypermethylation in granulocyte DNA to be predicted by non-genetic 
factors (gender, tobacco, and selenium) and to be associated with UCB risk, particularly with the 
predominant NMIBC, and effect modifications by trace elements and FOLH1. These findings 
underline the potential of D4Z4 methylation for the development of a novel biomarker for UCB. 
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Introduction 
Urothelial carcinoma of the bladder (UCB), one of the most common cancers in the 
Western world, is a heterogeneous group of tumors and develops along two divergent pathways 
characterized by distinct clinical and molecular features. Non-muscle-invasive bladder cancer 
(NMIBC), the predominant type of UCB (75-85%), harbors activating mutations in FGFR3, 
PIK3CA and RAS oncogenes while muscle-invasive bladder cancer (MIBC) is characterized by 
inactivating mutations in TP53 and RB genes (Cheng et al. 2011, Knowles 2008, Falke & Witjes 
2011). NMIBC is further divided into low- and high-risk groups that have varying risk of tumor 
recurrence and progression (Donat 2003, Falke & Witjes 2011). High rates of recurrence, mainly 
in NMIBC, make UCB the most expensive cancer to manage per patient (Sievert et al. 2009). 
Risk factors for UCB include cigarette smoking, exposure to arsenic in drinking water and to 
specific occupational carcinogens, and genetic variations in 12 genes, among them NAT2 slow 
acetylator phenotype, GSTM1 null genotype (Murta-Nascimento et al. 2007, Garcia-Closas et al. 
2005, Rothman et al. 2010). 
Aberrant epigenetic events, such as DNA methylation and histone modifications, are 
hallmarks of cancer, and can also interact with genetic changes to drive initiation and progression 
of cancer (Baylin & Jones 2011). Alterations in global and gene-specific DNA methylation have 
been observed in UCB (Heyn & Esteller 2012, Esteller 2008). Studies focusing on global 5-
methylcitosine and long interspersed nuclear element-1 (LINE-1) have reported an association 
between methylation in leukocyte DNA and risk of UCB (Moore et al. 2008, Wilhelm et al. 
2010, Cash et al. 2012). Methylation in other DNA sequences, such as D4Z4, has been shown to 
be relevant for disease. 
D4Z4 is a subtelomeric macrosatellite repeat array located on chromosomes 4q, 10q, and 
all acrocentric chromosomes (van der Maarel et al. 2012, Lyle et al. 1995). Each unit of this array 
contains a retrogene double homeobox 4  (DUX4), a transcription factor that has been shown to 
regulate genes that play a role in relevant cellular pathways (van der Maarel et al. 2012). D4Z4 
repeats have extremely high GC content, compared to the rest of the genome (Ehrlich et al. 
2007), and hypomethylation has been found associated with facioscapulohumeral muscular 
dystrophy (FSHD) (van der Maarel et al. 2012), immunodeficiency, centromeric region 
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instability, and facial anomalies (ICF) syndrome (Kondo et al. 2000). However, in cancer tissues 
conflicting results ranging from hypomethylation to hypermethylation have been described 
(Cadieux et al. 2006, Cheng et al. 2004, Choi et al. 2009, Fraga et al. 2005b, Katargin et al. 
2009, Tsumagari et al. 2008, Martinez et al. 2012). One study showed D4Z4 hypermethylation in 
UCB tissues compared to normal and adjacent normal tissues (Choi et al. 2009). 
The predictors of D4Z4 methylation are unknown, and no population study has 
systematically addressed the role of D4Z4 methylation in UCB and its interaction with 
environmental and genetic factors. Thus, the objectives of this study were to identify the 
predictors of D4Z4 methylation in granulocyte DNA, to assess the association between D4Z4 
methylation and UCB risk, and to explore effect modifications by selected personal, lifestyle, 
nutritional, environmental and genetic factors. 
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Methods 
Study population: Individuals involved in the present analysis come from the Spanish 
Bladder Cancer/EPICURO Study. This is a large case-control study of 1219 cases and 1271 
controls conducted between 1998 and 2001 in five regions of Spain (Asturias, Barcelona, Elche, 
Tenerife, and Valles). Details on methods of the study have been described elsewhere (Garcia-
Closas et al. 2005, Samanic et al. 2006). Cases were incident UCB between 20 and 81 years of 
age. Diagnosis for each patient was verified by a panel of expert pathologists according to the 
1998 ISUP/WHO classification system (Epstein et al. 1998). Controls were patients admitted to 
the same hospital as in cases for reasons not associated with exposures of interest. Controls were 
individually matched for age (± 5 years), gender, and region to cases. A total of 736 cases and 
740 controls had enough bisulfite-modified DNA for the quantification of D4Z4 methylation 
levels at six CpG sites. Of these, 23 cases and 22 controls were excluded because of missing 
values in at least one of the six CpG sites. Three cases were excluded because of missing data in 
age and gender. To limit heterogeneity, three non-white cases were also excluded from the 
analyses. For this analysis, the final study population was 707 cases and 718 controls. Using a 
computer-assisted personal interview, data on demographic and personal characteristics were 
collected. Data on B vitamins, fruit and vegetable, protein and alcohol intake were assessed using 
food frequency questionnaires (Garcia-Closas et al. 2007b). Written informed consent was 
obtained from each study participant before interview, and the study was approved by the US 
National Cancer Institute and local institutional review boards. 
D4Z4 methylation quantification using pyrosequencing: DNA isolated from 
granulocytes by standard methods was treated with sodium bisulfite using EZ-96 DNA 
METHYLATION-GOLDTM KIT (Zymo Research, Irvin, CA, USA), following the 
manufacturer’s protocol. PCR amplification of bisulfite-modified DNA was carried out using a 
set of forward primer (GGTGGTTYGGGGTAGGG), reverse primer (biotin-
CCCAAAAAAAAATAACAATTCTC), and sequencing primer 
(GGGAATATTTGGTTGGTTA) reported previously (Martinez et al. 2012). The 
pyrosequencing reaction was performed using PyroMarkTM Q24 System (QIAGEN, Valencia, 
CA, USA) according to the manufacturer’s recommendations. The methylation level at six CpG 
sites next to the sequencing primer was measured and the results were calculated by PyroMarkTM 
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Application Software version 2.0.6 (QIAGEN, Valencia, CA, USA). Bisulfite treatment of DNA 
converted unmethylated cytosine to uracil, which becomes thymine upon pyrosequencing, while 
the methylated cytosine remains unchanged. The mean D4Z4 methylation level at each of the six 
CpG positions was expressed as a percentage of unconverted methylated cytosine (C) over the 
total number of unconverted cytosine and thymine (T) ─ (C/C+T)*100%. As a quality control 
measure, 224 samples (121 cases and 103 controls) were run in duplicates and the within sample 
coefficient of variation was 0.88%. 
Genotyping: We selected 496 SNPs with minor allele frequency greater than or equal to 
5% from 24 candidate genes (ALDH1L1, AS3MT, ATIC, BHMT, CBS, CHDH, CTH, DHFR, 
DNMT1, DNMT3A, DNMT3B, FOLH1, GART, GNMT, MTHFD, MTHFR, MTHFS, MTR, 
MTRR, PEMT, SHMT1, SLC19A1, TCN2, TYMS), which are known to play a role in the one-
carbon metabolism pathway, DNA methylation and arsenic metabolism. Methods of genotyping 
have been previously described (Garcia-Closas et al. 2005, Garcia-Closas et al. 2007a, Rothman 
et al. 2010). All SNPs were in Hardy-Weinberg equilibrium (p-value > 0.05). Additionally, data 
on copy number variation in xenobiotic-metabolizing genes GSTM1 [present (++/+-) and null (--) 
genotypes], GSTT1 [present (++/+-) and null (--) genotypes], and NAT2 acetylator phenotype 
(rapid/intermediate and slow) were also included in the analyses. 
Trace elements analysis: Toenails were collected to measure the concentration of 12 
trace elements (aluminum, arsenic, cadmium, chromium, copper, iron, lead, manganese, nickel, 
selenium, vanadium, and zinc). After cleaning and washing, individual trace elements were 
quantified using inductively coupled plasma-mass spectrometry. Sample preparations, quality 
controls, and measurement of trace elements have been previously described in detail (Amaral et 
al. 2012c).   
FGFR3 mutation and expression analysis: Methods of FGFR3 mutation analysis have 
been previously reported (Hernandez et al. 2005, Hernandez et al. 2006). In brief, exon 7 was 
amplified in all NMIBC cases and exon 10 was amplified in all but nine cases with exon 7 
mutations, using PCR. Mutational analysis in MIBC cases was performed using a SNAPShot 
assay for the 13 most common FGFR3 mutations (van Oers et al. 2006, Hafner et al. 2006, 
Hafner et al. 2010). 
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Details on the FGFR3 expression analysis have been previously reported (Amaral et al. 
2012b). Briefly, tissue microarrays were made using formalin-fixed paraffin-embedded tissue of 
the UCB cases recruited to the SBC/EPICURO Study. For immunohistochemistry staining, the 
monoclonal antibody B9 was used as primary antibody and the Envision+ anti-mouse reagent 
was applied as secondary antibody (DAKO, Copenhagen, Denmark). The proportion of reactive 
cells (0-100%) and staining intensity (1+ to 3+) were assessed by a uropathologist. A histoscore 
was calculated by multiplying the percentage of reactive cells by the intensity. Cut-off definition: 
high expression was defined by a histoscore >30. 
Statistical methods: D4Z4 methylation level from the six CpG sites was averaged. To 
identify predictors of D4Z4 methylation among the control subjects, robust linear regression 
models were fitted to estimate unadjusted and multivariable adjusted beta coefficients (βs) and 
95% confidence intervals (CIs). The multivariable models were initially adjusted for age, gender, 
and region, and further adjustment was done by including smoking status into the models. 
Potential methylation predictors considered were age, gender, region, smoking status (never, 
occasional, former and current), tobacco type (never, blond tobacco only, black tobacco only, 
both types and unknown), number of cigarettes smoked per day, duration of cigarette smoking in 
years, pack-years, nutrient intake, body mass index (<25.0, 25-29.9 and ≥ 30.0), trace elements, 
and genotypes. 
Individuals were subsequently classified into two categories by the median of D4Z4 
methylation level (64.4%) among the control subjects. Methylation level below the median was 
used as the referent category. Continuous covariates were compared between categories (case-
control status) by the Mann-Whitney rank test and categorical covariates using the chi-square 
test. Logistic models, unadjusted and adjusted for age, gender, region, and smoking status, were 
used to estimate odds ratio (ORs) and 95% CIs for the association between D4Z4 methylation 
and UCB risk.  
We further tested effect modification of the association between D4Z4 methylation and 
risk of UCB by several non-genetic and genetic factors (e.g, age, gender, smoking, nutrient 
intakes, toenail trace elements and SNPs in genes involved in the one-carbon metabolism 
pathway). Interactions between D4Z4 methylation and these factors were tested by including the 
respective multiplicative interaction term in the multivariable adjusted logistic regression models. 
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The likelihood ratio test was used to compare the model with and without the interaction term 
and to calculate the p-value for the interaction. Because 496 SNPs (four modes of inheritance: 
additive, co-dominant, dominant, recessive) were checked for interaction with D4Z4 methylation, 
each interaction p-value was corrected for multiple testing using a permutation test. Briefly, this 
test was done by randomly shuffling the case-control status 10,000 times in a proportion similar 
to the distribution in the current analysis. The minimum p-value was recorded for each of 10,000 
replicates and the corrected chi-square p-values were estimated as the proportion of replication p-
values less than the corresponding uncorrected p-value.  
Multinomial logistic regression models were applied to assess the association between 
D4Z4 methylation and the different UCB clinicopathological and molecular subtypes: low-grade 
NMIBC, high-grade NMIBC, and MIBC; tumors with wild type and mutant FGFR3; tumors with 
low and high FGFR3 expression levels. Adjustment was performed for the same variables 
included in the logistic regression models. Heterogeneity between the respective risk estimates 
was assessed using the likelihood ratio test, comparing models with and without the OR 
constrained to be equal for the corresponding case groups. All tests were two-sided and p-value ≤ 
0.05 was considered significant. Statistical analyses were performed by STATA/SE version 10.1 
(StataCorp, College Station, TX, USA). 
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Results 
The characteristics of the 707 UCB cases and 718 controls included in the present study 
are shown in Table 5-1. Although not statistically significant, the median (interquartile range) 
D4Z4 methylation level was slightly higher in cases than in controls [65.6% (13.7) vs. 64.4% 
(13.6), p-value = 0.2]. The mean (standard deviation) of D4Z4 methylation level among cases 
and controls were 64.3% (10.1) and 63.6% (9.9), respectively. 
Predictors of D4Z4 methylation 
The levels of D4Z4 methylation were lower among females (β = -3.3; 95%CI -6.0 to -0.6, 
p-value = 0.02), smokers of blond tobacco, when compared to never smokers (β = -3.7; 95%CI -
6.5 to -0.9, p-value = 0.01), and was strongly inversely associated with toenail selenium 
concentration (adjusted β for a 1-µg/g increase = -8.1; 95%CI -12.7 to -3.5, p-value = 0.0006) 
(Table 5-2). On the other hand, arsenic showed a trend towards positive association with D4Z4 
methylation levels (adjusted β for a 1-µg/g increase = 13.3; 95%CI -0.9 to 27.4, p-value = 0.07). 
None of the other potential predictors included in the analyses were significantly associated with 
D4Z4 methylation level (Supplementary Table 5-1). Results from the multivariable model 
adjusted for age, gender and region only were not different from the association above 
(Supplementary Table 5-2). 
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Table 5-1 Characteristics of controls and cases with D4Z4 methylation data in the Spanish 
Bladder Cancer/EPICURO Study 
Characteristic Controls (n = 718) Cases (n = 707) P-value* 
Age in years, median (IQR) 66 (13) 68 (13) 0.0001 
Gender, n (%)       
Male 642 (89.4) 617 (87.3) 0.2 
Female 76 (10.6) 90 (12.7)   
Region, n (%)       
Barcelona 130 (18.1) 128 (18.1) 0.99 
Valles 117 (16.3) 113 (16.0)   
Elche 58 (8.1) 55 (7.8)   
Tenerife 122 (17.0) 120 (17.0)   
Asturias 291 (40.5) 291 (41.1)   
Smoking status, n (%)†       
Never 206 (28.8) 102 (14.5) <0.0001 
Occasional 53 (7.4) 30 (4.3)   
Former 261 (36.5) 266 (38.0)   
Current 195 (27.3) 303 (43.2)   
Tumor type, n (%)‡       
Low-grade NMIBC (TaG1/G2) ─ 382 (57.8)   
High-grade NMIBC (TaG3/T1) ─ 139 (21.1)   
MIBC (≥T2) ─ 139 (21.1)   
FGFR3 expression§       
Low (< 30%) ─ 239 (59.3)   
High (≥ 30%) ─ 164 (40.7)   
FGFR3 mutation status¶       
Wild type ─ 313 (59.4)   
Mutant ─ 214 (40.6)   
D4Z4 methylation level       
Median (IQR), in %† 64.4 (13.6) 65.6 (13.7) 0.2 
IQR, interquartile range; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive 
bladder cancer 
*Mann-Whitney test for age and D4Z4 methylation levels; Chi-square test for categorical 
variables. 
† Six cases and three controls have missing information on smoking status. 
‡ Forty-two cases could not be assigned to any T-G group because the paraffin blocks could not 
be retrieved and five cases were carcinoma in situ. 
§Three hundred four cases have missing FGFR3 expression data. 
¶One hundred eighty cases have missing data on FGFR3 mutation status. 
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Table 5-2 Significant predictors of D4Z4 methylation level among the control population in the Spanish Bladder Cancer/EPICURO 
Study 
Characteristic N D4Z4 methylation (%) Unadjusted model N Adjusted* Mean SD Median IQR β 95% CI P-value β 95% CI P-value 
Gender                             
Male 642 63.9 9.8 64.9 13.8 Reference       639 Reference       
Female 76 61.5 10.4 61.7 11.3 -2.4 -4.8 -0.1 0.04 76 -3.3 -6.0 -0.6 0.02 
Tobacco type                             
Never 206 63.7 9.9 64.4 12.7 Reference       206 Reference       
Blond tobacco only 82 61.6 11.0 61.4 17.5 -2.3 -4.9 0.3 0.08 82 -3.7 -6.5 -0.9 0.01 
Black tobacco only 171 64.3 9.4 65.6 11.5 0.6 -1.4 2.7 0.6 171 -0.4 -2.7 1.8 0.7 
Both types 126 63.7 10.1 65.6 13.8 0.2 -2.1 2.4 0.9 126 -0.9 -3.3 1.6 0.5 
Unknown 78 63.1 10.3 63.7 14.6 -0.9 -3.5 1.7 0.5 78 -2.2 -5.0 0.6 0.1 
Toenail trace element                         
Selenium, µg/g 521 ─ ─ ─ ─ -4.8 -11.1 1.5 0.1 521 -8.1 -12.7 -3.5 0.0006 
SD, standard deviation; IQR, interquartile range.                     
*Adjusted for age, gender, region, and smoking status (never, occasional, former and current smoker). Beta coefficients of tobacco type 
are adjusted for age, gender and region. 
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D4Z4 methylation and risk of UCB 
There was a borderline significantly increased risk of UCB among individuals with D4Z4 
methylation above or equal to the median compared to those with lower than the median 
(adjusted OR = 1.23; 95%CI 0.99 - 1.53, p-value = 0.06; Table 5-3). We also assessed whether 
the methylation level at each of the six CpG positions were individually associated with UCB 
risk. Similar patterns of risk estimates to the average D4Z4 methylation were observed 
(Supplementary Table 5-3). 
Statistically significant interactions impacting on this association were observed between 
D4Z4 hypermethylation and toenail iron (p-interaction = 0.003), manganese (p-interaction = 
0.04), and zinc (p-interaction = 0.01). The increased risk associated with D4Z4 hypermethylation 
was found to be significantly higher among subjects with lower levels of toenail iron and 
manganese and higher toenail levels of zinc (Table 5-4). There was no significant interaction 
between D4Z4 methylation and age, gender, smoking status, type of tobacco smoked, number of 
cigarettes smoked per day, duration of cigarette smoking, pack-years, nutrients and nine other 
trace elements (Supplementary Tables 5-4 and 5-5). 
A SNP rs11040387G>A located at the flanking 5' UTR of the folate hydrolase (prostate-
specific membrane antigen) 1 (FOLH1) significantly modified the effect of increased D4Z4 
methylation on UCB risk (p-interaction = 0.02, after correction for multiple testing). There was a 
3.5-fold significantly increased risk of UCB among subjects who carried at least one copy of the 
minor allele (OR = 3.51; 95%CI 1.95 - 6.44, p-value = 5.1 x 10-5) (Table 5-5). The rest of the 
SNPs that did not show significant interaction with D4Z4 methylation are shown in 
Supplementary Table 5-6, with the corresponding uncorrected and corrected p-values for multiple 
testing.  
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Table 5-3 Association between D4Z4 methylation level and urothelial carcinoma of the bladder 
risk stratified by clinicopathological and molecular subphenotypes in the Spanish Bladder 
Cancer/EPICURO Study 
D4Z4 Methylation Cases Controls OR 95% CI P-value 
Overall             
Model 1*             
   M1, < 64.4% 328 359 1 Reference   
   M2, ≥ 64.4% 379 359 1.16 0.94 1.42 0.2 
Model 2†             
   M1, < 64.4% 324 358 1 Reference       
   M2, ≥ 64.4% 377 357 1.23 0.99 1.53 0.06 
Tumor type‡             
Low-grade NMIBC             
   M1, < 64.4% 165 358 1 Reference       
   M2, ≥ 64.4% 214 357 1.37 1.06 1.78 0.02 
High-grade NMIBC             
   M1, < 64.4% 65 358 1 Reference       
   M2, ≥ 64.4% 71 357 1.17 0.80 1.71 0.4 
MIBC             
   M1, < 64.4% 73 358 1 Reference       
   M2, ≥ 64.4% 66 357 0.97 0.66 1.42 0.9 
High FGFR3 expression§  
Low-grade NMIBC             
   M1, < 64.4% 46 358 1 Reference       
   M2, ≥ 64.4% 71 357 1.63 1.08 2.47 0.02 
High-grade NMIBC             
   M1, < 64.4% 15 333 1 Reference       
   M2, ≥ 64.4% 6 329 0.46 0.17 1.24 0.1 
MIBC             
   M1, < 64.4% 13 358 1 Reference       
   M2, ≥ 64.4% 13 357 1.19 0.52 2.69 0.7 
M1, D4Z4 methylation level less than the median; M2, D4Z4 methylation level greater than or 
equal to the median; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive 
bladder cancer. 
*Unadjusted logistic regression model. 
†Adjusted for age, gender, region, and smoking status. 
‡P value for heterogeneity: low- vs high-grade NMIBC = 0.4; low-grade NMIBC vs MIBC = 
0.05; high-grade NMIBC vs MIBC=0.4. 
§P value for heterogeneity: low- vs high-grade NMIBC = 0.01; low-grade NMIBC vs MIBC = 
0.4; high-grade NMIBC vs MIBC=0.4. 
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Table 5-4 Association between D4Z4 methylation level and urothelial carcinoma of the bladder 
risk, by toenail concentrations of iron, manganese, and zinc in the Spanish Bladder 
Cancer/EPICURO Study 
D4Z4 Methylation Cases Controls OR* 95% CI P-value P-interaction 
Iron (Fe)               
Fe < 14.534 µg/g               
   M1, < 64.4% 139 149 1 Reference         
   M2, ≥ 64.4% 160 111 1.54 1.08 2.18 0.02   
Fe ≥ 14.534 µg/g               
   M1, < 64.4% 121 113 1 Reference         
   M2, ≥ 64.4% 137 147 0.94 0.65 1.36 0.7 0.003 
Manganese (Mn)               
Mn < 0.333 µg/g               
   M1, < 64.4% 139 138 1 Reference         
   M2, ≥ 64.4% 176 122 1.47 1.04 2.07 0.03   
Mn ≥ 0.333 µg/g               
   M1, < 64.4% 123 124 1 Reference         
   M2, ≥ 64.4% 122 137 0.95 0.65 1.37 0.8 0.04 
Zinc (Zn)               
Zn < 103.016 µg/g               
   M1, < 64.4% 146 125 1 Reference         
   M2, ≥ 64.4% 160 136 1.08 0.76 1.53 0.7   
Zn ≥ 103.016 µg/g               
   M1, < 64.4% 116 137 1 Reference         
   M2, ≥ 64.4% 138 123 1.37 0.95 1.97 0.09 0.01 
M1, D4Z4 methylation level less than the median; M2, D4Z4 methylation level greater than or 
equal to the median. 
* Adjusted for age, gender, region, and smoking status (never, occasional, former and current 
smoker). 
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D4Z4 methylation and risk of urothelial carcinoma of the bladder subphenotypes 
Analyses by tumor subtypes showed differences in the risk associated with higher D4Z4 
methylation level. D4Z4 hypermethylation was significantly associated with risk of low-grade 
NMIBC (OR = 1.37; 95%CI 1.06 - 1.78, p-value = 0.02), and this risk estimate was significantly 
different from that of MIBC (OR = 0.97; 95%CI 0.66 - 1.42, p-value = 0.9) (p heterogeneity = 0.05). 
Moreover we performed stratified analyses by FGFR3 expression level and mutation status in 
UCB tissues. In tumors overexpressing FGFR3, the increased risk of developing low-grade 
NMIBC was markedly elevated by more than 25% (OR = 1.63; 95%CI 1.08 - 2.47, p-value = 
0.02), while the odds ratio associated with high-grade NMIBC was 0.46 (95%CI 0.17 - 1.24, p-
value = 0.1; p heterogeneity = 0.01) (Table 5-3). The association between risk of UCB subtypes and 
D4Z4 methylation based on FGFR3 mutation status (wild type and mutant) was not statistically 
significant (Supplementary Table 5-7).  
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Table 5-5 Association between D4Z4 methylation level and urothelial carcinoma of the bladder risk, by genotype of a single 
nucleotide polymorphism in the folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1) gene in the Spanish Bladder 
Cancer/EPICURO Study 
D4Z4 Methylation Cases Controls OR* 95% CI P-value P-interaction Corrected       p-interaction† 
FOLH1 ─ rs11040387[GG]‡                 
   M1, < 64.4% 273 289 1 Reference           
   M2, ≥ 64.4% 287 308 1.02 0.80 1.31 0.9     
                  
FOLH1 ─ rs11040387[GA/AA]                
   M1, < 64.4% 41 61 1 Reference           
   M2, ≥ 64.4% 79 41 3.51 1.91 6.44 5.1 x 10-5 7.8 x 10-5 0.02 
M1, D4Z4 methylation level less than the median; M2, D4Z4 methylation level greater than or equal to the median. 
* Adjusted for age, gender, region, and smoking status. 
† Interaction p-value corrected for multiple testing using a permutation test. 
‡ Located at the flanking 5' UTR of FOLH1 in chromosome 11p11.12 (human genome build 36.3, location 49 450 312). Minor allele 
frequency = 7%. 
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Discussion and conclusions 
In the present study, we found that gender, type of tobacco and toenail selenium, and 
probably arsenic concentrations are independent predictors of D4Z4 macrosatellite repeat arrays. 
We also observed a slightly increased risk of UCB associated with higher levels of D4Z4 
methylation and that iron, manganese and zinc concentrations and FOLH1-rs11040387 modified 
such association. In addition, we found that the risk of UCB associated with higher levels of 
D4Z4 methylation was higher and significantly associated among low-grade NMIBC and tumors 
overexpressing FGFR3. 
Few evidences exist on predictors of global methylation. The lower D4Z4 methylation in 
females found in the present study are consistent with previous observations of lower level of 
DNA methylation globally and at other repetitive elements such as LINE-1 and Alu (Fuke et al. 
2004, Wilhelm et al. 2010, Hsiung et al. 2007, Zhu et al. 2012, El-Maarri et al. 2007, El-Maarri 
et al. 2011, Zhang et al. 2011, Cash et al. 2011). The association between blond tobacco smoking 
and lower D4Z4 methylation is in agreement with an earlier study that showed blond tobacco 
smokers had lower LINE-1 methylation (see Chapter III). An experimental study investigating 
the effect of cigarette smoke on the epigenome of bronchial epithelial cells reported that chronic 
exposure to cigarette smoke condensate resulted in demethylation, not only at D4Z4 repeats, but 
also at NBL2 and LINE-1 DNA repetitive sequences (Liu et al. 2010). These findings suggest 
that the association of altered DNA methylation with cigarette smoking might be dependent on 
the type of tobacco smoke. The inverse association between toenail selenium concentration and 
D4Z4 methylation is in agreement with a study by Pilsner et al. who reported an inverse 
association between plasma selenium and global DNA methylation (Pilsner et al. 2011). 
Selenium is an essential trace element found in the active sites of selenoproteins and its 
deficiency has been associated with various human diseases, including UCB (Rayman 2012, 
Amaral et al. 2010). 
To the best of our knowledge, this is the first study to report an association between D4Z4 
methylation in granulocyte DNA and UCB risk. This finding builds upon two previous reports 
showing that D4Z4 hypermethylation is observed in UCB tissue and cell lines (Choi et al. 2009, 
Cheng et al. 2004). D4Z4 tandem repeats located in the subtelomeric region of chromosome 4 
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have 11-100 units of D4Z4 each 3.3 kilobase long. Each repeat unit contains a copy of DUX4 
gene, which encodes a transcription factor and a well studied candidate gene for FSHD (Geng et 
al. 2012). It has been shown that DUX4 regulates a host of genes that are involved in various 
cellular processes including oncogenesis, immune function and apoptosis (Geng et al. 2012). 
Additionally, it has been demonstrated that DUX4 activates the transcriptional factor paired-like 
homeodomain 1 (PITX1) gene located in chromosome 5q31.1 (Dixit et al. 2007). PITX1 is a 
tumor-suppressor gene that has been shown to negatively regulate telomerase reverse 
transcriptase (TERT) gene (Qi et al. 2011), and RAS pathway to inhibit tumorigenesis 
(Kolfschoten et al. 2005). Of relevance, a recent genome-wide association study identified a 
common variant at TERT gene as a susceptibility locus to UCB (Rothman et al. 2010). Similarly, 
PITX1 has been also shown to directly activate TP53, itself a tumor-suppressor gene (Liu & 
Lobie 2007). It has been established that RAS and TP53 pathways are frequently altered in 
NMIBC and MIBC, respectively (Cheng et al. 2011, Knowles 2008, Falke & Witjes 2011), and 
reduced PITX1 expression has been found in bladder and other cancer types (Kolfschoten et al. 
2005). DUX4 expression is regulated by DNA methylation and chromatin structures (van der 
Maarel et al. 2012), and hypermethylation of D4Z4 has been shown to be inversely correlated 
with DUX4 expression in human papillomavirus-positive cervical cancer tissues (Katargin et al. 
2009). This indicates that, by suppression of DUX4 expression, D4Z4 hypermethylation might 
result in UCB through dysregulated expression of DUX4 target genes such as PITX1.The 
observation in the current study of DNA hypermethylation in D4Z4 repeats associated with 
increased risk suggests that D4Z4 methylation in peripheral blood cells could be used as a 
biomarker of UCB susceptibility. 
We also found that the effect of D4Z4 hypermethylation was modified by both 
environmental and genetic factors. Specifically iron, manganese, and zinc modified the risk 
conferred by increased D4Z4 methylation. The mechanism through which these trace elements 
could modify the risk is unknown. Iron, manganese and zinc are essential minerals, important for 
cellular homeostasis and protection from oxidative stress (Bleackley & Macgillivray 2011, 
Aguirre & Culotta 2012). Recently, it has been suggested that both acute and chronic oxidative 
stress can induce carcinogenesis through altered DNA methylation and other epigenetic 
modification (Johnstone & Baylin 2010). Iron, together with α-ketoglutarate, is an important 
cofactor for the ten-eleven translocation (TET1, TET2, TET3) family of DNA hydroxylases that 
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convert 5-methylcytosine to 5-hydroxymethylcytosine, a mechanism implicated in active and 
passive DNA demethylation (Tahiliani et al. 2009, Ito et al. 2011). We have recently shown that 
iron is associated with DNA methylation level in LINE-1 repetitive DNA sequences (see Chapter 
III). Like iron and other essential nutrients, zinc also modulates the epigenetic landscape. 
Betaine-homocysteine S-methyltransferase requires zinc as a cofactor to catalyze the transfer of 
methyl group from betaine to homocysteine to produce methionine, a precursor of S-adenosyl 
methionine (Ulrey et al. 2005). It has been demonstrated that zinc deficiency caused DNA and 
histone hypomethylation in rat liver (Wallwork & Duerre 1985). 
Furthermore, an interaction between D4Z4 methylation and rs11040387 located in the 
flanking 5’ UTR of FOLH1 was also observed in the present study. FOLH1, also known as 
glutamate carboxypeptidase II (Gene ID: 2346), is a type II transmembrane glycoprotein 
expressed in the membrane brush boarder of the proximal small intestine where it regulates folate 
absorption by catalyzing the hydrolysis of folate poly-γ-glutamates into monoglutamate 
derivatives (Heston 1997). A missense mutation in FOLH1 has been associated with abnormal 
plasma folate and total homocysteine concentrations, and altered enzyme activity (Halsted et al. 
2007), mechanisms through which common variations at this gene could result in impaired one-
carbon metabolism. FOLH1 is also found to be overexpressed in a multitude of solid tumors and 
their neovasculatures including UCB (Samplaski et al. 2011) where it is suggested to regulate 
angiogenesis by increasing the local concentration of folate, which in turn increases the 
production of the proangiogenic molecule nitric oxide by stimulating regeneration of the 
endothelial nitric oxide synthase cofactor, tetrahydrobiopterin (Gordon et al. 2008). In prostate 
cancer, overexpression is associated with advanced disease stage and poor prognosis (Samplaski 
et al. 2011). The SNP discussed above has not been previously reported in relation to UCB. 
The limitations of this study include the fact that blood samples were collected at time of 
diagnosis, although before the interview and initiation of treatment. The fact that most of UCB 
does not affect general performance supports the use of D4Z4 methylation as a long-term marker. 
Not all study subjects from the SBC/EPICURO Study had their D4Z4 methylation levels 
measured, and controls with this data were slightly younger and over-represented by males. 
However, comparing cases with and without D4Z4 methylation showed no significant differences 
between them (Supplementary Table 5-8). Importantly, the study also has important strengths. 
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Two of these are its large sample size and the multi-level integration of data including 
epidemiologic, clinical, environmental and genetic variables. Another strength of the study was 
the choice of pyrosequencing as the method to quantify D4Z4 methylation levels, which seems to 
provide highly reproducible and accurate results (Tost & Gut 2007). Samples were run in 
duplicates and the within sample coefficient of variation was 0.88%. 
To our knowledge, this is the first study showing that gender, tobacco type and selenium 
may independently predict the levels of D4Z4 methylation, and that D4Z4 hypermethylation 
increases the risk of low-grade NMIBC and FGFR3 overexpressing tumors. In addition, it is 
shown that the association between D4Z4 hypermethylation and risk of UCB can be modified by 
non-genetic (iron, manganese, and zinc) and genetic (FOLH1-rs11040387) factors. Therefore, 
measuring D4Z4 methylation in peripheral blood could be a potential biomarker of UCB 
susceptibility. The fact that D4Z4 hypermethylation is associated with specific UCB 
subtyphenotypes characterized by clinicopathological and molecular markers might imply the 
presence of a D4Z4 methylator phenotype of UCB. Further studies are required in larger 
populations to extend and replicate our findings. Moreover, experimental studies should be 
conducted to elucidate the consequences of D4Z4 hypermethylation in the bladder 
carcinogenesis. 
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Abstract 
Altered DNA methylation is an early event in the development of urothelial carcinoma of 
the bladder (UCB). We hypothesized that it might also impact on disease progression and 
assessed the association between genomic DNA methylation in granulocytes and UCB outcomes 
in the Spanish Bladder Cancer/EPICURO study. Methylation levels in DNA repeats - LINE-1 (N 
= 895) and D4Z4 (N = 665) - were measured by using pyrosequencing in newly diagnosed UCB 
patients that were followed-up for over 10 years. Primary diagnosis were homogeneously 
confirmed and classified by a panel of expert pathologists. Clinical and treatment data were 
collected from hospital charts. Association between methylation and UCB outcomes (recurrence, 
progression, relapse, mortality) was assessed by using unadjusted and adjusted Cox proportional 
hazards regression models. Neither LINE-1 nor D4Z4 methylation levels were significantly 
associated with recurrence, progression, or relapse in non-muscle-invasive bladder cancer 
patients, and progression, bladder cancer-specific or overall mortality in muscle-invasive bladder 
cancer patients. This is the first study to assess the association between LINE-1 and D4Z4 
methylation and UCB outcomes. The results of do not support genomic DNA methylation in 
granulocytes as an independent prognostic factor in UCB patients.  
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Introduction 
Patients with urothelial carcinoma of the bladder (UCB) present as non-muscle-invasive 
(NMIBC, 80%) or muscle-invasive bladder cancer (MIBC, 20%) at the time of diagnosis. 
NMIBC is characterized by increased rate of recurrence, few experiencing progression to muscle-
invasive disease. Clinicopathological parameters are commonly used for prognostication of the 
disease. However, they lack accuracy and novel markers are needed to improve prognostic 
accuracy (Netto 2012). Aberrant DNA methylation occurs early in the development of several 
cancer types including UCB and is considered a hallmark of cancer (Kim & Kim 2012). 
Hypomethylation of retrotransposons such as long interspersed nuclear elements 1 (LINE-1) and 
hypermethylation of the subtelomeric tandem repeat element D4Z4 have been observed in UCB 
(Neuhausen et al. 2006, Choi et al. 2009). Moreover, LINE-1 hypomethylation and promoter 
hypermethylation of specific genes in the tumor tissue have been shown to associate with 
significantly shorter UCB recurrence-free and disease-specific survival time (Kim & Kim 2012, 
Neuhausen et al. 2006).  
Altered DNA methylation in peripheral blood cells has been associated with elevated risk 
of developing UCB (Moore et al. 2008, Wilhelm et al. 2010, Cash et al. 2012). However, its 
effect on disease progression and mortality has not been studied. Here, we assessed the 
association between methylation levels at LINE-1 and D4Z4 sequences measured in granulocyte 
DNA and UCB outcomes, and whether this association is modified by selected factors. 
 
Methods 
Details of the study population, design, data collection, genotyping have been described 
elsewhere (Garcia-Closas et al. 2005, Rothman et al. 2010). After written informed consent and 
institutional review board approval, blood was drawn for DNA extraction at the time of diagnosis 
and before treatment. Patients were incident cases of UCB recruited from non-referral hospitals 
located in five regions of Spain. Diagnosis, tumor grade and stage were confirmed by a panel of 
expert pathologists. During follow-up, data on vital status, recurrence, progression and relapse 
were collected by trained nurses through telephone interviews and individual patient’s hospital 
charts. By pyrosequencing, the methylation levels of four CpG sites at LINE-1 and six CpG sites 
at D4Z4 elements were measured (see chapters III and V for details of methylation 
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quantifications). The average methylation level of the CpG sites for each repeat sequence was 
used in the final analysis.  
We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 
95% confidence intervals (95%CI) for each outcome: recurrence, progression, and relapse (event-
free survival) in NMIBC, and progression, disease-specific, and overall mortality in MIBC. 
LINE-1 methylation level was modeled as: (i) a continuous variable; (ii) categorized by the 
median; and (iii) in tertiles. D4Z4 methylation was modeled as: (i) a continuous variable and (ii) 
categorized by the median. Methylation level less than the median value (LINE-1 and D4Z4) and 
the middle tertile (LINE-1) were used as the reference group. Multiplicative interaction between 
DNA methylation and selected genetic and non-genetic variables was also assessed. We checked 
the Cox proportional hazards assumptions by plotting log-log survival curves for LINE-1 and 
D4Z4 methylation levels, by performing the time-dependent covariate test, and the scaled 
Schoenfeld residuals method. The proportional hazard assumptions were not violated (P value 
>0.05). P values less than or equal to 0.05 were considered to indicate statistical significance. All 
tests were two-sided. STATA/SE software, version 10.1 (StataCorp, College Station, Texas) was 
used for all statistical analyses. This study had an estimated power of 80% to detect HRs of 1.25 
and 1.40 associated with a methylation level above the median for all outcomes considered in 
NMIBC and MIBC patients, respectively. Power estimation was performed using Epi Info 
software, version 7.1.1.14 (CDC, Atlanta, Georgia). 
 
Results 
Patient characteristic stratified by LINE-1 and D4Z4 methylation levels are shown in 
Supplementary Tables S6-1 and S6-2. Median follow-up time for NMIBC patients with LINE-1 
and D4Z4 data was 76.1 and 76.2 months, and for MIBC patients was 23.3 and 25.5 months, 
respectively. In NMIBC patients, characteristics were similarly distributed across the different 
strata of LINE-1 methylation and D4Z4 methylation, except age which was directly associated 
with LINE-1 methylation. Characteristics of MIBC patients were also similarly distributed, with 
the exception of age and sex that were associated with D4Z4 methylation.  
LINE-1 methylation was not associated with outcomes in both NMIBC and MIBC 
patients in unadjusted and adjusted Cox regression models (Table 6-1). Likewise, D4Z4 
methylation was not associated with outcomes in both NMIBC and MIBC patients (Table 6-2). 
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Stratified analyses by FGFR3 mutation levels and expression status were also nonsignificant 
(data not shown). Furthermore, we found no effect modification by each of the following: 
smoking status, tobacco type, nutrient intakes, combined tumor stage and grade, type of 
treatment, 461 single nucleotide polymorphisms in 24 one-carbon metabolism pathway genes, 
NAT2 acetylation phenotype (rs1495741), GSTM1 and GSTT1 copy number variations, and UCB 
susceptibility loci (data not shown) (Rothman et al. 2010). 
 
103 
 
Table 6-1 Association between LINE-1 methylation in leukocyte DNA and outcomes of urothelial carcinoma of the bladder in the Spanish Bladder 
Cancer/EPICURO study 
LINE-1 
methylation* 
No. of 
Events 
Total No. 
of Patients HR (95% CI)† 
P- No. of 
Events 
Total No. 
of Patients 
Adjusted HR 
(95% CI)‡ 
P- 
Value Value 
NMIBC                 
Recurrence                 
Continuous 231 706 1.00 (0.97-1.02) 0.7 216 655 0.99 (0.97-1.02) 0.5 
M1 121 353 1 Reference   116 329 1 Reference   
M2 110 353 0.88 (0.68-1.14) 0.3 100 326 0.82 (0.62-1.08) 0.2 
T1 83 236 1.20 (0.88-1.65) 0.2 81 221 1.40 (1.00-1.95) 0.05 
T2 73 235 1 Reference   66 216 1 Reference   
T3 75 235 1.05 (0.76-1.45) 0.8 69 218 1.06 (0.75-1.50) 0.7 
Progression                 
Continuous 66 706 1.01 (0.98-1.05) 0.5 58 667 1.02 (0.98-1.07) 0.3 
M1 29 353 1 Reference   26 334 1 Reference   
M2 37 353 1.29 (0.79-2.10) 0.3 32 333 1.29 (0.75-2.20) 0.4 
T1 20 236 1.11 (0.59-2.10) 0.7 18 224 1.52 (0.74-3.13) 0.3 
T2 18 235 1 Reference   14 219 1 Reference   
T3 28 235 1.59 (0.88-2.88) 0.1 26 224 2.28 (1.15-4.51) 0.02 
Relapse                 
Continuous 277 706 0.99 (0.98-1.02) 0.6 256 667 0.99 (0.97-1.02) 0.6 
M1 143 353 1 Reference   135 334 1 Reference   
M2 134 353 0.91 (0.72-1.15) 0.4 121 333 0.88 (0.68-1.12) 0.3 
T1 99 236 1.22 (0.92-1.63) 0.2 95 224 1.43 (1.05-1.94) 0.02 
T2 86 235 1 Reference   76 219 1 Reference   
T3 92 235 1.10 (0.82-1.47) 0.5 85 224 1.18 (0.86-1.62) 0.3 
MIBC                 
Progression                 
Continuous 108 189 1.01 (0.98-1.03) 0.7 108 189 1.01 (0.98-1.04) 0.4 
M1 52 95 1 Reference   52 95 1 Reference   
M2 56 94 1.05 (0.72-1.53) 0.8 56 94 0.89 (0.60-1.33) 0.6 
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Table 6-1 (cont.) Association between LINE-1 methylation in leukocyte DNA and outcomes of urothelial carcinoma of the bladder in the Spanish 
Bladder Cancer/EPICURO study 
LINE-1 
Methylation* 
No. of 
Events 
Total No. of 
Patients HR (95% CI)† 
P- No. of 
Events 
Total No. of 
Patients 
Adjusted HR (95% 
CI)‡ 
P- 
Value Value 
T1 33 63 0.86 (0.54-1.37) 0.5 33 63 0.90 (0.53-1.51) 0.7 
T2 39 63 1 Reference   39 63 1 Reference   
T3 36 63 0.93 (0.59-1.47) 0.8 36 63 0.76 (0.46-1.26) 0.3 
BCSM                 
Continuous 91 189 1.00 (0.97-1.03) 0.9 91 189 1.01 (0.98-1.04) 0.6 
M1 42 95 1 Reference   42 95 1 Reference   
M2 49 94 1.17 (0.78-1.77) 0.4 49 94 1.06 (0.68-1.64) 0.8 
T1 31 63 1.18 (0.71-1.97) 0.5 31 63 1.10 (0.63-1.94) 0.7 
T2 28 63 1 Reference   28 63 1 Reference   
T3 32 63 1.21 (0.73-2.01) 0.5 32 63 1.00 (0.57-1.75) 1.0 
OM                 
Continuous 129 189 0.99 (0.97-1.02) 0.6 129 189 1.00 (0.97-1.02) 0.9 
M1 64 95 1 Reference   64 95 1 Reference   
M2 65 94 1.03 (0.73-1.45) 0.2 65 94 0.85 (0.59-1.23) 0.4 
T1 43 63 1.07 (0.70-1.63) 0.8 43 63 1.03 (0.65-1.63) 0.9 
T2 42 63 1 Reference   42 63 1 Reference   
T3 44 63 1.09 (0.71-1.66) 0.7 44 63 0.86 (0.54-1.37) 0.5 
HR, hazard ratio; Ref, referent; NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; M, median; T, tertile; 
BCSM, bladder cancer-specific mortality; OM, overall mortality. 
*Cutoff values used to categorize LINE-1 methylation in medians (57.6%), tertiles (56.6 and 58.9%) in NMIBC cases, and median (57.7%) and 
tertile (56.7 and 59.5%) in MIBC cases. 
†Crude model. 
‡Models adjusted for commonly used prognostic factors for urothelial carcinoma of the bladder. NMIBC recurrence adjusted for sex, residential 
area, tumor stage and grade, tumor size, multiplicity, and treatment; NMIBC progression adjusted for age, residential area, tumor stage and grade, 
multiplicity, number of recurrences, and treatment; NMIBC relapse adjusted for age, residential area, tumor stage and grade,  tumor size, 
multiplicity, and treatment; MIBC progression adjusted for residential area, tumor stage, nodal metastases, and treatment; MIBC disease specific 
and overall survival adjusted for residential area, tumor stage, nodal metastases, distant metastases, and treatment. 
105 
 
Table 6-2 Association between D4Z4 methylation in leukocyte DNA and outcomes of urothelial carcinoma of the bladder in the 
Spanish Bladder Cancer/EPICURO study 
D4Z4 Methylation* No. of Events 
Total No. of 
Patients HR (95% CI)† 
P- No. of 
Events 
Total No. of 
Patients 
Adjusted HR 
(95% CI)‡ 
P- 
Value Value 
NMIBC                 
Recurrence                 
Continuous 174 526 1.01 (0.998-1.03) 0.09 163 487 1.01 (0.99-1.03) 0.2 
M1 78 263 1 Reference   75 240 1 Reference   
M2 96 263 1.29 (0.96-1.74) 0.1 88 247 1.20 (0.87-1.64) 0.3 
Progression                 
Continuous 50 526 1.00 (0.98-1.03) 0.8 43 494 1.01 (0.98-1.04) 0.6 
M1 25 263 1 Reference   20 245 1 Reference   
M2 25 263 0.99 (0.57-1.73) 1.0 23 249 1.28 (0.68-2.41) 0.5 
Relapse                 
Continuous 207 526 1.01 (0.997-1.02) 0.1 191 494 1.01 (0.996-1.03) 0.2 
M1 96 263 1 Reference   88 245 1 Reference   
M2 111 263 1.21 (0.92-1.59) 0.2 103 249 1.24 (0.92-1.66) 0.2 
MIBC                 
Progression                 
Continuous 75 139 1.00 (0.98-1.02) 0.9 75 139 0.99 (0.97-1.02) 0.5 
M1 37 70 1 Reference   37 70 1 Reference   
M2 38 69 0.99 (0.63-1.56) 1.0 38 69 0.95 (0.57-1.58) 0.8 
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Table 6-2 (cont.) Association between D4Z4 methylation in leukocyte DNA and outcomes of urothelial carcinoma of the bladder in the 
Spanish Bladder Cancer/EPICURO study 
D4Z4 Methylation* No. of Events 
Total No. of 
Patients HR (95% CI)† 
P- No. of 
Events 
Total No. of 
Patients 
Adjusted HR 
(95% CI)‡ 
P- 
Value Value 
MIBC                 
BCSM                 
Continuous 65 139 1.00 (0.98-1.03) 0.8 65 139 0.99 (0.96-1.02) 0.4 
M1 30 70 1 Reference   30 70 1 Reference   
M2 35 69 1.13 (0.69-1.83) 0.3 35 69 1.00 (0.59-1.70) 1.0 
OM                 
Continuous 94 139 1.00 (0.97-1.02) 0.7 94 139 0.98 (0.96-1.01) 0.2 
M1 45 70 1 Reference   45 70 1 Reference   
M2 49 69 1.03 (0.69-1.55) 0.9 49 69 0.96 (0.62-1.48) 0.9 
HR, hazard ratio; Ref, referent; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer; M, median; 
BCSM, bladder cancer-specific mortality; OM, overall mortality. 
*Cutoff values used to categorize D4Z4 methylation in medians 65.8% in NMIBC cases, and 63.9% in MIBC cases. 
†Crude model. 
‡Models adjusted for commonly used prognostic factors for urothelial carcinoma of the bladder. NMIBC recurrence adjusted for sex, 
residential area, tumor stage and grade, tumor size, multiplicity, and treatment; NMIBC progression adjusted for age, residential area, 
tumor stage and grade, multiplicity, number of recurrences, and treatment; NMIBC relapse adjusted for age, residential area, tumor 
stage and grade,  tumor size, multiplicity, and treatment; MIBC progression adjusted for residential area, tumor stage, nodal 
metastases, and treatment; MIBC disease specific and overall survival adjusted for residential area, tumor stage, nodal metastases, 
distant metastases, and treatment. 
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Discussion and conclusions 
In this study, we aimed to assess the association between genomic DNA methylation and 
UCB outcomes and the potential effect modification by factors that contribute to UCB 
development and prognosis. Neither LINE-1 nor D4Z4 methylation was associated with any 
outcome in NMIBC and MIBC. Although previous studies have reported significant associations 
between tumor tissue LINE-1 and gene promoter methylation and UCB survival (Neuhausen et 
al. 2006, Kim & Kim 2012), the present findings do not support the use of LINE-1 and D4Z4 
methylation levels in neutrophils as independent prognostic markers for UCB. While this is a 
large study, it is the first to assess the association between genomic LINE-1 and D4Z4 
methylation and UCB survival. Therefore, independent studies are required to confirm the null 
results on DNA methylation in peripheral blood cells as a potential prognostic marker for UCB. 
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CHAPTER VII. GENERAL DISCUSSION 
DNA methylation and other epigenetic modifications are important for normal cellular 
differentiation and development. These modifications are influenced by both the internal and 
external environment; when these modifications go awry, they result in phenotypic and 
physiological changes potentially altering the risk of some diseases (Tammen et al. 2012). In 
brief, the objectives of this thesis were to identify potential genetic and non-genetic predictors of 
genomic DNA methylation at LINE-1 and D4Z4 repeat sequences in granulocytes; to assess the 
association between genomic DNA methylation and risk of UCB; and to determine the 
prognostic role of genomic DNA methylation on UCB outcomes. This thesis also aimed at 
evaluating effect modifications on both disease risk and survival by known and potential risk 
factors of UCB. 
Gender, tobacco type, trace elements (arsenic, iron, and nickel), and some single 
nucleotide polymorphisms (SNPs) in one-carbon metabolism pathway genes (DNMT3A, AS3MT, 
MTHFS, SLC19A1, and TCN2) were associated with levels of LINE-1. D4Z4 methylation levels 
were associated with gender, tobacco type and selenium. Females presented with lower levels of 
both LINE-1 and D4Z4 methylation levels. Arsenic, iron, and nickel were associated with LINE-
1 methylation, the latter two positively. Selenium was inversely associated with D4Z4 
methylation levels. Among common genetic variants evaluated, seven SNPs (DNMT3A-
rs7581217, AS3MT-rs7085104, MTHFS-rs1380642, SLC19A1-rs914238, TCN2-rs9621049, 
TCN2-rs9606756, and TCN2-rs4820887) showed association with LINE-1 methylation levels. 
Regarding risk of UCB, LINE-1 showed a U-shaped association, which was modified by five 
genetic variants (rs2124344, rs7215833, rs4646340, rs4646350, and rs4646341) at 
phosphatidylethanolamine N-methyltransferase (PEMT). D4Z4 hypermethylation was associated 
with low-grade NMIBC overexpressing FGFR3. The effect of D4Z4 methylation on the overall 
risk of UCB was modified by iron, manganese, zinc, and rs11040387 in folate hydrolase 
(prostate-specific membrane antigen) 1 (FOLH1). Neither LINE-1 nor D4Z4 methylation was 
associated with any of the outcomes of UCB.  
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7.1. Predictors of LINE-1 and D4Z4 methylation 
Compared to males, females had a 0.7% and 3.3% decreased level of LINE-1 and D4Z4 
methylation, respectively. Increasing studies have shown that females have significantly lower 
levels of LINE-1 methylation than males (Cash et al. 2011, Cash et al. 2012, El-Maarri et al. 
2007, El-Maarri et al. 2011, Fuke et al. 2004, Hsiung et al. 2007, Subramanyam et al. 2013, 
Wilhelm et al. 2010, Zhang et al. 2011, Zhu et al. 2012, Terry et al. 2011). The precise 
explanations for this observation are unknown. DNA methylation is one of the epigenetic 
mechanisms used to inactivate one of the two X chromosomes to ensure gene dosage 
compensation. LINE-1 sequences are thought to participate in this mechanism (Bailey et al. 
2000). Therefore, one would expect females to have higher levels of methylation than males. 
However, studies both in humans (peripheral blood cells) and mice have shown that 
transcriptionally active LINE-1 elements can be hypomethylated in the inactive X-chromosome, 
and that the presence of full-length active LINE-1 element may be correlated with the degree of 
inactivation (Singer et al. 2012, Chow et al. 2010). Given that active LINE-1s have full 
promoters at their 5’untranslated region (UTR) end and the pyrosequencing method detects those 
LINE-1s with full promoters (see Methods section in chapter III), could these active LINE-1s on 
the X chromosome correspond to the ones detected by pyrosequencing on the X chromosome, 
and hence their low methylation level? Further experimental studies may provide direct answer to 
this question. The study by Singer et al. also assessed the effect of chromosomal constitution on 
LINE-1 methylation by including individuals with numerical X chromosome abnormalities 
[Turner syndrome (45,X), and Klinefelter syndrome (47,XXY)] in their analysis. There was an 
inverse association between methylation and genome size, with samples from Klinefelter patients 
having the lowest LINE-1 methylation level, suggesting limited methylation capability in bigger 
genomes (Singer et al. 2012). Another potential explanation is the differences in male and female 
nutrient intake and loss, particularly of nutrients such as folate, vitamins B6 and B12, methionine, 
and choline. These nutrients are critical substrates of the one-carbon metabolism pathway that 
generate the methyl group donor - S-adenosylmethionine (SAM) - used in DNA methylation 
reactions (Hsiung et al. 2007). An earlier study by Poirier et al. comparing blood levels of SAM 
among males and females showed that the latter had a 40% decreased level of SAM as compared 
to the former (Poirier et al. 2001). An alternative explanation put forward to account for the 
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difference in LINE-1 methylation between males and females relates to hormonal factors. A 
study conducted on human cell lines treated with estrogen, progesterone and dihydrotestosterone 
showed that these hormones did not have any effect on DNA methylation level (El-Maarri et al. 
2011). There is no published data on D4Z4 methylation to compare the results of D4Z4 
methylation between genders. Some of the explanations described above, such as that of the one-
carbon metabolism-related nutrients, may contribute to this difference in D4Z4 methylation. 
Further investigations may shade light on the underlying mechanisms.  
In the present work, tobacco type was a significant predictor of both LINE-1 and D4Z4 
methylation. Compared to never smokers, smokers of blond tobacco presented a 0.7% and 3.7% 
decreased LINE-1 and D4Z4 methylation, respectively, whereas smoking black tobacco showed 
no significant association. These results suggest that the effect of smoking on DNA methylation 
could be dependent of the type of tobacco (blond vs. black) and that blond tobacco exert its effect 
through modulating the epigenome. Previous studies assessing the effect of smoking on global 
DNA methylation reported no evidence of association. However, these studies did not evaluate 
the effect of the type of tobacco smoked (Terry et al. 2011). An experimental study assessing the 
effect of tobacco smoke condensate on methylation pattern of respiratory epithelial cells found 
time dependent DNA demethylation in LINE-1, D4Z4, and NABL2 repeat sequences. Evidence 
from a bladder cancer study showed that smokers of blond tobacco who quit smoking several 
years before diagnosis were able to approximate their risk to that of never smokers (Samanic et 
al. 2006), suggesting a potentially reversible mechanism for blond tobacco-mediated 
carcinogenesis. The observation in this study related the influence of blond tobacco on DNA 
methylation may lend some mechanistic insight into the effects of tobacco type and smoking 
cessation. Given tobacco smoking is amenable to behavioral and medical interventions and that 
DNA methylation is a reversible epigenetic modification, these results may have relevant public 
health implications.  
 Of the twelve trace elements assessed in this study, arsenic, nickel, iron, and selenium 
showed significant associations with LINE-1 and D4Z4 methylation. Arsenic was inversely 
associated with LINE-1 methylation, whereas iron and nickel were positively associated. 
Selenium was inversely associated with D4Z4 methylation. For 1-μg/g increase in toenail arsenic 
concentration there was a 3.6% decrease in LINE-1 methylation level. This finding is in 
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agreement with previous results from human and laboratory studies on arsenic (Wilhelm et al. 
2010, Reichard & Puga 2010, Ren et al. 2011). Although the exact mechanisms through which 
arsenic bring about DNA methylation changes are not known, some potential explanations have 
been put forward. Arsenic is a known carcinogen and it is biotransformed by a sequential 
oxidative-methylation and reduction reactions by arsenic (+3 oxidation state) methyltransferase 
(AS3MT). This process utilizes multiple equivalents of SAM per molecule of arsenic to produce 
monomethylarsonic acid and dimethylarsinic acid before excretion through urine (Ren et al. 
2011, Reichard & Puga 2010). These reactions also result in the accumulation of S-
adenosylhomocysteine (SAH). This consumption of SAM as well as feedback inhibition of DNA 
methyltransferases (DNMTs) by SAH has been proposed as a potential mechanism (Reichard & 
Puga 2010). In addition, arsenic has been shown to directly interact with DNMTs and inhibit 
their activities (Ren et al. 2011). Therefore, by competing for SAM and inhibiting DNMTs, 
arsenic might lead to decreased LINE-1 methylation levels. 
Nickel was positively associated with LINE-1 methylation. The mechanism(s) through 
which nickel affects DNA methylation is far from clear. Results from studies conducted with cell 
lines, which are in agreement with the findings from the current study, suggest that nickel 
treatment induces global DNA methylation and chromatin structural changes (Lee et al. 1998, 
Lee et al. 1995). Likewise, iron was also positively associated with LINE-1 methylation. Iron is a 
critical element in the function of all cells, including transport proteins and enzymes such as 
oxygenases. Iron is an essential cofactor for 2-oxoglutarate (alpha-ketoglutarate) - dependent ten-
eleven translocation (TET1, TET2, TET3) family of methylcytosine hydroxylases, which have 
been suggested to play a role in DNA demethylation (Bhutani et al. 2011, Wu & Zhang 2010). 
These enzymes have recently been shown to sequentially oxidize 5-methylcytosine into 5-
hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine, which might represent new 
epigenetic states or intermediates in the DNA demethylation process (Tahiliani et al. 2009, Ito et 
al. 2011, Wu & Zhang 2011). Furthermore, hereditary hemochromatosis, a disease characterized 
by longstanding iron overload, has been shown to be associated with hypermethylation of critical 
genes in apoptosis and cell cycle (Lehmann et al. 2007). These results indicate the role of iron in 
epigenetic modifications. 
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D4Z4 methylation was inversely and strongly associated with selenium. For each increase 
in 1-μg/g of selenium there was an 8% decrease in D4Z4 methylation. This is consistent with a 
study that showed inverse association between selenium and the total genomic 5-methylcytosine 
content (Pilsner et al. 2011). Selenium is another essential element, critical for normal function of 
selenoproteins that have anti-oxidant and anti-inflammatory effects. Selenium deficiency has 
been associated with UCB and many other chronic diseases (Rayman 2012, Amaral et al. 2010). 
The mechanism by which selenium alters DNA methylation patterns is currently unclear and 
results from animal and in vitro studies have been inconsistent. Studies in cancer cell lines 
showed that treatment with selenium resulted in genomic DNA hypomethylation, inhibition, and 
down-regulation of DNMTs (Xiang et al. 2008, Fiala et al. 1998, Cox & Goorha 1986). It is 
likely that the observed association in this study might be the result of decreased DNMTs 
activity. 
This project also identified seven common germline variants that have not been 
previously reported before in relation to DNA methylation changes. These genetic variants were 
located in five genes – AS3MT, DNMT3A, MTHFS, SLC19A1, and TCN2; three SNPs were 
located in TCN2, and the rest were each located in one of the other four genes. Two of the three 
SNPs in TCN2 were missense variants: rs9606756 located at exon 2 results in isoleucine to valine 
substitution at position 23; and rs9621049 located in exon 7 results in serine to phenylalanine 
change at position 348. SNPs at AS3MT-rs7085104 and SLC19A1-rs914238 are located at the 
5’UTR, whereas MTHFS-rs1380642 is located at 3’UTR. TCN2-rs9606756 falls in the 
NAGNAG tandem acceptor site suggesting that it can have an effect on the alternative splicing of 
this gene (Hiller et al. 2006). Genetic variants located at regulatory sites such as 5’UTR and 
3’UTR may alter gene expression, interfere with mRNA stability and translation through effects 
on polyadenylation and regulatory protein-mRNA and microRNAs-mRNA interactions (Skeeles 
et al. 2013). Altogether, these variants, through alteration of transcription and translation, may 
affect the one-carbon metabolism pathway, and therefore DNA methylation.  
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7.2. DNA methylation and UCB risk and survival 
The effects of genomic DNA methylation at LINE-1 and D4Z4 elements on risk of UCB 
were also evaluated in this work. The results showed a U-shaped association between LINE-1 
methylation and UCB risk, that is, both low and high LINE-1 methylation levels were associated 
with a 30% increased risk. This association was significantly modified by variants in the one-
carbon metabolism gene PEMT. D4Z4 hypermethylation was associated with increased risk of 
UCB particularly in low-grade NMIBC with FGFR3 overexpression. 
Altered global DNA methylation in tumors occurs quite frequently and epidemiologic 
studies in peripheral blood cells have shown that both hypo- and hypermethylation may be 
associated with increased risk of cancer (Moore et al. 2008, Wilhelm et al. 2010, Cash et al. 
2012, Liao et al. 2011). Three previous studies conducted on global DNA methylation and UCB 
risk showed an inverse association (Moore et al. 2008, Wilhelm et al. 2010, Cash et al. 2012). 
The study by Cash et al. found a significant inverse association between UCB and LINE-1 
methylation only among never smokers, whereas the study by Wilhelm et al. showed the effect 
was stronger among females than males; both studies used the same assay to measure LINE-1 
methylation as in the present study. The observation that individuals in the lowest tertile have 
increased risk is consistent with these findings. However, the present study also showed levels of 
methylation in the highest tertile were associated with increased risk, which is in agreement with 
a study by Liao et al. showing a direct association between LINE-1 methylation and increased 
risk, albeit in renal cancer (Liao et al. 2011). U-shaped associations in cancer are not uncommon, 
as these have been reported elsewhere, for example, between folate and pancreatic cancer, 
telomere length and pancreatic cancer, serum vitamin D and prostate cancer, and serum sex 
hormones and prostate cancer (Chuang et al. 2011, Skinner et al. 2012, Tuohimaa et al. 2004, 
Salonia et al. 2012). How abnormal LINE-1 methylation level results in a nonlinear risk pattern 
on UCB is not known? It is known that the effect of DNA methylation is dependent on the 
genomic context it is located at (Jones 2012). This implies that the methylation pattern in LINE-1 
elements could have a differential effect depending on their location in the genome. 
Hypomethylated LINE-1 promoter can induce expression of MET oncogene in bladder tumors 
and other cancer types (Wolff et al. 2010, Weber et al. 2010), whereas methylated repetitive 
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elements such as LINE-1 located in gene bodies have been shown to facilitate gene expression 
and transcriptional elongation of the host gene (Jones 2012). Another explanation is that the U-
shaped association could be due to confounding by important risk factors of UCB such as 
smoking status, tobacco type and gender. However, adjustment with potential and other known 
risk factors of UCB did not change this association. Furthermore, stratified analysis showed that 
the observed association did not differ across smoking status, tobacco type or gender strata. 
Finally, differences between the present and the previous two case-control studies on 
LINE-1 methylation and UCB risk could be explained by such factors as the cell type for DNA 
extraction, the heterogeneity between assays, and difference in sample size. Regarding DNA 
source, each study used different cell types; one study used lymphocytes only (Cash et al. 2012), 
the other used buffy coat (Wilhelm et al. 2010), whereas the present study used granulocytes for 
LINE-1 and D4Z4 methylation quantification. Given DNA methylation patterns are cell specific, 
use of different white blood cells may give different results. Recent meta-analyses reported 
LINE-1 pyrosequencing assays are significantly heterogeneous between studies (Brennan & 
Flanagan 2012, Woo & Kim 2012). The sample size may account for observed differences. The 
sample size in the present study is almost twice as big as the other two studies. Alternatively, the 
possibility of chance finding cannot be ruled out and hence the results should be interpreted with 
caution.  
Higher level of D4Z4 methylation was directly associated with increased UCB risk. This 
result is supported by findings of studies showing that bladder tumor and bladder cancer cell lines 
have elevated levels of D4Z4 methylation compared to the adjacent normal tissue (Choi et al. 
2009, Cheng et al. 2004). D4Z4 repeat units contain the DUX4 gene, a germline transcription 
factor, which is implicated in regulating genes involved in apoptosis, immune system regulation, 
and carcinogenesis (Geng et al. 2012), and hypermethylation of D4Z4 has been associated with 
repression of this gene in tumor tissues (Katargin et al. 2009). One of the target genes for DUX4 
is paired-like homeodomain 1 (PITX1) (Dixit et al. 2007), a tumor suppressor gene that regulates 
TP53, RAS, and TERT genes (Kolfschoten et al. 2005, Liu & Lobie 2007, Qi et al. 2011). TP53 
and RAS genes are frequently altered in UCB. This indicates that the presently observed 
association between increased risk and elevated D4Z4 methylation could be related to the 
deregulation of DUX4 gene and the subsequent downstream effects. An alternative explanation is 
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that D4Z4 methylation could result in higher-order chromatin structural change with a positional 
effect. The association of both LINE-1 and D4Z4 with risk of UCB was modified by one-carbon 
metabolism genes PEMT and FOLH1, respectively. This highlights the importance of the one-
carbon metabolism pathway in the modulation UCB cancer risk. Further epidemiological and 
experimental investigations are warranted to clarify the underlying mechanism behind these 
associations.  
The association between LINE-1 and D4Z4 methylation in peripheral blood cells and the 
UCB outcomes has not been studied before. This study was the largest with longer follow-up 
time and detailed clinicopathological and molecular data to explore the prognostic value of 
genomic DNA methylation in granulocyte DNA. Both LINE-1 and D4Z4 methylation levels 
modeled showed no significant association with individual outcome in NMIBC (recurrence, 
progression and relapse) and MIBC (progression, bladder cancer-specific mortality and overall 
mortality) in both unadjusted and adjusted Cox proportional hazards models. Similar 
nonsignificant associations were observed in stratified analysis according to treatment, selected 
risk factors of UCB, and subphenotype analyses according to FGFR3 mutation status and 
expression levels. A single study in 96 bladder cancer tissues reported an inverse association 
between LINE-1 methylation and recurrence and disease-specific survival time in the unadjusted 
model (Neuhausen et al. 2006). Further study is needed to evaluate the prognostic potential of 
genomic DNA methylation.   
7.3. Strengths and limitations of this study 
Limitations of this study are related to the nature of the study design, timing of baseline 
and exposure data, and blood sample collections, selection and misclassification biases. The 
SBC/EPICURO study was a multi-center hospital-based case-control study conducted in five 
regions of Spain (Asturias, Barcelona, Elche, Tenerife, and Valles). Therefore the distribution of 
exposures such as smoking habits among controls might not be representative of the source 
population in these five regions. Sociodemographic characteristics and tobacco smoking data 
were collected retrospectively through interview using risk factor questionnaires and the response 
rates for these questionnaires were 84 and 88% for cases and controls, respectively (Samanic et 
al. 2006). Although these response rates were higher, the possibility of selection bias due to 
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differences between participants and non-participants cannot be excluded. Also during the 
interview process the possibility of recall bias cannot be ruled out for both cases and controls. 
But because each case-control pair was recruited and matched from the same non-referral 
hospital, substantial selection and differential recall biases are not expected.  
Blood sample used for DNA methylation determination was collected following 
admission to hospital but before treatment were started. DNA methylation is a stable yet dynamic 
epigenetic modification and hence it might be influenced by the disease process as well as 
hospital stay. The observed associations in this study might be the result of reverse causation. 
However, a prospective study that evaluated the association between DNA methylation in 
repetitive sequences and cancer risk reported that altered global DNA methylation was 
significantly associated risk of cancer (Zhu et al. 2011) indicating changes in DNA methylation 
preceded the disease process. Besides that, in the present project the diagnoses of the control 
subjects were not associated with both LINE-1 and D4Z4 methylation levels. Another potential 
problem is not all study participants had enough DNA to quantify genomic methylation. 
However, comparing those participants with and without DNA methylation data showed no 
substantial difference in the distribution of matching variables and smoking status (see Chapter 
III and Chapter V). Another limitation is the age and gender distribution of the control subjects 
used for the assessment of potential predictors of D4Z4 and LINE-1 methylation. Most of these 
subjects were older and predominantly males. This might limit the external validity of the result 
on DNA methylation predictors and therefore it should only apply for this demographic group.  
Regarding data on genomic DNA methylation, methylation levels at four LINE-1 CpG 
sites from granulocytes were used as a surrogate for genome wide DNA methylation content. 
Methylation levels at CpG sites located in other genomic regions and repetitive DNA sequences 
such as Alu could also be used. However, only LINE-1 elements were validated as a surrogate for 
global DNA methylation levels (Estecio et al. 2007, Yang et al. 2004). Methylation level at six 
CpG sites in D4Z4 tandem repeats was also used as an additional marker in this study to evaluate 
macrosatellite methylation levels and UCB risk and progression. The levels of methylation in 
granulocytes might or might not differ from that of urothelial cells. Nonetheless methylation in 
granulocytes can be used as a biomarker of UCB risk and prognosis.  
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Usual dietary intakes of B vitamins, protein and fruits and vegetables were estimated from 
a comprehensive food frequency questionnaire and therefore it might not reflect the absolute 
content of each nutrient. Additionally not all the study participants returned the questionnaire but 
there was no significant difference in characteristics of those who had and had not completed the 
questionnaires (Garcia-Closas et al. 2007b). The smaller number of females in this study and 
missing data for dietary intakes, trace elements, FGFR3 mutation and expression levels and 
might have limited the analyses for these variables due to reduced sample size.  
Strengths of this work include its sample size, availability of diverse and reliable data on 
exposure status, genotype, clinicopatholical and molecular characteristics of tumor tissues. The 
SBC/EPICURO is largest study to date to evaluate the effects of genomic DNA methylation on 
UCB risk and survival. Bisulfite modification of DNA is the gold standard before measuring 
DNA methylation. LINE-1 and D4Z4 methylation levels were quantified by using 
pyrosequencing which is reliable method that provides accurate measurement (Lara et al. 2011, 
Laird 2010, Tost & Gut 2007). The within-sample coefficient of variations for LINE-1 and D4Z4 
were 4.53 and 0.88%, respectively. All UCB patients included in the study were incident cases. 
Diagnosis, tumor stage and grade were confirmed by a panel of expert pathologists. Trained 
nurses collected data on vital status through direct telephone interviews the individual patient or 
their relatives, and UCB outcomes and treatments of UCB were retrieved from patient’s hospital 
charts. Reliable information on trace elements were collected which was evidenced by their lower 
within-sample coefficient of variation (Amaral et al. 2012c). Genotypes with call rates of more 
than 95% were included in this analysis and a stringent cutoff value of p-value >0.05 was used to 
indicate departure from Hardy-Weinberg equilibrium. 
7.4. Clinical and public health genomics implications 
DNA methylation is a potentially reversible epigenetic modification. In this thesis, some 
factors potentially modifiable through medical interventions were associated with both LINE-1 
and D4Z4 methylation levels. LINE-1 and D4Z4 methylation levels were associated with risk of 
UCB; particularly D4Z4 methylation was associated with a specific UCB subphenotype with 
distinct clinicopathological and molecular features. These results may have clinical and public 
health implications. One implication is to target DNA methylation using methylation modifying 
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drugs in individuals with specific exposure profile (for example arsenic exposed individuals) to 
mitigate the consequence of the exposure. Another benefit to public health genomics is that DNA 
methylation can be used to identify specific group individuals at high risk of onset of a certain 
disease or benefit from a specific preventive or therapeutic intervention. These approaches not 
only help realize targeted interventions also save time and recourses.  
However, considering the level of evidence of an individual case-control study, further 
independent larger prospective cohort studies or preventive trials are required to provide accurate 
risk estimates to help harness the potential of DNA methylation in the clinical and public health 
settings. 
7.5. Future directions 
This thesis has identified novel predictors of genomic DNA methylation. In addition, it 
showed that genomic DNA methylation at was associated with increased risk of UCB. To 
identify additional factors that influence genomic DNA methylation, further studies with diverse 
internal and external exposure data are needed. Experimental studies in model systems will 
clarify the molecular mechanisms how these factors modulate DNA methylation and affect health 
and disease. To ascertain causality between DNA methylation and UCB risk and also enable 
subgroup analysis, well powered population based prospective studies using pre- and post-
diagnosis collected DNA are required. Applying methods such as microarrays or single-base 
resolution bisulfite sequencing measure genome-wide methylation (Jones 2012) to identify novel 
CpG positions associated with UCB risk and progression are desirable. But until new studies 
recruit sufficient study subjects, establishing international collaboration between existing studies 
to enable detailed subgroup analyses, and identify novel DNA methylation*environment and 
DNA methylation*gene interactions is recommended.  
Recently 5-methylcytocine has been shown to undergo sequential oxidative reaction 
catalyzed by iron(II)- and α-ketoglutarate-dependent TET family of hydroxylases to generate 5-
hydroxymethylcytosine, 5-formylcytosine, and finally 5-carboxycytosine (Tahiliani et al. 2009, 
Ito et al. 2011). 5-hydroxymethylcytosine was found in considerable amount in LINE-1 
sequences (Booth et al. 2012), and significantly globally reduced levels, compared to the 
matched normal tissues,  have been reported in various human cancer types (lung, prostate, liver, 
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pancreatic, and breast cancers) (Yang et al. 2013). Therefore, it will be interesting to investigate 
how 5-hydroxymethylcytosine and the other cytosine modifications associate with UCB risk, 
progression as well as with 5-methylcytosine itself. 
Finally, integrating DNA methylation with other ‘omics’ data would greatly improve our 
understanding of UCB, improve clinical outcomes, and help design novel preventive strategies to 
eventually reduce morbidity and mortality from the disease and improve quality of life. 
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CHAPTER VIII. CONCLUSIONS 
Based on the results from this study, I conclude that: 
I. Gender, tobacco type, arsenic, iron, nickel, and common genetic variants in the one-
carbon metabolism pathway genes DNMT3A, AS3MT, MTHFS, SLC19A1, and TCN2, are 
independent predictors of LINE-1 methylation levels.  
II. Gender, tobacco type, and selenium are independent predictors of D4Z4 methylation 
levels.  
III. LINE-1 methylation levels are non-linearly associated with urothelial carcinoma of the 
bladder (UCB), i.e. both low and high levels of LINE-1 methylation conferred an 
increased risk for the disease. 
IV. Five single nucleotide polymorphisms in PEMT genes may modify the association 
between LINE-1 methylation and risk of UCB. 
V. High D4Z4 methylation levels increased the risk of developing low-grade non-muscle 
invasive bladder cancer overexpressing FGFR3. 
VI. The effect of D4Z4 methylation is modified by levels of iron, nickel, and manganese. 
FLOH1-rs11040387 may also modify the risk of UCB conferred by D4Z4 methylation. 
VII. LINE-1 and D4Z4 methylation levels had no prognostic value on recurrence, progression 
and survival in patients with non-muscle invasive and muscle invasive bladder cancer.  
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CONCLUSIONES 
Basándonos en los resultados del presente estudio, concluyo que: 
I. El género, el tipo de tabaco, el arsénico, el hierro, el níquel, y variantes genéticas comunes 
en genes de la vía del metabolismo del monocarbono (DNMT3A, AS3MT, MTHFS, 
SLC19A1 y TCN2) son predictores independientes  de los niveles de metilación de LINE-
1.  
II. El género, el tipo de tabaco y el selenio son predictores independientes de los niveles de 
metilación de D4Z4. 
III. Los niveles de metilación de LINE-1 están asociados con el carcinoma uroterial de vejiga 
(CUV) de manera no lineal, de tal modo que niveles de baja y alta metilación en LINE-1 
confieren un aumento del riesgo de padecer la enfermedad. 
IV. Cinco polimorfismos de nucleótido simple del gen PEMT modifican modificar la 
asociación entre la metilación de LINE-1 y el riesgo de desarrollar CUV. 
V. Niveles elevados de metilación de D4Z4 incrementan el riesgo de desarrollar cáncer de 
vejiga no-invasivo del músculo de bajo grado con sobreexpresión de FGFR3. 
VI. El efecto de la metilación de D4Z4 es modificado por los niveles de hierro, níquel y 
manganeso. FLOH1-rs11040387 también modificar la susceptibilidad al CUV conferida 
por la metilación de D4Z4. 
VII. Los niveles de metilación de LINE-1 y D4Z4 no tienen valor pronóstico independiente de 
recurrencia, progresión y supervivencia tanto en pacientes con cáncer de vejiga no-
invasivo como invasivo del músculo.  
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Supplementary Table S3-1 List of genes involved in the one-carbon metabolism pathway selected for the present study 
Chromosome location Gene symbol [ID]* Gene name Gene function 
1p31.1 CTH Cystathionase Converts cystathione derived from methionine into 
cysteine. 
1p36.3 MTHFR Methylenetetrahydrofolate 
reductase (NAD(P)H) 
Catalyzes the conversion of 5,10-methylenetetrahydrofolate 
to 5-methyltetrahydrofolate. 
1q43 MTR 5-methyltetrahydrofolate-
homocysteine 
methyltransferase 
Catalyzes the final step in methionine biosynthesis. 
2p23 DNMT3A DNA (cytosine-5-)-
methyltransferase 3 alpha 
Functions in de novo methylation of cytosine residues. 
2q35 ATIC 5-aminoimidazole-4-
carboxamide ribonucleotide 
formyltransferase/IMP(inosine 
monophosphate) 
cyclohydrolase 
Catalyzes the last two steps of the de novo purine 
biosynthetic pathway. The N-terminal domain has 
phosphoribosylaminoimidazolecarboxamide 
formyltransferase activity, and the C-terminal domain has 
IMP cyclohydrolase activity. 
3p21.1 CHDH Choline dehydrogenase Encodes a protein that localizes to the mitochondrion. 
Variations in this gene can affect susceptibility to choline 
deficiency. 
3q21.3 ALDH1L1 Aldehyde dehydrogenase 1 
family, member L1 
Catalyzes the conversion of 10-formyltetrahydrofolate, 
NADP, and water to tetrahydrofolate, NADPH, and carbon 
dioxide. 
5p15.31 MTRR 5-methyltetrahydrofolate-
homocysteine 
methyltransferase reductase 
Regenerates a functional methionine synthase via reductive 
methylation 
5q11.2-q13.2 DHFR Dihydrofolate reductase Converts dihydrofolate into tetrahydrofolate, a methyl 
group shuttle required for the de novo synthesis of purines, 
thymidylic acid, and certain amino acids. 
5q13.1-q15 BHMT Betaine-homocysteine S-
methyltransferase 
Catalyzes the conversion of betaine and homocysteine to 
dimethylglycine and methionine, respectively. 
6p12 GNMT Glycine N-methyltransferase Catalyzes the conversion of S-adenosyl-L-methionine 
(along with glycine) to S-adenosyl-L-homocysteine and 
sarcosine. 
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Supplementary Table S3-1 (cont.) List of genes involved in the one-carbon metabolism pathway selected for the present study 
Chromosome location Gene symbol [ID]* Gene name Gene function 
10q24.32 AS3MT Arsenic (+3 oxidation state) 
methyltransferase 
Catalyzes the transfer of a methyl group from S-adenosyl-L-
methionine to trivalent arsenical and play a role in arsenic 
metabolism. 
11p11.2 FOLH1 Folate hydrolase (prostate-
specific membrane 
antigen)1/glutamate 
carboxypeptidase II/ 
Acts as a glutamate carboxypeptidase on different alternative 
substrates, including the nutrient folate and the neuropeptide 
N-acetyl-l-aspartyl-l-glutamate.  
14q24 MTHFD Methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 1 
Catalyzes one of three sequential reactions in the 
interconversion of 1-carbon derivatives of tetrahydrofolate. 
15q25.1 MTHFS 5,10-methenyltetrahydrofolate 
synthetase 
Catalyzes the conversion of 5-formyltetrahydrofolate to 5,10-
methenyltetrahydrofolate, a precursor of reduced folates 
involved in 1-carbon metabolism. 
17p11.2 PEMT Phosphatidylethanolamine N-
methyltransferase 
Converts phosphatidylethanolamine to phosphatidylcholine 
by sequential methylation in the liver. 
17p11.2 SHMT1 Serine hydroxymethyltransferase 
1 
Catalyzes the reversible conversion of serine and 
tetrahydrofolate to glycine and 5,10-methylene 
tetrahydrofolate. This reaction provides one carbon units for 
synthesis of methionine, thymidylate, and purines in the 
cytoplasm. 
18p11.32 TYMS Thymidylate synthetase Catalyzes the methylation of deoxyuridylate to 
deoxythymidylate using 5,10-methylenetetrahydrofolate as a 
cofactor. 
19p13.2 DNMT1 DNA (cytosine-5-)-
methyltransferase 1 
Establishes and regulates tissue-specific patterns of 
methylated cytosine residues. 
20q11.2 DNMT3B DNA (cytosine-5-)-
methyltransferase 3 beta 
Functions in de novo methylation of cytosine residues. 
21q22.1; 21q22.11 GART Glycinamide ribonucleotide 
transformylase 
Encodes a protein that has phosphoribosylglycinamide 
formyltransferase, phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase activity which is 
required for de novo purine biosynthesis. 
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Supplementary Table S3-1 (cont.) List of genes involved in the one-carbon metabolism pathway selected for the present study 
Chromosome location Gene symbol [ID]* Gene name Gene function 
21q22.3 CBS Cystathionine-beta-synthase Acts as a homotetramer to catalyze the conversion of 
homocysteine to cystathionine, the first step in the 
transsulfuration pathway. 
21q22.3 SLC19A1 Solute carrier family 19 (folate 
transporter), member 1 
Transports folate and is involved in the regulation of 
intracellular concentrations of folate. 
22q12.2 TCN2 Transcobalamin II Binds and mediates the transport of vitamin B12 into cells. 
*Maglott D, Ostell J, Pruitt KD, Tatusova T. 2005. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 33:D54-D58. 
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Supplementary Table S3-2 Distribution of SNPs studied in the present study by genotyping platform 
Genotyping Assay Gene Symbol dbSNP ID Gene Symbol dbSNP ID 
Illumina Infinium® Human1M-Duo     
  AS3MT rs4532960 ATIC rs3821353 
  AS3MT rs10509760 ATIC rs16853782 
  AS3MT rs1046778 ATIC rs1464864 
  AS3MT rs7085854 ATIC rs7563206 
  AS3MT rs10748835 ATIC rs4673981 
  AS3MT rs3740392 ATIC rs4531931 
  AS3MT rs7085104 ATIC rs6750194 
  AS3MT rs11191439 ATIC rs6760069 
  AS3MT rs3740394 CHDH rs920253 
  AS3MT rs11191457 CHDH rs6801605 
  AS3MT rs12416687 CHDH rs13317328 
  ATIC rs4610054 CHDH rs3755817 
  ATIC rs10165919 CHDH rs9001 
  ATIC rs12997662 CHDH rs6445606 
  ATIC rs1404772 CHDH rs3774616 
  ATIC rs11683778 CHDH rs2289209 
  ATIC rs10498034 CHDH rs9835128 
  ATIC rs6706415 CHDH rs2241807 
  ATIC rs4673993 CHDH rs9836592 
  ATIC rs10498036 DNMT1 rs2288349 
  ATIC rs3772078 DNMT1 rs2288350 
  ATIC rs4476347 DNMT1 rs8111085 
  ATIC rs7604984 DNMT1 rs2162560 
  ATIC rs11892429 DNMT1 rs4804125 
  ATIC rs6757920 DNMT1 rs11672909 
  ATIC rs4369857 DNMT1 rs6511677 
  ATIC rs11687225 DNMT1 rs11085720 
  ATIC rs16853834 DNMT1 rs7253062 
  ATIC rs1880586 DNMT1 rs35918857 
  ATIC rs2372535 DNMT1 rs4804122 
  ATIC rs1983462 DNMT1 rs17291414 
  ATIC rs12614943 DNMT1 rs4804494 
  ATIC rs10179873 DNMT1 rs9305012 
  ATIC rs4673965 DNMT1 rs16999714 
  ATIC rs10932605 DNMT1 rs2116940 
  ATIC rs9789571 DNMT1 rs8101626 
  ATIC rs10197653 DNMT1 rs10418707 
  ATIC rs1808119 DNMT1 rs8112895 
  ATIC rs4673991 DNMT1 rs10420338 
  ATIC rs7604425 DNMT1 rs12462004 
  ATIC rs4672768 DNMT1 rs4804490 
  ATIC rs16853826 DNMT1 rs2290684 
  ATIC rs10197559 DNMT1 rs2228611 
  ATIC rs1404774 DNMT1 rs759920 
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Supplementary Table S3-2 (cont.) 
Genotyping Assay Gene Symbol dbSNP ID Gene Symbol dbSNP ID 
  DNMT3A rs6722613 DNMT3B rs4911107 
  DNMT3A rs7581217 DNMT3B rs910085 
  DNMT3A rs7575625 DNMT3B rs6058891 
  DNMT3A rs1465825 DNMT3B rs2424932 
  DNMT3A rs12987326 DNMT3A rs12999687 
  DNMT3A rs734693 DNMT3B rs6058893 
  DNMT3A rs13401241 DNMT3B rs6087990 
  DNMT3A rs11694842 DNMT3B rs6058897 
  DNMT3A rs7583409 DNMT3B rs4911263 
  DNMT3A rs13427202 DNMT3B rs2424928 
  DNMT3A rs11887120 DNMT3B rs4911108 
  DNMT3A rs12995968 DNMT3B rs6141813 
  DNMT3A rs13002567 DNMT3B rs6058896 
  DNMT3A rs10460566 DNMT3B rs6058883 
  DNMT3A rs6711622 DNMT3B rs853858 
  DNMT3A rs13036246 DNMT3B rs6119286 
  DNMT3A rs749130 DNMT3B rs437302 
  DNMT3A rs17745484 DNMT3B rs2424921 
  DNMT3A rs1550117 FOLH1 rs7102702 
  DNMT3A rs6749992 FOLH1 rs1819409 
  DNMT3A rs7586294 FOLH1 rs11040432 
  DNMT3A rs11892646 FOLH1 rs11040387 
  DNMT3A rs11677670 FOLH1 rs12098986 
  DNMT3A rs11683424 FOLH1 rs202712 
  DNMT3A rs7560488 FOLH1 rs1814175 
  DNMT3A rs7587636 FOLH1 rs3862350 
  DNMT3A rs11681447 FOLH1 rs679470 
  DNMT3A rs6713377 FOLH1 rs7929543 
  DNMT3A rs2304429 FOLH1 rs2696935 
  DNMT3A rs2289093 FOLH1 rs7117247 
  DNMT3A rs34048824 FOLH1 rs11040261 
  DNMT3A rs7594432 FOLH1 rs10769558 
  DNMT3A rs7605753 FOLH1 rs1917321 
  DNMT3A rs1369703 FOLH1 rs4144700 
  DNMT3B rs6119285 FOLH1 rs7358352 
  DNMT3B rs2424913 FOLH1 rs588458 
  DNMT3B rs2424908 FOLH1 rs7113251 
  DNMT3B rs2424914 FOLH1 rs3862342 
  DNMT3B rs6058894 FOLH1 rs17556442 
  DNMT3B rs6057645 FOLH1 rs10839229 
  DNMT3B rs6087988 FOLH1 rs11040390 
  DNMT3B rs6058869 FOLH1 rs4094478 
  DNMT3B rs709046 FOLH1 rs12293923 
  DNMT3B rs2424922 FOLH1 rs7951180 
  DNMT3B rs2424906 FOLH1 rs1164685 
150 
 
Supplementary Table S3-2 (cont.) 
Genotyping Assay Gene Symbol dbSNP ID Gene Symbol dbSNP ID 
  FOLH1 rs10839295 FOLH1 rs11040421 
  FOLH1 rs10839296 FOLH1 rs12222221 
  FOLH1 rs10839224 FOLH1 rs1847638 
  FOLH1 rs16906158 FOLH1 rs1917311 
  FOLH1 rs10839210 GART rs2834235 
  FOLH1 rs7120743 GART rs4817577 
  FOLH1 rs10501325 GART rs6517178 
  FOLH1 rs3960835 GART rs7283354 
  FOLH1 rs7113075 GART rs4817580 
  FOLH1 rs2696923 GART rs2834233 
  FOLH1 rs11040263 GART rs12482067 
  FOLH1 rs683680 GART rs8971 
  FOLH1 rs10400277 GART rs2834232 
  FOLH1 rs202718 GART rs2154583 
  FOLH1 rs34033751 GART rs4817579 
  FOLH1 rs11040353 GART rs2834231 
  FOLH1 rs7111215 GNMT rs3800292 
  FOLH1 rs648372 GNMT rs4987173 
  FOLH1 rs7111711 GNMT rs10948059 
  FOLH1 rs650826 GNMT rs7759302 
  FOLH1 rs7926211 GNMT rs9462856 
  FOLH1 rs11607791 MTHFD1 rs2281603 
  FOLH1 rs1164681 MTHFD1 rs7144437 
  FOLH1 rs12797843 MTHFD1 rs17101854 
  FOLH1 rs12797853 MTHFD1 rs3783728 
  FOLH1 rs7124266 MTHFD1 rs2983733 
  FOLH1 rs632220 MTHFD1 rs4902278 
  FOLH1 rs202700 MTHFD1 rs11627387 
  FOLH1 rs202676 MTHFD1 rs1256095 
  FOLH1 rs1809986 MTHFD1 rs8019804 
  FOLH1 rs11040416 MTHFD1 rs1256114 
  FOLH1 rs7117025 MTHFD1 rs9323450 
  FOLH1 rs7107178 MTHFD1 rs2983736 
  FOLH1 rs7934591 MTHFD1 rs11629135 
  FOLH1 rs10839239 MTHFD1 rs2987981 
  FOLH1 rs598841 MTHFD1 rs1076991 
  FOLH1 rs2865908 MTHFD1 rs1956545 
  FOLH1 rs1846285 MTHFD1 rs3818239 
  FOLH1 rs4441015 MTHFD1 rs11627525 
  FOLH1 rs11040106 MTHFD1 rs17751556 
  FOLH1 rs2866358 MTHFD1 rs2987969 
  FOLH1 rs17728676 MTHFD1 rs1256107 
  FOLH1 rs6485991 MTHFD1 rs1256112 
  FOLH1 rs660439 MTHFD1 rs10498514 
  FOLH1 rs7102641 MTHFD1 rs11158542 
  FOLH1 rs4495895 MTHFD1 rs8015278 
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Supplementary Table S3-2 (cont.) 
Genotyping Assay Gene Symbol dbSNP ID Gene Symbol dbSNP ID 
  MTHFD1 rs1950902 MTHFS rs4779141 
  MTHFD1 rs2236222 MTHFS rs17211644 
  MTHFD1 rs35020344 MTHFS rs1870576 
  MTHFD1 rs6573559 MTHFS rs17209637 
  MTHFD1 rs12884767 MTHFS rs1077965 
  MTHFD1 rs2236225 MTHFS rs3893384 
  MTHFD1 rs2295639 MTHFS rs6495441 
  MTHFD1 rs8011839 MTHFS rs4778721 
  MTHFD1 rs2236224 MTHFS rs282795 
  MTHFD1 rs1256142 MTHFS rs282778 
  MTHFD1 rs8003379 MTHFS rs898436 
  MTHFD1 rs17824591 MTHFS rs16971249 
  MTHFD1 rs8003567 MTHFS rs12898670 
  MTHFD1 rs11158540 MTHFS rs2733103 
  MTHFD1 rs11158538 MTHFS rs12913164 
  MTHFD1 rs8018032 MTHFS rs282792 
  MTHFS rs1473406 MTHFS rs1604503 
  MTHFS rs204942 MTHFS rs17285431 
  MTHFS rs2115536 MTHFS rs17279885 
  MTHFS rs17279286 MTHFS rs2586154 
  MTHFS rs582172 MTHFS rs12592743 
  MTHFS rs11852515 MTHFS rs435689 
  MTHFS rs376863 MTHFS rs12903985 
  MTHFS rs1081231 MTHFS rs4779148 
  MTHFS rs2035027 MTHFS rs1081235 
  MTHFS rs4393531 MTHFS rs600671 
  MTHFS rs7177659 MTHFS rs17279753 
  MTHFS rs2586153 MTHFS rs445263 
  MTHFS rs8041943 MTHFS rs4778719 
  MTHFS rs282776 MTHFS rs6495446 
  MTHFS rs282802 MTHFS rs282787 
  MTHFS rs1880580 MTHFS rs16971260 
  MTHFS rs16971253 MTHFS rs16971450 
  MTHFS rs4779140 MTHFS rs7174668 
  MTHFS rs7175620 MTHFS rs685487 
  MTHFS rs4779165 MTHFS rs12438477 
  MTHFS rs166868 MTHFS rs10163099 
  MTHFS rs372447 MTHFS rs12900076 
  MTHFS rs282772 MTHFS rs12591436 
  MTHFS rs11855092 MTHFS rs1074390 
  MTHFS rs12905663 MTHFS rs282814 
  MTHFS rs3897953 MTHFS rs443394 
  MTHFS rs16971231 MTHFS rs12148881 
  MTHFS rs8923 MTHFS rs12898642 
  MTHFS rs378057 MTHFS rs12910340 
  MTHFS rs2586182 MTHFS rs7177027 
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Supplementary Table S3-2 (cont.) 
Genotyping Assay Gene Symbol dbSNP ID Gene Symbol dbSNP ID 
  MTHFS rs17284990 PEMT rs3760188 
  MTHFS rs16971252 SLC19A1 rs2838969 
  MTHFS rs1380642 SLC19A1 rs9976878 
  MTHFS rs2115540 SLC19A1 rs2838970 
  MTHFS rs770144 SLC19A1 rs9977111 
  MTHFS rs2733106 SLC19A1 rs1051266 
  MTHFS rs1460177 SLC19A1 rs2183601 
  MTHFS rs8034036 SLC19A1 rs3788190 
  PEMT rs7217764 SLC19A1 rs12482346 
  PEMT rs748196 SLC19A1 rs767138 
  PEMT rs8074074 SLC19A1 rs8128681 
  PEMT rs7219568 SLC19A1 rs8129350 
  PEMT rs4244599 SLC19A1 rs8129445 
  PEMT rs9897362 SLC19A1 rs2838964 
  PEMT rs750546 SLC19A1 rs4819128 
  PEMT rs11869600 SLC19A1 rs8128676 
  PEMT rs4646404 SLC19A1 rs2150460 
  PEMT rs2124344 SLC19A1 rs9974061 
  PEMT rs4646341 SLC19A1 rs6518253 
  PEMT rs8081810 SLC19A1 rs914232 
  PEMT rs9910747 SLC19A1 rs2330183 
  PEMT rs4924922 SLC19A1 rs1023159 
  PEMT rs1020697 SLC19A1 rs944422 
  PEMT rs897453 SLC19A1 rs1888530 
  PEMT rs4646383 SLC19A1 rs4819138 
  PEMT rs11658944 SLC19A1 rs12373907 
  PEMT rs4646385 SLC19A1 rs2838958 
  PEMT rs1109859 SLC19A1 rs12627639 
  PEMT rs4646350 SLC19A1 rs914231 
  PEMT rs4646340 SLC19A1 rs2877078 
  PEMT rs4646359 SLC19A1 rs9306139 
  PEMT rs11871738 SLC19A1 rs2838965 
  PEMT rs11656215 SLC19A1 rs1888533 
  PEMT rs4646344 SLC19A1 rs1055345 
  PEMT rs3785499 SLC19A1 rs3177999 
  PEMT rs7946 SLC19A1 rs7279305 
  PEMT rs8068641 SLC19A1 rs7276295 
  PEMT rs4646364 SLC19A1 rs4818789 
  PEMT rs4925048 TCN2 rs16988828 
  PEMT rs4479310 TCN2 rs5749135 
  PEMT rs4646410 TCN2 rs740234 
  PEMT rs9890064 TCN2 rs1801198 
  PEMT rs12453139 TCN2 rs2267163 
  PEMT rs7215833 TCN2 rs5753231 
  PEMT rs7220132 TCN2 rs2283873 
  PEMT rs8074191 TCN2 rs4820887 
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Supplementary Table S3-2 (cont.) 
Genotyping Assay Gene Symbol dbSNP ID Gene Symbol dbSNP ID 
  TCN2 rs10418 SLC19A1 rs4434082 
  TCN2 rs1131603 SLC19A1 rs11701960 
  TCN2 rs5749131 SLC19A1 rs9980967 
  TCN2 rs9606756 SLC19A1 rs2838973 
  TCN2 rs2301955 SLC19A1 rs4819130 
  TCN2 rs9621049 SLC19A1 rs914238 
  TCN2 rs9306264 SLC19A1 rs2838977 
  SLC19A1 rs3788200     
  SLC19A1 rs2838961     
  SLC19A1 rs8128050     
Illumina GoldenGate®        
  ALDH1L1 rs1127717  TYMS rs1059394  
  ALDH1L1 rs2305230      
  ALDH1L1 rs9282690      
  BHMT rs567754      
  BHMT rs617219      
  CBS rs234706      
  CBS rs12613      
  CBS rs6586282      
  CTH rs663465      
  CTH rs663649      
  CTH rs6413471      
  CTH rs473334      
  CTH rs515064      
  CTH rs559062      
  DHFR rs35709834      
  DHFR rs865646      
  DHFR rs1650697      
  MTHFD rs1667627      
  MTHFR MTHFR_02__2_i_order     
  MTHFR rs1801133      
  MTHFR rs2066470      
  MTHFR rs12121543      
  MTR MTR_01__2_i_order     
  MTR rs1805087      
  MTR rs2275565      
  MTR rs2275566      
  MTRR rs2287780      
  MTRR rs9332      
  MTRR rs10380      
  MTRR rs1802059      
  MTRR rs8659      
  MTRR rs2287779      
  SLC19A1 rs1051298      
  TYMS rs699517      
  TYMS rs2790      
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Supplementary Table S3-2 (cont.) 
Genotyping Assay Gene Symbol dbSNP ID 
TaqMan®     
  MTHFR rs1801131  
  MTHFR MTHFR_02_ORDER 
  MTR MTR_01_ORDER 
  MTRR rs1801394  
  SHMT1 rs1979277  
  SHMT1 rs1979276  
  SHMT1 rs3783  
  SLC19A1 rs1051296  
dbSNP ID, dbSNP identifier number. 
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Supplementary Table S3-3 List of single nucleotide polymorphisms with significant Fisher's exact test selected for further analysis (p-
value ≤ 0.05) 
dbSNP Identifier N MAF Chromosome Location* Gene Region in the gene P-HWE Fisher's exact test p-value† 
rs11683424 875 0.12 2 25342636 DNMT3A Intron 0.20 0.006 
rs7581217 875 0.39 2 25378448 DNMT3A Intron 0.62 0.002 
rs1550117 875 0.08 2 25419411 DNMT3A Flanking 5'UTR 0.81 0.009 
rs4369857 875 0.04 2 215841917 ATIC Flanking 5'UTR 1.00 0.02 
rs7563206 874 0.47 2 215898899 ATIC Intron 0.84 0.04 
rs1880586 875 0.47 2 215903416 ATIC Intron 0.89 0.04 
rs4673991 875 0.32 2 215920334 ATIC Intron 0.31 0.004 
rs4673993 875 0.32 2 215920584 ATIC Intron 0.31 0.004 
rs4672768 873 0.32 2 215922369 ATIC Intron 0.31 0.005 
rs10498036 875 0.40 2 215922737 ATIC Flanking 3'UTR 0.57 0.004 
rs7604984 875 0.40 2 215925884 ATIC Flanking 3'UTR 0.62 0.003 
rs7085104 875 0.38 10 104618863 AS3MT Flanking 5'UTR 1.00 0.02 
rs1077965 875 0.41 15 77852392 MTHFS Flanking 3'UTR 0.58 0.007 
rs11855092 875 0.24 15 77877293 MTHFS Flanking 3'UTR 0.31 0.03 
rs1380642 875 0.18 15 77883926 MTHFS Flanking 3'UTR 0.57 0.01 
rs4646340 875 0.37 17 17434740 PEMT Intron 0.51 0.04 
rs7215833 875 0.36 17 17448033 PEMT Flanking 5'UTR 0.51 0.02 
rs914238 875 0.49 21 45840089 SLC19A1 Flanking 5'UTR 0.89 0.002 
rs2838965 873 0.42 21 45846212 SLC19A1 Flanking 5'UTR 0.33 0.02 
rs9606756 875 0.12 22 29336860 TCN2 Exon 0.87 0.005 
rs9621049 875 0.11 22 29343419 TCN2 Exon 0.86 0.02 
rs4820887 875 0.10 22 29346914 TCN2 Intron 0.85 0.01 
MAF, minor allele frequency. P-HWE, Chi-square test p-value for Hardy-Weinberg equilibrium.     
*Human Genome Build 36.3 location.             
†Fisher’s exact test p-value from comparison of categorical variables LINE-1 methylation in tertiles (<56.7%, 56.7–58.6%, and 
>58.6%) and SNPs modeled according to codominant mode of in heritance coded as "0" for wild type, "1" heterozygous variant, "2" 
for homozygous variant. 
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Supplementary Table S3-4 Distributional characteristics of study subjects and LINE-1 
methylation in the SBC/EPICURO Study 
Variables N Percent  LINE-1 methylation (%) P-value* 
Median (IQR) 
Age (years)         
<60 253 28.4 57.4 (3.7) 0.9 
60-69 342 38.3 57.4 (3.2)   
70+ 297 33.3 57.5 (3.2)   
Gender         
Male  792 88.8 57.5 (3.3) 0.04 
Female 100 11.2 57.1 (3.2)   
Region         
Barcelona 168 18.8 57.5 (3.0) 0.1 
Vallès 135 15.1 57.1 (2.6)   
Elche 73 8.2 57.1 (2.5)   
Tenerife 145 16.3 57.3 (3.2)   
Asturias 371 41.6 57.7 (3.9)   
Body mass index (kg/m²)         
<25.0 372 53.4 57.4 (3.3) 0.9 
25.0-26.99 148 21.2 57.4 (3.7)   
27.0-29.99 120 17.2 57.5 (3.2)   
≥30.0 57 8.2 57.6 (3.5)   
Missing data 195       
Smoking status         
Non-smoker 255 28.7 57.4 (3.2) 0.2 
Occasional smoker 66 7.4 58.0 (3.3)   
Former smoker 329 37.0 57.4 (3.3)   
Current smoker 239 26.9 57.4 (3.7)   
Missing data 3       
Tobacco type         
Non-smoker 255 31.0 57.4 (3.2) 0.2 
Blond only 99 12.0 57.0 (3.2)   
Black only 219 26.5 57.7 (3.6)   
Blond and black 154 18.7 57.3 (3.6)   
Unknown 97 11.8 57.7 (3.0)   
Missing data 68       
Controls' diagnosis         
Hernia 332 37.2 57.4 (3.1) 0.8 
Fracture & Trauma 263 29.5 57.5 (4.0)   
Hydrocele 122 13.7 57.6 (3.3)   
Other Abdominal Surgery 99 11.1 57.2 (2.9)   
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Supplementary Table S3-4 (cont.) Distributional characteristics of study subjects and LINE-1 
methylation in the SBC/EPICURO Study 
Variables N Percent  LINE-1 methylation (%) P-value* 
Median (IQR) 
Other Diseases 76 8.5 57.6 (3.8)   
Vitamin B1 intake (µg/day/kcal)       
< 0.66 323 50.1 57.5 (3.8) 0.4 
≥0.66 322 49.9 57.4 (3.3)   
Missing data 247       
Vitamin B2 intake (µg/day/kcal)       
< 0.91 323 50.1 57.4 (3.7) 0.9 
≥0.91 322 49.9 57.5 (3.6)   
Missing Data 247       
Vitamin B3 intake (µg/day/kcal)       
<10.08 323 50.1 57.5 (3.9) 0.5 
≥10.08 322 49.9 57.4 (3.3)   
Missing Data 247       
Vitamin B6 intake (µg/day/kcal)       
<1.00 323 50.1 57.4 (3.9) 0.5 
≥1.00 322 49.9 57.4 (3.4)   
Missing Data 247       
Vitamin B12 intake (µg/day/kcal)       
<3.98 323 50.1 57.4 (3.7) 0.8 
≥3.98 322 49.9 57.4 (3.6)   
Missing Data 247       
Folate intake (µg/day/kcal)         
<166.74 323 50.1 57.4 (3.9) 0.5 
≥166.74 322 49.9 57.5 (3.3)   
Missing Data 247       
Protein intake (µg/day/kcal)         
<46.68 323 50.1 57.4 (3.7) 0.97 
≥4.33 322 49.9 57.4 (3.6)   
Missing Data 247       
Alcohol intake (µg/day/kcal)         
<4.33 323 50.1 57.4 (3.6) 0.4 
≥4.33 322 49.9 57.4 (3.8)   
Missing Data 247       
Fruit intake (g/day/kcal)         
<172.71 320 50.1 57.3 (3.2) 0.6 
≥172.71 319 49.9 57.6 (4.2)   
Missing Data 253       
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Supplementary Table S3-4 (cont.) Distributional characteristics of study subjects and LINE-1 
methylation in the SBC/EPICURO Study 
Variables N Percent  LINE-1 methylation (%) P-value* 
Median (IQR) 
Vegetable intake (g/day/kcal)         
<107.12 320 50.0 57.3 (4.0) 0.3 
≥107.12 320 50.0 57.6 (3.3)   
Missing Data 252       
Fruit and vegetable intake (g/day/kcal)     
<295.61 320 50.1 57.4 (3.5) 0.9 
≥295.61 319 49.9 57.4 (3.9)   
Missing Data 253       
Toenail aluminum (µg/g)         
< 10.51 329 50.0 57.5 (3.6) 0.5 
≥ 10.51 329 50.0 57.4 (3.3)   
Missing Data 234       
Toenail arsenic (µg/g)         
<0.07 330 50.1 57.5 (3.8) 0.7 
≥0.07 329 49.9 57.4 (3.3)   
Missing Data 233       
Toenail cadmium (µg/g)         
<0.01 330 50.1 57.5 (3.2) 0.4 
≥0.01 329 49.9 57.4 (3.6)   
Missing Data 233       
Toenail chromium (µg/g)         
< 0.41 330 50.1 57.5 (3.8) 0.6 
≥ 0.41 329 49.9 57.4 (3.2)   
Missing Data 233       
Toenail copper (µg/g)         
< 3.38 329 49.9 57.5 (3.3) 0.9 
≥3.38 330 50.1 57.4 (3.5)   
Missing Data 233       
Toenail iron (µg/g)         
< 14.61 329 50.0 57.4 (3.1) 0.3 
≥ 14.61 329 50.0 57.6 (3.7)   
Missing Data 234       
Toenail lead (µg/g)         
<0.40 329 50.1 57.5 (3.1) 0.7 
≥0.40 330 49.9 57.4 (3.6)   
Missing Data 233       
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Supplementary Table S3-4 (cont.) Distributional characteristics of study subjects and LINE-1 
methylation in the SBC/EPICURO Study 
Variables N Percent  LINE-1 methylation (%) P-value* 
Median (IQR) 
Toenail manganese (µg/g) 
    < 0.33 330 50.1 57.4 (3.3) 0.9 
≥ 0.33 329 49.9 57.5 (3.6)   
Missing Data 233       
Toenail nickel (µg/g)         
< 0.47 329 49.9 57.5 (3.0) 0.8 
≥ 0.47 330 50.1 57.4 (3.9)   
Missing Data 233       
Toenail selenium (µg/g)         
<0.56 330 50.1 57.4 (3.4) 0.6 
≥0.56 329 49.9 57.5 (3.5)   
Missing Data 233       
Toenail vanadium (µg/g)         
< 0.02 326 50.1 57.5 (3.7) 0.6 
≥ 0.02 325 49.9 57.4 (3.3)   
Missing Data 241       
Toenail zinc (µg/g)         
< 103.20 329 49.9 57.5 (3.3) 0.8 
≥103.20 330 50.1 57.4 (3.7)   
Missing data 233       
NAT2 phenotype         
Rapid/Intermediate acetylator 389 43.9 57.4 (3.5) 0.8 
Slow acetylator 498 56.1 57.5 (3.2)   
Missing data 5       
GSTM1 genotype         
(+/+, +/-) 421 47.7 57.4 (3.5) 0.6 
(-/-) 462 52.3 57.5 (3.1)   
Missing data 9       
GSTT1 genotype         
(+/+, +/-) 688 77.7 57.5 (3.3) 0.2 
(-/-) 198 22.3 57.4 (3.3)   
Missing data 6       
IQR, interquartile range. 
*P-value from the Kruskal-Wallis test. 
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Supplementary Table S3-5 Association between LINE-1 methylation and individual 
characteristics of study subjects in the SBC/EPICURO Study 
Variables N β (95% CI)* P-value 
Age (years) 892 -0.004 (-0.02, 0.01) 0.6 
Gender       
Male  792 Ref   
Female 100 -0.5 (-1.0, 0.04) 0.07 
Region       
Barcelona 168 Ref   
Valles 135 -0.2 (-0.7, 0.4) 0.6 
Elche 73 -0.5 (-1.1, 0.2) 0.2 
Tenerife 145 -0.1 (-0.7, 0.4) 0.6 
Asturias 371 0.2 (-0.3, 0.6) 0.5 
Body mass index (kg/m²)       
<25.0 372 Ref   
25.0-26.99 148 -0.1 (-0.6, 0.3) 0.5 
27.0-29.99 120 0.2 (-0.3, 0.7) 0.3 
≥30.0 57 0.007 (-0.7, 0.7) 0.9 
Missing data 195     
Controls' diagnosis       
Hernia 332 Ref   
Fracture & Trauma 263 -0.04 (-0.5, 0.4) 0.8 
Hydrocele 122 0.2 (-0.4, 0.7) 0.5 
Other Abdominal Surgery 99 0.1 (-0.7, 0.4) 0.6 
Other Diseases 76 0.2 (-0.4, 0.8) 0.6 
Dietary intake†       
Vitamin B1 (µg/day/kcal) 645 0.6 (-0.5, 1.8) 0.3 
Vitamin B2 (µg/day/kcal) 645 0.2 (-0.5, 0.9) 0.6 
Vitamin B3 (µg/day/kcal) 645 0.03 (-0.04, 0.1) 0.4 
Vitamin B6 (µg/day/kcal) 645 0.8 (0.01, 1.7) 0.05 
Vitamin B12 (µg/day/kcal) 645 -0.03 (-0.08, 0.02) 0.2 
Folate (µg/day/kcal) 645 0.002 (-0.001, 0.01) 0.1 
Protein (µg/day/kcal) 645 0.01 (-0.01, 0.03) 0.3 
Alcohol (µg/day/kcal) 645 -0.01 (-0.03, 0.02) 0.5 
Fruit (g/day/kcal) 639 0.0001 (-0.001, 0.002) 0.9 
Vegetable (g/day/kcal) 640 0.002 (-0.0004, 0.004) 0.1 
Fruit and vegetable (g/day/kcal) 639 0.001 (-0.001, 0.002) 0.4 
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Supplementary Table S3-5 (cont.) Association between LINE-1 methylation and individual 
characteristics of study subjects in the SBC/EPICURO Study 
Variables N β (95% CI)* P-values 
Toenail trace elements‡       
Aluminium (µg/g) 658 -0.003 (-0.01, 0.002) 0.2 
Arsenic (µg/g) 659 -3.3 (-5.7, -1.0) 0.006 
Cadmium (µg/g) 659 0.1 (-0.3, 0.6) 0.7 
Chromium (µg/g) 659 -0.01 (-0.05, 0.03) 0.7 
Copper (µg/g) 659 -0.01 (-0.06, 0.05) 0.8 
Iron (µg/g) 658 0.002 (0.001, 0.004) 0.008 
Lead (µg/g) 659 -0.05 (-0.1, 0.03) 0.2 
Manganese (µg/g) 659 -0.05 (-0.2, 0.06) 0.4 
Nickel (µg/g) 659 0.02 (0.01, 0.03) 0.004 
Selenium (µg/g) 659 0.4 (-0.6, 1.3) 0.4 
Vanadium (µg/g) 651 -0.8 (-2.9, 1.3) 0.4 
Zinc (µg/g) 659 -0.001 (-0.004, 0.001) 0.4 
NAT2 phenotype       
Rapid/Intermediate 389 Ref   
Slow 498 0.2 (-0.1, 0.5) 0.2 
Missing data 5     
GSTM1 genotype       
(+/+, +/-) 421 Ref   
(-/-) 462 0.02 (-0.3, 0.3) 0.9 
Missing data 9     
GSTT1 genotype       
(+/+, +/-) 688 Ref   
(-/-) 198 -0.2 (-0.6, 0.2) 0.4 
Missing data 6     
*Adjusted for age, gender, and region. 
†Data available for those who completed food frequency questionnaire. 
‡Data available for those who provided toe nail for trace element assessment. 
Note: the exposure contrast for trace elements is 1-µg/g and for dietary variables is 1-μg/day/kcal.   
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Supplementary Table S3-6 Association between LINE-1 methylation levels and 15 single nucleotide polymorphisms in genes involved in the one-carbon metabolism pathway with nonsignificant results 
Gene dbSNP N Genotype Additive MOI P-value N Genotype Codominant MOI Global N Genotype Dominant MOI P-value N Genotype Recessive MOI P-value Identifier β (95% CI)* β (95% CI)* P-Value† β (95% CI)* β (95% CI)* 
DNMT3A rs11683424 872 C>T -0.3 (-0.6, 0.1) 0.1 677 CC Ref 0.3 677 CC Ref   855 CC/CT Ref   
            178 CT -0.2 (-0.6, 0.2)   195 CT/TT -0.2 (-0.6, 0.1) 0.2 17 TT -0.8 (-2.0, 0.3) 0.2 
            17 TT -0.9 (-2.0, 0.3)                   
DNMT3A rs1550117 872 G>A 0.2 (-0.2, 0.7) 0.3 743 GG Ref 0.5 743 GG Ref   868 GG/GA Ref   
            125 GA 0.3 (-0.2, 0.7)   129 GA/AA 0.3 (-0.2, 0.7) 0.3 4 AA 0.3 (-2.1, 2.6) 0.8 
            4 AA 0.3 (-2.0, 2.7)                   
ATIC rs4369857 872 A>C 0.4 (-0.2, 0.9) 0.2 796 AA Ref 0.3 796 AA Ref   871 AA/AC Ref   
            75 AC 0.4 (-0.1, 1.0)   76 AC/CC 0.4 (-0.1, 0.9) 0.1 1 CC 0.1 (-4.6, 4.8) 1.0 
            1 CC 0.2 (-4.5, 4.8)                   
ATIC rs7563206 871 C>T -0.2 (-0.4, 0.01) 0.07 242 CC Ref 0.2 242 CC Ref   681 CC/CT Ref   
            439 CT -0.2 (-0.5, 0.2)   629 CT/TT -0.3 (-0.6, 0.1) 0.2 190 TT -0.3 (-0.7, 0.1) 0.1 
            190 TT -0.4 (-0.9, 0.03)                   
ATIC rs1880586 872 A>G -0.2 (-0.4, 0.01) 0.06 242 AA Ref 0.2 242 AA Ref   681 AA/AG Ref   
            439 AG -0.2 (-0.6, 0.2)   630 AG/GG -0.3 (-0.6, 0.1) 0.1 191 GG -0.3 (-0.7, 0.1) 0.1 
            191 GG -0.4 (-0.9, 0.02)                   
ATIC rs4673991 872 C>T 0.1 (-0.1, 0.4) 0.3 394 CC Ref 0.5 394 CC Ref   789 CC/CT Ref   
            395 CT 0.09 (-0.2, 0.4)   478 CT/TT 0.1 (-0.2, 0.5) 0.4 83 TT 0.3 (-0.3, 0.8) 0.3 
            83 TT 0.3 (-0.3, 0.9)                   
ATIC rs4673993 872 T>C 0.1 (-0.1, 0.4) 0.3 394 TT Ref 0.5 394 TT Ref   789 TT/TC Ref   
            395 TC 0.1 (-0.2, 0.4)   478 TC/CC 0.1 (-0.2, 0.5) 0.4 83 CC 0.3 (-0.3, 0.8) 0.3 
            83 CC 0.3 (-0.3, 0.9)                   
ATIC rs4672768 870 G>A 0.1 (-0.1, 0.4) 0.4 393 GG Ref 0.6 393 GG Ref   787 GG/GA Ref   
            394 GA 0.1 (-0.2, 0.4)   477 GA/AA 0.1 (-0.2, 0.4) 0.5 83 AA 0.3 (-0.3, 0.8) 0.3 
            83 AA 0.3 (-0.3, 0.9)                   
ATIC rs10498036 872 G>T 0.1 (-0.1, 0.3) 0.3 315 GG Ref 0.5 315 GG Ref   727 GG/GT Ref   
            412 GT 0.2 (-0.1, 0.6)    557 GT/TT 0.2 (-0.1, 0.5) 0.2 145 TT 0.1 (-0.3, 0.5) 0.7 
            145 TT 0.2 (-0.3, 0.7)                   
ATIC rs7604984 872 A>G 0.1 (-0.08, 0.4) 0.2 313 AA Ref 0.3 313 AA Ref   727 AA/AG Ref   
            414 AG 0.3 (-0.1, 0.6)   559 AG/GG 0.3 (-0.1, 0.6) 0.1 145 GG 0.1 (-0.3, 0.5) 0.7 
            145 GG 0.2 (-0.2, 0.7)                   
MTHFS rs1077965 872 T>C 0.01 (-0.2, 0.2) 0.9 311 TT Ref 0.2 311 TT Ref   725 TT/TC Ref   
            414 TC 0.3 (-0.07, 0.6)   561 TC/CC 0.2 (-0.1, 0.5) 0.3 147 CC -0.2 (-0.7, 0.2) 0.3 
            147 CC -0.1 (-0.5, 0.4)                   
MTHFS rs11855092 872 G>A -0.03 (-0.3, 0.2) 0.8 509 GG Ref 0.2 509 GG Ref   816 GG/GA Ref   
            307 GA 0.2 (-0.2, 0.5)   363 GA/AA 0.1 (-0.2, 0.4) 0.7 56 AA -0.5 (-1.1, 0.2) 0.2 
            56 AA -0.4 (-1.1, 0.3)                   
PEMT rs4646340 872 A>G 0.08 (-0.2, 0.3) 0.5 341 AA Ref 0.1 341 AA Ref   757 AA/AG Ref   
            416 AG 0.3 (-0.03, 0.7)   531 AG/GG 0.2 (-0.1, 0.6) 0.2 115 GG -0.2 (-0.7, 0.3) 0.4 
            115 GG -0.02 (-0.5, 0.5)                   
PEMT rs7215833 872 C>T 0.09 (-0.1, 0.3) 0.5 351 CC Ref 0.1 351 CC Ref   763 CC/CT Ref   
            412 CT 0.3 (-0.01, 0.7)   521 CT/TT 0.3 (-0.1, 0.6) 0.1 109 TT -0.2 (-0.7, 0.3) 0.5 
            109 TT -0.01 (-0.5, 0.5)                   
SLC19A1 rs2838965 870 G>A 0.1 (-0.3, 0.4) 0.4 296 GG Ref 0.1 296 GG Ref   708 GG/GA Ref   
            412 GA 0.4 (0.04, 0.8)   574 GA/AA 0.3(-0.04, 0.6) 0.1 162 AA -0.1 (-0.5, 0.3) 0.5 
            162 AA 0.1 (-0.4, 0.5)                   
MAF minor allele frequency; MOI mode of inheritance.                           
*Adjusted for age, gender, region and smoking status                           
†Global p-value was estimated by using a two-degrees of freedom likelihood-ratio test.                     
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Supplementary Table S3-7 Multivariable model of association between LINE-1 methylation and 
individual characteristics, toenail trace elements and single nucleotide polymorphisms among 
study subjects in the SBC/EPICURO Study 
Variable N β (95% CI)* P-value Global p-value† 
Age (years) 601 -0.01 (-0.03, 0.01) 0.2   
Gender         
Male 534 Ref     
Female 67 -1.0 (-1.7, -0.3) 0.006   
Region         
Barcelona 131 Ref     
Valles 90 -0.05 (-0.7, 0.6) 0.9   
Elche 57 -0.4 (-1.2, 0.3) 0.3   
Tenerife 82 0.2 (-0.5, 0.9) 0.5   
Asturias 241 0.1 (-0.4, 0.7) 0.6   
Tobacco Type         
Non-smoker 187 Ref     
Blond only 76 -0.5 (-1.2, 0.2) 0.1   
Black only 156 0.09 (-0.5, 0.7) 0.7   
Blond and black 118 -0.6 (-1.2, 0.05) 0.07   
Unknown 64 -0.07 (-0.8, 0.7) 0.9   
Toenail Trace Element         
Arsenic (µg/g) 601 -4.8 (-7.8, -1.8) 0.002   
Iron (µg/g) 601 0.003 (0.001, 0.01) 0.0004   
Nickel (µg/g) 601 0.01 (0.004, 0.03) 0.005   
Gene, dbSNP identifier         
DNMT3A-rs7581217, C>T 601 0.3 (0.003, 0.6) 0.048   
AS3MT-rs7085104         
AA/AG 518 Ref     
GG 83 0.5 (-0.07, 1.1) 0.09   
MTHFS-rs1380642         
CC 409 Ref     
CT 167 0.4 (-0.02, 0.9) 0.06 0.005 
TT 25 -1.2 (-2.2, -0.2) 0.02   
SLC19A1-rs914238         
TT 159 Ref     
TC 293 0.3 (-0.1, 0.8) 0.2 0.07 
CC 149 -0.2 (-0.8, 0.3) 0.5   
TCN2-rs9621049         
CC/CT 593 Ref     
TT 8 4.3 (0.9, 7.6) 0.01   
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Supplementary Table S3-7 (cont.) Multivariable model of association between LINE-1 
methylation and individual characteristics, toenail trace elements and single nucleotide 
polymorphisms among study subjects in the SBC/EPICURO Study 
Variable N β (95% CI)* P-value Global p-value† 
TCN2-rs9606756         
AA/AG 594 Ref     
GG 7 -2.3 (-7.1, 2.5) 0.3   
TCN2-rs4820887         
GG/GA 595 Ref     
AA 6 -0.6 (-6.7, 5.6) 0.9   
*Fully adjusted robust regression coefficient. 
†Global p-value was estimated by using a two-degrees of freedom likelihood-ratio test. 
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Supplementary Figure S3-1 Distribution of LINE-1 methylation among study subjects in the 
SBC/EPICURO study 
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For Supplementary Table S4-1, please see Supplementary Table S3-1 
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Supplementary Table S4-2 Association between individual LINE-1 CpG position and urothelial carcinoma of the bladder risk in the 
SBC/EPICURO study 
Methylation     Unadjusted Model         Adjusted Model* 
in tertiles† Cases Controls OR 95% CI P-value   Tertiles Cases Controls OR 95% CI P-value 
LINE-1 CpG1                             
T1 344 298 1.20 0.96 1.50 0.1   T1 344 297 1.15 0.91 1.46 0.2 
T2 286 297 1 Referent         T2 284 296 1 Referent       
T3 322 297 1.13 0.90 1.41 0.3   T3 318 296 1.10 0.87 1.40 0.4 
                              
LINE-1 CpG2                             
T1 337 298 1.32 1.05 1.66 0.02   T1 334 297 1.24 0.98 1.58 0.08 
T2 255 297 1 Referent         T2 255 296 1 Referent       
T3 360 297 1.41 1.12 1.77 0.003   T3 357 296 1.42 1.11 1.80 0.005 
                              
LINE-1 CpG3                             
T1 329 298 1.18 0.94 1.48 0.1   T1 326 296 1.13 0.89 1.44 0.3 
T2 277 297 1 Referent         T2 277 296 1 Referent       
T3 346 297 1.25 1.00 1.57 0.05   T3 343 297 1.20 0.94 1.52 0.1 
                              
LINE-1 CpG4                             
T1 317 298 1.15 0.92 1.45 0.2   T1 315 296 1.15 0.91 1.47 0.2 
T2 274 297 1 Referent         T2 272 297 1 Referent       
T3 361 297 1.32 1.05 1.65 0.02   T3 359 296 1.33 1.05 1.68 0.02 
*Model adjusted for age, gender, region, smoking status (never, occasional, former and current smoker). 
†Tertile cut-offs: CpG1: 76.78%, 78.23%; CpG2: 45.59%, 48.07%; CpG3: 58.25%, 60.18%; CpG4: 45.44%, 48.38%. 
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Supplementary Table S4-3 Association between LINE-1 methylation and risk of bladder cancer 
stratified by tumor subphenotypes in the SBC/EPICURO study 
LINE-1 methylation 
(tertiles) Cases Controls OR* 95% CI P 
Low-grade NNIBC             
T1 (<56.68) 190 296 1.33 1.00 1.77 0.05 
T2 (56.68-<58.65) 136 297 1 Referent     
T3 (≥58.65) 194 296 1.37 1.03 1.82 0.03 
              
High-grade NMIBC             
T1 (<56.68) 63 296 1.12 0.74 1.69 0.58 
T2 (56.68-<58.65) 54 297 1 Referent     
T3 (≥58.65) 59 296 1.14 0.75 1.73 0.53 
              
MIBC             
T1 (<56.68%) 66 296 1.16 0.77 1.74 0.50 
T2 (56.68-<58.65%) 55 297 1 Referent     
T3 (≥58.65%) 83 296 1.62 1.09 2.41 0.02 
*Adjusted model for age, gender, region and smoking status (never, occasional, former and 
current smoker). 
P value for heterogeneity: low- vs high-grade NMIBC = 0.5; low-grade NMIBC vs MIBC = 
0.6; high-grade NMIBC vs MIBC=0.4. 
NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.  
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Supplementary Table S4-4 Association between LINE-1 methylation and urothelial carcinoma of 
the bladder risk stratified by age, gender and smoking status in the SBC/EPICURO study 
LINE-1 methylation 
(tertiles) Cases Controls OR* 95% CI P-value P interaction 
Age               
Age <60 years               
T1 (<56.68%) 84 91 1.12 0.69 1.82 0.6 0.2 
T2 (56.68-<58.65%) 53 72 1 Referent         
T3 (≥58.65%) 72 90 0.93 0.56 1.53 0.7   
Age 60 - 69 years               
T1 (<56.68%) 124 107 1.25 0.84 1.86 0.3   
T2 (56.68-<58.65%) 108 119 1 Referent         
T3 (≥58.65%) 109 114 1.11 0.74 1.66 0.6   
Age ≥ 70 years               
T1 (<56.68%) 127 98 1.41 0.95 2.09 0.08   
T2 (56.68-<58.65%) 99 106 1 Referent         
T3 (≥58.65%) 170 92 1.96 1.33 2.88 0.0006   
                
Gender               
LINE-1 methylation 
(tertiles) Cases Controls OR† 95% CI P-value P interaction 
Male               
T1 (<56.68%) 285 257 1.26 0.98 1.64 0.08 0.5 
T2 (56.68-<58.65%) 230 265 1 Referent         
T3 (≥58.65%) 305 267 1.28 0.99 1.66 0.06   
Female               
T1 (<56.68%) 50 39 1.28 0.65 2.50 0.5   
T2 (56.68-<58.65%) 30 32 1 Referent         
T3 (≥58.65%) 46 29 1.76 0.87 3.56 0.1   
                
Smoking status               
LINE-1 methylation 
(tertiles) Cases Controls OR‡ 95% CI P-value P interaction 
Never smoker               
T1 (<56.68%) 54 84 2.06 1.17 3.62 0.01 0.2 
T2 (56.68-<58.65%) 30 94 1 Referent         
T3 (≥58.65%) 53 77 2.05 1.16 3.63 0.01   
Ever smoker               
T1 (<56.68%) 281 212 1.18 0.90 1.53 0.2   
T2 (56.68-<58.65%) 230 203 1 Referent         
T3 (≥58.65%) 298 219 1.21 0.93 1.57 0.2   
*Adjusted for gender, region and smoking status (never, occasional, former and current smoker). 
Age categorized by the median age was used to calculate the interaction p-value. 
†Adjusted for age, region and smoking status (never, occasional, former and current smoker). 
‡Adjusted for age, gender and region. Smoking status categorized as never smoker and ever 
smoker was used to calculate the interaction p-value. 
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Supplementary Table S4-5 Association between LINE-1 methylation and urothelial carcinoma of 
the bladder risk adjusted for tobacco type, B vitamins, protein, alcohol intakes, trace elements, and 
variations in GSTM1 and GSTT1 in the SBC/EPICURO study 
Adjusted for: LINE-1 methylation (tertiles) Cases Controls OR 95% CI 
P-
value 
P 
interaction 
Tobacco type* T1 (<56.68%) 335 296 1.28 1.00 1.63 0.05 0.2 
  T2 (56.68-<58.65%) 260 297 1 Referent         
  T3 (≥58.65%) 351 296 1.39 1.09 1.78 0.008   
                  
Vitamin B1 
intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.12 0.84 1.48 0.4 0.5 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.23 0.93 1.62 0.2   
                  
Vitamin B2 
intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.12 0.84 1.48 0.4 0.7 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.23 0.93 1.63 0.1   
                  
Vitamin B3 
intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.12 0.85 1.49 0.4 0.5 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.24 0.94 1.64 0.1   
                  
Vitamin B6 
intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.11 0.83 1.47 0.5 0.7 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.24 0.93 1.63 0.1   
                  
Vitamin B12 
intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.12 0.84 1.49 0.4 0.8 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.24 0.94 1.65 0.1   
                  
Folate intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.11 0.84 1.48 0.5 0.4 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.24 0.94 1.64 0.1   
                  
Protein intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.13 0.85 1.50 0.4 0.7 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.25 0.95 1.66 0.1   
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Supplementary Table S4-5 (cont.) Association between LINE-1 methylation and urothelial 
carcinoma of the bladder risk adjusted for tobacco type, B vitamins, protein, alcohol intakes, trace 
elements, and variations in GSTM1 and GSTT1 in the SBC/EPICURO study 
Adjusted for: LINE-1 methylation (tertiles) Cases Controls OR 95% CI 
P-
value 
P 
interaction 
Alcohol intake 
(µg/day/kcal)† 
T1 (<56.68%) 249 220 1.11 0.84 1.48 0.5 0.9 
T2 (56.68-<58.65%) 194 204 1 Referent         
T3 (≥58.65%) 268 220 1.22 0.92 1.61 0.2   
                  
Aluminum† T1 (<56.68%) 257 220 1.17 0.89 1.55 0.2 0.5 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.20 0.91 1.58 0.2   
                  
Arsenic† T1 (<56.68%) 257 221 1.14 0.87 1.51 0.3 0.9 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.17 0.89 1.54 0.3   
                  
Cadmium† T1 (<56.68%) 257 221 1.17 0.88 1.54 0.3 0.4 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.21 0.92 1.59 0.2   
                  
Chromium† T1 (<56.68%) 257 221 1.13 0.86 1.50 0.4 0.5 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.17 0.89 1.54 0.3   
                  
Copper† T1 (<56.68%) 257 221 1.15 0.87 1.53 0.3 0.9 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.18 0.90 1.55 0.2   
                  
Iron† T1 (<56.68%) 255 221 1.15 0.87 1.52 0.3 0.4 
  T2 (56.68-<58.65%) 206 207 1 Referent         
  T3 (≥58.65%) 276 230 1.19 0.90 1.57 0.2   
                  
Lead† T1 (<56.68%) 257 221 1.13 0.86 1.50 0.4 0.5 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.17 0.89 1.54 0.3   
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Supplementary Table S4-5 (cont.) Association between LINE-1 methylation and urothelial 
carcinoma of the bladder risk adjusted for tobacco type, B vitamins, protein, alcohol intakes, trace 
elements, and variations in GSTM1 and GSTT1 in the SBC/EPICURO study 
Adjusted for: LINE-1 methylation (tertiles) Cases Controls OR 95% CI 
P-
value 
P 
interaction 
Manganese† T1 (<56.68%) 257 221 1.16 0.88 1.53 0.3 0.2 
  T2 (56.68-<58.65%) 207 208 
1 
Referent         
  T3 (≥58.65%) 277 230 1.20 0.91 1.58 0.2   
                  
Nickel† T1 (<56.68%) 257 221 1.13 0.86 1.50 0.4 0.9 
  T2 (56.68-<58.65%) 207 208 1 Referent         
  T3 (≥58.65%) 277 230 1.16 0.88 1.53 0.3   
                 Selenium† T1 (<56.68%) 257 221 1.14 0.86 1.50 0.4 0.5 
  T2 (56.68-<58.65%) 207 208 
1 
Referent         
  T3 (≥58.65%) 277 230 1.17 0.89 1.54 0.3   
                  
Vanadium† T1 (<56.68%) 248 218 1.12 0.85 1.49 0.4 0.3 
  T2 (56.68-<58.65%) 206 205 
1 
Referent         
  T3 (≥58.65%) 270 228 1.16 0.88 1.53 0.3   
                  
Zinc† T1 (<56.68%) 257 221 1.15 0.87 1.52 0.3 0.9 
  T2 (56.68-<58.65%) 207 208 
1 
Referent         
  T3 (≥58.65%) 277 230 1.18 0.89 1.55 0.2   
                  
GSTM1† T1 (<56.68%) 332 296 1.24 0.98 1.58 0.08 0.5 
  T2 (56.68-<58.65%) 258 291 
1 
Referent         
  T3 (≥58.65%) 346 293 1.33 1.04 1.69 0.02   
                  
GSTT1† T1 (<56.68%) 335 295 1.26 0.99 1.60 0.06 0.5 
  T2 (56.68-<58.65%) 259 295 
1 
Referent         
  T3 (≥58.65%) 348 293 1.34 1.05 1.70 0.02   
*Model adjusted for age, gender, region, tobacco type. 
†Variable included in a model adjusted for age, gender, region, smoking status (never, occasional, former 
and current smoker). 
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Supplementary Table S4-6 Corrected likelihood ratio test p-values of the interaction between 
LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
SNPs modeled in additive mode of inheritance 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs2124344 17 PEMT 1797 0.36 0.77 0.0003 0.2 
rs4646350 17 PEMT 1798 0.36 0.83 0.0007 0.3 
rs10179873 2 ATIC 1798 0.30 0.63 0.002 0.6 
rs11892429 2 ATIC 1798 0.29 1.00 0.002 0.6 
rs10197559 2 ATIC 1788 0.29 0.87 0.002 0.7 
rs1983462 2 ATIC 1798 0.31 0.47 0.002 0.7 
rs4646341 17 PEMT 1795 0.37 0.56 0.002 0.7 
rs10197653 2 ATIC 1798 0.29 0.74 0.003 0.8 
rs6706415 2 ATIC 1798 0.31 0.81 0.003 0.8 
rs4646340 17 PEMT 1798 0.37 0.51 0.003 0.8 
rs7215833 17 PEMT 1798 0.36 0.51 0.005 0.9 
rs7581217 2 DNMT3A 1798 0.39 0.62 0.006 0.9 
rs11683424 2 DNMT3A 1798 0.12 0.20 0.007 1.0 
rs4646359 17 PEMT 1798 0.46 0.15 0.010 1.0 
rs7604984 2 ATIC 1798 0.40 0.62 0.010 1.0 
rs798766 4 TMEM129-TACC3-FGFR3 1798 0.18 0.21 0.01 1.0 
rs11656215 17 PEMT 1798 0.46 0.20 0.01 1.0 
rs10498036 2 ATIC 1798 0.40 0.57 0.01 1.0 
rs11855092 15 MTHFS 1798 0.24 0.31 0.01 1.0 
rs4673993 2 ATIC 1798 0.32 0.31 0.02 1.0 
rs1077965 15 MTHFS 1797 0.41 0.58 0.02 1.0 
rs4244599 17 PEMT 1774 0.47 0.34 0.02 1.0 
rs1880580 15 MTHFS 1798 0.31 0.38 0.02 1.0 
rs435689 15 MTHFS 1798 0.49 0.50 0.02 1.0 
rs4924922 17 PEMT 1798 0.37 0.43 0.02 1.0 
rs4673991 2 ATIC 1797 0.32 0.31 0.02 1.0 
rs282814 15 MTHFS 1798 0.22 0.84 0.02 1.0 
rs4672768 2 ATIC 1794 0.32 0.31 0.02 1.0 
rs7560488 2 DNMT3A 1731 0.48 0.15 0.02 1.0 
rs12997662 2 ATIC 1798 0.34 0.26 0.02 1.0 
rs7563206 2 ATIC 1796 0.47 0.84 0.03 1.0 
rs4646344 17 PEMT 1798 0.46 0.45 0.03 1.0 
rs4817580 21 GART 1797 0.10 0.70 0.03 1.0 
rs6057645 20 DNMT3B 1797 0.04 0.22 0.04 1.0 
rs9890064 17 PEMT 1798 0.43 0.41 0.04 1.0 
rs12905663 15 MTHFS 1788 0.29 0.80 0.04 1.0 
rs4646385 17 PEMT 1798 0.45 0.37 0.04 1.0 
rs11869600 17 PEMT 1796 0.37 0.38 0.04 1.0 
rs1880586 2 ATIC 1797 0.47 0.89 0.05 1.0 
rs6495441 15 MTHFS 1798 0.25 0.93 0.05 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs3760188 17 PEMT 1798 0.46 0.38 0.05 1.0 
rs11871738 17 PEMT 1798 0.38 0.67 0.06 1.0 
rs6749992 2 DNMT3A 1798 0.47 0.79 0.06 1.0 
rs4646404 17 PEMT 1792 0.35 0.26 0.06 1.0 
rs2289209 3 CHDH 1798 0.04 0.67 0.06 1.0 
rs740234 22 TCN2 1798 0.23 0.39 0.07 1.0 
rs9835128 3 CHDH 1797 0.16 0.38 0.08 1.0 
rs750546 17 PEMT 1773 0.45 0.19 0.08 1.0 
rs1814175 11 FOLH1 1793 0.40 0.40 0.08 1.0 
rs7605753 2 DNMT3A 1797 0.47 0.68 0.08 1.0 
rs10380 5 MTRR 1793 0.10 0.56 0.08 1.0 
rs17824591 14 MTHFD1 1796 0.23 0.63 0.08 1.0 
rs10839295 11 FOLH1 1797 0.40 0.48 0.08 1.0 
rs3862350 11 FOLH1 1765 0.40 0.15 0.09 1.0 
rs2733106 15 MTHFS 1793 0.15 0.69 0.09 1.0 
rs6119285 20 DNMT3B 1795 0.04 0.20 0.1 1.0 
rs748196 17 PEMT 1795 0.44 0.89 0.1 1.0 
rs1917311 11 FOLH1 1753 0.40 0.72 0.1 1.0 
rs7111215 11 FOLH1 1774 0.40 0.52 0.1 1.0 
rs2183601 21 SLC19A1 1797 0.20 0.92 0.1 1.0 
rs282776 15 MTHFS 1798 0.36 0.47 0.1 1.0 
rs282787 15 MTHFS 1798 0.04 0.34 0.1 1.0 
rs2586153 15 MTHFS 1777 0.15 0.59 0.1 1.0 
rs9606756 22 TCN2 1798 0.12 0.87 0.1 1.0 
rs16988828 22 TCN2 1798 0.09 0.09 0.1 1.0 
rs2838973 21 SLC19A1 1798 0.20 0.92 0.1 1.0 
rs7583409 2 DNMT3A 1795 0.36 0.38 0.1 1.0 
rs4531931 2 ATIC 1796 0.31 0.23 0.1 1.0 
rs2150460 21 SLC19A1 1798 0.20 1.00 0.1 1.0 
rs10509760 10 AS3MT 1798 0.13 0.88 0.1 1.0 
rs2424913 20 DNMT3B 1797 0.37 0.39 0.1 1.0 
rs4476347 2 ATIC 1798 0.25 0.28 0.1 1.0 
rs3740394 10 AS3MT 1797 0.13 1.00 0.1 1.0 
rs1380642 15 MTHFS 1798 0.18 0.57 0.1 1.0 
rs4434082 21 SLC19A1 1797 0.20 1.00 0.1 1.0 
rs7102702 11 FOLH1 1741 0.04 1.00 0.2 1.0 
rs1950902 14 MTHFD1 1798 0.15 1.00 0.2 1.0 
rs4779148 15 MTHFS 1798 0.10 0.45 0.2 1.0 
rs9976878 21 SLC19A1 1797 0.20 1.00 0.2 1.0 
rs11191439 10 AS3MT 1795 0.12 0.75 0.2 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs9306139 21 SLC19A1 1796 0.20 1.00 0.2 1.0 
rs1802059 5 MTRR 1792 0.36 0.60 0.2 1.0 
rs1014971 22 CBX6 APOBEC3A 1797 0.30 0.23 0.2 1.0 
rs3862342 11 FOLH1 1795 0.28 0.93 0.2 1.0 
rs5749135 22 TCN2 1798 0.43 0.07 0.2 1.0 
rs10932605 2 ATIC 1798 0.14 0.39 0.2 1.0 
rs4369857 2 ATIC 1798 0.04 1.00 0.2 1.0 
rs897453 17 PEMT 1790 0.47 0.54 0.2 1.0 
rs17209637 15 MTHFS 1794 0.26 0.79 0.2 1.0 
rs6058897 20 DNMT3B 1798 0.44 0.17 0.2 1.0 
rs443394 15 MTHFS 1798 0.42 0.30 0.2 1.0 
rs1604503 15 MTHFS 1798 0.15 0.59 0.2 1.0 
rs12995968 2 DNMT3A 1798 0.04 0.66 0.2 1.0 
rs6757920 2 ATIC 1794 0.48 0.09 0.2 1.0 
rs4925048 17 PEMT 1797 0.10 0.17 0.2 1.0 
rs6760069 2 ATIC 1797 0.15 0.35 0.2 1.0 
rs2866358 11 FOLH1 1781 0.38 0.35 0.2 1.0 
rs582172 15 MTHFS 1798 0.42 0.45 0.2 1.0 
rs10948059 6 GNMT 1778 0.49 0.54 0.2 1.0 
rs11040416 11 FOLH1 1798 0.42 0.58 0.2 1.0 
rs2424906 20 DNMT3B 1798 0.37 0.28 0.2 1.0 
rs2301955 22 TCN2 1794 0.43 0.10 0.2 1.0 
rs9980967 21 SLC19A1 1797 0.11 0.38 0.2 1.0 
rs2294008 8 PSCA 1798 0.46 0.73 0.2 1.0 
rs1127717 3 ALDH1L1 1793 0.24 1.00 0.2 1.0 
rs1164685 11 FOLH1 1793 0.38 0.47 0.2 1.0 
rs12898670 15 MTHFS 1796 0.34 0.70 0.2 1.0 
rs9462856 6 GNMT 1798 0.42 0.53 0.2 1.0 
rs17211644 15 MTHFS 1798 0.10 0.72 0.2 1.0 
rs1074390 15 MTHFS 1798 0.38 0.77 0.2 1.0 
rs2838964 21 SLC19A1 1798 0.06 0.77 0.2 1.0 
rs2733103 15 MTHFS 1797 0.15 0.51 0.2 1.0 
rs4911108 20 DNMT3B 1793 0.28 0.87 0.2 1.0 
rs6518253 21 SLC19A1 1797 0.46 0.63 0.2 1.0 
rs7276295 21 SLC19A1 1798 0.06 0.56 0.2 1.0 
rs1495741 8 NAT2 1798 0.24 1.00 0.2 1.0 
rs9621049 22 TCN2 1798 0.11 0.86 0.2 1.0 
rs6058896 20 DNMT3B 1797 0.09 0.67 0.2 1.0 
rs588458 11 FOLH1 1772 0.38 0.52 0.2 1.0 
rs34048824 2 DNMT3A 1797 0.51 0.74 0.2 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs914238 21 SLC19A1 1798 0.49 0.89 0.3 1.0 
rs11040421 11 FOLH1 1798 0.14 0.78 0.3 1.0 
rs2115536 15 MTHFS 1798 0.49 0.22 0.3 1.0 
rs4144700 11 FOLH1 1798 0.38 0.47 0.3 1.0 
rs910085 20 DNMT3B 1797 0.29 0.93 0.3 1.0 
rs166868 15 MTHFS 1796 0.37 0.94 0.3 1.0 
rs6058894 20 DNMT3B 1797 0.08 1.00 0.3 1.0 
rs1055345 21 SLC19A1 1797 0.29 0.10 0.3 1.0 
rs7586294 2 DNMT3A 1797 0.47 0.73 0.3 1.0 
rs16971253 15 MTHFS 1797 0.10 1.00 0.3 1.0 
rs13427202 2 DNMT3A 1797 0.47 0.68 0.3 1.0 
rs1256112 14 MTHFD1 1798 0.40 0.29 0.3 1.0 
rs2838965 21 SLC19A1 1792 0.42 0.33 0.3 1.0 
rs12797853 11 FOLH1 1794 0.13 0.46 0.3 1.0 
rs4911107 20 DNMT3B 1798 0.31 1.00 0.3 1.0 
rs2283873 22 TCN2 1779 0.03 0.49 0.3 1.0 
rs2305230 3 ALDH1L1 1792 0.20 0.30 0.3 1.0 
rs10418 22 TCN2 1772 0.21 0.41 0.3 1.0 
rs3785499 17 PEMT 1798 0.48 0.54 0.3 1.0 
rs7219568 17 PEMT 1798 0.06 0.52 0.3 1.0 
rs12797843 11 FOLH1 1798 0.13 0.37 0.3 1.0 
rs2267163 22 TCN2 1794 0.43 0.06 0.3 1.0 
rs6058883 20 DNMT3B 1797 0.39 0.36 0.3 1.0 
rs11887120 2 DNMT3A 1798 0.41 0.44 0.3 1.0 
rs2424928 20 DNMT3B 1798 0.39 0.26 0.3 1.0 
rs2115540 15 MTHFS 1797 0.49 0.20 0.3 1.0 
rs9332 5 MTRR 1793 0.12 0.34 0.3 1.0 
rs6713377 2 DNMT3A 1797 0.47 0.89 0.3 1.0 
rs4673965 2 ATIC 1798 0.40 0.94 0.3 1.0 
rs2424914 20 DNMT3B 1798 0.39 0.39 0.3 1.0 
rs7124266 11 FOLH1 1798 0.30 0.94 0.3 1.0 
rs7575625 2 DNMT3A 1797 0.47 0.89 0.3 1.0 
rs4646364 17 PEMT 1797 0.03 0.15 0.3 1.0 
rs10839296 11 FOLH1 1777 0.25 0.65 0.3 1.0 
rs6058891 20 DNMT3B 1796 0.39 0.32 0.3 1.0 
rs17285431 15 MTHFS 1798 0.17 0.08 0.3 1.0 
rs7111711 11 FOLH1 1798 0.25 0.86 0.3 1.0 
rs4532960 10 AS3MT 1797 0.44 0.89 0.3 1.0 
rs709046 20 DNMT3B 1798 0.03 1.00 0.3 1.0 
rs10748835 10 AS3MT 1798 0.44 0.89 0.3 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs4495895 11 FOLH1 1751 0.09 0.39 0.3 1.0 
NA 1 MTR_01_ORDER 1793 0.16 0.81 0.4 1.0 
rs10501325 11 FOLH1 1798 0.06 0.08 0.4 1.0 
rs12121543 1 MTHFR 1793 0.22 0.32 0.4 1.0 
rs1460177 15 MTHFS 1797 0.08 0.37 0.4 1.0 
rs11040387 11 FOLH1 1785 0.07 0.31 0.4 1.0 
rs1801198 22 TCN2 1797 0.43 0.08 0.4 1.0 
rs473334 1 CTH 1793 0.31 0.81 0.4 1.0 
rs663649 1 CTH 1793 0.31 0.81 0.4 1.0 
rs710521 3 TP63 1798 0.26 0.93 0.4 1.0 
rs7107178 11 FOLH1 1796 0.25 0.86 0.4 1.0 
rs8101626 19 DNMT1 1798 0.39 0.89 0.4 1.0 
rs2162560 19 DNMT1 1797 0.38 0.94 0.4 1.0 
rs2288349 19 DNMT1 1797 0.38 0.78 0.4 1.0 
rs2035027 15 MTHFS 1798 0.16 0.80 0.4 1.0 
rs12482346 21 SLC19A1 1797 0.48 0.10 0.4 1.0 
rs11892646 2 DNMT3A 1797 0.11 0.87 0.4 1.0 
rs2424921 20 DNMT3B 1798 0.39 0.32 0.4 1.0 
rs2424922 20 DNMT3B 1796 0.39 0.29 0.4 1.0 
rs16971450 15 MTHFS 1797 0.16 0.80 0.4 1.0 
rs6511677 19 DNMT1 1797 0.38 0.89 0.4 1.0 
rs7117247 11 FOLH1 1798 0.06 0.08 0.4 1.0 
rs4820887 22 TCN2 1798 0.10 0.85 0.4 1.0 
rs9789571 2 ATIC 1798 0.42 0.89 0.4 1.0 
rs6750194 2 ATIC 1784 0.07 0.62 0.4 1.0 
rs16906158 11 FOLH1 1796 0.08 1.00 0.4 1.0 
rs10400277 11 FOLH1 1774 0.13 0.37 0.4 1.0 
rs2275566 1 MTR 1793 0.41 0.53 0.4 1.0 
rs2116940 19 DNMT1 1797 0.08 0.64 0.4 1.0 
rs7175620 15 MTHFS 1797 0.22 0.14 0.4 1.0 
rs1081235 15 MTHFS 1798 0.20 0.67 0.4 1.0 
rs17279286 15 MTHFS 1797 0.05 0.73 0.4 1.0 
rs4804122 19 DNMT1 1798 0.39 0.52 0.4 1.0 
rs515064 1 CTH 1793 0.35 0.50 0.4 1.0 
rs4779165 15 MTHFS 1797 0.16 0.80 0.4 1.0 
rs4673981 2 ATIC 1798 0.40 1.00 0.4 1.0 
rs10163099 15 MTHFS 1792 0.26 0.48 0.4 1.0 
rs1369703 2 DNMT3A 1798 0.44 0.10 0.4 1.0 
rs13002567 2 DNMT3A 1798 0.28 0.40 0.4 1.0 
rs2304429 2 DNMT3A 1798 0.43 0.10 0.4 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs1805087 1 MTR 1793 0.16 0.81 0.4 1.0 
rs3788190 21 SLC19A1 1795 0.47 0.10 0.4 1.0 
rs6087990 20 DNMT3B 1797 0.32 0.64 0.4 1.0 
rs1550117 2 DNMT3A 1797 0.08 0.81 0.4 1.0 
rs7174668 15 MTHFS 1798 0.21 0.48 0.4 1.0 
rs204942 15 MTHFS 1798 0.21 0.31 0.4 1.0 
rs7594432 2 DNMT3A 1798 0.44 0.13 0.4 1.0 
rs7217764 17 PEMT 1798 0.05 0.51 0.4 1.0 
rs11683778 2 ATIC 1796 0.03 0.54 0.5 1.0 
rs282795 15 MTHFS 1797 0.32 0.88 0.5 1.0 
rs9001 3 CHDH 1793 0.09 0.21 0.5 1.0 
rs6495446 15 MTHFS 1797 0.26 0.38 0.5 1.0 
NA 1 MTR_01_2_i_order 1793 0.16 0.81 0.5 1.0 
rs632220 11 FOLH1 1798 0.09 0.30 0.5 1.0 
rs4393531 15 MTHFS 1795 0.47 0.63 0.5 1.0 
rs6058869 20 DNMT3B 1797 0.33 0.76 0.5 1.0 
rs1956545 14 MTHFD1 1797 0.08 0.17 0.5 1.0 
rs1164681 11 FOLH1 1798 0.12 0.25 0.5 1.0 
rs12462004 19 DNMT1 1795 0.08 0.64 0.5 1.0 
rs1667627 14 MTHFD2 1792 0.47 0.34 0.5 1.0 
rs378057 15 MTHFS 1797 0.14 0.89 0.5 1.0 
rs9282690 3 ALDH1L1 1793 0.08 1.00 0.5 1.0 
rs770144 15 MTHFS 1798 0.20 1.00 0.5 1.0 
rs202700 11 FOLH1 1734 0.23 0.77 0.5 1.0 
rs1870576 15 MTHFS 1780 0.46 0.06 0.5 1.0 
rs4646410 17 PEMT 1795 0.31 0.94 0.5 1.0 
rs7929543 11 FOLH1 1798 0.07 0.81 0.5 1.0 
rs7220132 17 PEMT 1798 0.29 0.57 0.5 1.0 
rs4819138 21 SLC19A1 1797 0.40 0.89 0.5 1.0 
rs12903985 15 MTHFS 1797 0.29 0.14 0.5 1.0 
rs6485991 11 FOLH1 1791 0.17 0.81 0.5 1.0 
rs6711622 2 DNMT3A 1798 0.44 1.00 0.5 1.0 
rs2288350 19 DNMT1 1798 0.08 0.64 0.5 1.0 
rs7177027 15 MTHFS 1797 0.24 0.40 0.5 1.0 
rs7253062 19 DNMT1 1798 0.38 1.00 0.5 1.0 
rs7604425 2 ATIC 1798 0.35 0.94 0.5 1.0 
rs4804125 19 DNMT1 1797 0.08 0.64 0.5 1.0 
rs1051296 21 SLC19A1 1786 0.48 0.10 0.5 1.0 
rs4987173 6 GNMT 1798 0.50 0.46 0.5 1.0 
rs7085104 10 AS3MT 1798 0.38 1.00 0.5 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs8111085 19 DNMT1 1797 0.08 0.64 0.5 1.0 
rs2241807 3 CHDH 1798 0.42 0.89 0.5 1.0 
rs10839229 11 FOLH1 1795 0.08 0.35 0.5 1.0 
rs11672909 19 DNMT1 1797 0.08 0.81 0.5 1.0 
rs2236224 14 MTHFD1 1798 0.36 0.07 0.5 1.0 
rs10165919 2 ATIC 1797 0.35 0.88 0.5 1.0 
rs660439 11 FOLH1 1794 0.23 0.85 0.5 1.0 
rs2838977 21 SLC19A1 1796 0.40 0.72 0.5 1.0 
rs202712 11 FOLH1 1796 0.23 0.85 0.5 1.0 
rs1081231 15 MTHFS 1797 0.17 0.71 0.5 1.0 
rs914232 21 SLC19A1 1797 0.45 0.17 0.5 1.0 
rs2330183 21 SLC19A1 1757 0.45 0.05 0.5 1.0 
rs11892031 2 UGT1A 1798 0.09 1.00 0.5 1.0 
rs6119286 20 DNMT3B 1798 0.02 0.38 0.5 1.0 
rs7117025 11 FOLH1 1798 0.09 0.30 0.5 1.0 
rs10498514 14 MTHFD1 1798 0.03 0.56 0.5 1.0 
rs8112895 19 DNMT1 1798 0.08 0.81 0.5 1.0 
rs1051298 21 SLC19A1 1790 0.47 0.17 0.5 1.0 
rs10839239 11 FOLH1 1795 0.23 0.85 0.5 1.0 
rs11701960 21 SLC19A1 1797 0.18 0.91 0.5 1.0 
rs11040261 11 FOLH1 1797 0.09 0.39 0.5 1.0 
rs2877078 21 SLC19A1 1786 0.40 0.94 0.5 1.0 
rs4479310 17 PEMT 1798 0.30 0.63 0.5 1.0 
rs11607791 11 FOLH1 1796 0.07 1.00 0.5 1.0 
rs6141813 20 DNMT3B 1798 0.14 1.00 0.5 1.0 
rs10418707 19 DNMT1 1796 0.08 0.64 0.6 1.0 
rs12293923 11 FOLH1 1792 0.09 0.19 0.6 1.0 
rs11158540 14 MTHFD1 1798 0.35 0.94 0.6 1.0 
rs8074191 17 PEMT 1778 0.28 0.93 0.6 1.0 
rs3960835 11 FOLH1 1798 0.06 0.12 0.6 1.0 
rs12913164 15 MTHFS 1798 0.08 0.34 0.6 1.0 
rs1256107 14 MTHFD1 1796 0.49 0.50 0.6 1.0 
rs4804494 19 DNMT1 1797 0.08 0.64 0.6 1.0 
rs1808119 2 ATIC 1797 0.19 0.82 0.6 1.0 
rs4804490 19 DNMT1 1796 0.08 0.64 0.6 1.0 
rs7358352 11 FOLH1 1797 0.09 0.30 0.6 1.0 
rs914231 21 SLC19A1 1791 0.45 0.19 0.6 1.0 
rs11040263 11 FOLH1 1795 0.09 0.19 0.6 1.0 
rs598841 11 FOLH1 1791 0.08 0.19 0.6 1.0 
rs683680 11 FOLH1 1797 0.09 0.14 0.6 1.0 
180 
 
Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs11694842 2 DNMT3A 1797 0.28 0.36 0.6 1.0 
rs10839224 11 FOLH1 1798 0.08 0.35 0.6 1.0 
rs650826 11 FOLH1 1796 0.09 0.14 0.6 1.0 
rs920253 3 CHDH 1798 0.02 0.08 0.6 1.0 
rs2838970 21 SLC19A1 1797 0.40 0.78 0.6 1.0 
rs35020344 14 MTHFD1 1797 0.48 0.42 0.6 1.0 
rs6586282 21 CBS 1792 0.18 0.16 0.6 1.0 
rs16971252 15 MTHFS 1798 0.06 0.34 0.6 1.0 
rs759920 19 DNMT1 1798 0.46 0.79 0.6 1.0 
rs4819128 21 SLC19A1 1798 0.45 0.13 0.6 1.0 
rs6058893 20 DNMT3B 1798 0.32 0.49 0.6 1.0 
rs7177659 15 MTHFS 1796 0.49 0.09 0.6 1.0 
rs16853834 2 ATIC 1798 0.17 0.71 0.6 1.0 
rs3897953 15 MTHFS 1798 0.10 0.25 0.6 1.0 
rs1256095 14 MTHFD1 1782 0.48 0.50 0.6 1.0 
rs16971231 15 MTHFS 1794 0.05 0.14 0.6 1.0 
rs8659 5 MTRR 1790 0.35 0.33 0.6 1.0 
rs10420338 19 DNMT1 1798 0.47 0.64 0.6 1.0 
rs2275565 1 MTR 1793 0.19 0.66 0.6 1.0 
rs2236225 14 MTHFD1 1797 0.43 0.24 0.6 1.0 
rs17556442 11 FOLH1 1792 0.06 0.12 0.6 1.0 
rs8034036 15 MTHFS 1795 0.11 0.23 0.6 1.0 
rs853858 20 DNMT3B 1796 0.37 0.19 0.6 1.0 
rs4778721 15 MTHFS 1798 0.22 0.09 0.6 1.0 
rs4778719 15 MTHFS 1798 0.22 0.09 0.6 1.0 
rs9306264 22 TCN2 1797 0.05 1.00 0.6 1.0 
rs282772 15 MTHFS 1798 0.14 0.25 0.6 1.0 
rs445263 15 MTHFS 1798 0.29 0.68 0.6 1.0 
rs12373907 21 SLC19A1 1797 0.38 0.20 0.6 1.0 
rs9642880 8 MYC 1797 0.44 0.78 0.6 1.0 
rs7113251 11 FOLH1 1798 0.06 0.12 0.6 1.0 
rs9323450 14 MTHFD1 1798 0.31 0.69 0.6 1.0 
rs2372535 2 ATIC 1798 0.14 0.89 0.6 1.0 
rs1819409 11 FOLH1 1783 0.09 0.10 0.6 1.0 
NA 1 MTHFR_02_ORDER 1658 0.39 0.33 0.6 1.0 
rs1109859 17 PEMT 1770 0.18 0.64 0.6 1.0 
rs1801131 1 MTHFR 1710 0.28 0.34 0.6 1.0 
rs8074074 17 PEMT 1796 0.30 0.87 0.6 1.0 
rs2790 18 TYMS 1789 0.20 0.67 0.6 1.0 
rs10498034 2 ATIC 1798 0.16 0.90 0.6 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs17101854 14 MTHFD1 1797 0.03 0.53 0.6 1.0 
rs2295639 14 MTHFD1 1797 0.03 0.54 0.6 1.0 
rs376863 15 MTHFS 1772 0.50 0.73 0.6 1.0 
rs8102137 19 CCNE1 1798 0.33 0.13 0.6 1.0 
rs2287779 5 MTRR 1791 0.03 0.52 0.6 1.0 
rs2287780 5 MTRR 1793 0.03 0.52 0.6 1.0 
rs2281603 14 MTHFD1 1798 0.20 0.34 0.6 1.0 
rs2228611 19 DNMT1 1798 0.46 0.79 0.6 1.0 
rs1979276 17 SHMT1 1808 0.31 0.94 0.6 1.0 
rs1917321 11 FOLH1 1790 0.50 0.54 0.6 1.0 
rs1650697 5 DHFR 1791 0.23 0.06 0.6 1.0 
rs9897362 17 PEMT 1798 0.06 0.77 0.6 1.0 
rs34033751 11 FOLH1 1776 0.11 0.23 0.6 1.0 
rs12592743 15 MTHFS 1798 0.10 0.12 0.6 1.0 
rs3783 17 SHMT1 1806 0.26 0.30 0.6 1.0 
rs7113075 11 FOLH1 1797 0.08 0.64 0.7 1.0 
rs12900076 15 MTHFS 1793 0.08 0.25 0.7 1.0 
rs12098986 11 FOLH1 1795 0.09 0.20 0.7 1.0 
rs17728676 11 FOLH1 1797 0.06 0.14 0.7 1.0 
rs16853826 2 ATIC 1796 0.13 0.88 0.7 1.0 
rs1051266 21 SLC19A1 1798 0.45 0.20 0.7 1.0 
rs767138 21 SLC19A1 1795 0.41 0.89 0.7 1.0 
rs9977111 21 SLC19A1 1750 0.33 0.14 0.7 1.0 
rs17284990 15 MTHFS 1798 0.21 0.62 0.7 1.0 
rs9305012 19 DNMT1 1797 0.08 0.64 0.7 1.0 
rs1059394 18 TYMS 1791 0.31 0.64 0.7 1.0 
rs11040353 11 FOLH1 1795 0.08 0.64 0.7 1.0 
rs7926211 11 FOLH1 1794 0.09 0.19 0.7 1.0 
rs2290684 19 DNMT1 1797 0.46 0.79 0.7 1.0 
rs11677670 2 DNMT3A 1788 0.18 0.64 0.7 1.0 
rs600671 15 MTHFS 1797 0.45 0.34 0.7 1.0 
rs4610054 2 ATIC 1794 0.38 0.67 0.7 1.0 
rs1801394 5 MTRR 1808 0.49 0.50 0.7 1.0 
rs4441015 11 FOLH1 1753 0.14 0.40 0.7 1.0 
rs4779140 15 MTHFS 1797 0.48 0.79 0.7 1.0 
rs7085854 10 AS3MT 1797 0.22 0.85 0.7 1.0 
rs282778 15 MTHFS 1798 0.25 0.86 0.7 1.0 
rs13401241 2 DNMT3A 1798 0.45 0.28 0.7 1.0 
rs1473406 15 MTHFS 1796 0.15 0.79 0.7 1.0 
rs1131603 22 TCN2 1797 0.04 0.66 0.7 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs2834233 21 GART 1797 0.09 0.08 0.7 1.0 
rs16971260 15 MTHFS 1798 0.04 1.00 0.7 1.0 
rs282792 15 MTHFS 1798 0.37 0.47 0.7 1.0 
rs1846285 11 FOLH1 1795 0.16 0.54 0.7 1.0 
rs2983733 14 MTHFD1 1798 0.44 0.68 0.7 1.0 
rs4818789 21 SLC19A1 1798 0.25 0.06 0.7 1.0 
rs12482067 21 GART 1798 0.02 0.24 0.7 1.0 
rs6413471 1 CTH 1793 0.05 0.72 0.7 1.0 
rs9836592 3 CHDH 1798 0.32 0.14 0.7 1.0 
rs7934591 11 FOLH1 1798 0.08 0.81 0.7 1.0 
rs898436 15 MTHFS 1793 0.45 0.37 0.7 1.0 
rs12222221 11 FOLH1 1798 0.08 1.00 0.7 1.0 
rs11040390 11 FOLH1 1798 0.08 1.00 0.7 1.0 
rs4819130 21 SLC19A1 1794 0.45 0.15 0.7 1.0 
rs372447 15 MTHFS 1798 0.38 0.77 0.7 1.0 
rs2586182 15 MTHFS 1798 0.14 0.78 0.7 1.0 
rs202718 11 FOLH1 1798 0.15 0.79 0.7 1.0 
rs1404772 2 ATIC 1798 0.08 0.34 0.7 1.0 
rs699517 18 TYMS 1791 0.31 0.64 0.7 1.0 
rs8068641 17 PEMT 1792 0.11 0.62 0.7 1.0 
rs17291414 19 DNMT1 1798 0.28 0.73 0.7 1.0 
rs11191457 10 AS3MT 1794 0.22 1.00 0.7 1.0 
rs401681 5 TERT-CLPTM1L 1798 0.46 0.84 0.7 1.0 
rs3788200 21 SLC19A1 1798 0.45 0.31 0.7 1.0 
rs4779141 15 MTHFS 1793 0.34 0.55 0.7 1.0 
rs11627387 14 MTHFD1 1798 0.30 0.81 0.7 1.0 
rs8003379 14 MTHFD1 1796 0.25 0.78 0.7 1.0 
rs4646383 17 PEMT 1797 0.09 0.53 0.7 1.0 
rs13317328 3 CHDH 1798 0.09 0.06 0.7 1.0 
rs7587636 2 DNMT3A 1798 0.45 0.25 0.7 1.0 
rs3177999 21 SLC19A1 1790 0.46 0.17 0.7 1.0 
rs202676 11 FOLH1 1788 0.17 0.72 0.7 1.0 
rs8129350 21 SLC19A1 1797 0.34 0.76 0.7 1.0 
rs2983736 14 MTHFD1 1793 0.44 0.73 0.7 1.0 
rs3818239 14 MTHFD1 1787 0.13 0.66 0.7 1.0 
rs7946 17 PEMT 1798 0.30 0.52 0.7 1.0 
rs1464864 2 ATIC 1798 0.30 0.81 0.7 1.0 
rs5753231 22 TCN2 1797 0.16 0.62 0.7 1.0 
rs3893384 15 MTHFS 1798 0.42 0.44 0.7 1.0 
rs12999687 2 DNMT3A 1795 0.45 0.68 0.7 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs6087988 20 DNMT3B 1798 0.19 1.00 0.7 1.0 
rs9974061 21 SLC19A1 1798 0.18 0.82 0.7 1.0 
rs11040432 11 FOLH1 1797 0.08 1.00 0.7 1.0 
rs6722613 2 DNMT3A 1798 0.40 0.89 0.7 1.0 
rs648372 11 FOLH1 1772 0.16 0.46 0.8 1.0 
rs234706 21 CBS 1793 0.33 0.36 0.8 1.0 
rs437302 20 DNMT3B 1797 0.08 1.00 0.8 1.0 
rs12591436 15 MTHFS 1798 0.35 0.55 0.8 1.0 
rs8128050 21 SLC19A1 1794 0.34 0.94 0.8 1.0 
rs1888530 21 SLC19A1 1760 0.47 0.08 0.8 1.0 
rs8128676 21 SLC19A1 1754 0.22 0.92 0.8 1.0 
rs7951180 11 FOLH1 1778 0.17 0.55 0.8 1.0 
rs3772078 2 ATIC 1797 0.20 0.29 0.8 1.0 
rs11158538 14 MTHFD1 1795 0.45 0.78 0.8 1.0 
rs2066470 1 MTHFR 1788 0.08 0.39 0.8 1.0 
rs16853782 2 ATIC 1798 0.20 0.34 0.8 1.0 
rs679470 11 FOLH1 1797 0.17 0.63 0.8 1.0 
rs11158542 14 MTHFD1 1798 0.30 0.81 0.8 1.0 
rs2586154 15 MTHFS 1798 0.14 0.89 0.8 1.0 
rs944422 21 SLC19A1 1791 0.35 0.76 0.8 1.0 
rs1888533 21 SLC19A1 1797 0.48 0.42 0.8 1.0 
rs2424932 20 DNMT3B 1797 0.43 0.15 0.8 1.0 
rs8015278 14 MTHFD1 1798 0.07 0.18 0.8 1.0 
rs12438477 15 MTHFS 1797 0.36 0.61 0.8 1.0 
rs1076991 14 MTHFD1 1798 0.45 0.63 0.8 1.0 
rs12898642 15 MTHFS 1798 0.43 0.34 0.8 1.0 
rs3821353 2 ATIC 1798 0.20 0.17 0.8 1.0 
rs11687225 2 ATIC 1797 0.40 0.72 0.8 1.0 
rs12884767 14 MTHFD1 1798 0.04 0.14 0.8 1.0 
rs8128681 21 SLC19A1 1798 0.33 0.94 0.8 1.0 
rs685487 15 MTHFS 1798 0.36 0.34 0.8 1.0 
rs5749131 22 TCN2 1798 0.42 0.13 0.8 1.0 
rs282802 15 MTHFS 1798 0.29 0.09 0.8 1.0 
rs1256114 14 MTHFD1 1797 0.11 0.86 0.8 1.0 
rs35709834 5 DHFR 1793 0.04 0.62 0.8 1.0 
rs9910747 17 PEMT 1798 0.07 0.47 0.8 1.0 
rs11085720 19 DNMT1 1798 0.41 0.44 0.8 1.0 
rs7144437 14 MTHFD1 1797 0.07 0.10 0.8 1.0 
rs13036246 2 DNMT3A 1797 0.48 0.08 0.8 1.0 
rs3740392 10 AS3MT 1794 0.29 0.41 0.8 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs1020697 17 PEMT 1770 0.10 0.35 0.8 1.0 
rs2865908 11 FOLH1 1798 0.18 0.50 0.8 1.0 
rs6573559 14 MTHFD1 1798 0.30 0.94 0.8 1.0 
rs7102641 11 FOLH1 1793 0.08 0.47 0.8 1.0 
rs3774616 3 CHDH 1798 0.04 1.00 0.8 1.0 
rs12613 21 CBS 1793 0.09 0.83 0.8 1.0 
rs1465825 2 DNMT3A 1797 0.27 1.00 0.8 1.0 
rs1023159 21 SLC19A1 1796 0.42 0.78 0.8 1.0 
rs1979277 17 SHMT1 1809 0.27 0.87 0.8 1.0 
rs11040106 11 FOLH1 1787 0.36 0.66 0.9 1.0 
rs12148881 15 MTHFS 1797 0.26 0.19 0.9 1.0 
rs16971249 15 MTHFS 1798 0.08 0.09 0.9 1.0 
rs2424908 20 DNMT3B 1798 0.17 0.40 0.9 1.0 
rs734693 2 DNMT3A 1795 0.29 0.51 0.9 1.0 
rs2838961 21 SLC19A1 1797 0.34 0.94 0.9 1.0 
rs12453139 17 PEMT 1797 0.26 0.66 0.9 1.0 
NA 1 MTHFR_02_2_i_order 1793 0.39 0.35 0.9 1.0 
rs1801133 1 MTHFR 1793 0.39 0.35 0.9 1.0 
rs17745484 2 DNMT3A 1797 0.35 0.30 0.9 1.0 
rs4902278 14 MTHFD1 1791 0.07 0.18 0.9 1.0 
rs2838958 21 SLC19A1 1794 0.46 0.63 0.9 1.0 
rs8018032 14 MTHFD1 1798 0.45 0.95 0.9 1.0 
rs10839210 11 FOLH1 1796 0.21 0.18 0.9 1.0 
rs1046778 10 AS3MT 1798 0.32 0.70 0.9 1.0 
rs12987326 2 DNMT3A 1798 0.37 0.47 0.9 1.0 
rs11681447 2 DNMT3A 1796 0.29 0.62 0.9 1.0 
rs2987969 14 MTHFD1 1797 0.45 0.95 0.9 1.0 
rs2834232 21 GART 1797 0.26 0.73 0.9 1.0 
rs8971 21 GART 1795 0.26 0.73 0.9 1.0 
rs2289093 2 DNMT3A 1798 0.29 0.62 0.9 1.0 
rs1847638 11 FOLH1 1729 0.21 0.47 0.9 1.0 
rs17279885 15 MTHFS 1798 0.20 0.67 0.9 1.0 
rs2834231 21 GART 1798 0.26 0.73 0.9 1.0 
rs8011839 14 MTHFD1 1798 0.17 0.72 0.9 1.0 
rs1256142 14 MTHFD1 1798 0.44 0.10 0.9 1.0 
rs8923 15 MTHFS 1798 0.08 0.15 0.9 1.0 
rs10460566 2 DNMT3A 1798 0.27 0.86 0.9 1.0 
rs6445606 3 CHDH 1798 0.29 0.10 0.9 1.0 
rs11852515 15 MTHFS 1798 0.11 0.74 0.9 1.0 
rs10769558 11 FOLH1 1797 0.21 0.18 0.9 1.0 
185 
 
Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs2236222 14 MTHFD1 1798 0.10 0.27 0.9 1.0 
rs6517178 21 GART 1798 0.40 0.72 0.9 1.0 
rs12627639 21 SLC19A1 1797 0.21 0.68 0.9 1.0 
rs17279753 15 MTHFS 1798 0.19 0.51 0.9 1.0 
rs12614943 2 ATIC 1798 0.27 0.73 0.9 1.0 
rs3783728 14 MTHFD1 1798 0.08 0.64 0.9 1.0 
rs8129445 21 SLC19A1 1798 0.32 0.70 0.9 1.0 
rs12416687 10 AS3MT 1797 0.27 0.15 0.9 1.0 
rs4094478 11 FOLH1 1770 0.20 0.34 0.9 1.0 
rs2154583 21 GART 1791 0.40 0.67 0.9 1.0 
rs1809986 11 FOLH1 1798 0.36 0.38 0.9 1.0 
rs4817579 21 GART 1798 0.34 0.15 0.9 1.0 
rs8003567 14 MTHFD1 1798 0.11 0.47 0.9 1.0 
rs7283354 21 GART 1798 0.34 0.15 0.9 1.0 
rs749130 2 DNMT3A 1798 0.45 0.37 0.9 1.0 
rs35918857 19 DNMT1 1797 0.02 0.25 0.9 1.0 
rs16999714 19 DNMT1 1796 0.21 0.26 0.9 1.0 
rs8081810 17 PEMT 1797 0.20 0.92 0.9 1.0 
rs7279305 21 SLC19A1 1797 0.35 1.00 0.9 1.0 
rs7120743 11 FOLH1 1774 0.36 0.77 0.9 1.0 
rs1404774 2 ATIC 1784 0.22 0.42 1.0 1.0 
rs559062 1 CTH 1793 0.22 0.85 1.0 1.0 
rs4817577 21 GART 1797 0.34 0.20 1.0 1.0 
rs3755817 3 CHDH 1797 0.30 0.42 1.0 1.0 
rs4911263 20 DNMT3B 1798 0.32 1.00 1.0 1.0 
rs17751556 14 MTHFD1 1798 0.08 0.65 1.0 1.0 
rs12910340 15 MTHFS 1798 0.42 0.73 1.0 1.0 
rs2838969 21 SLC19A1 1798 0.07 0.79 1.0 1.0 
rs2696923 11 FOLH1 1798 0.21 0.12 1.0 1.0 
rs8041943 15 MTHFS 1794 0.41 0.37 1.0 1.0 
rs11629135 14 MTHFD1 1797 0.11 0.38 1.0 1.0 
rs11627525 14 MTHFD1 1798 0.11 0.08 1.0 1.0 
rs865646 5 DHFR 1736 0.36 0.55 1.0 1.0 
rs2834235 21 GART 1797 0.39 0.67 1.0 1.0 
rs2696935 11 FOLH1 1798 0.21 0.12 1.0 1.0 
rs663465 1 CTH_01 1792 0.42 0.36 1.0 1.0 
rs8019804 14 MTHFD1 1798 0.07 1.00 1.0 1.0 
rs6801605 3 CHDH 1798 0.37 1.00 1.0 1.0 
rs3800292 6 GNMT 1798 0.06 0.57 1.0 1.0 
rs2987981 14 MTHFD1 1798 0.26 1.00 1.0 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=524) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs11658944 17 PEMT 1797 0.05 0.49 1.0 1.0 
rs617219 5 BHMT 1790 0.32 0.94 1.0 1.0 
rs567754 5 BHMT 1792 0.29 0.74 1.0 1.0 
rs7759302 6 GNMT 1798 0.06 0.57 1.0 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
SNPs modeled in codominant mode of inheritance 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7215833 17 PEMT 1798 0.36 0.51 0.0001 0.08 
rs2124344 17 PEMT 1797 0.36 0.77 0.0001 0.08 
rs4646340 17 PEMT 1798 0.37 0.51 0.0002 0.1 
rs4646341 17 PEMT 1795 0.37 0.56 0.0004 0.2 
rs4646350 17 PEMT 1798 0.36 0.83 0.0004 0.2 
rs7604984 2 ATIC 1798 0.40 0.62 0.004 0.9 
rs4646359 17 PEMT 1798 0.46 0.15 0.004 0.9 
rs10498036 2 ATIC 1798 0.40 0.57 0.005 0.9 
rs11892429 2 ATIC 1798 0.29 1.00 0.007 1.0 
rs10197559 2 ATIC 1788 0.29 0.87 0.007 1.0 
rs11683424 2 DNMT3A 1798 0.12 0.20 0.008 1.0 
rs9890064 17 PEMT 1798 0.43 0.41 0.009 1.0 
rs10179873 2 ATIC 1798 0.30 0.63 0.009 1.0 
rs798766 4 TMEM129-
TACC3-FGFR3 
1798 0.18 0.21 0.009 1.0 
rs10197653 2 ATIC 1798 0.29 0.74 0.01 1.0 
rs4673991 2 ATIC 1797 0.32 0.31 0.01 1.0 
rs4673993 2 ATIC 1798 0.32 0.31 0.01 1.0 
rs4672768 2 ATIC 1794 0.32 0.31 0.01 1.0 
rs11855092 15 MTHFS 1798 0.24 0.31 0.01 1.0 
rs1983462 2 ATIC 1798 0.31 0.47 0.02 1.0 
rs7560488 2 DNMT3A 1731 0.48 0.15 0.02 1.0 
rs6706415 2 ATIC 1798 0.31 0.81 0.02 1.0 
rs1077965 15 MTHFS 1797 0.41 0.58 0.02 1.0 
rs435689 15 MTHFS 1798 0.49 0.50 0.02 1.0 
rs1880580 15 MTHFS 1798 0.31 0.38 0.02 1.0 
rs7604425 2 ATIC 1798 0.35 0.94 0.02 1.0 
rs4924922 17 PEMT 1798 0.37 0.43 0.02 1.0 
rs282814 15 MTHFS 1798 0.22 0.84 0.02 1.0 
rs7581217 2 DNMT3A 1798 0.39 0.62 0.02 1.0 
rs6495441 15 MTHFS 1798 0.25 0.93 0.02 1.0 
rs10165919 2 ATIC 1797 0.35 0.88 0.02 1.0 
rs12903985 15 MTHFS 1797 0.29 0.14 0.03 1.0 
rs204942 15 MTHFS 1798 0.21 0.31 0.03 1.0 
rs2733106 15 MTHFS 1793 0.15 0.69 0.03 1.0 
rs11656215 17 PEMT 1798 0.46 0.20 0.03 1.0 
rs7174668 15 MTHFS 1798 0.21 0.48 0.04 1.0 
rs4673965 2 ATIC 1798 0.40 0.94 0.04 1.0 
rs4646404 17 PEMT 1792 0.35 0.26 0.04 1.0 
rs4244599 17 PEMT 1774 0.47 0.34 0.05 1.0 
rs2586153 15 MTHFS 1777 0.15 0.59 0.05 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4925048 17 PEMT 1797 0.10 0.17 0.06 1.0 
rs4393531 15 MTHFS 1795 0.47 0.63 0.06 1.0 
rs11869600 17 PEMT 1796 0.37 0.38 0.07 1.0 
rs7563206 2 ATIC 1796 0.47 0.84 0.07 1.0 
rs12997662 2 ATIC 1798 0.34 0.26 0.07 1.0 
rs282795 15 MTHFS 1797 0.32 0.88 0.08 1.0 
rs11871738 17 PEMT 1798 0.38 0.67 0.08 1.0 
rs4646385 17 PEMT 1798 0.45 0.37 0.08 1.0 
rs4817580 21 GART 1797 0.10 0.70 0.09 1.0 
rs1880586 2 ATIC 1797 0.47 0.89 0.09 1.0 
rs750546 17 PEMT 1773 0.45 0.19 0.09 1.0 
rs4610054 2 ATIC 1794 0.38 0.67 0.10 1.0 
rs12905663 15 MTHFS 1788 0.29 0.80 0.1 1.0 
rs10509760 10 AS3MT 1798 0.13 0.88 0.1 1.0 
rs4646344 17 PEMT 1798 0.46 0.45 0.1 1.0 
rs3740394 10 AS3MT 1797 0.13 1.00 0.1 1.0 
rs17209637 15 MTHFS 1794 0.26 0.79 0.1 1.0 
rs944422 21 SLC19A1 1791 0.35 0.76 0.1 1.0 
rs4819130 21 SLC19A1 1794 0.45 0.15 0.1 1.0 
rs2838961 21 SLC19A1 1797 0.34 0.94 0.1 1.0 
rs6713377 2 DNMT3A 1797 0.47 0.89 0.1 1.0 
rs11040421 11 FOLH1 1798 0.14 0.78 0.1 1.0 
rs3760188 17 PEMT 1798 0.46 0.38 0.1 1.0 
rs10418 22 TCN2 1772 0.21 0.41 0.1 1.0 
rs7575625 2 DNMT3A 1797 0.47 0.89 0.1 1.0 
NA 1 MTHFR_02_ORDER 1658 0.39 0.33 0.1 1.0 
rs6749992 2 DNMT3A 1798 0.47 0.79 0.1 1.0 
rs914238 21 SLC19A1 1798 0.49 0.89 0.1 1.0 
rs8129350 21 SLC19A1 1797 0.34 0.76 0.1 1.0 
rs1604503 15 MTHFS 1798 0.15 0.59 0.2 1.0 
rs10380 5 MTRR 1793 0.10 0.56 0.2 1.0 
rs4817577 21 GART 1797 0.34 0.20 0.2 1.0 
rs17824591 14 MTHFD1 1796 0.23 0.63 0.2 1.0 
rs1014971 22 CBX6 APOBEC3A 1797 0.30 0.23 0.2 1.0 
rs8102137 19 CCNE1 1798 0.33 0.13 0.2 1.0 
rs6058897 20 DNMT3B 1798 0.44 0.17 0.2 1.0 
rs7279305 21 SLC19A1 1797 0.35 1.00 0.2 1.0 
rs7283354 21 GART 1798 0.34 0.15 0.2 1.0 
rs1051266 21 SLC19A1 1798 0.45 0.20 0.2 1.0 
rs13036246 2 DNMT3A 1797 0.48 0.08 0.2 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12898670 15 MTHFS 1796 0.34 0.70 0.2 1.0 
rs1074390 15 MTHFS 1798 0.38 0.77 0.2 1.0 
rs1380642 15 MTHFS 1798 0.18 0.57 0.2 1.0 
rs11191439 10 AS3MT 1795 0.12 0.75 0.2 1.0 
rs2866358 11 FOLH1 1781 0.38 0.35 0.2 1.0 
rs11892646 2 DNMT3A 1797 0.11 0.87 0.2 1.0 
rs1460177 15 MTHFS 1797 0.08 0.37 0.2 1.0 
rs4817579 21 GART 1798 0.34 0.15 0.2 1.0 
rs9001 3 CHDH 1793 0.09 0.21 0.2 1.0 
rs7605753 2 DNMT3A 1797 0.47 0.68 0.2 1.0 
rs7220132 17 PEMT 1798 0.29 0.57 0.2 1.0 
rs3177999 21 SLC19A1 1790 0.46 0.17 0.2 1.0 
rs740234 22 TCN2 1798 0.23 0.39 0.2 1.0 
rs2733103 15 MTHFS 1797 0.15 0.51 0.2 1.0 
rs9835128 3 CHDH 1797 0.16 0.38 0.2 1.0 
rs1495741 8 NAT2 1798 0.24 1.00 0.2 1.0 
rs3788200 21 SLC19A1 1798 0.45 0.31 0.2 1.0 
rs8034036 15 MTHFS 1795 0.11 0.23 0.2 1.0 
rs1109859 17 PEMT 1770 0.18 0.64 0.2 1.0 
rs4144700 11 FOLH1 1798 0.38 0.47 0.2 1.0 
rs10839295 11 FOLH1 1797 0.40 0.48 0.2 1.0 
rs1814175 11 FOLH1 1793 0.40 0.40 0.2 1.0 
rs11852515 15 MTHFS 1798 0.11 0.74 0.2 1.0 
rs12910340 15 MTHFS 1798 0.42 0.73 0.2 1.0 
rs16971253 15 MTHFS 1797 0.10 1.00 0.2 1.0 
rs7583409 2 DNMT3A 1795 0.36 0.38 0.2 1.0 
rs1917311 11 FOLH1 1753 0.40 0.72 0.2 1.0 
rs853858 20 DNMT3B 1796 0.37 0.19 0.2 1.0 
rs7111215 11 FOLH1 1774 0.40 0.52 0.2 1.0 
rs9606756 22 TCN2 1798 0.12 0.87 0.2 1.0 
rs3862350 11 FOLH1 1765 0.40 0.15 0.2 1.0 
rs5753231 22 TCN2 1797 0.16 0.62 0.2 1.0 
rs8128050 21 SLC19A1 1794 0.34 0.94 0.2 1.0 
rs1164685 11 FOLH1 1793 0.38 0.47 0.3 1.0 
rs4779141 15 MTHFS 1793 0.34 0.55 0.3 1.0 
rs582172 15 MTHFS 1798 0.42 0.45 0.3 1.0 
rs2241807 3 CHDH 1798 0.42 0.89 0.3 1.0 
rs1127717 3 ALDH1L1 1793 0.24 1.00 0.3 1.0 
rs7586294 2 DNMT3A 1797 0.47 0.73 0.3 1.0 
rs2424913 20 DNMT3B 1797 0.37 0.39 0.3 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4531931 2 ATIC 1796 0.31 0.23 0.3 1.0 
rs9332 5 MTRR 1793 0.12 0.34 0.3 1.0 
rs710521 3 TP63 1798 0.26 0.93 0.3 1.0 
rs3755817 3 CHDH 1797 0.30 0.42 0.3 1.0 
rs4476347 2 ATIC 1798 0.25 0.28 0.3 1.0 
rs166868 15 MTHFS 1796 0.37 0.94 0.3 1.0 
rs282772 15 MTHFS 1798 0.14 0.25 0.3 1.0 
rs282776 15 MTHFS 1798 0.36 0.47 0.3 1.0 
rs6518253 21 SLC19A1 1797 0.46 0.63 0.3 1.0 
rs588458 11 FOLH1 1772 0.38 0.52 0.3 1.0 
rs748196 17 PEMT 1795 0.44 0.89 0.3 1.0 
rs2838965 21 SLC19A1 1792 0.42 0.33 0.3 1.0 
rs10839296 11 FOLH1 1777 0.25 0.65 0.3 1.0 
rs445263 15 MTHFS 1798 0.29 0.68 0.3 1.0 
rs7107178 11 FOLH1 1796 0.25 0.86 0.3 1.0 
rs1809986 11 FOLH1 1798 0.36 0.38 0.3 1.0 
rs2838973 21 SLC19A1 1798 0.20 0.92 0.3 1.0 
rs2424906 20 DNMT3B 1798 0.37 0.28 0.3 1.0 
rs8129445 21 SLC19A1 1798 0.32 0.70 0.3 1.0 
rs1650697 5 DHFR 1791 0.23 0.06 0.3 1.0 
rs13427202 2 DNMT3A 1797 0.47 0.68 0.3 1.0 
NA 1 MTHFR_02_2_i_order 1793 0.39 0.35 0.3 1.0 
rs1801133 1 MTHFR 1793 0.39 0.35 0.3 1.0 
rs7085104 10 AS3MT 1798 0.38 1.00 0.3 1.0 
rs7111711 11 FOLH1 1798 0.25 0.86 0.3 1.0 
rs17211644 15 MTHFS 1798 0.10 0.72 0.3 1.0 
rs1802059 5 MTRR 1792 0.36 0.60 0.3 1.0 
rs2183601 21 SLC19A1 1797 0.20 0.92 0.3 1.0 
rs7951180 11 FOLH1 1778 0.17 0.55 0.4 1.0 
rs3783 17 SHMT1 1806 0.26 0.30 0.4 1.0 
rs1801131 1 MTHFR 1710 0.28 0.34 0.4 1.0 
rs3862342 11 FOLH1 1795 0.28 0.93 0.4 1.0 
rs2330183 21 SLC19A1 1757 0.45 0.05 0.4 1.0 
rs8074074 17 PEMT 1796 0.30 0.87 0.4 1.0 
rs914231 21 SLC19A1 1791 0.45 0.19 0.4 1.0 
rs914232 21 SLC19A1 1797 0.45 0.17 0.4 1.0 
rs1059394 18 TYMS 1791 0.31 0.64 0.4 1.0 
rs1081231 15 MTHFS 1797 0.17 0.71 0.4 1.0 
rs6058891 20 DNMT3B 1796 0.39 0.32 0.4 1.0 
rs2838958 21 SLC19A1 1794 0.46 0.63 0.4 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs2116940 19 DNMT1 1797 0.08 0.64 0.4 1.0 
rs4819128 21 SLC19A1 1798 0.45 0.13 0.4 1.0 
rs6586282 21 CBS 1792 0.18 0.16 0.4 1.0 
rs1950902 14 MTHFD1 1798 0.15 1.00 0.4 1.0 
rs7120743 11 FOLH1 1774 0.36 0.77 0.4 1.0 
rs2150460 21 SLC19A1 1798 0.20 1.00 0.4 1.0 
rs2424921 20 DNMT3B 1798 0.39 0.32 0.4 1.0 
rs897453 17 PEMT 1790 0.47 0.54 0.4 1.0 
rs2424914 20 DNMT3B 1798 0.39 0.39 0.4 1.0 
rs6058883 20 DNMT3B 1797 0.39 0.36 0.4 1.0 
rs4911263 20 DNMT3B 1798 0.32 1.00 0.4 1.0 
rs3893384 15 MTHFS 1798 0.42 0.44 0.4 1.0 
rs13317328 3 CHDH 1798 0.09 0.06 0.4 1.0 
rs699517 18 TYMS 1791 0.31 0.64 0.4 1.0 
rs2283873 22 TCN2 1778 0.03 0.49 0.4 1.0 
rs17745484 2 DNMT3A 1797 0.35 0.30 0.4 1.0 
rs34048824 2 DNMT3A 1797 0.51 0.74 0.4 1.0 
rs2294008 8 PSCA 1798 0.46 0.73 0.4 1.0 
rs8081810 17 PEMT 1797 0.20 0.92 0.4 1.0 
rs4434082 21 SLC19A1 1797 0.20 1.00 0.4 1.0 
rs4479310 17 PEMT 1798 0.30 0.63 0.4 1.0 
rs6760069 2 ATIC 1797 0.15 0.35 0.4 1.0 
rs11040106 11 FOLH1 1787 0.36 0.66 0.4 1.0 
rs11040416 11 FOLH1 1798 0.42 0.58 0.4 1.0 
rs9976878 21 SLC19A1 1797 0.20 1.00 0.4 1.0 
rs2275565 1 MTR 1793 0.19 0.66 0.4 1.0 
rs6141813 20 DNMT3B 1798 0.14 1.00 0.4 1.0 
rs4646410 17 PEMT 1795 0.31 0.94 0.4 1.0 
rs12884767 14 MTHFD1 1798 0.04 0.14 0.4 1.0 
rs648372 11 FOLH1 1772 0.16 0.46 0.4 1.0 
rs10163099 15 MTHFS 1792 0.26 0.48 0.4 1.0 
rs9974061 21 SLC19A1 1798 0.18 0.82 0.4 1.0 
rs12462004 19 DNMT1 1795 0.08 0.64 0.5 1.0 
rs9306139 21 SLC19A1 1796 0.20 1.00 0.5 1.0 
rs5749135 22 TCN2 1798 0.43 0.07 0.5 1.0 
rs9462856 6 GNMT 1798 0.42 0.53 0.5 1.0 
rs9789571 2 ATIC 1798 0.42 0.89 0.5 1.0 
rs2424922 20 DNMT3B 1796 0.39 0.29 0.5 1.0 
rs12453139 17 PEMT 1797 0.26 0.66 0.5 1.0 
rs7946 17 PEMT 1798 0.30 0.52 0.5 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs10932605 2 ATIC 1798 0.14 0.39 0.5 1.0 
rs6757920 2 ATIC 1794 0.48 0.09 0.5 1.0 
rs2424928 20 DNMT3B 1798 0.39 0.26 0.5 1.0 
rs2834233 21 GART 1797 0.09 0.08 0.5 1.0 
rs1917321 11 FOLH1 1790 0.50 0.54 0.5 1.0 
rs2275566 1 MTR 1793 0.41 0.53 0.5 1.0 
rs4804125 19 DNMT1 1797 0.08 0.64 0.5 1.0 
rs378057 15 MTHFS 1797 0.14 0.89 0.5 1.0 
rs679470 11 FOLH1 1797 0.17 0.63 0.5 1.0 
rs2288350 19 DNMT1 1798 0.08 0.64 0.5 1.0 
rs8111085 19 DNMT1 1797 0.08 0.64 0.5 1.0 
rs443394 15 MTHFS 1798 0.42 0.30 0.5 1.0 
rs11672909 19 DNMT1 1797 0.08 0.81 0.5 1.0 
rs1956545 14 MTHFD1 1797 0.08 0.17 0.5 1.0 
rs12591436 15 MTHFS 1798 0.35 0.55 0.5 1.0 
rs2301955 22 TCN2 1794 0.43 0.10 0.5 1.0 
rs7124266 11 FOLH1 1798 0.30 0.94 0.5 1.0 
rs4532960 10 AS3MT 1797 0.44 0.89 0.5 1.0 
rs3785499 17 PEMT 1798 0.48 0.54 0.5 1.0 
rs8112895 19 DNMT1 1798 0.08 0.81 0.5 1.0 
rs10748835 10 AS3MT 1798 0.44 0.89 0.5 1.0 
rs202676 11 FOLH1 1788 0.17 0.72 0.5 1.0 
rs12797843 11 FOLH1 1798 0.13 0.37 0.5 1.0 
rs10948059 6 GNMT 1778 0.49 0.54 0.5 1.0 
rs6495446 15 MTHFS 1797 0.26 0.38 0.5 1.0 
rs2267163 22 TCN2 1794 0.43 0.06 0.5 1.0 
rs8074191 17 PEMT 1778 0.28 0.93 0.5 1.0 
rs10418707 19 DNMT1 1796 0.08 0.64 0.5 1.0 
rs4646364 17 PEMT 1795 0.03 0.15 0.5 1.0 
rs6119286 20 DNMT3B 1798 0.02 0.38 0.5 1.0 
rs12797853 11 FOLH1 1794 0.13 0.46 0.5 1.0 
rs4804494 19 DNMT1 1797 0.08 0.64 0.5 1.0 
rs4804490 19 DNMT1 1796 0.08 0.64 0.5 1.0 
rs4819138 21 SLC19A1 1797 0.40 0.89 0.5 1.0 
rs1256112 14 MTHFD1 1798 0.40 0.29 0.5 1.0 
rs660439 11 FOLH1 1794 0.23 0.85 0.5 1.0 
rs4911108 20 DNMT3B 1793 0.28 0.87 0.5 1.0 
rs2281603 14 MTHFD1 1798 0.20 0.34 0.6 1.0 
rs202718 11 FOLH1 1798 0.15 0.79 0.6 1.0 
rs1055345 21 SLC19A1 1797 0.29 0.10 0.6 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs9980967 21 SLC19A1 1797 0.11 0.38 0.6 1.0 
rs1870576 15 MTHFS 1780 0.46 0.06 0.6 1.0 
rs473334 1 CTH 1793 0.31 0.81 0.6 1.0 
rs663649 1 CTH 1793 0.31 0.81 0.6 1.0 
rs6087990 20 DNMT3B 1797 0.32 0.64 0.6 1.0 
rs11683778 2 ATIC 1795 0.03 0.54 0.6 1.0 
rs6485991 11 FOLH1 1791 0.17 0.81 0.6 1.0 
rs10839239 11 FOLH1 1795 0.23 0.85 0.6 1.0 
rs12438477 15 MTHFS 1797 0.36 0.61 0.6 1.0 
rs202700 11 FOLH1 1734 0.23 0.77 0.6 1.0 
rs1465825 2 DNMT3A 1797 0.27 1.00 0.6 1.0 
rs7175620 15 MTHFS 1797 0.22 0.14 0.6 1.0 
rs16906158 11 FOLH1 1796 0.08 1.00 0.6 1.0 
rs9306264 22 TCN2 1796 0.05 1.00 0.6 1.0 
rs10460566 2 DNMT3A 1798 0.27 0.86 0.6 1.0 
rs12482346 21 SLC19A1 1797 0.48 0.10 0.6 1.0 
rs2790 18 TYMS 1789 0.20 0.67 0.6 1.0 
rs2305230 3 ALDH1L1 1792 0.20 0.30 0.6 1.0 
rs2236225 14 MTHFD1 1797 0.43 0.24 0.6 1.0 
rs515064 1 CTH 1793 0.35 0.50 0.6 1.0 
rs9977111 21 SLC19A1 1750 0.33 0.14 0.6 1.0 
rs2304429 2 DNMT3A 1798 0.43 0.10 0.6 1.0 
rs2066470 1 MTHFR 1788 0.08 0.39 0.6 1.0 
rs202712 11 FOLH1 1796 0.23 0.85 0.6 1.0 
rs2115536 15 MTHFS 1798 0.49 0.22 0.6 1.0 
rs910085 20 DNMT3B 1797 0.29 0.93 0.6 1.0 
rs17285431 15 MTHFS 1798 0.17 0.08 0.6 1.0 
rs9323450 14 MTHFD1 1798 0.31 0.69 0.6 1.0 
rs7177027 15 MTHFS 1797 0.24 0.40 0.6 1.0 
rs3788190 21 SLC19A1 1795 0.47 0.10 0.6 1.0 
rs1801198 22 TCN2 1797 0.43 0.08 0.6 1.0 
rs11040353 11 FOLH1 1795 0.08 0.64 0.6 1.0 
rs9305012 19 DNMT1 1797 0.08 0.64 0.6 1.0 
rs10400277 11 FOLH1 1774 0.13 0.37 0.6 1.0 
rs4911107 20 DNMT3B 1798 0.31 1.00 0.6 1.0 
rs12222221 11 FOLH1 1798 0.08 1.00 0.6 1.0 
rs11040390 11 FOLH1 1798 0.08 1.00 0.6 1.0 
rs2372535 2 ATIC 1798 0.14 0.89 0.6 1.0 
rs11040432 11 FOLH1 1797 0.08 1.00 0.6 1.0 
NA 1 MTR_01_ORDER 1793 0.16 0.81 0.6 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT 
Corrected 
P LRT 
rs8128681 21 SLC19A1 1798 0.33 0.94 0.6 1.0 
rs2115540 15 MTHFS 1797 0.49 0.20 0.6 1.0 
rs2035027 15 MTHFS 1798 0.16 0.80 0.7 1.0 
rs234706 21 CBS 1793 0.33 0.36 0.7 1.0 
rs600671 15 MTHFS 1797 0.45 0.34 0.7 1.0 
rs9282690 3 ALDH1L1 1793 0.08 1.00 0.7 1.0 
rs2162560 19 DNMT1 1797 0.38 0.94 0.7 1.0 
rs2236224 14 MTHFD1 1798 0.36 0.07 0.7 1.0 
rs1808119 2 ATIC 1797 0.19 0.82 0.7 1.0 
rs6711622 2 DNMT3A 1798 0.44 1.00 0.7 1.0 
rs9897362 17 PEMT 1798 0.06 0.77 0.7 1.0 
rs12898642 15 MTHFS 1798 0.43 0.34 0.7 1.0 
rs2287779 5 MTRR 1791 0.03 0.52 0.7 1.0 
rs2287780 5 MTRR 1793 0.03 0.52 0.7 1.0 
rs2586182 15 MTHFS 1798 0.14 0.78 0.7 1.0 
rs2288349 19 DNMT1 1797 0.38 0.78 0.7 1.0 
rs4778721 15 MTHFS 1798 0.22 0.09 0.7 1.0 
rs4778719 15 MTHFS 1798 0.22 0.09 0.7 1.0 
rs6511677 19 DNMT1 1797 0.38 0.89 0.7 1.0 
rs282802 15 MTHFS 1798 0.29 0.09 0.7 1.0 
rs16971450 15 MTHFS 1797 0.16 0.80 0.7 1.0 
rs376863 15 MTHFS 1772 0.50 0.73 0.7 1.0 
rs11687225 2 ATIC 1797 0.40 0.72 0.7 1.0 
rs11158542 14 MTHFD1 1798 0.30 0.81 0.7 1.0 
rs1369703 2 DNMT3A 1798 0.44 0.10 0.7 1.0 
rs4646383 17 PEMT 1797 0.09 0.53 0.7 1.0 
rs8101626 19 DNMT1 1798 0.39 0.89 0.7 1.0 
rs898436 15 MTHFS 1793 0.45 0.37 0.7 1.0 
rs11887120 2 DNMT3A 1798 0.41 0.44 0.7 1.0 
rs10420338 19 DNMT1 1798 0.47 0.64 0.7 1.0 
rs1805087 1 MTR 1793 0.16 0.81 0.7 1.0 
rs1979276 17 SHMT1 1808 0.31 0.94 0.7 1.0 
rs1888530 21 SLC19A1 1760 0.47 0.08 0.7 1.0 
rs12121543 1 MTHFR 1793 0.22 0.32 0.7 1.0 
rs11701960 21 SLC19A1 1797 0.18 0.91 0.7 1.0 
rs8659 5 MTRR 1790 0.35 0.33 0.7 1.0 
rs11158540 14 MTHFD1 1798 0.35 0.94 0.7 1.0 
rs4779165 15 MTHFS 1797 0.16 0.80 0.7 1.0 
rs11694842 2 DNMT3A 1797 0.28 0.36 0.7 1.0 
rs7177659 15 MTHFS 1796 0.49 0.09 0.7 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1979277 17 SHMT1 1809 0.27 0.87 0.7 1.0 
rs617219 5 BHMT 1790 0.32 0.94 0.7 1.0 
rs13002567 2 DNMT3A 1798 0.28 0.40 0.7 1.0 
rs7113075 11 FOLH1 1797 0.08 0.64 0.7 1.0 
rs759920 19 DNMT1 1798 0.46 0.79 0.7 1.0 
rs4673981 2 ATIC 1798 0.40 1.00 0.7 1.0 
rs1081235 15 MTHFS 1798 0.20 0.67 0.7 1.0 
rs17284990 15 MTHFS 1798 0.21 0.62 0.7 1.0 
rs1667627 14 MTHFD2 1792 0.47 0.34 0.7 1.0 
rs7085854 10 AS3MT 1797 0.22 0.85 0.7 1.0 
rs7934591 11 FOLH1 1798 0.08 0.81 0.8 1.0 
rs1473406 15 MTHFS 1796 0.15 0.79 0.8 1.0 
rs11191457 10 AS3MT 1794 0.22 1.00 0.8 1.0 
rs7594432 2 DNMT3A 1798 0.44 0.13 0.8 1.0 
rs2228611 19 DNMT1 1798 0.46 0.79 0.8 1.0 
rs3818239 14 MTHFD1 1787 0.13 0.66 0.8 1.0 
rs282792 15 MTHFS 1798 0.37 0.47 0.8 1.0 
rs1051298 21 SLC19A1 1790 0.47 0.17 0.8 1.0 
rs12614943 2 ATIC 1798 0.27 0.73 0.8 1.0 
NA 1 MTR_01_2_i_order 1793 0.16 0.81 0.8 1.0 
rs2838977 21 SLC19A1 1796 0.40 0.72 0.8 1.0 
rs1023159 21 SLC19A1 1796 0.42 0.78 0.8 1.0 
rs4804122 19 DNMT1 1798 0.39 0.52 0.8 1.0 
rs3772078 2 ATIC 1797 0.20 0.29 0.8 1.0 
rs770144 15 MTHFS 1798 0.20 1.00 0.8 1.0 
rs5749131 22 TCN2 1798 0.42 0.13 0.8 1.0 
rs2877078 21 SLC19A1 1786 0.40 0.94 0.8 1.0 
rs6058869 20 DNMT3B 1797 0.33 0.76 0.8 1.0 
rs1164681 11 FOLH1 1798 0.12 0.25 0.8 1.0 
rs1888533 21 SLC19A1 1797 0.48 0.42 0.8 1.0 
rs2987981 14 MTHFD1 1798 0.26 1.00 0.8 1.0 
rs9836592 3 CHDH 1798 0.32 0.14 0.8 1.0 
rs1847638 11 FOLH1 1729 0.21 0.47 0.8 1.0 
rs1256107 14 MTHFD1 1796 0.49 0.50 0.8 1.0 
rs1051296 21 SLC19A1 1786 0.48 0.10 0.8 1.0 
rs1846285 11 FOLH1 1795 0.16 0.54 0.8 1.0 
rs35020344 14 MTHFD1 1797 0.48 0.42 0.8 1.0 
rs6722613 2 DNMT3A 1798 0.40 0.89 0.8 1.0 
rs12987326 2 DNMT3A 1798 0.37 0.47 0.8 1.0 
rs11607791 11 FOLH1 1796 0.07 1.00 0.8 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7253062 19 DNMT1 1798 0.38 1.00 0.8 1.0 
rs6445606 3 CHDH 1798 0.29 0.10 0.8 1.0 
rs8041943 15 MTHFS 1794 0.41 0.37 0.8 1.0 
rs2290684 19 DNMT1 1797 0.46 0.79 0.8 1.0 
rs9642880 8 MYC 1797 0.44 0.78 0.8 1.0 
rs1256114 14 MTHFD1 1797 0.11 0.86 0.8 1.0 
rs8003379 14 MTHFD1 1796 0.25 0.78 0.8 1.0 
rs6573559 14 MTHFD1 1798 0.30 0.94 0.8 1.0 
rs2586154 15 MTHFS 1798 0.14 0.89 0.8 1.0 
rs3821353 2 ATIC 1798 0.20 0.17 0.8 1.0 
rs16853826 2 ATIC 1796 0.13 0.88 0.8 1.0 
rs4987173 6 GNMT 1798 0.50 0.46 0.8 1.0 
rs7929543 11 FOLH1 1798 0.07 0.81 0.8 1.0 
rs8019804 14 MTHFD1 1798 0.07 1.00 0.8 1.0 
rs11627387 14 MTHFD1 1798 0.30 0.81 0.8 1.0 
rs1404774 2 ATIC 1784 0.22 0.42 0.8 1.0 
rs16971249 15 MTHFS 1798 0.08 0.09 0.8 1.0 
rs401681 5 TERT-CLPTM1L 1798 0.46 0.84 0.8 1.0 
rs16853782 2 ATIC 1798 0.20 0.34 0.8 1.0 
rs1801394 5 MTRR 1808 0.49 0.50 0.9 1.0 
rs3740392 10 AS3MT 1794 0.29 0.41 0.9 1.0 
rs2838970 21 SLC19A1 1797 0.40 0.78 0.9 1.0 
rs2834231 21 GART 1798 0.26 0.73 0.9 1.0 
rs10498034 2 ATIC 1798 0.16 0.90 0.9 1.0 
rs282778 15 MTHFS 1798 0.25 0.86 0.9 1.0 
rs16853834 2 ATIC 1798 0.17 0.71 0.9 1.0 
rs2834232 21 GART 1797 0.26 0.73 0.9 1.0 
rs8971 21 GART 1795 0.26 0.73 0.9 1.0 
rs1256095 14 MTHFD1 1782 0.48 0.50 0.9 1.0 
rs6058893 20 DNMT3B 1798 0.32 0.49 0.9 1.0 
rs35709834 5 DHFR 1791 0.04 0.62 0.9 1.0 
rs4779140 15 MTHFS 1797 0.48 0.79 0.9 1.0 
rs8923 15 MTHFS 1798 0.08 0.15 0.9 1.0 
rs2696935 11 FOLH1 1798 0.21 0.12 0.9 1.0 
rs4441015 11 FOLH1 1753 0.14 0.40 0.9 1.0 
rs2865908 11 FOLH1 1798 0.18 0.50 0.9 1.0 
rs12373907 21 SLC19A1 1797 0.38 0.20 0.9 1.0 
rs11085720 19 DNMT1 1798 0.41 0.44 0.9 1.0 
rs34033751 11 FOLH1 1776 0.11 0.23 0.9 1.0 
rs1256142 14 MTHFD1 1798 0.44 0.10 0.9 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs767138 21 SLC19A1 1795 0.41 0.89 0.9 1.0 
rs12613 21 CBS 1793 0.09 0.83 0.9 1.0 
rs12999687 2 DNMT3A 1795 0.45 0.68 0.9 1.0 
rs8128676 21 SLC19A1 1754 0.22 0.92 0.9 1.0 
rs11658944 17 PEMT 1794 0.05 0.49 0.9 1.0 
rs2983733 14 MTHFD1 1798 0.44 0.68 0.9 1.0 
rs1046778 10 AS3MT 1798 0.32 0.70 0.9 1.0 
rs4818789 21 SLC19A1 1798 0.25 0.06 0.9 1.0 
rs17291414 19 DNMT1 1798 0.28 0.73 0.9 1.0 
rs559062 1 CTH 1793 0.22 0.85 0.9 1.0 
rs4094478 11 FOLH1 1770 0.20 0.34 0.9 1.0 
rs35918857 19 DNMT1 1796 0.02 0.25 0.9 1.0 
rs372447 15 MTHFS 1798 0.38 0.77 0.9 1.0 
rs6087988 20 DNMT3B 1798 0.19 1.00 0.9 1.0 
rs11677670 2 DNMT3A 1788 0.18 0.64 0.9 1.0 
rs17279885 15 MTHFS 1798 0.20 0.67 0.9 1.0 
rs11158538 14 MTHFD1 1795 0.45 0.78 0.9 1.0 
rs17279753 15 MTHFS 1798 0.19 0.51 0.9 1.0 
rs2696923 11 FOLH1 1798 0.21 0.12 0.9 1.0 
rs2983736 14 MTHFD1 1793 0.44 0.73 0.9 1.0 
rs13401241 2 DNMT3A 1798 0.45 0.28 0.9 1.0 
rs567754 5 BHMT 1792 0.29 0.74 0.9 1.0 
rs16999714 19 DNMT1 1796 0.21 0.26 0.9 1.0 
rs11681447 2 DNMT3A 1796 0.29 0.62 0.9 1.0 
rs2424932 20 DNMT3B 1797 0.43 0.15 0.9 1.0 
rs8003567 14 MTHFD1 1798 0.11 0.47 0.9 1.0 
rs6801605 3 CHDH 1798 0.37 1.00 0.9 1.0 
rs8015278 14 MTHFD1 1798 0.07 0.18 0.9 1.0 
rs1404772 2 ATIC 1798 0.08 0.34 1.0 1.0 
rs685487 15 MTHFS 1798 0.36 0.34 1.0 1.0 
rs2424908 20 DNMT3B 1798 0.17 0.40 1.0 1.0 
rs1464864 2 ATIC 1798 0.30 0.81 1.0 1.0 
rs734693 2 DNMT3A 1795 0.29 0.51 1.0 1.0 
rs7587636 2 DNMT3A 1798 0.45 0.25 1.0 1.0 
rs8068641 17 PEMT 1792 0.11 0.62 1.0 1.0 
rs7144437 14 MTHFD1 1797 0.07 0.10 1.0 1.0 
rs8011839 14 MTHFD1 1798 0.17 0.72 1.0 1.0 
rs17751556 14 MTHFD1 1798 0.08 0.65 1.0 1.0 
rs10769558 11 FOLH1 1797 0.21 0.18 1.0 1.0 
rs10839210 11 FOLH1 1796 0.21 0.18 1.0 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=457) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs2236222 14 MTHFD1 1798 0.10 0.27 1.0 1.0 
rs2289093 2 DNMT3A 1798 0.29 0.62 1.0 1.0 
rs11629135 14 MTHFD1 1797 0.11 0.38 1.0 1.0 
rs12416687 10 AS3MT 1797 0.27 0.15 1.0 1.0 
rs1076991 14 MTHFD1 1798 0.45 0.63 1.0 1.0 
rs12148881 15 MTHFS 1797 0.26 0.19 1.0 1.0 
rs4902278 14 MTHFD1 1791 0.07 0.18 1.0 1.0 
rs749130 2 DNMT3A 1798 0.45 0.37 1.0 1.0 
rs865646 5 DHFR 1736 0.36 0.55 1.0 1.0 
rs12627639 21 SLC19A1 1797 0.21 0.68 1.0 1.0 
rs8018032 14 MTHFD1 1798 0.45 0.95 1.0 1.0 
rs663465 1 CTH 1792 0.42 0.36 1.0 1.0 
rs2987969 14 MTHFD1 1797 0.45 0.95 1.0 1.0 
rs2154583 21 GART 1791 0.40 0.67 1.0 1.0 
rs6517178 21 GART 1798 0.40 0.72 1.0 1.0 
rs11627525 14 MTHFD1 1798 0.11 0.08 1.0 1.0 
rs2834235 21 GART 1797 0.39 0.67 1.0 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
SNPs modeled in dominant mode of inheritance 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4646359 17 PEMT 1798 0.46 0.15 0.0007 0.3 
rs11892429 2 ATIC 1798 0.29 1.00 0.0010 0.4 
rs7604984 2 ATIC 1798 0.40 0.62 0.001 0.4 
rs10197559 2 ATIC 1788 0.29 0.87 0.001 0.5 
rs10498036 2 ATIC 1798 0.40 0.57 0.002 0.6 
rs10179873 2 ATIC 1798 0.30 0.63 0.002 0.6 
rs9890064 17 PEMT 1798 0.43 0.41 0.002 0.6 
rs11855092 15 MTHFS 1798 0.24 0.31 0.002 0.7 
rs10197653 2 ATIC 1798 0.29 0.74 0.003 0.8 
rs1983462 2 ATIC 1798 0.31 0.47 0.003 0.8 
rs4673993 2 ATIC 1798 0.32 0.31 0.004 0.9 
rs4924922 17 PEMT 1798 0.37 0.43 0.004 0.9 
rs6706415 2 ATIC 1798 0.31 0.81 0.004 0.9 
rs4673991 2 ATIC 1797 0.32 0.31 0.004 0.9 
rs4672768 2 ATIC 1794 0.32 0.31 0.005 0.9 
rs4244599 17 PEMT 1774 0.47 0.34 0.009 1.0 
rs435689 15 MTHFS 1798 0.49 0.50 0.009 1.0 
rs11656215 17 PEMT 1798 0.46 0.20 0.010 1.0 
rs12997662 2 ATIC 1798 0.34 0.26 0.02 1.0 
rs2733106 15 MTHFS 1793 0.15 0.69 0.02 1.0 
rs4646385 17 PEMT 1798 0.45 0.37 0.02 1.0 
rs750546 17 PEMT 1773 0.45 0.19 0.02 1.0 
rs12905663 15 MTHFS 1788 0.29 0.80 0.02 1.0 
rs798766 4 TMEM129-TACC3-FGFR3 1798 0.18 0.21 0.02 1.0 
rs6057645 20 DNMT3B 1797 0.04 0.22 0.03 1.0 
rs4817580 21 GART 1797 0.10 0.70 0.03 1.0 
rs2586153 15 MTHFS 1777 0.15 0.59 0.03 1.0 
rs4673965 2 ATIC 1798 0.40 0.94 0.03 1.0 
rs7581217 2 DNMT3A 1798 0.39 0.62 0.04 1.0 
rs11683424 2 DNMT3A 1798 0.12 0.20 0.04 1.0 
rs6749992 2 DNMT3A 1798 0.47 0.79 0.04 1.0 
rs7604425 2 ATIC 1798 0.35 0.94 0.05 1.0 
rs2289209 3 CHDH 1798 0.04 0.67 0.05 1.0 
rs10165919 2 ATIC 1797 0.35 0.88 0.05 1.0 
rs1880580 15 MTHFS 1798 0.31 0.38 0.06 1.0 
rs2866358 11 FOLH1 1781 0.38 0.35 0.06 1.0 
rs1074390 15 MTHFS 1798 0.38 0.77 0.06 1.0 
rs1077965 15 MTHFS 1797 0.41 0.58 0.06 1.0 
rs1917311 11 FOLH1 1753 0.40 0.72 0.06 1.0 
rs7605753 2 DNMT3A 1797 0.47 0.68 0.06 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs740234 22 TCN2 1798 0.23 0.39 0.07 1.0 
rs7111215 11 FOLH1 1774 0.40 0.52 0.07 1.0 
rs10509760 10 AS3MT 1798 0.13 0.88 0.07 1.0 
rs3740394 10 AS3MT 1797 0.13 1.00 0.07 1.0 
rs1164685 11 FOLH1 1793 0.38 0.47 0.08 1.0 
rs4144700 11 FOLH1 1798 0.38 0.47 0.08 1.0 
rs6119285 20 DNMT3B 1795 0.04 0.20 0.08 1.0 
rs10839295 11 FOLH1 1797 0.40 0.48 0.08 1.0 
rs1814175 11 FOLH1 1793 0.40 0.40 0.08 1.0 
rs16988828 22 TCN2 1798 0.09 0.09 0.09 1.0 
rs3862350 11 FOLH1 1765 0.40 0.15 0.09 1.0 
rs1604503 15 MTHFS 1798 0.15 0.59 0.10 1.0 
rs2733103 15 MTHFS 1797 0.15 0.51 0.10 1.0 
rs11191439 10 AS3MT 1795 0.12 0.75 0.10 1.0 
rs588458 11 FOLH1 1772 0.38 0.52 0.10 1.0 
rs1380642 15 MTHFS 1798 0.18 0.57 0.1 1.0 
rs282776 15 MTHFS 1798 0.36 0.47 0.1 1.0 
rs748196 17 PEMT 1795 0.44 0.89 0.1 1.0 
rs914238 21 SLC19A1 1798 0.49 0.89 0.1 1.0 
rs9835128 3 CHDH 1797 0.16 0.38 0.1 1.0 
rs4819130 21 SLC19A1 1794 0.45 0.15 0.1 1.0 
rs1051266 21 SLC19A1 1798 0.45 0.20 0.1 1.0 
rs4393531 15 MTHFS 1795 0.47 0.63 0.1 1.0 
rs282787 15 MTHFS 1798 0.04 0.34 0.1 1.0 
rs4610054 2 ATIC 1794 0.38 0.67 0.1 1.0 
rs11040416 11 FOLH1 1798 0.42 0.58 0.1 1.0 
rs11040421 11 FOLH1 1798 0.14 0.78 0.2 1.0 
rs2183601 21 SLC19A1 1797 0.20 0.92 0.2 1.0 
rs2150460 21 SLC19A1 1798 0.20 1.00 0.2 1.0 
rs6760069 2 ATIC 1797 0.15 0.35 0.2 1.0 
rs3177999 21 SLC19A1 1790 0.46 0.17 0.2 1.0 
rs10380 5 MTRR 1793 0.10 0.56 0.2 1.0 
rs10932605 2 ATIC 1798 0.14 0.39 0.2 1.0 
rs4434082 21 SLC19A1 1797 0.20 1.00 0.2 1.0 
rs3788200 21 SLC19A1 1798 0.45 0.31 0.2 1.0 
rs9606756 22 TCN2 1798 0.12 0.87 0.2 1.0 
rs2330183 21 SLC19A1 1757 0.45 0.05 0.2 1.0 
rs2241807 3 CHDH 1798 0.42 0.89 0.2 1.0 
rs282814 15 MTHFS 1798 0.22 0.84 0.2 1.0 
rs3862342 11 FOLH1 1795 0.28 0.93 0.2 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs914232 21 SLC19A1 1797 0.45 0.17 0.2 1.0 
rs4369857 2 ATIC 1798 0.04 1.00 0.2 1.0 
rs1950902 14 MTHFD1 1798 0.15 1.00 0.2 1.0 
NA 1 MTHFR_02_ORDER 1658 0.39 0.33 0.2 1.0 
rs6518253 21 SLC19A1 1797 0.46 0.63 0.2 1.0 
rs17211644 15 MTHFS 1798 0.10 0.72 0.2 1.0 
rs2838973 21 SLC19A1 1798 0.20 0.92 0.2 1.0 
rs4819128 21 SLC19A1 1798 0.45 0.13 0.2 1.0 
rs914231 21 SLC19A1 1791 0.45 0.19 0.2 1.0 
rs443394 15 MTHFS 1798 0.42 0.30 0.2 1.0 
rs10839296 11 FOLH1 1777 0.25 0.65 0.2 1.0 
rs9980967 21 SLC19A1 1797 0.11 0.38 0.2 1.0 
rs9976878 21 SLC19A1 1797 0.20 1.00 0.2 1.0 
rs34048824 2 DNMT3A 1797 0.51 0.74 0.2 1.0 
rs7107178 11 FOLH1 1796 0.25 0.86 0.2 1.0 
rs4779148 15 MTHFS 1798 0.10 0.45 0.2 1.0 
rs9306139 21 SLC19A1 1796 0.20 1.00 0.2 1.0 
rs1127717 3 ALDH1L1 1793 0.24 1.00 0.2 1.0 
rs7111711 11 FOLH1 1798 0.25 0.86 0.2 1.0 
rs2294008 8 PSCA 1798 0.46 0.73 0.2 1.0 
rs7124266 11 FOLH1 1798 0.30 0.94 0.2 1.0 
rs4646344 17 PEMT 1798 0.46 0.45 0.2 1.0 
rs7583409 2 DNMT3A 1795 0.36 0.38 0.2 1.0 
rs10501325 11 FOLH1 1798 0.06 0.08 0.2 1.0 
rs663649 1 CTH 1793 0.31 0.81 0.2 1.0 
rs473334 1 CTH 1793 0.31 0.81 0.2 1.0 
rs12995968 2 DNMT3A 1798 0.04 0.66 0.2 1.0 
rs6058897 20 DNMT3B 1798 0.44 0.17 0.2 1.0 
rs12482346 21 SLC19A1 1797 0.48 0.10 0.2 1.0 
rs1550117 2 DNMT3A 1797 0.08 0.81 0.2 1.0 
rs7102702 11 FOLH1 1741 0.04 1.00 0.2 1.0 
rs1917321 11 FOLH1 1790 0.50 0.54 0.3 1.0 
rs7117247 11 FOLH1 1798 0.06 0.08 0.3 1.0 
rs9462856 6 GNMT 1798 0.42 0.53 0.3 1.0 
rs6087990 20 DNMT3B 1797 0.32 0.64 0.3 1.0 
rs2116940 19 DNMT1 1797 0.08 0.64 0.3 1.0 
rs5749135 22 TCN2 1798 0.43 0.07 0.3 1.0 
rs12797843 11 FOLH1 1798 0.13 0.37 0.3 1.0 
rs3788190 21 SLC19A1 1795 0.47 0.10 0.3 1.0 
rs4911108 20 DNMT3B 1793 0.28 0.87 0.3 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs6757920 2 ATIC 1794 0.48 0.09 0.3 1.0 
rs3760188 17 PEMT 1798 0.46 0.38 0.3 1.0 
rs17824591 14 MTHFD1 1796 0.23 0.63 0.3 1.0 
rs1870576 15 MTHFS 1780 0.46 0.06 0.3 1.0 
rs6495441 15 MTHFS 1798 0.25 0.93 0.3 1.0 
rs1802059 5 MTRR 1792 0.36 0.60 0.3 1.0 
rs2424913 20 DNMT3B 1797 0.37 0.39 0.3 1.0 
rs11040387 11 FOLH1 1785 0.07 0.31 0.3 1.0 
rs4532960 10 AS3MT 1797 0.44 0.89 0.3 1.0 
rs1650697 5 DHFR 1791 0.23 0.06 0.3 1.0 
rs2301955 22 TCN2 1794 0.43 0.10 0.3 1.0 
rs10748835 10 AS3MT 1798 0.44 0.89 0.3 1.0 
rs1801131 1 MTHFR 1710 0.28 0.34 0.3 1.0 
rs6485991 11 FOLH1 1791 0.17 0.81 0.3 1.0 
rs7276295 21 SLC19A1 1798 0.06 0.56 0.3 1.0 
rs2838964 21 SLC19A1 1798 0.06 0.77 0.3 1.0 
rs17285431 15 MTHFS 1798 0.17 0.08 0.3 1.0 
rs202700 11 FOLH1 1734 0.23 0.77 0.3 1.0 
rs7085104 10 AS3MT 1798 0.38 1.00 0.3 1.0 
rs282772 15 MTHFS 1798 0.14 0.25 0.3 1.0 
rs2162560 19 DNMT1 1797 0.38 0.94 0.3 1.0 
rs17209637 15 MTHFS 1794 0.26 0.79 0.3 1.0 
rs515064 1 CTH 1793 0.35 0.50 0.3 1.0 
rs1369703 2 DNMT3A 1798 0.44 0.10 0.3 1.0 
rs12462004 19 DNMT1 1795 0.08 0.64 0.3 1.0 
rs4911107 20 DNMT3B 1798 0.31 1.00 0.3 1.0 
rs2035027 15 MTHFS 1798 0.16 0.80 0.3 1.0 
rs660439 11 FOLH1 1794 0.23 0.85 0.3 1.0 
rs11869600 17 PEMT 1796 0.37 0.38 0.3 1.0 
rs910085 20 DNMT3B 1797 0.29 0.93 0.3 1.0 
rs2838965 21 SLC19A1 1792 0.42 0.33 0.3 1.0 
rs3783 17 SHMT1 1806 0.26 0.30 0.3 1.0 
rs376863 15 MTHFS 1772 0.50 0.73 0.3 1.0 
rs3785499 17 PEMT 1798 0.48 0.54 0.3 1.0 
rs2283873 22 TCN2 1779 0.03 0.49 0.3 1.0 
rs6511677 19 DNMT1 1797 0.38 0.89 0.3 1.0 
rs2838958 21 SLC19A1 1794 0.46 0.63 0.3 1.0 
rs4476347 2 ATIC 1798 0.25 0.28 0.3 1.0 
rs16906158 11 FOLH1 1796 0.08 1.00 0.3 1.0 
rs12797853 11 FOLH1 1794 0.13 0.46 0.3 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7563206 2 ATIC 1796 0.47 0.84 0.3 1.0 
rs10839239 11 FOLH1 1795 0.23 0.85 0.3 1.0 
rs7219568 17 PEMT 1798 0.06 0.52 0.3 1.0 
rs16971450 15 MTHFS 1797 0.16 0.80 0.3 1.0 
rs4804125 19 DNMT1 1797 0.08 0.64 0.3 1.0 
rs202712 11 FOLH1 1796 0.23 0.85 0.4 1.0 
rs2288350 19 DNMT1 1798 0.08 0.64 0.4 1.0 
rs10420338 19 DNMT1 1798 0.47 0.64 0.4 1.0 
rs4531931 2 ATIC 1796 0.31 0.23 0.4 1.0 
rs4817579 21 GART 1798 0.34 0.15 0.4 1.0 
rs853858 20 DNMT3B 1796 0.37 0.19 0.4 1.0 
rs8111085 19 DNMT1 1797 0.08 0.64 0.4 1.0 
rs6141813 20 DNMT3B 1798 0.14 1.00 0.4 1.0 
rs4817577 21 GART 1797 0.34 0.20 0.4 1.0 
rs600671 15 MTHFS 1797 0.45 0.34 0.4 1.0 
rs7283354 21 GART 1798 0.34 0.15 0.4 1.0 
rs9977111 21 SLC19A1 1750 0.33 0.14 0.4 1.0 
rs10948059 6 GNMT 1778 0.49 0.54 0.4 1.0 
rs11672909 19 DNMT1 1797 0.08 0.81 0.4 1.0 
rs4925048 17 PEMT 1797 0.10 0.17 0.4 1.0 
rs8034036 15 MTHFS 1795 0.11 0.23 0.4 1.0 
rs6058896 20 DNMT3B 1797 0.09 0.67 0.4 1.0 
rs17279286 15 MTHFS 1797 0.05 0.73 0.4 1.0 
rs2288349 19 DNMT1 1797 0.38 0.78 0.4 1.0 
rs6058894 20 DNMT3B 1797 0.08 1.00 0.4 1.0 
rs4646364 17 PEMT 1797 0.03 0.15 0.4 1.0 
rs2424906 20 DNMT3B 1798 0.37 0.28 0.4 1.0 
rs8112895 19 DNMT1 1798 0.08 0.81 0.4 1.0 
rs759920 19 DNMT1 1798 0.46 0.79 0.4 1.0 
rs12121543 1 MTHFR 1793 0.22 0.32 0.4 1.0 
rs1014971 22 CBX6 APOBEC3A 1797 0.30 0.23 0.4 1.0 
rs7220132 17 PEMT 1798 0.29 0.57 0.4 1.0 
rs4779165 15 MTHFS 1797 0.16 0.80 0.4 1.0 
rs9789571 2 ATIC 1798 0.42 0.89 0.4 1.0 
rs582172 15 MTHFS 1798 0.42 0.45 0.4 1.0 
rs8101626 19 DNMT1 1798 0.39 0.89 0.4 1.0 
rs2305230 3 ALDH1L1 1792 0.20 0.30 0.4 1.0 
rs898436 15 MTHFS 1793 0.45 0.37 0.4 1.0 
rs10418707 19 DNMT1 1796 0.08 0.64 0.4 1.0 
rs4479310 17 PEMT 1798 0.30 0.63 0.4 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11871738 17 PEMT 1798 0.38 0.67 0.4 1.0 
rs9001 3 CHDH 1793 0.09 0.21 0.4 1.0 
rs4819138 21 SLC19A1 1797 0.40 0.89 0.4 1.0 
rs9332 5 MTRR 1793 0.12 0.34 0.4 1.0 
rs4804494 19 DNMT1 1797 0.08 0.64 0.4 1.0 
rs12591436 15 MTHFS 1798 0.35 0.55 0.4 1.0 
rs13002567 2 DNMT3A 1798 0.28 0.40 0.4 1.0 
rs7594432 2 DNMT3A 1798 0.44 0.13 0.4 1.0 
rs4804490 19 DNMT1 1796 0.08 0.64 0.4 1.0 
rs1808119 2 ATIC 1797 0.19 0.82 0.4 1.0 
rs2228611 19 DNMT1 1798 0.46 0.79 0.4 1.0 
rs1081235 15 MTHFS 1798 0.20 0.67 0.4 1.0 
rs1880586 2 ATIC 1797 0.47 0.89 0.4 1.0 
rs7560488 2 DNMT3A 1731 0.48 0.15 0.4 1.0 
rs7951180 11 FOLH1 1778 0.17 0.55 0.4 1.0 
rs12438477 15 MTHFS 1797 0.36 0.61 0.4 1.0 
rs1956545 14 MTHFD1 1797 0.08 0.17 0.4 1.0 
rs10400277 11 FOLH1 1774 0.13 0.37 0.4 1.0 
NA 1 MTHFR_02_2_i_order 1793 0.39 0.35 0.4 1.0 
rs1801133 1 MTHFR 1793 0.39 0.35 0.4 1.0 
rs2424914 20 DNMT3B 1798 0.39 0.39 0.4 1.0 
rs6058883 20 DNMT3B 1797 0.39 0.36 0.4 1.0 
rs1109859 17 PEMT 1770 0.18 0.64 0.4 1.0 
rs4673981 2 ATIC 1798 0.40 1.00 0.4 1.0 
rs1888530 21 SLC19A1 1760 0.47 0.08 0.4 1.0 
rs11887120 2 DNMT3A 1798 0.41 0.44 0.4 1.0 
rs9282690 3 ALDH1L1 1793 0.08 1.00 0.4 1.0 
rs11040106 11 FOLH1 1787 0.36 0.66 0.4 1.0 
NA 1 MTR_01_ORDER 1793 0.16 0.81 0.4 1.0 
rs648372 11 FOLH1 1772 0.16 0.46 0.4 1.0 
rs1051298 21 SLC19A1 1790 0.47 0.17 0.4 1.0 
rs2834233 21 GART 1797 0.09 0.08 0.4 1.0 
rs8102137 19 CCNE1 1798 0.33 0.13 0.4 1.0 
rs2790 18 TYMS 1789 0.20 0.67 0.4 1.0 
rs2236224 14 MTHFD1 1798 0.36 0.07 0.4 1.0 
rs10839229 11 FOLH1 1795 0.08 0.35 0.4 1.0 
rs709046 20 DNMT3B 1798 0.03 1.00 0.5 1.0 
rs4804122 19 DNMT1 1798 0.39 0.52 0.5 1.0 
rs4646404 17 PEMT 1792 0.35 0.26 0.5 1.0 
rs1051296 21 SLC19A1 1786 0.48 0.10 0.5 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs234706 21 CBS 1793 0.33 0.36 0.5 1.0 
rs2424921 20 DNMT3B 1798 0.39 0.32 0.5 1.0 
rs3960835 11 FOLH1 1798 0.06 0.12 0.5 1.0 
rs5753231 22 TCN2 1797 0.16 0.62 0.5 1.0 
rs2115536 15 MTHFS 1798 0.49 0.22 0.5 1.0 
rs1055345 21 SLC19A1 1797 0.29 0.10 0.5 1.0 
rs6058869 20 DNMT3B 1797 0.33 0.76 0.5 1.0 
rs1809986 11 FOLH1 1798 0.36 0.38 0.5 1.0 
rs11694842 2 DNMT3A 1797 0.28 0.36 0.5 1.0 
rs2267163 22 TCN2 1794 0.43 0.06 0.5 1.0 
rs202676 11 FOLH1 1788 0.17 0.72 0.5 1.0 
rs1460177 15 MTHFS 1797 0.08 0.37 0.5 1.0 
rs2290684 19 DNMT1 1797 0.46 0.79 0.5 1.0 
rs16971253 15 MTHFS 1797 0.10 1.00 0.5 1.0 
rs16971252 15 MTHFS 1798 0.06 0.34 0.5 1.0 
rs897453 17 PEMT 1790 0.47 0.54 0.5 1.0 
rs679470 11 FOLH1 1797 0.17 0.63 0.5 1.0 
rs202718 11 FOLH1 1798 0.15 0.79 0.5 1.0 
rs16971231 15 MTHFS 1794 0.05 0.14 0.5 1.0 
rs10839224 11 FOLH1 1798 0.08 0.35 0.5 1.0 
rs11683778 2 ATIC 1796 0.03 0.54 0.5 1.0 
rs2877078 21 SLC19A1 1786 0.40 0.94 0.5 1.0 
rs4495895 11 FOLH1 1751 0.09 0.39 0.5 1.0 
rs2424928 20 DNMT3B 1798 0.39 0.26 0.5 1.0 
rs7929543 11 FOLH1 1798 0.07 0.81 0.5 1.0 
rs6058891 20 DNMT3B 1796 0.39 0.32 0.5 1.0 
rs11701960 21 SLC19A1 1797 0.18 0.91 0.5 1.0 
rs17556442 11 FOLH1 1792 0.06 0.12 0.5 1.0 
rs445263 15 MTHFS 1798 0.29 0.68 0.5 1.0 
rs11892031 2 UGT1A 1798 0.09 1.00 0.5 1.0 
rs9621049 22 TCN2 1798 0.11 0.86 0.5 1.0 
rs11158540 14 MTHFD1 1798 0.35 0.94 0.5 1.0 
rs9305012 19 DNMT1 1797 0.08 0.64 0.5 1.0 
rs7113251 11 FOLH1 1798 0.06 0.12 0.5 1.0 
rs5749131 22 TCN2 1798 0.42 0.13 0.5 1.0 
rs2586182 15 MTHFS 1798 0.14 0.78 0.5 1.0 
rs3755817 3 CHDH 1797 0.30 0.42 0.5 1.0 
rs2838977 21 SLC19A1 1796 0.40 0.72 0.5 1.0 
rs6119286 20 DNMT3B 1798 0.02 0.38 0.5 1.0 
rs7217764 17 PEMT 1798 0.05 0.51 0.5 1.0 
206 
 
Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1473406 15 MTHFS 1796 0.15 0.79 0.5 1.0 
rs1846285 11 FOLH1 1795 0.16 0.54 0.5 1.0 
rs7120743 11 FOLH1 1774 0.36 0.77 0.5 1.0 
NA 1 MTR_01_2_i_order 1793 0.16 0.81 0.5 1.0 
rs1805087 1 MTR 1793 0.16 0.81 0.5 1.0 
rs282778 15 MTHFS 1798 0.25 0.86 0.5 1.0 
rs2304429 2 DNMT3A 1798 0.43 0.10 0.5 1.0 
rs632220 11 FOLH1 1798 0.09 0.30 0.5 1.0 
rs8003379 14 MTHFD1 1796 0.25 0.78 0.5 1.0 
rs1801198 22 TCN2 1797 0.43 0.08 0.5 1.0 
rs16853834 2 ATIC 1798 0.17 0.71 0.5 1.0 
rs282802 15 MTHFS 1798 0.29 0.09 0.6 1.0 
rs9974061 21 SLC19A1 1798 0.18 0.82 0.6 1.0 
rs17728676 11 FOLH1 1797 0.06 0.14 0.6 1.0 
rs4779140 15 MTHFS 1797 0.48 0.79 0.6 1.0 
rs4987173 6 GNMT 1798 0.50 0.46 0.6 1.0 
rs12913164 15 MTHFS 1798 0.08 0.34 0.6 1.0 
rs11607791 11 FOLH1 1796 0.07 1.00 0.6 1.0 
rs3897953 15 MTHFS 1798 0.10 0.25 0.6 1.0 
rs710521 3 TP63 1798 0.26 0.93 0.6 1.0 
rs2424922 20 DNMT3B 1796 0.39 0.29 0.6 1.0 
rs7085854 10 AS3MT 1797 0.22 0.85 0.6 1.0 
rs683680 11 FOLH1 1797 0.09 0.14 0.6 1.0 
rs770144 15 MTHFS 1798 0.20 1.00 0.6 1.0 
rs12592743 15 MTHFS 1798 0.10 0.12 0.6 1.0 
rs1888533 21 SLC19A1 1797 0.48 0.42 0.6 1.0 
rs11191457 10 AS3MT 1794 0.22 1.00 0.6 1.0 
rs17745484 2 DNMT3A 1797 0.35 0.30 0.6 1.0 
rs9323450 14 MTHFD1 1798 0.31 0.69 0.6 1.0 
rs6750194 2 ATIC 1784 0.07 0.62 0.6 1.0 
rs3818239 14 MTHFD1 1787 0.13 0.66 0.6 1.0 
rs10498514 14 MTHFD1 1798 0.03 0.56 0.6 1.0 
rs7253062 19 DNMT1 1798 0.38 1.00 0.6 1.0 
rs2115540 15 MTHFS 1797 0.49 0.20 0.6 1.0 
rs9306264 22 TCN2 1797 0.05 1.00 0.6 1.0 
rs650826 11 FOLH1 1796 0.09 0.14 0.6 1.0 
rs2275566 1 MTR 1793 0.41 0.53 0.6 1.0 
rs4779141 15 MTHFS 1793 0.34 0.55 0.6 1.0 
rs1495741 8 MYC 1798 0.24 1.00 0.6 1.0 
rs1256112 14 MTHFD1 1798 0.40 0.29 0.6 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4820887 22 TCN2 1798 0.10 0.85 0.6 1.0 
rs8074191 17 PEMT 1778 0.28 0.93 0.6 1.0 
rs8659 5 MTRR 1790 0.35 0.33 0.6 1.0 
rs1023159 21 SLC19A1 1796 0.42 0.78 0.6 1.0 
rs598841 11 FOLH1 1791 0.08 0.19 0.6 1.0 
rs13036246 2 DNMT3A 1797 0.48 0.08 0.6 1.0 
rs11892646 2 DNMT3A 1797 0.11 0.87 0.6 1.0 
rs7358352 11 FOLH1 1797 0.09 0.30 0.6 1.0 
rs10418 22 TCN2 1772 0.21 0.41 0.6 1.0 
rs8074074 17 PEMT 1796 0.30 0.87 0.6 1.0 
rs12098986 11 FOLH1 1795 0.09 0.20 0.6 1.0 
rs6058893 20 DNMT3B 1798 0.32 0.49 0.6 1.0 
rs7117025 11 FOLH1 1798 0.09 0.30 0.6 1.0 
rs16853826 2 ATIC 1796 0.13 0.88 0.6 1.0 
rs11040263 11 FOLH1 1795 0.09 0.19 0.6 1.0 
rs12910340 15 MTHFS 1798 0.42 0.73 0.6 1.0 
rs12293923 11 FOLH1 1792 0.09 0.19 0.6 1.0 
rs8128681 21 SLC19A1 1798 0.33 0.94 0.6 1.0 
rs12373907 21 SLC19A1 1797 0.38 0.20 0.6 1.0 
rs11687225 2 ATIC 1797 0.40 0.72 0.6 1.0 
rs3893384 15 MTHFS 1798 0.42 0.44 0.6 1.0 
rs2287779 5 MTRR 1791 0.03 0.52 0.6 1.0 
rs1256107 14 MTHFD1 1796 0.49 0.50 0.6 1.0 
rs2287780 5 MTRR 1793 0.03 0.52 0.6 1.0 
rs1081231 15 MTHFS 1797 0.17 0.71 0.6 1.0 
rs1256095 14 MTHFD1 1782 0.48 0.50 0.7 1.0 
rs2586154 15 MTHFS 1798 0.14 0.89 0.7 1.0 
rs7586294 2 DNMT3A 1797 0.47 0.73 0.7 1.0 
rs8128676 21 SLC19A1 1754 0.22 0.92 0.7 1.0 
rs4646410 17 PEMT 1795 0.31 0.94 0.7 1.0 
rs1979277 17 SHMT1 1809 0.27 0.87 0.7 1.0 
rs2983733 14 MTHFD1 1798 0.44 0.68 0.7 1.0 
rs378057 15 MTHFS 1797 0.14 0.89 0.7 1.0 
rs4911263 20 DNMT3B 1798 0.32 1.00 0.7 1.0 
rs6087988 20 DNMT3B 1798 0.19 1.00 0.7 1.0 
rs12999687 2 DNMT3A 1795 0.45 0.68 0.7 1.0 
rs7279305 21 SLC19A1 1797 0.35 1.00 0.7 1.0 
rs6413471 1 CTH 1793 0.05 0.72 0.7 1.0 
rs13427202 2 DNMT3A 1797 0.47 0.68 0.7 1.0 
rs11677670 2 DNMT3A 1788 0.18 0.64 0.7 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1819409 11 FOLH1 1783 0.09 0.10 0.7 1.0 
rs7926211 11 FOLH1 1794 0.09 0.19 0.7 1.0 
rs920253 3 CHDH 1798 0.02 0.08 0.7 1.0 
rs1164681 11 FOLH1 1798 0.12 0.25 0.7 1.0 
rs12898670 15 MTHFS 1796 0.34 0.70 0.7 1.0 
rs2066470 1 MTHFR 1788 0.08 0.39 0.7 1.0 
rs10163099 15 MTHFS 1792 0.26 0.48 0.7 1.0 
rs12900076 15 MTHFS 1793 0.08 0.25 0.7 1.0 
rs1131603 22 TCN2 1797 0.04 0.66 0.7 1.0 
rs12987326 2 DNMT3A 1798 0.37 0.47 0.7 1.0 
rs10498034 2 ATIC 1798 0.16 0.90 0.7 1.0 
rs11040261 11 FOLH1 1797 0.09 0.39 0.7 1.0 
rs2295639 14 MTHFD1 1797 0.03 0.54 0.7 1.0 
rs35020344 14 MTHFD1 1797 0.48 0.42 0.7 1.0 
rs9836592 3 CHDH 1798 0.32 0.14 0.7 1.0 
rs1404772 2 ATIC 1798 0.08 0.34 0.7 1.0 
rs6722613 2 DNMT3A 1798 0.40 0.89 0.7 1.0 
rs7175620 15 MTHFS 1797 0.22 0.14 0.7 1.0 
rs12614943 2 ATIC 1798 0.27 0.73 0.7 1.0 
rs1020697 17 PEMT 1770 0.10 0.35 0.7 1.0 
rs2838970 21 SLC19A1 1797 0.40 0.78 0.7 1.0 
rs2983736 14 MTHFD1 1793 0.44 0.73 0.7 1.0 
rs6495446 15 MTHFS 1797 0.26 0.38 0.7 1.0 
rs17284990 15 MTHFS 1798 0.21 0.62 0.7 1.0 
rs9897362 17 PEMT 1798 0.06 0.77 0.7 1.0 
rs767138 21 SLC19A1 1795 0.41 0.89 0.7 1.0 
rs8068641 17 PEMT 1792 0.11 0.62 0.7 1.0 
rs17101854 14 MTHFD1 1797 0.03 0.53 0.7 1.0 
rs4818789 21 SLC19A1 1798 0.25 0.06 0.7 1.0 
rs437302 20 DNMT3B 1797 0.08 1.00 0.7 1.0 
rs16971260 15 MTHFS 1798 0.04 1.00 0.7 1.0 
rs1979276 17 SHMT1 1808 0.31 0.94 0.7 1.0 
rs1046778 10 AS3MT 1798 0.32 0.70 0.7 1.0 
rs13401241 2 DNMT3A 1798 0.45 0.28 0.7 1.0 
rs166868 15 MTHFS 1796 0.37 0.94 0.7 1.0 
rs7946 17 PEMT 1798 0.30 0.52 0.7 1.0 
rs8081810 17 PEMT 1797 0.20 0.92 0.7 1.0 
rs16971249 15 MTHFS 1798 0.08 0.09 0.8 1.0 
rs4778721 15 MTHFS 1798 0.22 0.09 0.8 1.0 
rs4778719 15 MTHFS 1798 0.22 0.09 0.8 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1464864 2 ATIC 1798 0.30 0.81 0.8 1.0 
rs3772078 2 ATIC 1797 0.20 0.29 0.8 1.0 
rs8015278 14 MTHFD1 1798 0.07 0.18 0.8 1.0 
rs16853782 2 ATIC 1798 0.20 0.34 0.8 1.0 
rs7587636 2 DNMT3A 1798 0.45 0.25 0.8 1.0 
rs7113075 11 FOLH1 1797 0.08 0.64 0.8 1.0 
rs2424908 20 DNMT3B 1798 0.17 0.40 0.8 1.0 
rs7177027 15 MTHFS 1797 0.24 0.40 0.8 1.0 
rs617219 5 BHMT 1790 0.32 0.94 0.8 1.0 
rs4441015 11 FOLH1 1753 0.14 0.40 0.8 1.0 
rs7177659 15 MTHFS 1796 0.49 0.09 0.8 1.0 
rs2838961 21 SLC19A1 1797 0.34 0.94 0.8 1.0 
rs6586282 21 CBS 1792 0.18 0.16 0.8 1.0 
rs12903985 15 MTHFS 1797 0.29 0.14 0.8 1.0 
rs1667627 14 MTHFD2 1792 0.47 0.34 0.8 1.0 
rs17279885 15 MTHFS 1798 0.20 0.67 0.8 1.0 
rs12148881 15 MTHFS 1797 0.26 0.19 0.8 1.0 
rs7144437 14 MTHFD1 1797 0.07 0.10 0.8 1.0 
rs2275565 1 MTR 1793 0.19 0.66 0.8 1.0 
rs2281603 14 MTHFD1 1798 0.20 0.34 0.8 1.0 
rs2372535 2 ATIC 1798 0.14 0.89 0.8 1.0 
rs2236225 14 MTHFD1 1797 0.43 0.24 0.8 1.0 
rs7934591 11 FOLH1 1798 0.08 0.81 0.8 1.0 
rs3821353 2 ATIC 1798 0.20 0.17 0.8 1.0 
rs12482067 21 GART 1798 0.02 0.24 0.8 1.0 
rs7575625 2 DNMT3A 1797 0.47 0.89 0.8 1.0 
rs6713377 2 DNMT3A 1797 0.47 0.89 0.8 1.0 
rs4646383 17 PEMT 1797 0.09 0.53 0.8 1.0 
rs3740392 10 AS3MT 1794 0.29 0.41 0.8 1.0 
rs1256142 14 MTHFD1 1798 0.44 0.10 0.8 1.0 
rs8041943 15 MTHFS 1794 0.41 0.37 0.8 1.0 
rs2865908 11 FOLH1 1798 0.18 0.50 0.8 1.0 
rs2424932 20 DNMT3B 1797 0.43 0.15 0.8 1.0 
rs1076991 14 MTHFD1 1798 0.45 0.63 0.8 1.0 
rs8129445 21 SLC19A1 1798 0.32 0.70 0.8 1.0 
rs34033751 11 FOLH1 1776 0.11 0.23 0.8 1.0 
rs16999714 19 DNMT1 1796 0.21 0.26 0.8 1.0 
rs944422 21 SLC19A1 1791 0.35 0.76 0.8 1.0 
rs3774616 3 CHDH 1798 0.04 1.00 0.8 1.0 
rs11040353 11 FOLH1 1795 0.08 0.64 0.8 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs35709834 5 DHFR 1793 0.04 0.62 0.8 1.0 
rs17291414 19 DNMT1 1798 0.28 0.73 0.8 1.0 
rs1801394 5 MTRR 1808 0.49 0.50 0.8 1.0 
rs559062 1 CTH 1793 0.22 0.85 0.8 1.0 
rs8923 15 MTHFS 1798 0.08 0.15 0.9 1.0 
rs12222221 11 FOLH1 1798 0.08 1.00 0.9 1.0 
rs11040390 11 FOLH1 1798 0.08 1.00 0.9 1.0 
rs1404774 2 ATIC 1784 0.22 0.42 0.9 1.0 
rs749130 2 DNMT3A 1798 0.45 0.37 0.9 1.0 
rs4902278 14 MTHFD1 1791 0.07 0.18 0.9 1.0 
rs11158538 14 MTHFD1 1795 0.45 0.78 0.9 1.0 
rs734693 2 DNMT3A 1795 0.29 0.51 0.9 1.0 
rs17279753 15 MTHFS 1798 0.19 0.51 0.9 1.0 
rs9642880 8 MYC 1797 0.44 0.78 0.9 1.0 
rs12627639 21 SLC19A1 1797 0.21 0.68 0.9 1.0 
rs12613 21 CBS 1793 0.09 0.83 0.9 1.0 
rs6711622 2 DNMT3A 1798 0.44 1.00 0.9 1.0 
rs2987981 14 MTHFD1 1798 0.26 1.00 0.9 1.0 
rs11040432 11 FOLH1 1797 0.08 1.00 0.9 1.0 
rs8011839 14 MTHFD1 1798 0.17 0.72 0.9 1.0 
rs865646 5 DHFR 1736 0.36 0.55 0.9 1.0 
rs7102641 11 FOLH1 1793 0.08 0.47 0.9 1.0 
rs372447 15 MTHFS 1798 0.38 0.77 0.9 1.0 
rs12884767 14 MTHFD1 1798 0.04 0.14 0.9 1.0 
rs9910747 17 PEMT 1798 0.07 0.47 0.9 1.0 
rs8128050 21 SLC19A1 1794 0.34 0.94 0.9 1.0 
rs567754 5 BHMT 1792 0.29 0.74 0.9 1.0 
rs8129350 21 SLC19A1 1797 0.34 0.76 0.9 1.0 
rs1059394 18 TYMS 1791 0.31 0.64 0.9 1.0 
rs7759302 6 GNMT 1798 0.06 0.57 0.9 1.0 
rs699517 18 TYMS 1791 0.31 0.64 0.9 1.0 
rs663465 1 CTH 1792 0.42 0.36 0.9 1.0 
rs4094478 11 FOLH1 1770 0.20 0.34 0.9 1.0 
rs11085720 19 DNMT1 1798 0.41 0.44 0.9 1.0 
rs10839210 11 FOLH1 1796 0.21 0.18 0.9 1.0 
rs13317328 3 CHDH 1798 0.09 0.06 0.9 1.0 
rs8003567 14 MTHFD1 1798 0.11 0.47 0.9 1.0 
rs6445606 3 CHDH 1798 0.29 0.10 0.9 1.0 
rs2289093 2 DNMT3A 1798 0.29 0.62 0.9 1.0 
rs685487 15 MTHFS 1798 0.36 0.34 0.9 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=519) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1256114 14 MTHFD1 1797 0.11 0.86 0.9 1.0 
rs2987969 14 MTHFD1 1797 0.45 0.95 0.9 1.0 
rs11627387 14 MTHFD1 1798 0.30 0.81 0.9 1.0 
rs35918857 19 DNMT1 1797 0.02 0.25 0.9 1.0 
rs1465825 2 DNMT3A 1797 0.27 1.00 0.9 1.0 
rs8018032 14 MTHFD1 1798 0.45 0.95 0.9 1.0 
rs282795 15 MTHFS 1797 0.32 0.88 0.9 1.0 
rs3783728 14 MTHFD1 1798 0.08 0.64 0.9 1.0 
rs1847638 11 FOLH1 1729 0.21 0.47 0.9 1.0 
rs2696923 11 FOLH1 1798 0.21 0.12 0.9 1.0 
rs12416687 10 AS3MT 1797 0.27 0.15 0.9 1.0 
rs17751556 14 MTHFD1 1798 0.08 0.65 1.0 1.0 
rs10769558 11 FOLH1 1797 0.21 0.18 1.0 1.0 
rs6517178 21 GART 1798 0.40 0.72 1.0 1.0 
rs11681447 2 DNMT3A 1796 0.29 0.62 1.0 1.0 
rs2236222 14 MTHFD1 1798 0.10 0.27 1.0 1.0 
rs12898642 15 MTHFS 1798 0.43 0.34 1.0 1.0 
rs6801605 3 CHDH 1798 0.37 1.00 1.0 1.0 
rs2696935 11 FOLH1 1798 0.21 0.12 1.0 1.0 
rs401681 5 TERT-CLPTM1L 1798 0.46 0.84 1.0 1.0 
rs3800292 6 GNMT 1798 0.06 0.57 1.0 1.0 
rs11852515 15 MTHFS 1798 0.11 0.74 1.0 1.0 
rs8019804 14 MTHFD1 1798 0.07 1.00 1.0 1.0 
rs11158542 14 MTHFD1 1798 0.30 0.81 1.0 1.0 
rs2834235 21 GART 1797 0.39 0.67 1.0 1.0 
rs282792 15 MTHFS 1798 0.37 0.47 1.0 1.0 
rs11627525 14 MTHFD1 1798 0.11 0.08 1.0 1.0 
rs10460566 2 DNMT3A 1798 0.27 0.86 1.0 1.0 
rs12453139 17 PEMT 1797 0.26 0.66 1.0 1.0 
rs7174668 15 MTHFS 1798 0.21 0.48 1.0 1.0 
rs11658944 17 PEMT 1797 0.05 0.49 1.0 1.0 
rs2154583 21 GART 1791 0.40 0.67 1.0 1.0 
rs11629135 14 MTHFD1 1797 0.11 0.38 1.0 1.0 
rs8971 21 GART 1795 0.26 0.73 1.0 1.0 
rs2834232 21 GART 1797 0.26 0.73 1.0 1.0 
rs2834231 21 GART 1798 0.26 0.73 1.0 1.0 
rs204942 15 MTHFS 1798 0.21 0.31 1.0 1.0 
rs6573559 14 MTHFD1 1798 0.30 0.94 1.0 1.0 
rs2838969 21 SLC19A1 1798 0.07 0.79 1.0 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
SNPs modeled in recessive mode of inheritance 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7560488 2 DNMT3A 1731 0.48 0.15 0.003 0.8 
rs282814 15 MTHFS 1798 0.22 0.84 0.005 0.9 
rs11683424 2 DNMT3A 1798 0.12 0.20 0.005 0.9 
rs6495441 15 MTHFS 1798 0.25 0.93 0.006 0.9 
rs204942 15 MTHFS 1798 0.21 0.31 0.007 1.0 
rs4646404 17 PEMT 1792 0.35 0.26 0.009 1.0 
rs4925048 17 PEMT 1797 0.10 0.17 0.01 1.0 
rs7174668 15 MTHFS 1798 0.21 0.48 0.01 1.0 
rs12903985 15 MTHFS 1797 0.29 0.14 0.01 1.0 
rs7563206 2 ATIC 1796 0.47 0.84 0.01 1.0 
rs11869600 17 PEMT 1796 0.37 0.38 0.02 1.0 
rs11871738 17 PEMT 1798 0.38 0.67 0.02 1.0 
rs1077965 15 MTHFS 1797 0.41 0.58 0.02 1.0 
rs1880580 15 MTHFS 1798 0.31 0.38 0.02 1.0 
rs1880586 2 ATIC 1797 0.47 0.89 0.02 1.0 
rs7581217 2 DNMT3A 1798 0.39 0.62 0.02 1.0 
rs798766 4 TMEM129-TACC3-FGFR3 1798 0.18 0.21 0.02 1.0 
rs282795 15 MTHFS 1797 0.32 0.88 0.02 1.0 
rs4646344 17 PEMT 1798 0.46 0.45 0.03 1.0 
rs11852515 15 MTHFS 1798 0.11 0.74 0.04 1.0 
rs3760188 17 PEMT 1798 0.46 0.38 0.04 1.0 
rs10418 22 TCN2 1772 0.21 0.41 0.04 1.0 
rs12898670 15 MTHFS 1796 0.34 0.70 0.05 1.0 
rs6713377 2 DNMT3A 1797 0.47 0.89 0.05 1.0 
rs17209637 15 MTHFS 1794 0.26 0.79 0.05 1.0 
rs11892646 2 DNMT3A 1797 0.11 0.87 0.05 1.0 
rs1495741 8 NAT2 1798 0.24 1.00 0.05 1.0 
rs7575625 2 DNMT3A 1797 0.47 0.89 0.06 1.0 
rs17824591 14 MTHFD1 1796 0.23 0.63 0.06 1.0 
rs944422 21 SLC19A1 1791 0.35 0.76 0.06 1.0 
rs8129350 21 SLC19A1 1797 0.34 0.76 0.07 1.0 
rs1014971 22 CBXB APOBEC3A 1797 0.30 0.23 0.07 1.0 
rs2838961 21 SLC19A1 1797 0.34 0.94 0.08 1.0 
rs166868 15 MTHFS 1796 0.37 0.94 0.09 1.0 
rs1460177 15 MTHFS 1797 0.08 0.37 0.09 1.0 
rs16971253 15 MTHFS 1797 0.10 1.00 0.09 1.0 
rs9001 3 CHDH 1793 0.09 0.21 0.10 1.0 
rs7586294 2 DNMT3A 1797 0.47 0.73 0.1 1.0 
rs10380 5 MTRR 1793 0.10 0.56 0.1 1.0 
rs4531931 2 ATIC 1796 0.31 0.23 0.1 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs8128050 21 SLC19A1 1794 0.34 0.94 0.1 1.0 
rs13427202 2 DNMT3A 1797 0.47 0.68 0.1 1.0 
rs710521 3 TP63 1798 0.26 0.93 0.1 1.0 
rs6706415 2 ATIC 1798 0.31 0.81 0.1 1.0 
rs1983462 2 ATIC 1798 0.31 0.47 0.1 1.0 
rs435689 15 MTHFS 1798 0.49 0.50 0.1 1.0 
rs4476347 2 ATIC 1798 0.25 0.28 0.1 1.0 
rs13317328 3 CHDH 1798 0.09 0.06 0.1 1.0 
rs7279305 21 SLC19A1 1797 0.35 1.00 0.1 1.0 
rs8102137 19 CCNE1 1798 0.33 0.13 0.1 1.0 
rs582172 15 MTHFS 1798 0.42 0.45 0.1 1.0 
rs6586282 21 CBS 1792 0.18 0.16 0.1 1.0 
rs10197653 2 ATIC 1798 0.29 0.74 0.1 1.0 
rs6058897 20 DNMT3B 1798 0.44 0.17 0.2 1.0 
rs13036246 2 DNMT3A 1797 0.48 0.08 0.2 1.0 
rs10179873 2 ATIC 1798 0.30 0.63 0.2 1.0 
rs11656215 17 PEMT 1798 0.46 0.20 0.2 1.0 
rs897453 17 PEMT 1790 0.47 0.54 0.2 1.0 
rs2424913 20 DNMT3B 1797 0.37 0.39 0.2 1.0 
rs1059394 18 TYMS 1791 0.31 0.64 0.2 1.0 
rs9332 5 MTRR 1793 0.12 0.34 0.2 1.0 
rs7583409 2 DNMT3A 1795 0.36 0.38 0.2 1.0 
rs2275565 1 MTR 1793 0.19 0.66 0.2 1.0 
rs1081231 15 MTHFS 1797 0.17 0.71 0.2 1.0 
rs7220132 17 PEMT 1798 0.29 0.57 0.2 1.0 
rs2424906 20 DNMT3B 1798 0.37 0.28 0.2 1.0 
rs699517 18 TYMS 1791 0.31 0.64 0.2 1.0 
rs10163099 15 MTHFS 1792 0.26 0.48 0.2 1.0 
rs8129445 21 SLC19A1 1798 0.32 0.70 0.2 1.0 
rs378057 15 MTHFS 1797 0.14 0.89 0.2 1.0 
rs4779141 15 MTHFS 1793 0.34 0.55 0.2 1.0 
rs12910340 15 MTHFS 1798 0.42 0.73 0.2 1.0 
rs4646410 17 PEMT 1795 0.31 0.94 0.2 1.0 
rs1109859 17 PEMT 1770 0.18 0.64 0.2 1.0 
rs12453139 17 PEMT 1797 0.26 0.66 0.2 1.0 
rs6058891 20 DNMT3B 1796 0.39 0.32 0.2 1.0 
rs10498036 2 ATIC 1798 0.40 0.57 0.2 1.0 
rs8074074 17 PEMT 1796 0.30 0.87 0.2 1.0 
rs9835128 3 CHDH 1797 0.16 0.38 0.2 1.0 
rs6495446 15 MTHFS 1797 0.26 0.38 0.2 1.0 
214 
 
Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1802059 5 MTRR 1792 0.36 0.60 0.2 1.0 
rs4393531 15 MTHFS 1795 0.47 0.63 0.2 1.0 
rs8034036 15 MTHFS 1795 0.11 0.23 0.2 1.0 
rs2838965 21 SLC19A1 1792 0.42 0.33 0.3 1.0 
rs1256112 14 MTHFD1 1798 0.40 0.29 0.3 1.0 
rs445263 15 MTHFS 1798 0.29 0.68 0.3 1.0 
rs7175620 15 MTHFS 1797 0.22 0.14 0.3 1.0 
rs2275566 1 MTR 1793 0.41 0.53 0.3 1.0 
rs2424922 20 DNMT3B 1796 0.39 0.29 0.3 1.0 
rs9606756 22 TCN2 1798 0.12 0.87 0.3 1.0 
rs5753231 22 TCN2 1797 0.16 0.62 0.3 1.0 
rs4673991 2 ATIC 1797 0.32 0.31 0.3 1.0 
rs4672768 2 ATIC 1794 0.32 0.31 0.3 1.0 
rs2281603 14 MTHFD1 1798 0.20 0.34 0.3 1.0 
rs9897362 17 PEMT 1798 0.06 0.77 0.3 1.0 
rs4673993 2 ATIC 1798 0.32 0.31 0.3 1.0 
rs2424928 20 DNMT3B 1798 0.39 0.26 0.3 1.0 
rs11040353 11 FOLH1 1795 0.08 0.64 0.3 1.0 
rs6058883 20 DNMT3B 1797 0.39 0.36 0.3 1.0 
rs7604984 2 ATIC 1798 0.40 0.62 0.3 1.0 
rs7946 17 PEMT 1798 0.30 0.52 0.3 1.0 
rs11040432 11 FOLH1 1797 0.08 1.00 0.3 1.0 
rs12222221 11 FOLH1 1798 0.08 1.00 0.3 1.0 
rs11040390 11 FOLH1 1798 0.08 1.00 0.3 1.0 
rs2424914 20 DNMT3B 1798 0.39 0.39 0.3 1.0 
rs8081810 17 PEMT 1797 0.20 0.92 0.3 1.0 
rs7177027 15 MTHFS 1797 0.24 0.40 0.3 1.0 
rs11892429 2 ATIC 1798 0.29 1.00 0.3 1.0 
rs2372535 2 ATIC 1798 0.14 0.89 0.3 1.0 
rs2424921 20 DNMT3B 1798 0.39 0.32 0.3 1.0 
rs4817577 21 GART 1797 0.34 0.20 0.3 1.0 
rs11040421 11 FOLH1 1798 0.14 0.78 0.3 1.0 
rs1465825 2 DNMT3A 1797 0.27 1.00 0.3 1.0 
rs10460566 2 DNMT3A 1798 0.27 0.86 0.3 1.0 
rs1055345 21 SLC19A1 1797 0.29 0.10 0.3 1.0 
rs4244599 17 PEMT 1774 0.47 0.34 0.3 1.0 
rs2838973 21 SLC19A1 1798 0.20 0.92 0.3 1.0 
rs853858 20 DNMT3B 1796 0.37 0.19 0.3 1.0 
rs6711622 2 DNMT3A 1798 0.44 1.00 0.3 1.0 
rs3893384 15 MTHFS 1798 0.42 0.44 0.3 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs10948059 6 GNMT 1778 0.49 0.54 0.3 1.0 
rs7283354 21 GART 1798 0.34 0.15 0.3 1.0 
rs10197559 2 ATIC 1788 0.29 0.87 0.3 1.0 
rs2236225 14 MTHFD1 1797 0.43 0.24 0.3 1.0 
rs1127717 3 ALDH1L1 1793 0.24 1.00 0.3 1.0 
rs2115540 15 MTHFS 1797 0.49 0.20 0.3 1.0 
rs3755817 3 CHDH 1797 0.30 0.42 0.3 1.0 
rs10165919 2 ATIC 1797 0.35 0.88 0.3 1.0 
rs2267163 22 TCN2 1794 0.43 0.06 0.3 1.0 
rs7604425 2 ATIC 1798 0.35 0.94 0.3 1.0 
rs6757920 2 ATIC 1794 0.48 0.09 0.3 1.0 
rs8074191 17 PEMT 1778 0.28 0.93 0.3 1.0 
rs914238 21 SLC19A1 1798 0.49 0.89 0.3 1.0 
rs2115536 15 MTHFS 1798 0.49 0.22 0.3 1.0 
rs3862350 11 FOLH1 1765 0.40 0.15 0.4 1.0 
rs11158542 14 MTHFD1 1798 0.30 0.81 0.4 1.0 
rs4817579 21 GART 1798 0.34 0.15 0.4 1.0 
rs4911263 20 DNMT3B 1798 0.32 1.00 0.4 1.0 
rs12997662 2 ATIC 1798 0.34 0.26 0.4 1.0 
rs5749135 22 TCN2 1798 0.43 0.07 0.4 1.0 
rs17745484 2 DNMT3A 1797 0.35 0.30 0.4 1.0 
rs4646350 17 PEMT 1798 0.36 0.83 0.4 1.0 
rs1814175 11 FOLH1 1793 0.40 0.40 0.4 1.0 
rs4778721 15 MTHFS 1798 0.22 0.09 0.4 1.0 
rs4778719 15 MTHFS 1798 0.22 0.09 0.4 1.0 
rs10839295 11 FOLH1 1797 0.40 0.48 0.4 1.0 
rs1801198 22 TCN2 1797 0.43 0.08 0.4 1.0 
rs9789571 2 ATIC 1798 0.42 0.89 0.4 1.0 
rs12898642 15 MTHFS 1798 0.43 0.34 0.4 1.0 
rs1380642 15 MTHFS 1798 0.18 0.57 0.4 1.0 
rs1667627 14 MTHFD2 1792 0.47 0.34 0.4 1.0 
rs4646383 17 PEMT 1797 0.09 0.53 0.4 1.0 
rs6749992 2 DNMT3A 1798 0.47 0.79 0.4 1.0 
rs7605753 2 DNMT3A 1797 0.47 0.68 0.4 1.0 
rs6518253 21 SLC19A1 1797 0.46 0.63 0.4 1.0 
rs2124344 17 PEMT 1797 0.36 0.77 0.4 1.0 
rs1809986 11 FOLH1 1798 0.36 0.38 0.4 1.0 
rs2183601 21 SLC19A1 1797 0.20 0.92 0.4 1.0 
rs282792 15 MTHFS 1798 0.37 0.47 0.4 1.0 
rs2304429 2 DNMT3A 1798 0.43 0.10 0.4 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE 
P 
LRT 
Corrected 
P LRT 
rs9974061 21 SLC19A1 1798 0.18 0.82 0.4 1.0 
rs7085104 10 AS3MT 1798 0.38 1.00 0.4 1.0 
rs7934591 11 FOLH1 1798 0.08 0.81 0.4 1.0 
NA 1 MTHFR 1658 0.39 0.33 0.4 1.0 
rs7113075 11 FOLH1 1797 0.08 0.64 0.4 1.0 
rs9462856 6 GNMT 1798 0.42 0.53 0.4 1.0 
NA 1 MTHFR_02_2_i_order 1793 0.39 0.35 0.4 1.0 
rs1801133 1 MTHFR 1793 0.39 0.35 0.4 1.0 
rs748196 17 PEMT 1795 0.44 0.89 0.4 1.0 
rs2301955 22 TCN2 1794 0.43 0.10 0.4 1.0 
rs2066470 1 MTHFR 1788 0.08 0.39 0.4 1.0 
rs2305230 3 ALDH1L1 1792 0.20 0.30 0.4 1.0 
rs3785499 17 PEMT 1798 0.48 0.54 0.4 1.0 
rs4610054 2 ATIC 1794 0.38 0.67 0.4 1.0 
rs7120743 11 FOLH1 1774 0.36 0.77 0.4 1.0 
rs3862342 11 FOLH1 1795 0.28 0.93 0.4 1.0 
rs4646385 17 PEMT 1798 0.45 0.37 0.4 1.0 
rs2294008 8 PSCA 1798 0.46 0.73 0.5 1.0 
rs9976878 21 SLC19A1 1797 0.20 1.00 0.5 1.0 
rs4646359 17 PEMT 1798 0.46 0.15 0.5 1.0 
rs4479310 17 PEMT 1798 0.30 0.63 0.5 1.0 
rs1979276 17 SHMT1 1808 0.31 0.94 0.5 1.0 
rs9306139 21 SLC19A1 1796 0.20 1.00 0.5 1.0 
rs7951180 11 FOLH1 1778 0.17 0.55 0.5 1.0 
rs12797853 11 FOLH1 1794 0.13 0.46 0.5 1.0 
rs7177659 15 MTHFS 1796 0.49 0.09 0.5 1.0 
rs1956545 14 MTHFD1 1797 0.08 0.17 0.5 1.0 
rs1164681 11 FOLH1 1798 0.12 0.25 0.5 1.0 
rs1256114 14 MTHFD1 1797 0.11 0.86 0.5 1.0 
rs282776 15 MTHFS 1798 0.36 0.47 0.5 1.0 
rs11627387 14 MTHFD1 1798 0.30 0.81 0.5 1.0 
rs6573559 14 MTHFD1 1798 0.30 0.94 0.5 1.0 
rs1950902 14 MTHFD1 1798 0.15 1.00 0.5 1.0 
NA 1 MTR 1793 0.16 0.81 0.5 1.0 
rs9642880 8 MYC 1797 0.44 0.78 0.5 1.0 
rs740234 22 TCN2 1798 0.23 0.39 0.5 1.0 
rs9323450 14 MTHFD1 1798 0.31 0.69 0.5 1.0 
rs1847638 11 FOLH1 1729 0.21 0.47 0.5 1.0 
rs2150460 21 SLC19A1 1798 0.20 1.00 0.5 1.0 
rs282772 15 MTHFS 1798 0.14 0.25 0.5 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs3740394 10 AS3MT 1797 0.13 1.00 0.5 1.0 
rs11887120 2 DNMT3A 1798 0.41 0.44 0.5 1.0 
rs10509760 10 AS3MT 1798 0.13 0.88 0.5 1.0 
rs1805087 1 MTR 1793 0.16 0.81 0.5 1.0 
rs4924922 17 PEMT 1798 0.37 0.43 0.5 1.0 
rs34048824 2 DNMT3A 1797 0.51 0.74 0.5 1.0 
rs401681 5 TERT-CLPTM1L 1798 0.46 0.84 0.5 1.0 
rs17284990 15 MTHFS 1798 0.21 0.62 0.5 1.0 
rs2834231 21 GART 1798 0.26 0.73 0.5 1.0 
rs2834232 21 GART 1797 0.26 0.73 0.5 1.0 
rs8971 21 GART 1795 0.26 0.73 0.5 1.0 
rs8019804 14 MTHFD1 1798 0.07 1.00 0.5 1.0 
rs4819138 21 SLC19A1 1797 0.40 0.89 0.5 1.0 
rs679470 11 FOLH1 1797 0.17 0.63 0.5 1.0 
rs7107178 11 FOLH1 1796 0.25 0.86 0.5 1.0 
rs4532960 10 AS3MT 1797 0.44 0.89 0.6 1.0 
rs7111711 11 FOLH1 1798 0.25 0.86 0.6 1.0 
rs4817580 21 GART 1797 0.10 0.70 0.6 1.0 
rs6445606 3 CHDH 1798 0.29 0.10 0.6 1.0 
rs10748835 10 AS3MT 1798 0.44 0.89 0.6 1.0 
rs3772078 2 ATIC 1797 0.20 0.29 0.6 1.0 
rs10839296 11 FOLH1 1777 0.25 0.65 0.6 1.0 
rs4434082 21 SLC19A1 1797 0.20 1.00 0.6 1.0 
rs35020344 14 MTHFD1 1797 0.48 0.42 0.6 1.0 
rs3783 17 SHMT1 1806 0.26 0.30 0.6 1.0 
rs648372 11 FOLH1 1772 0.16 0.46 0.6 1.0 
rs770144 15 MTHFS 1798 0.20 1.00 0.6 1.0 
rs8659 5 MTRR 1790 0.35 0.33 0.6 1.0 
rs11040106 11 FOLH1 1787 0.36 0.66 0.6 1.0 
rs443394 15 MTHFS 1798 0.42 0.30 0.6 1.0 
rs17211644 15 MTHFS 1798 0.10 0.72 0.6 1.0 
rs1801394 5 MTRR 1808 0.49 0.50 0.6 1.0 
rs34033751 11 FOLH1 1776 0.11 0.23 0.6 1.0 
rs6141813 20 DNMT3B 1798 0.14 1.00 0.6 1.0 
rs3821353 2 ATIC 1798 0.20 0.17 0.6 1.0 
rs202718 11 FOLH1 1798 0.15 0.79 0.6 1.0 
rs8128681 21 SLC19A1 1798 0.33 0.94 0.6 1.0 
rs1604503 15 MTHFS 1798 0.15 0.59 0.6 1.0 
rs2834233 21 GART 1797 0.09 0.08 0.6 1.0 
rs202676 11 FOLH1 1788 0.17 0.72 0.6 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE 
P 
LRT 
Corrected 
P LRT 
rs910085 20 DNMT3B 1797 0.29 0.93 0.6 1.0 
rs10400277 11 FOLH1 1774 0.13 0.37 0.6 1.0 
rs4911108 20 DNMT3B 1793 0.28 0.87 0.6 1.0 
rs2987981 14 MTHFD1 1798 0.26 1.00 0.6 1.0 
rs1256107 14 MTHFD1 1796 0.49 0.50 0.6 1.0 
rs11687225 2 ATIC 1797 0.40 0.72 0.6 1.0 
rs2838970 21 SLC19A1 1797 0.40 0.78 0.6 1.0 
rs9836592 3 CHDH 1798 0.32 0.14 0.6 1.0 
rs4441015 11 FOLH1 1753 0.14 0.40 0.6 1.0 
rs1801131 1 MTHFR 1710 0.28 0.34 0.6 1.0 
rs12905663 15 MTHFS 1788 0.29 0.80 0.6 1.0 
NA 1 MTR_01_2_i_order 1793 0.16 0.81 0.6 1.0 
rs617219 5 BHMT 1790 0.32 0.94 0.6 1.0 
rs12797843 11 FOLH1 1798 0.13 0.37 0.6 1.0 
rs372447 15 MTHFS 1798 0.38 0.77 0.6 1.0 
rs7253062 19 DNMT1 1798 0.38 1.00 0.6 1.0 
rs11085720 19 DNMT1 1798 0.41 0.44 0.6 1.0 
rs4911107 20 DNMT3B 1798 0.31 1.00 0.6 1.0 
rs8101626 19 DNMT1 1798 0.39 0.89 0.6 1.0 
rs6722613 2 DNMT3A 1798 0.40 0.89 0.7 1.0 
rs4819130 21 SLC19A1 1794 0.45 0.15 0.7 1.0 
rs4673965 2 ATIC 1798 0.40 0.94 0.7 1.0 
rs2696935 11 FOLH1 1798 0.21 0.12 0.7 1.0 
rs7111215 11 FOLH1 1774 0.40 0.52 0.7 1.0 
rs750546 17 PEMT 1773 0.45 0.19 0.7 1.0 
rs16853782 2 ATIC 1798 0.20 0.34 0.7 1.0 
rs2288349 19 DNMT1 1797 0.38 0.78 0.7 1.0 
rs1650697 5 DHFR 1791 0.23 0.06 0.7 1.0 
rs12613 21 CBS 1793 0.09 0.83 0.7 1.0 
rs2241807 3 CHDH 1798 0.42 0.89 0.7 1.0 
rs1404774 2 ATIC 1784 0.22 0.42 0.7 1.0 
rs3740392 10 AS3MT 1794 0.29 0.41 0.7 1.0 
rs17291414 19 DNMT1 1798 0.28 0.73 0.7 1.0 
rs8111085 19 DNMT1 1797 0.08 0.64 0.7 1.0 
rs12462004 19 DNMT1 1795 0.08 0.64 0.7 1.0 
rs10418707 19 DNMT1 1796 0.08 0.64 0.7 1.0 
rs2116940 19 DNMT1 1797 0.08 0.64 0.7 1.0 
rs8112895 19 DNMT1 1798 0.08 0.81 0.7 1.0 
rs2288350 19 DNMT1 1798 0.08 0.64 0.7 1.0 
rs10498034 2 ATIC 1798 0.16 0.90 0.7 1.0 
219 
 
Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4804490 19 DNMT1 1796 0.08 0.64 0.7 1.0 
rs11672909 19 DNMT1 1797 0.08 0.81 0.7 1.0 
rs9305012 19 DNMT1 1797 0.08 0.64 0.7 1.0 
rs4804125 19 DNMT1 1797 0.08 0.64 0.7 1.0 
rs4804494 19 DNMT1 1797 0.08 0.64 0.7 1.0 
rs2236224 14 MTHFD1 1798 0.36 0.07 0.7 1.0 
rs8041943 15 MTHFS 1794 0.41 0.37 0.7 1.0 
rs11191439 10 AS3MT 1795 0.12 0.75 0.7 1.0 
rs2838977 21 SLC19A1 1796 0.40 0.72 0.7 1.0 
rs4646341 17 PEMT 1795 0.37 0.56 0.7 1.0 
rs8923 15 MTHFS 1798 0.08 0.15 0.7 1.0 
rs1979277 17 SHMT1 1809 0.27 0.87 0.7 1.0 
rs12591436 15 MTHFS 1798 0.35 0.55 0.7 1.0 
rs11701960 21 SLC19A1 1797 0.18 0.91 0.7 1.0 
rs2790 18 TYMS 1789 0.20 0.67 0.7 1.0 
rs2838958 21 SLC19A1 1794 0.46 0.63 0.7 1.0 
rs12614943 2 ATIC 1798 0.27 0.73 0.7 1.0 
rs1917311 11 FOLH1 1753 0.40 0.72 0.7 1.0 
rs4987173 6 GNMT 1798 0.50 0.46 0.7 1.0 
rs515064 1 CTH 1793 0.35 0.50 0.7 1.0 
rs767138 21 SLC19A1 1795 0.41 0.89 0.7 1.0 
rs11158540 14 MTHFD1 1798 0.35 0.94 0.7 1.0 
rs2586182 15 MTHFS 1798 0.14 0.78 0.7 1.0 
rs11040416 11 FOLH1 1798 0.42 0.58 0.7 1.0 
rs1256095 14 MTHFD1 1782 0.48 0.50 0.7 1.0 
rs4673981 2 ATIC 1798 0.40 1.00 0.7 1.0 
rs9282690 3 ALDH1L1 1793 0.08 1.00 0.7 1.0 
rs11681447 2 DNMT3A 1796 0.29 0.62 0.7 1.0 
rs12121543 1 MTHFR 1793 0.22 0.32 0.7 1.0 
rs2865908 11 FOLH1 1798 0.18 0.50 0.7 1.0 
rs4804122 19 DNMT1 1798 0.39 0.52 0.7 1.0 
rs16853826 2 ATIC 1796 0.13 0.88 0.7 1.0 
rs685487 15 MTHFS 1798 0.36 0.34 0.7 1.0 
rs11158538 14 MTHFD1 1795 0.45 0.78 0.7 1.0 
rs4094478 11 FOLH1 1770 0.20 0.34 0.7 1.0 
rs3177999 21 SLC19A1 1790 0.46 0.17 0.7 1.0 
rs11607791 11 FOLH1 1796 0.07 1.00 0.7 1.0 
rs2877078 21 SLC19A1 1786 0.40 0.94 0.7 1.0 
rs6058893 20 DNMT3B 1798 0.32 0.49 0.8 1.0 
rs12987326 2 DNMT3A 1798 0.37 0.47 0.8 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs3788200 21 SLC19A1 1798 0.45 0.31 0.8 1.0 
rs4818789 21 SLC19A1 1798 0.25 0.06 0.8 1.0 
rs8003567 14 MTHFD1 1798 0.11 0.47 0.8 1.0 
rs2236222 14 MTHFD1 1798 0.10 0.27 0.8 1.0 
rs11629135 14 MTHFD1 1797 0.11 0.38 0.8 1.0 
rs16971249 15 MTHFS 1798 0.08 0.09 0.8 1.0 
rs16906158 11 FOLH1 1796 0.08 1.00 0.8 1.0 
rs2696923 11 FOLH1 1798 0.21 0.12 0.8 1.0 
rs9890064 17 PEMT 1798 0.43 0.41 0.8 1.0 
rs2586153 15 MTHFS 1777 0.15 0.59 0.8 1.0 
rs6058869 20 DNMT3B 1797 0.33 0.76 0.8 1.0 
rs1256142 14 MTHFD1 1798 0.44 0.10 0.8 1.0 
rs1051266 21 SLC19A1 1798 0.45 0.20 0.8 1.0 
rs7594432 2 DNMT3A 1798 0.44 0.13 0.8 1.0 
rs12373907 21 SLC19A1 1797 0.38 0.20 0.8 1.0 
rs2733106 15 MTHFS 1793 0.15 0.69 0.8 1.0 
rs10769558 11 FOLH1 1797 0.21 0.18 0.8 1.0 
rs282802 15 MTHFS 1798 0.29 0.09 0.8 1.0 
rs4646340 17 PEMT 1798 0.37 0.51 0.8 1.0 
rs10839210 11 FOLH1 1796 0.21 0.18 0.8 1.0 
rs2162560 19 DNMT1 1797 0.38 0.94 0.8 1.0 
rs6511677 19 DNMT1 1797 0.38 0.89 0.8 1.0 
rs1081235 15 MTHFS 1798 0.20 0.67 0.8 1.0 
rs17285431 15 MTHFS 1798 0.17 0.08 0.8 1.0 
rs17751556 14 MTHFD1 1798 0.08 0.65 0.8 1.0 
rs2424932 20 DNMT3B 1797 0.43 0.15 0.8 1.0 
rs13401241 2 DNMT3A 1798 0.45 0.28 0.8 1.0 
rs2289093 2 DNMT3A 1798 0.29 0.62 0.8 1.0 
rs6801605 3 CHDH 1798 0.37 1.00 0.8 1.0 
rs1888533 21 SLC19A1 1797 0.48 0.42 0.8 1.0 
rs1051296 21 SLC19A1 1786 0.48 0.10 0.8 1.0 
rs10839239 11 FOLH1 1795 0.23 0.85 0.8 1.0 
rs11191457 10 AS3MT 1794 0.22 1.00 0.8 1.0 
rs2586154 15 MTHFS 1798 0.14 0.89 0.8 1.0 
rs1870576 15 MTHFS 1780 0.46 0.06 0.8 1.0 
rs660439 11 FOLH1 1794 0.23 0.85 0.8 1.0 
rs7085854 10 AS3MT 1797 0.22 0.85 0.8 1.0 
rs17279753 15 MTHFS 1798 0.19 0.51 0.8 1.0 
rs12438477 15 MTHFS 1797 0.36 0.61 0.8 1.0 
rs12416687 10 AS3MT 1797 0.27 0.15 0.8 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE 
P 
LRT 
Corrected 
P LRT 
rs559062 1 CTH 1793 0.22 0.85 0.8 1.0 
rs7124266 11 FOLH1 1798 0.30 0.94 0.8 1.0 
rs1051298 21 SLC19A1 1790 0.47 0.17 0.8 1.0 
rs734693 2 DNMT3A 1795 0.29 0.51 0.8 1.0 
rs1023159 21 SLC19A1 1796 0.42 0.78 0.8 1.0 
rs11694842 2 DNMT3A 1797 0.28 0.36 0.8 1.0 
rs2983733 14 MTHFD1 1798 0.44 0.68 0.8 1.0 
rs12482346 21 SLC19A1 1797 0.48 0.10 0.8 1.0 
rs567754 5 BHMT 1792 0.29 0.74 0.8 1.0 
rs8011839 14 MTHFD1 1798 0.17 0.72 0.8 1.0 
rs202712 11 FOLH1 1796 0.23 0.85 0.8 1.0 
rs13002567 2 DNMT3A 1798 0.28 0.40 0.8 1.0 
rs1473406 15 MTHFS 1796 0.15 0.79 0.8 1.0 
rs3818239 14 MTHFD1 1787 0.13 0.66 0.8 1.0 
rs7587636 2 DNMT3A 1798 0.45 0.25 0.8 1.0 
rs4779165 15 MTHFS 1797 0.16 0.80 0.8 1.0 
rs2035027 15 MTHFS 1798 0.16 0.80 0.8 1.0 
rs16971450 15 MTHFS 1797 0.16 0.80 0.9 1.0 
rs2983736 14 MTHFD1 1793 0.44 0.73 0.9 1.0 
rs1076991 14 MTHFD1 1798 0.45 0.63 0.9 1.0 
rs1369703 2 DNMT3A 1798 0.44 0.10 0.9 1.0 
rs1046778 10 AS3MT 1798 0.32 0.70 0.9 1.0 
rs1464864 2 ATIC 1798 0.30 0.81 0.9 1.0 
rs7929543 11 FOLH1 1798 0.07 0.81 0.9 1.0 
rs12999687 2 DNMT3A 1795 0.45 0.68 0.9 1.0 
rs202700 11 FOLH1 1734 0.23 0.77 0.9 1.0 
rs1808119 2 ATIC 1797 0.19 0.82 0.9 1.0 
rs8018032 14 MTHFD1 1798 0.45 0.95 0.9 1.0 
rs11677670 2 DNMT3A 1788 0.18 0.64 0.9 1.0 
rs914231 21 SLC19A1 1791 0.45 0.19 0.9 1.0 
rs11855092 15 MTHFS 1798 0.24 0.31 0.9 1.0 
rs17279885 15 MTHFS 1798 0.20 0.67 0.9 1.0 
rs2154583 21 GART 1791 0.40 0.67 0.9 1.0 
rs16999714 19 DNMT1 1796 0.21 0.26 0.9 1.0 
rs2733103 15 MTHFS 1797 0.15 0.51 0.9 1.0 
rs3788190 21 SLC19A1 1795 0.47 0.10 0.9 1.0 
rs9980967 21 SLC19A1 1797 0.11 0.38 0.9 1.0 
rs6760069 2 ATIC 1797 0.15 0.35 0.9 1.0 
rs9977111 21 SLC19A1 1750 0.33 0.14 0.9 1.0 
rs6517178 21 GART 1798 0.40 0.72 0.9 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs2987969 14 MTHFD1 1797 0.45 0.95 0.9 1.0 
rs1917321 11 FOLH1 1790 0.50 0.54 0.9 1.0 
rs8015278 14 MTHFD1 1798 0.07 0.18 0.9 1.0 
rs7144437 14 MTHFD1 1797 0.07 0.10 0.9 1.0 
rs4902278 14 MTHFD1 1791 0.07 0.18 0.9 1.0 
rs8068641 17 PEMT 1792 0.11 0.62 0.9 1.0 
rs11627525 14 MTHFD1 1798 0.11 0.08 0.9 1.0 
rs6485991 11 FOLH1 1791 0.17 0.81 0.9 1.0 
rs234706 21 CBS 1793 0.33 0.36 0.9 1.0 
rs7215833 17 PEMT 1798 0.36 0.51 0.9 1.0 
rs10932605 2 ATIC 1798 0.14 0.39 0.9 1.0 
rs1164685 11 FOLH1 1793 0.38 0.47 0.9 1.0 
rs4779140 15 MTHFS 1797 0.48 0.79 0.9 1.0 
rs588458 11 FOLH1 1772 0.38 0.52 0.9 1.0 
rs663649 1 CTH 1793 0.31 0.81 1.0 1.0 
rs473334 1 CTH 1793 0.31 0.81 1.0 1.0 
rs16853834 2 ATIC 1798 0.17 0.71 1.0 1.0 
rs1846285 11 FOLH1 1795 0.16 0.54 1.0 1.0 
rs914232 21 SLC19A1 1797 0.45 0.17 1.0 1.0 
rs4144700 11 FOLH1 1798 0.38 0.47 1.0 1.0 
rs2866358 11 FOLH1 1781 0.38 0.35 1.0 1.0 
rs759920 19 DNMT1 1798 0.46 0.79 1.0 1.0 
rs5749131 22 TCN2 1798 0.42 0.13 1.0 1.0 
rs4819128 21 SLC19A1 1798 0.45 0.13 1.0 1.0 
rs1888530 21 SLC19A1 1760 0.47 0.08 1.0 1.0 
rs6087990 20 DNMT3B 1797 0.32 0.64 1.0 1.0 
rs600671 15 MTHFS 1797 0.45 0.34 1.0 1.0 
rs2290684 19 DNMT1 1797 0.46 0.79 1.0 1.0 
rs898436 15 MTHFS 1793 0.45 0.37 1.0 1.0 
rs749130 2 DNMT3A 1798 0.45 0.37 1.0 1.0 
rs8003379 14 MTHFD1 1796 0.25 0.78 1.0 1.0 
rs12148881 15 MTHFS 1797 0.26 0.19 1.0 1.0 
rs1404772 2 ATIC 1798 0.08 0.34 1.0 1.0 
rs865646 5 DHFR 1736 0.36 0.55 1.0 1.0 
rs2834235 21 GART 1797 0.39 0.67 1.0 1.0 
rs2424908 20 DNMT3B 1798 0.17 0.40 1.0 1.0 
rs1074390 15 MTHFS 1798 0.38 0.77 1.0 1.0 
rs8128676 21 SLC19A1 1754 0.22 0.92 1.0 1.0 
rs663465 1 CTH 1792 0.42 0.36 1.0 1.0 
rs2228611 19 DNMT1 1798 0.46 0.79 1.0 1.0 
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Supplementary Table S4-6 (cont.) Corrected likelihood ratio test p-values of the interaction 
between LINE-1 methylation and SNPs in one-carbon metabolism pathway and bladder cancer 
susceptibility genes and in the SBS/EPICURO study 
dbSNP (N=446) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs10420338 19 DNMT1 1798 0.47 0.64 1.0 1.0 
rs6087988 20 DNMT3B 1798 0.19 1.00 1.0 1.0 
rs2330183 21 SLC19A1 1757 0.45 0.05 1.0 1.0 
rs12627639 21 SLC19A1 1797 0.21 0.68 1.0 1.0 
rs282778 15 MTHFS 1798 0.25 0.86 1.0 1.0 
rs376863 15 MTHFS 1772 0.50 0.73 1.0 1.0 
N, number of subjects; MAF, minor allele frequency; P HWE - Hardy-Weinberg Equilibrium 
chi-square test p-value; P LRT, likelihood ratio test p-value for interaction; NA - dbSNP 
identifier not available  
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Supplementary Table S4-7 Comparisons of controls and cases with LINE-1 methylation data and without LINE-1 methylation data 
Variables 
Controls   Cases 
With LINE-1 
data, N=892 
Without LINE-1 
data, N=259 P-value   
With LINE-1 
data, N=952 
Without LINE-1 
data, N=219 P-value 
Age in years, median (IQR) 66 (13) 69 (12) 0.001a   68 (13) 68 (13) 0.8* 
Gender               
Male 792 (88.8) 217 (83.8) 0.03   826 (89.8) 202 (92.2) 0.03 
Female 100 (11.2) 42 (16.2)     126 (13.2) 17 (7.8)   
Region               
Barcelona 168 (18.8) 50 (19.3) 0.2   162 (17.0) 46 (21.0) 0.5 
Valles 135 (15.1) 33 (12.7)     148 (15.5) 36 (16.4)   
Elche 73 (8.2) 11 (4.3)     72 (7.6) 16 (7.3)   
Tenerife 145 (16.3) 43 (16.6)     173 (18.2) 31 (14.2)   
Asturias 371 (41.6) 122 (47.1)     397 (41.7) 90 (41.1)   
Smoking status               
Never 255 (28.7) 66 (26.1) 0.3   137 (14.5) 23 (10.6) 0.1 
Occasional 66 (7.4) 27 (10.7)     34 (3.6) 12 (5.5)   
Former 329 (37.0) 97 (38.3)     376 (39.7) 77 (35.3)   
Current 239 (26.9) 63 (24.9)     399 (42.2) 106 (48.6)   
Missing 3 6     6 1   
*Mann–Whitney U test p-value.             
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Supplementary Figure S4-1 Results for urothelial carcinoma of the bladder risk and LINE-1 
methylation level modeled as a continuous variable using restricted cubic spline regression in 
logistic regression model adjusted for age, gender, region and smoking status. The solid line 
shows the point estimates and the broken lines show the lower and upper 95% confidence 
intervals. 
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Supplementary Table S5-1 Nonsignificant predictors of D4Z4 methylation level among the control population in the Spanish Bladder 
Cancer/EPICURO Study 
Characteristic N D4Z4 methylation (%) Unadjusted model N Adjusted model* Mean SD Median IQR β 95% CI P-value β 95% CI P-value 
Age  718 ─ ─ ─ ─ 0.01 -0.1 0.1 0.7 715 0.02 -0.1 0.1 0.6 
Region                             
Barcelona 130 61.9 11.0 64.1 12.5 Reference       130 Reference       
Valles 117 64.4 10.4 63.3 14.8 2.1 -0.4 4.6 0.1 117 1.9 -0.6 4.5 0.1 
Elche 58 64.2 9.3 65.0 12.9 1.7 -1.4 4.8 0.3 58 1.8 -1.3 4.9 0.3 
Tenerife 122 64.6 8.9 65.5 11.0 2.0 -0.4 4.5 0.1 121 2.0 -0.5 4.5 0.1 
Asturias 291 63.6 9.6 64.2 14.1 1.1 -1.0 3.1 0.3 289 1.0 -1.0 3.1 0.3 
Smoking status                             
Never 206 63.7 9.9 64.4 12.7 Reference       206 Reference       
Occasional 53 64.7 8.1 64.8 9.1 0.7 -2.3 3.8 0.6 53 -0.2 -3.3 2.9 0.9 
Former 261 63.7 9.6 64.5 14.7 -0.2 -2.0 1.7 0.9 261 -1.2 -3.2 0.8 0.3 
Current 195 63.1 10.7 64.1 14.0 -0.4 -2.3 1.6 0.7 195 -1.3 -3.5 0.9 0.2 
Body mass index†                             
< 25.0 305 64.0 9.6 65.2 14.0 Reference       303 Reference       
25.0 - 29.9 215 64.2 9.3 65.3 11.8 0.5 -1.2 2.2 0.6 215 0.4 -1.4 2.1 0.7 
≥ 30.0 40 60.2 12.8 62.1 18.5 -2.6 -5.8 0.7 0.1 40 -2.8 -6.1 0.5 0.09 
Controls' diagnosis                             
Hernia 278 64.1 10.0 64.4 13.1 Reference       276 Reference       
Fracture & Trauma 194 62.9 10.4 63.6 14.9 -1.2 -3.0 0.7 0.2 193 -0.9 -2.9 1.0 0.4 
Hydrocele 107 63.5 9.3 65.0 11.8 -0.7 -3.0 1.5 0.5 107 -1.1 -3.5 1.3 0.4 
Other Abdominal Surgery 84 64.4 8.9 65.2 12.2 0.1 -2.4 2.5 0.96 84 0.2 -2.2 2.7 0.8 
Other Diseases 55 62.7 10.4 64.1 13.4 -1.0 -3.9 1.9 0.5 55 -0.8 -3.9 2.2 0.6 
GSTM1                             
GSTM1 (++/+-) 338 63.1 9.8 63.9 12.6 Reference       336 Reference       
GSTM1 (--) 373 64.0 10.0 65.1 14.3 0.8 -0.6 2.3 0.3 372 0.8 -0.7 2.3 0.3 
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Supplementary Table S5-1 (cont.) Nonsignificant predictors of D4Z4 methylation level among the control population in the Spanish 
Bladder Cancer/EPICURO Study 
Characteristic N D4Z4 methylation (%) Unadjusted model N Adjusted model* Mean SD Median IQR β 95% CI P-value β 95% CI P-value 
GSTT1                             
GSTT1 (++/+-) 561 63.5 10.0 64.5 13.5 Reference       558 Reference       
GSTT1 (--) 151 64.0 9.6 64.3 14.0 0.2 -1.6 2.0 0.8 151 0.3 -1.5 2.1 0.8 
NAT2 acetylator                             
Rapid/Intermediate 306 64.0 9.8 65.3 13.3 Reference       305 Reference       
Slow 409 63.2 9.9 63.8 13.3 -0.9 -2.3 0.6 0.3 407 -0.7 -2.2 0.8 0.4 
Nutrient intake in μg/kcal/day                           
Vitamin B1 513 ─ ─ ─ ─ 2.8 -2.2 7.8 0.3 512 2.7 -2.6 8.0 0.3 
Vitamin B2 513 ─ ─ ─ ─ -0.2 -3.3 2.9 0.9 512 -0.5 -3.7 2.7 0.8 
Vitamin B3 513 ─ ─ ─ ─ 0.1 -0.2 0.4 0.6 512 0.1 -0.2 0.4 0.6 
Vitamin B6 513 ─ ─ ─ ─ 1.4 -2.1 4.9 0.4 512 1.1 -2.7 4.8 0.6 
Vitamin B12 513 ─ ─ ─ ─ 0.04 -0.2 0.3 0.7 512 0.1 -0.2 0.4 0.6 
Folate 513 ─ ─ ─ ─ 0.01 -0.01 0.02 0.3 512 0.01 -0.01 0.02 0.3 
Protein 513 ─ ─ ─ ─ -0.004 -0.1 0.1 0.9 512 -0.01 -0.1 0.1 0.9 
Alcohol 513 ─ ─ ─ ─ 0.02 -0.1 0.1 0.7 512 0.04 -0.1 0.1 0.5 
Fruit and vegetables in g/day/kcal                         
Fruit 508 ─ ─ ─ ─ 0.0005 -0.01 0.01 0.9 507 -0.001 -0.01 0.01 0.9 
Vegetables 508 ─ ─ ─ ─ 0.003 -0.01 0.01 0.5 507 0.004 -0.01 0.01 0.4 
Fruit and vegetables 
combined 507 ─ ─ ─ ─ 0.001 -0.004 0.01 0.7 506 0.001 -0.004 0.01 0.8 
Toenail trace elements in µg/g                           
Aluminum 520 ─ ─ ─ ─ 0.01 -0.01 0.04 0.3 520 0.01 -0.02 0.04 0.5 
Arsenic 521 ─ ─ ─ ─ 11.5 -1.9 24.9 0.09 521 13.3 -0.9 27.4 0.07 
Cadmium 521 ─ ─ ─ ─ -0.2 -2.0 1.6 0.8 521 -0.2 -2.1 1.6 0.8 
Chromium 520 ─ ─ ─ ─ 0.1 -0.2 0.5 0.4 520 0.2 -0.2 0.5 0.3 
Copper 521 ─ ─ ─ ─ -0.3 -0.6 0.1 0.1 521 -0.3 -0.6 0.1 0.1 
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Supplementary Table S5-1 (cont.) Nonsignificant predictors of D4Z4 methylation level among the control population in the Spanish 
Bladder Cancer/EPICURO Study 
Characteristic N D4Z4 methylation (%) Unadjusted model N Adjusted model* Mean SD Median IQR β 95% CI P-value β 95% CI P-value 
Toenail trace elements in µg/g                           
Iron 519 ─ ─ ─ ─ 0.01 -0.01 0.03 0.2 519 0.004 -0.002 0.01 0.2 
Lead 521 ─ ─ ─ ─ -0.04 -0.5 0.4 0.9 521 -0.01 -0.4 0.4 0.96 
Manganese 521 ─ ─ ─ ─ 0.3 -0.3 0.8 0.3 521 0.2 -0.3 0.8 0.4 
Nickel 521 ─ ─ ─ ─ 0.01 -0.04 0.05 0.7 521 0.01 -0.04 0.05 0.8 
Vanadium 513 ─ ─ ─ ─ 3.3 -5.5 12.0 0.5 513 2.5 -6.6 11.6 0.6 
Zinc 521 ─ ─ ─ ─ -0.01 -0.02 0.003 0.2 521 -0.01 -0.02 0.005 0.2 
SD, standard deviation; IQR, interquartile range. 
*Adjusted for age, gender, region, and smoking status (never, occasional, former, and current smoker). Beta coefficients of tobacco type are 
adjusted for age, gender and region. 
†Body mass index is the weight in kilograms divided by the square of the height in meters. 
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Supplementary Table S5-2 Predictors of D4Z4 methylation level among the control population in 
the Spanish Bladder Cancer/EPICURO Study 
Characteristic Adjusted model* N β 95% CI P-value 
Age  718 0.03 -0.05 0.1 0.5 
Gender           
Male 642 Reference       
Female 76 -2.5 -4.9 -0.1 0.04 
Region           
Barcelona 130 Reference       
Valles 117 2.0 -0.5 4.5 0.1 
Elche 58 1.9 -1.2 5.0 0.2 
Tenerife 122 2.0 -0.4 4.5 0.1 
Asturias 291 1.1 -1.0 3.2 0.3 
Smoking status           
Never 206 Reference       
Occasional 53 -0.2 -3.3 2.9 0.9 
Former 261 -1.2 -3.2 0.8 0.3 
Current 195 -1.3 -3.5 0.9 0.2 
Tobacco type           
Never 206 Reference       
Blond tobacco only 82 -3.7 -6.5 -0.9 0.01 
Black tobacco only 171 -0.4 -2.7 1.8 0.7 
Both types 126 -0.9 -3.3 1.6 0.5 
Unknown 78 -2.2 -5.0 0.6 0.1 
Body mass index†           
< 25.0 305 Reference       
25.0 - 29.9 215 0.4 -1.3 2.2 0.7 
≥ 30.0 40 -2.5 -5.8 0.8 0.1 
Controls' diagnosis           
Hernia 278 Reference       
Fracture & Trauma 194 -0.9 -2.9 1.1 0.4 
Hydrocele 107 -1.1 -3.5 1.3 0.4 
Other Abdominal Surgery 84 0.1 -2.4 2.6 0.9 
Other Diseases 55 -0.9 -3.9 2.2 0.6 
GSTM1           
GSTM1 (++/+-) 338 Reference       
GSTM1 (--) 373 0.7 -0.7 2.2 0.3 
GSTT1           
GSTT1 (++/+-) 561 Reference       
GSTT1 (--) 151 0.2 -1.6 2.0 0.8 
NAT2 acetylator           
Rapid/Intermediate 306 Reference       
Slow 409 -0.7 -2.2 0.8 0.4 
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Supplementary Table S5-2 (cont.) Predictors of D4Z4 methylation level among the control 
population in the Spanish Bladder Cancer/EPICURO Study 
Characteristic Adjusted model* N β 95% CI P-value 
Nutrient intake in μg/kcal/day         
Vitamin B1 513 2.9 -2.4 8.2 0.3 
Vitamin B2 513 -0.4 -3.7 2.8 0.8 
Vitamin B3 513 0.1 -0.2 0.4 0.5 
Vitamin B6 513 1.5 -2.2 5.3 0.4 
Vitamin B12 513 0.1 -0.2 0.3 0.7 
Folate 513 0.01 -0.01 0.02 0.2 
Protein 513 0.002 -0.1 0.1 0.96 
Alcohol 513 0.02 -0.1 0.1 0.7 
Fruit and vegetables in g/day/kcal       
Fruit 508 0.00001 -0.01 0.01 0.99 
Vegetables 508 0.004 -0.005 0.01 0.4 
Fruit and vegetables combined 507 0.001 -0.004 0.01 0.7 
Toenail trace elements in µg/g         
Aluminum 520 0.01 -0.02 0.04 0.5 
Arsenic 521 13.0 -1.1 27.1 0.07 
Cadmium 521 -0.3 -2.1 1.6 0.8 
Chromium 520 0.2 -0.2 0.5 0.3 
Copper 521 -0.3 -0.6 0.1 0.1 
Iron 519 0.004 -0.002 0.01 0.2 
Lead 521 -0.01 -0.4 0.4 0.97 
Manganese 521 0.3 -0.3 0.8 0.4 
Nickel 521 0.01 -0.04 0.05 0.8 
Selenium 521 -7.9 -12.5 -3.4 0.0006 
Vanadium 513 2.6 -6.5 11.7 0.6 
Zinc 521 -0.01 -0.02 0.004 0.2 
*Adjusted for age, gender, and region. 
†Body mass index is the weight in kilograms divided by the square of the height in meters. 
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Supplementary Table S5-3 Association of each individual D4Z4 CpG site methylation level and 
risk of bladder cancer in the Spanish Bladder Cancer/EPICURO Study 
D4Z4 methylation Cases Controls OR* 95% CI P-value 
D4Z4-CpG1             
M1, < 70.1% 316 358 1 Reference       
M2, ≥ 70.1% 385 357 1.26 1.01 1.57 0.04 
D4Z4-CpG2             
M1, < 59.6% 310 358 1 Reference       
M2, ≥ 59.6% 391 357 1.33 1.07 1.66 0.01 
D4Z4-CpG3             
M1, < 63.9% 331 356 1 Reference       
M2, ≥ 63.9% 370 359 1.13 0.90 1.40 0.3 
D4Z4-CpG4             
M1, < 55.5% 343 358 1 Reference       
M2, ≥ 55.5% 358 357 1.08 0.87 1.35 0.5 
D4Z4-CpG5             
M1, < 64.8% 323 357 1 Reference       
M2, ≥ 64.8% 378 358 1.20 0.96 1.50 0.1 
D4Z4-CpG6             
M1, < 71.9% 325 358 1 Reference       
M2, ≥ 71.9% 376 357 1.21 0.97 1.50 0.09 
M1, D4Z4 methylation level less than the median; M2, D4Z4 methylation level greater 
than or equal to the median. 
*Adjusted for age, gender, region, and smoking status. 
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Supplementary Table S5-4 Association between D4Z4 methylation level and urothelial 
carcinoma of the bladder risk, by age groups, gender, smoking status, and tobacco type in the 
Spanish Bladder Cancer/EPICURO Study 
D4Z4 Methylation Cases Controls OR 95% CI P-value P-interaction 
Age*               
Age <60 years               
   M1, < 64.4% 77 102 1 Reference         
   M2, ≥ 64.4% 74 100 1.04 0.67 1.62 0.9   
Age 60-69 years               
   M1, < 64.4% 127 139 1 Reference         
   M2, ≥ 64.4% 134 146 1.08 0.75 1.56 0.7   
Age 70+ years               
   M1, < 64.4% 120 117 1 Reference         
   M2, ≥ 64.4% 169 111 1.61 1.11 2.33 0.01 0.2 
Gender†               
Males               
   M1, < 64.4% 273 309 1 Reference         
   M2, ≥ 64.4% 338 330 1.20 0.95 1.52 0.1   
Females               
   M1, < 64.4% 51 49 1 Reference         
   M2, ≥ 64.4% 39 27 1.35 0.69 2.62 0.4 0.6 
Smoking status‡               
Never               
   M1, < 64.4% 52 103 1 Reference         
   M2, ≥ 64.4% 50 103 1.25 0.75 2.09 0.4   
Occasional               
   M1, < 64.4% 12 25 1 Reference         
   M2, ≥ 64.4% 18 28 0.94 0.31 2.80 0.9   
Former               
   M1, < 64.4% 116 129 1 Reference         
   M2, ≥ 64.4% 150 132 1.27 0.89 1.80 0.2   
Current               
   M1, < 64.4% 144 101 1 Reference         
   M2, ≥ 64.4% 159 94 1.16 0.80 1.68 0.4 0.98 
Tobacco type§               
Never smoker               
   M1, < 64.4% 52 103 1 Reference         
   M2, ≥ 64.4% 50 103 1.25 0.75 2.09 0.4   
Blond tobacco only               
   M1, < 64.4% 25 46 1 Reference         
   M2, ≥ 64.4% 29 36 1.50 0.71 3.17 0.3   
Black tobacco only               
   M1, < 64.4% 105 83 1 Reference         
   M2, ≥ 64.4% 134 87 1.20 0.80 1.80 0.4   
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Supplementary Table S5-4 (cont.) Association between D4Z4 methylation level and urothelial 
carcinoma of the bladder risk, by age groups, gender, smoking status, and tobacco type in the 
Spanish Bladder Cancer/EPICURO Study 
D4Z4 Methylation Cases Controls OR 95% CI P-value P-interaction 
Tobacco type§               
Both types               
   M1, < 64.4% 86 57 1 Reference         
   M2, ≥ 64.4% 97 69 0.93 0.58 1.49 0.8   
Unknown               
   M1, < 64.4% 44 44 1 Reference         
   M2, ≥ 64.4% 49 34 1.47 0.78 2.75 0.2 0.7 
M1, D4Z4 methylation level less than the median; M2, D4Z4 methylation level greater than 
or equal to the median. 
*Adjusted for gender, region, and smoking status (never, occasional, former, and current 
smoker). 
†Adjusted for age, region, and smoking status (never, occasional, former, and current 
smoker). 
‡Data were adjusted for age, gender and region.  
§Adjusted for age, gender, region, and smoking status (never, occasional, former, and 
current smoker). 
Note: No interaction was observed between D4Z4 methylation and number of cigarettes 
smoked per day (P-interaction = 0.4), duration of cigarette smoking in years (P-interaction = 
1.0), and pack-years (P-interaction = 0.4) with effect on urothelial carcinoma of the bladder 
risk. 
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Supplementary Table S5-5 Association between D4Z4 
methylation level and urothelial carcinoma of the bladder 
risk, by nutrient, fruit and vegetable intake, and trace 
elements in the Spanish Bladder Cancer/EPICURO Study 
Characteristic P-interaction* 
Nutrients in μg/kcal/day 
 Vitamin B1 0.9 
Vitamin B2 0.6 
Vitamin B3 0.6 
Vitamin B6 0.8 
Vitamin B12 0.98 
Folate 0.7 
Protein 0.4 
Alcohol 0.8 
Fruit and vegetables in g/day/kcal  
Fruits 0.7 
Vegetables 0.98 
Fruit and vegetables 0.8 
Toenail trace elements in µg/g  
Aluminum 0.1 
Arsenic 0.1 
Cadmium 0.6 
Chromium 0.6 
Copper 0.2 
Lead 0.3 
Nickel 0.3 
Selenium 0.4 
Vanadium 0.1 
*Interaction p-value calculated from logistic regression 
models adjusted for age, gender, region, and smoking 
status. 
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Supplementary Table S5-6 Uncorrected and corrected p-values for the interaction between D4Z4 
methylation levels and selected SNPs in the one-carbon metabolism pathway in the Spanish Bladder 
Cancer/EPICURO Study 
SNPs modeled in additive mode of inheritance 
dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11040387 11 FOLH1 1379 0.07 0.4 0.0002 0.05 
rs7358352 11 FOLH1 1387 0.09 0.4 0.001 0.2 
rs12098986 11 FOLH1 1386 0.09 0.2 0.001 0.2 
rs632220 11 FOLH1 1388 0.09 0.4 0.001 0.3 
rs598841 11 FOLH1 1383 0.09 0.2 0.001 0.3 
rs11040261 11 FOLH1 1388 0.09 0.4 0.001 0.3 
rs1819409 11 FOLH1 1376 0.09 0.3 0.001 0.3 
rs12293923 11 FOLH1 1383 0.09 0.2 0.001 0.3 
rs650826 11 FOLH1 1386 0.09 0.2 0.001 0.3 
rs683680 11 FOLH1 1387 0.09 0.2 0.002 0.4 
rs7117025 11 FOLH1 1388 0.09 0.4 0.002 0.4 
rs7926211 11 FOLH1 1385 0.09 0.2 0.002 0.4 
rs11040263 11 FOLH1 1385 0.09 0.2 0.003 0.5 
rs4495895 11 FOLH1 1353 0.09 0.4 0.005 0.7 
rs2865908 11 FOLH1 1388 0.19 0.9 0.006 0.7 
rs3821353 2 ATIC 1388 0.21 0.4 0.006 0.8 
rs2236224 14 MTHFD1 1388 0.36 0.1 0.007 0.8 
rs4094478 11 FOLH1 1365 0.20 0.7 0.007 0.8 
rs6495449 15 MTHFS 1388 0.11 0.09 0.008 0.8 
rs7929543 11 FOLH1 1388 0.08 1.0 0.009 0.9 
rs10839210 11 FOLH1 1386 0.21 0.5 0.009 0.9 
rs10769558 11 FOLH1 1388 0.21 0.5 0.009 0.9 
rs1847638 11 FOLH1 1335 0.21 1.0 0.01 0.9 
rs16853782 2 ATIC 1388 0.21 0.7 0.01 0.9 
rs6058869 20 DNMT3B 1388 0.33 0.7 0.01 0.9 
rs1256142 14 MTHFD1 1388 0.44 0.07 0.01 0.9 
rs11191457 10 AS3MT 1385 0.23 0.4 0.01 0.9 
rs3772078 2 ATIC 1388 0.21 0.6 0.01 0.9 
rs6087990 20 DNMT3B 1388 0.33 0.6 0.01 0.9 
rs4441015 11 FOLH1 1353 0.15 0.5 0.02 1.0 
rs7085854 10 AS3MT 1387 0.23 0.6 0.02 1.0 
rs2696923 11 FOLH1 1388 0.21 0.3 0.02 1.0 
rs6058893 20 DNMT3B 1388 0.33 0.2 0.02 1.0 
rs11607791 11 FOLH1 1387 0.07 1.0 0.02 1.0 
rs7124266 11 FOLH1 1388 0.30 0.6 0.02 1.0 
rs11040198 11 FOLH1 1381 0.21 0.2 0.02 1.0 
rs2305230 3 ALDH1L1 1387 0.19 0.7 0.02 1.0 
rs2696935 11 FOLH1 1388 0.21 0.4 0.02 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7111711 11 FOLH1 1388 0.25 0.9 0.02 1.0 
rs10839296 11 FOLH1 1371 0.25 0.8 0.02 1.0 
rs2834235 21 GART 1388 0.38 0.7 0.02 1.0 
rs4817577 21 GART 1388 0.34 0.9 0.02 1.0 
rs7107178 11 FOLH1 1387 0.25 1.0 0.02 1.0 
rs11040421 11 FOLH1 1388 0.15 0.6 0.02 1.0 
rs4817579 21 GART 1388 0.35 1.0 0.03 1.0 
rs7283354 21 GART 1388 0.34 0.9 0.03 1.0 
rs4911107 20 DNMT3B 1388 0.32 0.6 0.03 1.0 
rs585800 5 BHMT 1388 0.26 0.05 0.03 1.0 
rs2236225 14 MTHFD1 1387 0.43 0.2 0.04 1.0 
rs10839229 11 FOLH1 1386 0.08 0.3 0.04 1.0 
rs865646 5 DHFR 1340 0.34 0.4 0.04 1.0 
rs10839224 11 FOLH1 1388 0.08 0.3 0.04 1.0 
rs2838958 21 SLC19A1 1385 0.45 0.7 0.04 1.0 
rs2154583 21 GART 1384 0.39 0.7 0.04 1.0 
rs11158542 14 MTHFD1 1388 0.29 0.8 0.05 1.0 
rs6517178 21 GART 1388 0.39 0.7 0.05 1.0 
rs16906158 11 FOLH1 1387 0.08 0.6 0.05 1.0 
rs12438477 15 MTHFS 1387 0.36 0.4 0.05 1.0 
rs473334 1 CTH 1388 0.31 0.9 0.05 1.0 
rs16853826 2 ATIC 1386 0.13 0.9 0.05 1.0 
rs663649 1 CTH 1388 0.31 0.9 0.05 1.0 
rs4779140 15 MTHFS 1387 0.48 0.6 0.05 1.0 
rs7560488 2 DNMT3A 1333 0.47 0.2 0.05 1.0 
rs3862342 11 FOLH1 1386 0.28 0.8 0.06 1.0 
rs11040432 11 FOLH1 1387 0.08 1.0 0.06 1.0 
rs34033751 11 FOLH1 1371 0.11 0.4 0.06 1.0 
rs6573559 14 MTHFD1 1388 0.29 1.0 0.06 1.0 
rs7587636 2 DNMT3A 1388 0.45 0.1 0.06 1.0 
rs6141813 20 DNMT3B 1388 0.13 0.8 0.06 1.0 
rs9974061 21 SLC19A1 1388 0.18 1.0 0.06 1.0 
rs11627387 14 MTHFD1 1388 0.29 0.9 0.07 1.0 
rs13401241 2 DNMT3A 1388 0.45 0.1 0.07 1.0 
rs9323450 14 MTHFD1 1388 0.30 0.8 0.07 1.0 
rs11634787 15 MTHFS 1388 0.09 0.3 0.07 1.0 
rs12913164 15 MTHFS 1388 0.07 0.8 0.07 1.0 
rs2834233 21 GART 1387 0.08 0.5 0.08 1.0 
rs4911263 20 DNMT3B 1388 0.32 1.0 0.08 1.0 
rs2281603 14 MTHFD1 1388 0.19 0.2 0.08 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12903985 15 MTHFS 1388 0.28 0.4 0.09 1.0 
rs1164681 11 FOLH1 1388 0.12 0.5 0.09 1.0 
rs7934591 11 FOLH1 1388 0.08 0.8 0.09 1.0 
rs2424921 20 DNMT3B 1388 0.39 0.3 0.09 1.0 
rs2424932 20 DNMT3B 1387 0.43 0.5 0.09 1.0 
rs8659 5 MTRR 1386 0.35 0.3 0.1 1.0 
rs11040353 11 FOLH1 1387 0.08 0.8 0.1 1.0 
rs7113075 11 FOLH1 1387 0.08 0.8 0.1 1.0 
rs10418 22 TCN2 1367 0.21 0.7 0.1 1.0 
rs7563206 2 ATIC 1387 0.47 0.6 0.1 1.0 
rs6058891 20 DNMT3B 1386 0.39 0.2 0.1 1.0 
rs2035027 15 MTHFS 1388 0.16 0.5 0.1 1.0 
rs7220132 17 PEMT 1388 0.29 0.7 0.1 1.0 
rs2424928 20 DNMT3B 1388 0.39 0.2 0.1 1.0 
rs4646410 17 PEMT 1384 0.31 0.9 0.1 1.0 
rs8074074 17 PEMT 1386 0.29 0.8 0.1 1.0 
rs12900076 15 MTHFS 1385 0.08 0.6 0.1 1.0 
rs3897953 15 MTHFS 1388 0.09 0.8 0.1 1.0 
rs11040390 11 FOLH1 1388 0.08 1.0 0.1 1.0 
rs6706415 2 ATIC 1388 0.30 0.4 0.1 1.0 
rs12222221 11 FOLH1 1388 0.08 1.0 0.1 1.0 
rs6058897 20 DNMT3B 1388 0.43 0.2 0.1 1.0 
rs12592743 15 MTHFS 1388 0.09 0.5 0.1 1.0 
rs2424922 20 DNMT3B 1387 0.39 0.2 0.1 1.0 
rs1846285 11 FOLH1 1385 0.17 0.2 0.1 1.0 
rs6058883 20 DNMT3B 1387 0.39 0.3 0.1 1.0 
rs4779165 15 MTHFS 1387 0.16 0.4 0.1 1.0 
rs910085 20 DNMT3B 1387 0.29 0.5 0.1 1.0 
rs4479310 17 PEMT 1388 0.29 0.6 0.1 1.0 
rs2424914 20 DNMT3B 1388 0.39 0.4 0.1 1.0 
rs16971450 15 MTHFS 1387 0.16 0.4 0.1 1.0 
rs6495441 15 MTHFS 1388 0.24 0.3 0.1 1.0 
rs1880580 15 MTHFS 1388 0.30 0.09 0.1 1.0 
rs9910747 17 PEMT 1388 0.07 0.4 0.1 1.0 
rs2838956 21 SLC19A1 1373 0.44 0.07 0.1 1.0 
rs7946 17 PEMT 1387 0.29 0.4 0.1 1.0 
rs559062 1 CTH 1388 0.22 0.6 0.1 1.0 
rs663465 1 CTH 1387 0.41 0.4 0.1 1.0 
rs9890064 17 PEMT 1388 0.43 0.4 0.1 1.0 
rs1046778 10 AS3MT 1388 0.33 0.8 0.1 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1880586 2 ATIC 1387 0.47 0.6 0.2 1.0 
rs1404772 2 ATIC 1388 0.08 0.4 0.2 1.0 
rs6087988 20 DNMT3B 1388 0.20 0.6 0.2 1.0 
rs3760188 17 PEMT 1388 0.46 0.6 0.2 1.0 
rs9332 5 MTRR 1388 0.12 0.2 0.2 1.0 
rs4819128 21 SLC19A1 1388 0.44 0.2 0.2 1.0 
rs12898642 15 MTHFS 1387 0.43 0.2 0.2 1.0 
rs4818789 21 SLC19A1 1388 0.25 0.5 0.2 1.0 
rs4646344 17 PEMT 1388 0.47 0.7 0.2 1.0 
rs16988828 22 TCN2 1388 0.09 0.2 0.2 1.0 
rs7102641 11 FOLH1 1385 0.08 0.4 0.2 1.0 
rs1074390 15 MTHFS 1388 0.37 0.6 0.2 1.0 
rs6749992 2 DNMT3A 1388 0.47 0.8 0.2 1.0 
rs7605753 2 DNMT3A 1388 0.47 0.6 0.2 1.0 
rs3755817 3 CHDH 1387 0.30 0.5 0.2 1.0 
rs10179873 2 ATIC 1388 0.30 0.4 0.2 1.0 
rs1051298 21 SLC19A1 1387 0.46 0.3 0.2 1.0 
rs13317328 3 CHDH 1388 0.10 0.1 0.2 1.0 
rs11852515 15 MTHFS 1388 0.12 0.7 0.2 1.0 
rs1983462 2 ATIC 1388 0.30 0.3 0.2 1.0 
rs1380642 15 MTHFS 1388 0.18 0.3 0.2 1.0 
NA 1 MTR_01_OR 1389 0.16 0.7 0.2 1.0 
rs2066470 1 MTHFR 1384 0.09 0.2 0.2 1.0 
rs2424913 20 DNMT3B 1387 0.37 0.2 0.2 1.0 
rs4911108 20 DNMT3B 1384 0.29 0.7 0.2 1.0 
rs2372535 2 ATIC 1388 0.15 1.0 0.2 1.0 
rs10197559 2 ATIC 1380 0.29 0.9 0.2 1.0 
rs1888530 21 SLC19A1 1358 0.47 0.07 0.2 1.0 
rs202676 11 FOLH1 1380 0.17 0.8 0.2 1.0 
rs2424906 20 DNMT3B 1388 0.38 0.2 0.2 1.0 
rs4646404 17 PEMT 1383 0.36 0.3 0.2 1.0 
rs2115536 15 MTHFS 1388 0.50 0.05 0.2 1.0 
rs12416687 10 AS3MT 1388 0.28 0.06 0.2 1.0 
rs10380 5 MTRR 1388 0.10 0.4 0.2 1.0 
rs515064 1 CTH 1388 0.36 0.8 0.2 1.0 
rs11892429 2 ATIC 1388 0.29 0.7 0.2 1.0 
rs9282690 3 ALDH1L1 1388 0.07 0.8 0.2 1.0 
rs914232 21 SLC19A1 1387 0.44 0.2 0.2 1.0 
rs10197653 2 ATIC 1388 0.29 0.1 0.2 1.0 
rs3788200 21 SLC19A1 1388 0.45 0.3 0.2 1.0 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1950902 14 MTHFD1 1388 0.14 0.4 0.2 1.0 
rs6711622 2 DNMT3A 1388 0.44 1.0 0.2 1.0 
rs35020344 14 MTHFD1 1387 0.47 0.7 0.2 1.0 
rs914231 21 SLC19A1 1383 0.44 0.2 0.2 1.0 
rs16971253 15 MTHFS 1387 0.10 1.0 0.2 1.0 
rs3788190 21 SLC19A1 1387 0.47 0.1 0.2 1.0 
rs11677670 2 DNMT3A 1382 0.17 0.5 0.3 1.0 
rs4646359 17 PEMT 1388 0.45 0.3 0.3 1.0 
rs770144 15 MTHFS 1388 0.20 0.3 0.3 1.0 
rs12482346 21 SLC19A1 1388 0.47 0.1 0.3 1.0 
rs1051266 21 SLC19A1 1388 0.45 0.2 0.3 1.0 
rs1917311 11 FOLH1 1353 0.40 0.4 0.3 1.0 
rs8074191 17 PEMT 1372 0.28 0.9 0.3 1.0 
rs7215833 17 PEMT 1388 0.35 0.5 0.3 1.0 
rs2115540 15 MTHFS 1387 0.50 0.05 0.3 1.0 
rs17745484 2 DNMT3A 1387 0.35 0.8 0.3 1.0 
rs7111215 11 FOLH1 1368 0.40 0.2 0.3 1.0 
rs7117247 11 FOLH1 1388 0.07 0.1 0.3 1.0 
rs8041943 15 MTHFS 1385 0.42 0.6 0.3 1.0 
rs2838964 21 SLC19A1 1388 0.07 1.0 0.3 1.0 
rs9897362 17 PEMT 1388 0.06 0.3 0.3 1.0 
rs2330183 21 SLC19A1 1358 0.44 0.05 0.3 1.0 
rs679470 11 FOLH1 1387 0.17 0.6 0.3 1.0 
rs740234 22 TCN2 1388 0.23 0.8 0.3 1.0 
rs282778 15 MTHFS 1388 0.27 0.8 0.3 1.0 
rs10400277 11 FOLH1 1368 0.13 0.6 0.3 1.0 
rs1805087 1 MTR 1388 0.17 0.7 0.3 1.0 
rs17279286 15 MTHFS 1387 0.05 0.7 0.3 1.0 
rs1051296 21 SLC19A1 1375 0.47 0.1 0.3 1.0 
rs12613 21 CBS 1388 0.08 1.0 0.3 1.0 
rs7583409 2 DNMT3A 1387 0.35 0.4 0.3 1.0 
rs6495446 15 MTHFS 1387 0.26 0.1 0.3 1.0 
rs12999687 2 DNMT3A 1386 0.45 0.8 0.3 1.0 
rs11085720 19 DNMT1 1388 0.42 0.5 0.3 1.0 
rs10519256 15 MTHFS 1388 0.11 0.1 0.3 1.0 
rs3740392 10 AS3MT 1385 0.29 0.1 0.3 1.0 
rs34048824 2 DNMT3A 1387 0.50 1.0 0.3 1.0 
rs7253062 19 DNMT1 1388 0.39 0.7 0.3 1.0 
rs4819130 21 SLC19A1 1384 0.45 0.2 0.3 1.0 
rs2290684 19 DNMT1 1388 0.47 0.8 0.3 1.0 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1667627 14 MTHFD2 1387 0.46 0.2 0.3 1.0 
rs7217764 17 PEMT 1388 0.05 1.0 0.3 1.0 
rs282795 15 MTHFS 1387 0.32 0.7 0.3 1.0 
rs4646341 17 PEMT 1385 0.36 0.5 0.3 1.0 
rs4804122 19 DNMT1 1388 0.40 0.4 0.3 1.0 
rs10163099 15 MTHFS 1385 0.26 0.1 0.3 1.0 
rs588458 11 FOLH1 1367 0.38 0.3 0.3 1.0 
rs1164685 11 FOLH1 1385 0.38 0.3 0.3 1.0 
rs4532960 10 AS3MT 1387 0.44 0.3 0.3 1.0 
rs1256107 14 MTHFD1 1387 0.48 0.7 0.3 1.0 
rs3177999 21 SLC19A1 1380 0.45 0.2 0.3 1.0 
rs12905663 15 MTHFS 1381 0.27 0.2 0.3 1.0 
rs10748835 10 AS3MT 1388 0.44 0.3 0.3 1.0 
rs2838961 21 SLC19A1 1388 0.34 1.0 0.3 1.0 
rs10501325 11 FOLH1 1388 0.07 0.1 0.3 1.0 
rs9606756 22 TCN2 1388 0.10 0.7 0.3 1.0 
NA 1 MTR_01_2_i 1388 0.17 0.7 0.3 1.0 
rs12591436 15 MTHFS 1388 0.35 0.6 0.3 1.0 
rs1256095 14 MTHFD1 1377 0.48 0.8 0.3 1.0 
rs11158540 14 MTHFD1 1388 0.34 0.9 0.4 1.0 
rs7174668 15 MTHFS 1388 0.20 0.2 0.4 1.0 
rs7759302 6 GNMT 1388 0.06 1.0 0.4 1.0 
rs648372 11 FOLH1 1370 0.17 0.5 0.4 1.0 
rs7575625 2 DNMT3A 1388 0.47 0.9 0.4 1.0 
rs600671 15 MTHFS 1387 0.46 0.1 0.4 1.0 
rs10932605 2 ATIC 1388 0.14 0.3 0.4 1.0 
rs4144700 11 FOLH1 1388 0.38 0.3 0.4 1.0 
rs1801131 1 MTHFR 1322 0.28 0.9 0.4 1.0 
rs898436 15 MTHFS 1384 0.46 0.1 0.4 1.0 
rs6713377 2 DNMT3A 1387 0.47 0.9 0.4 1.0 
rs282776 15 MTHFS 1388 0.36 1.0 0.4 1.0 
rs8101626 19 DNMT1 1388 0.39 0.7 0.4 1.0 
rs4779141 15 MTHFS 1386 0.34 0.8 0.4 1.0 
rs6750194 2 ATIC 1375 0.08 0.4 0.4 1.0 
rs202718 11 FOLH1 1388 0.15 0.9 0.4 1.0 
rs11869600 17 PEMT 1386 0.38 0.3 0.4 1.0 
rs9001 3 CHDH 1385 0.10 0.3 0.4 1.0 
rs4244599 17 PEMT 1371 0.46 0.4 0.4 1.0 
rs4646340 17 PEMT 1388 0.36 0.5 0.4 1.0 
rs4987173 6 GNMT 1388 0.51 0.8 0.4 1.0 
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D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12614943 2 ATIC 1388 0.28 1.0 0.4 1.0 
rs8128676 21 SLC19A1 1350 0.22 1.0 0.4 1.0 
rs759920 19 DNMT1 1388 0.47 0.7 0.4 1.0 
rs1076991 14 MTHFD1 1388 0.45 1.0 0.4 1.0 
rs1109859 17 PEMT 1367 0.18 0.8 0.4 1.0 
rs2866358 11 FOLH1 1372 0.38 0.2 0.4 1.0 
rs4646350 17 PEMT 1388 0.36 0.6 0.4 1.0 
rs5749131 22 TCN2 1388 0.43 0.2 0.4 1.0 
rs2275566 1 MTR 1388 0.42 0.1 0.4 1.0 
rs4925048 17 PEMT 1386 0.09 0.1 0.4 1.0 
rs8019804 14 MTHFD1 1388 0.07 1.0 0.4 1.0 
rs204942 15 MTHFS 1388 0.20 0.1 0.4 1.0 
rs282814 15 MTHFS 1388 0.21 0.8 0.4 1.0 
rs2124344 17 PEMT 1387 0.36 0.7 0.4 1.0 
rs11158538 14 MTHFD1 1385 0.45 0.9 0.4 1.0 
rs2838965 21 SLC19A1 1384 0.42 0.05 0.4 1.0 
rs2275565 1 MTR 1388 0.20 0.6 0.4 1.0 
rs3893384 15 MTHFS 1388 0.42 0.5 0.4 1.0 
rs1081231 15 MTHFS 1387 0.18 0.8 0.4 1.0 
rs2288349 19 DNMT1 1387 0.39 0.5 0.4 1.0 
rs2983733 14 MTHFD1 1388 0.45 0.9 0.4 1.0 
rs7951180 11 FOLH1 1369 0.17 0.4 0.4 1.0 
rs685487 15 MTHFS 1388 0.37 0.09 0.4 1.0 
rs1256114 14 MTHFD1 1387 0.11 0.7 0.4 1.0 
rs2733103 15 MTHFS 1387 0.15 0.2 0.4 1.0 
rs2983736 14 MTHFD1 1385 0.45 0.9 0.4 1.0 
rs1956545 14 MTHFD1 1387 0.08 0.5 0.4 1.0 
rs750546 17 PEMT 1373 0.43 0.5 0.4 1.0 
rs10948059 6 GNMT 1370 0.48 0.8 0.4 1.0 
rs944422 21 SLC19A1 1384 0.35 0.9 0.4 1.0 
rs3893350 15 MTHFS 1388 0.13 0.1 0.4 1.0 
rs1802059 5 MTRR 1387 0.37 0.4 0.5 1.0 
rs2228611 19 DNMT1 1388 0.47 0.8 0.5 1.0 
rs12910340 15 MTHFS 1388 0.42 1.0 0.5 1.0 
rs12121543 1 MTHFR 1388 0.22 0.9 0.5 1.0 
rs4531931 2 ATIC 1387 0.31 0.5 0.5 1.0 
rs617219 5 BHMT 1387 0.32 0.7 0.5 1.0 
rs10420338 19 DNMT1 1388 0.47 0.6 0.5 1.0 
rs8129350 21 SLC19A1 1387 0.35 0.9 0.5 1.0 
rs12797843 11 FOLH1 1388 0.13 0.6 0.5 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs9835128 3 CHDH 1387 0.17 0.4 0.5 1.0 
rs16971249 15 MTHFS 1388 0.07 0.08 0.5 1.0 
rs17291414 19 DNMT1 1388 0.27 0.5 0.5 1.0 
rs12899781 15 MTHFS 1383 0.17 0.06 0.5 1.0 
rs10165919 2 ATIC 1387 0.35 0.6 0.5 1.0 
rs17285431 15 MTHFS 1388 0.17 0.1 0.5 1.0 
rs1888533 21 SLC19A1 1388 0.48 0.3 0.5 1.0 
rs10498034 2 ATIC 1388 0.17 1.0 0.5 1.0 
rs3800292 6 GNMT 1388 0.06 0.8 0.5 1.0 
rs4646385 17 PEMT 1388 0.43 0.5 0.5 1.0 
rs4817580 21 GART 1387 0.10 0.5 0.5 1.0 
rs1369703 2 DNMT3A 1388 0.45 0.2 0.5 1.0 
rs3740394 10 AS3MT 1387 0.12 0.3 0.5 1.0 
rs1460177 15 MTHFS 1388 0.09 0.4 0.5 1.0 
rs11887120 2 DNMT3A 1388 0.42 0.5 0.5 1.0 
rs853858 20 DNMT3B 1386 0.37 0.2 0.5 1.0 
rs11040416 11 FOLH1 1388 0.42 0.4 0.5 1.0 
rs10509760 10 AS3MT 1388 0.12 0.3 0.5 1.0 
rs1256112 14 MTHFD1 1388 0.40 0.4 0.5 1.0 
rs699517 18 TYMS 1387 0.31 0.6 0.5 1.0 
rs1059394 18 TYMS 1387 0.31 0.6 0.5 1.0 
rs1077965 15 MTHFS 1387 0.41 0.4 0.5 1.0 
rs372447 15 MTHFS 1388 0.38 0.9 0.5 1.0 
rs8015278 14 MTHFD1 1388 0.07 0.8 0.5 1.0 
rs6760069 2 ATIC 1387 0.14 0.5 0.5 1.0 
rs17556442 11 FOLH1 1384 0.06 0.05 0.5 1.0 
rs748196 17 PEMT 1385 0.42 0.9 0.5 1.0 
rs443394 15 MTHFS 1388 0.41 0.3 0.5 1.0 
rs8011839 14 MTHFD1 1388 0.18 0.4 0.5 1.0 
rs2289195 2 DNMT3A 1387 0.44 0.2 0.5 1.0 
rs11627525 14 MTHFD1 1388 0.10 0.3 0.5 1.0 
rs7604984 2 ATIC 1388 0.40 0.4 0.5 1.0 
rs7594432 2 DNMT3A 1388 0.45 0.3 0.5 1.0 
rs10498036 2 ATIC 1388 0.40 0.4 0.5 1.0 
rs11871738 17 PEMT 1388 0.38 0.4 0.6 1.0 
rs7177659 15 MTHFS 1387 0.50 0.08 0.6 1.0 
rs9621049 22 TCN2 1388 0.10 0.8 0.6 1.0 
rs378057 15 MTHFS 1387 0.14 1.0 0.6 1.0 
rs202712 11 FOLH1 1387 0.23 0.7 0.6 1.0 
rs7177027 15 MTHFS 1388 0.24 0.08 0.6 1.0 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7604425 2 ATIC 1388 0.35 0.7 0.6 1.0 
rs6511677 19 DNMT1 1387 0.39 0.6 0.6 1.0 
rs6722613 2 DNMT3A 1388 0.40 1.0 0.6 1.0 
rs8034036 15 MTHFS 1386 0.11 0.09 0.6 1.0 
rs11191439 10 AS3MT 1387 0.12 0.2 0.6 1.0 
rs11694842 2 DNMT3A 1387 0.28 0.4 0.6 1.0 
rs2162560 19 DNMT1 1387 0.39 0.6 0.6 1.0 
rs10839239 11 FOLH1 1386 0.23 0.6 0.6 1.0 
rs4673965 2 ATIC 1388 0.40 1.0 0.6 1.0 
rs17211644 15 MTHFS 1388 0.10 0.7 0.6 1.0 
rs445263 15 MTHFS 1388 0.30 0.9 0.6 1.0 
rs11687225 2 ATIC 1387 0.40 0.9 0.6 1.0 
rs12997662 2 ATIC 1387 0.33 0.7 0.6 1.0 
rs16853834 2 ATIC 1388 0.16 1.0 0.6 1.0 
rs660439 11 FOLH1 1384 0.23 0.7 0.6 1.0 
rs734693 2 DNMT3A 1387 0.29 0.2 0.6 1.0 
rs4902278 14 MTHFD1 1383 0.07 0.6 0.6 1.0 
rs4646383 17 PEMT 1387 0.09 0.5 0.6 1.0 
rs8923 15 MTHFS 1388 0.08 0.1 0.6 1.0 
rs8128050 21 SLC19A1 1385 0.35 0.9 0.6 1.0 
rs4820887 22 TCN2 1388 0.09 0.6 0.6 1.0 
rs11892646 2 DNMT3A 1387 0.12 0.6 0.6 1.0 
rs2409495 21 GART 1388 0.19 0.05 0.6 1.0 
rs3783 17 SHMT1 1398 0.26 0.6 0.6 1.0 
rs1464864 2 ATIC 1388 0.30 0.8 0.6 1.0 
rs4369857 2 ATIC 1388 0.05 0.7 0.6 1.0 
rs17824591 14 MTHFD1 1386 0.23 0.2 0.6 1.0 
rs16999714 19 DNMT1 1386 0.21 0.1 0.6 1.0 
rs8068641 17 PEMT 1382 0.11 0.4 0.6 1.0 
rs1801394 5 MTRR 1398 0.49 0.8 0.6 1.0 
rs1081235 15 MTHFS 1388 0.19 0.3 0.6 1.0 
rs2987969 14 MTHFD1 1387 0.45 0.7 0.6 1.0 
rs17728676 11 FOLH1 1387 0.07 0.1 0.6 1.0 
rs234706 21 CBS 1388 0.32 0.1 0.6 1.0 
rs166868 15 MTHFS 1387 0.36 1.0 0.6 1.0 
rs2289209 3 CHDH 1388 0.05 1.0 0.6 1.0 
rs731991 22 TCN2 1343 0.48 0.1 0.7 1.0 
NA 1 MTHFR_02_2_i 1388 0.40 0.5 0.7 1.0 
rs1127717 3 ALDH1L1 1388 0.24 0.6 0.7 1.0 
rs1801133 1 MTHFR 1388 0.40 0.5 0.7 1.0 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11855092 15 MTHFS 1388 0.23 0.07 0.7 1.0 
rs7144437 14 MTHFD1 1387 0.07 0.6 0.7 1.0 
rs2288350 19 DNMT1 1387 0.08 0.6 0.7 1.0 
rs12898670 15 MTHFS 1387 0.32 0.9 0.7 1.0 
rs4672768 2 ATIC 1385 0.31 0.9 0.7 1.0 
rs2267163 22 TCN2 1386 0.43 0.2 0.7 1.0 
rs1055345 21 SLC19A1 1387 0.29 0.3 0.7 1.0 
rs4673993 2 ATIC 1388 0.31 0.9 0.7 1.0 
rs8018032 14 MTHFD1 1388 0.45 0.7 0.7 1.0 
rs12797853 11 FOLH1 1385 0.13 0.7 0.7 1.0 
rs1801198 22 TCN2 1387 0.43 0.3 0.7 1.0 
rs8081810 17 PEMT 1387 0.21 0.9 0.7 1.0 
rs1979276 17 SHMT1 1395 0.30 1.0 0.7 1.0 
rs8111085 19 DNMT1 1387 0.08 0.6 0.7 1.0 
rs11658944 17 PEMT 1387 0.05 0.7 0.7 1.0 
rs914238 21 SLC19A1 1388 0.49 0.4 0.7 1.0 
rs2289093 2 DNMT3A 1388 0.28 0.2 0.7 1.0 
rs10839295 11 FOLH1 1387 0.39 0.5 0.7 1.0 
rs2150460 21 SLC19A1 1388 0.21 0.9 0.7 1.0 
rs2790 18 TYMS 1384 0.20 0.7 0.7 1.0 
rs11681447 2 DNMT3A 1386 0.28 0.2 0.7 1.0 
rs4673991 2 ATIC 1387 0.31 0.9 0.7 1.0 
rs4610054 2 ATIC 1383 0.38 1.0 0.7 1.0 
rs282772 15 MTHFS 1388 0.13 0.3 0.7 1.0 
rs1650697 5 DHFR 1385 0.23 0.1 0.7 1.0 
rs8003379 14 MTHFD1 1387 0.24 0.4 0.7 1.0 
rs11683424 2 DNMT3A 1388 0.12 0.5 0.7 1.0 
rs17284990 15 MTHFS 1388 0.22 0.5 0.7 1.0 
rs11672909 19 DNMT1 1387 0.08 0.6 0.7 1.0 
rs2838969 21 SLC19A1 1388 0.07 1.0 0.7 1.0 
rs2183601 21 SLC19A1 1388 0.21 1.0 0.7 1.0 
rs6801605 3 CHDH 1388 0.38 0.6 0.7 1.0 
rs9306139 21 SLC19A1 1386 0.21 0.8 0.7 1.0 
rs8003567 14 MTHFD1 1388 0.10 0.8 0.7 1.0 
rs10460566 2 DNMT3A 1388 0.27 0.3 0.7 1.0 
rs2838973 21 SLC19A1 1388 0.21 1.0 0.7 1.0 
rs7581217 2 DNMT3A 1388 0.39 0.2 0.7 1.0 
rs9976878 21 SLC19A1 1387 0.21 0.8 0.7 1.0 
rs282792 15 MTHFS 1388 0.39 0.6 0.7 1.0 
rs1814175 11 FOLH1 1384 0.39 0.4 0.7 1.0 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs10418707 19 DNMT1 1387 0.08 0.6 0.8 1.0 
rs749130 2 DNMT3A 1388 0.44 0.6 0.8 1.0 
rs9789571 2 ATIC 1388 0.42 1.0 0.8 1.0 
rs3862350 11 FOLH1 1360 0.39 0.2 0.8 1.0 
rs1020697 17 PEMT 1361 0.10 0.3 0.8 1.0 
rs4804494 19 DNMT1 1387 0.08 0.6 0.8 1.0 
rs9836592 3 CHDH 1388 0.31 0.3 0.8 1.0 
rs1979277 17 SHMT1 1398 0.27 0.8 0.8 1.0 
rs4804490 19 DNMT1 1386 0.08 0.6 0.8 1.0 
rs11040106 11 FOLH1 1379 0.36 0.6 0.8 1.0 
rs567754 5 BHMT 1387 0.29 0.9 0.8 1.0 
rs11656215 17 PEMT 1388 0.45 0.4 0.8 1.0 
rs435689 15 MTHFS 1388 0.49 0.9 0.8 1.0 
rs4434082 21 SLC19A1 1387 0.21 0.9 0.8 1.0 
rs1550117 2 DNMT3A 1387 0.08 1.0 0.8 1.0 
rs2838970 21 SLC19A1 1387 0.39 0.9 0.8 1.0 
rs376863 15 MTHFS 1366 0.50 0.9 0.8 1.0 
rs8129445 21 SLC19A1 1388 0.32 0.9 0.8 1.0 
rs3774616 3 CHDH 1388 0.05 1.0 0.8 1.0 
rs3818239 14 MTHFD1 1380 0.13 0.9 0.8 1.0 
rs6058896 20 DNMT3B 1388 0.08 0.8 0.8 1.0 
rs1808119 2 ATIC 1388 0.20 1.0 0.8 1.0 
rs8128681 21 SLC19A1 1388 0.32 0.9 0.8 1.0 
rs9462856 6 GNMT 1388 0.41 0.9 0.8 1.0 
rs1809986 11 FOLH1 1388 0.37 1.0 0.8 1.0 
rs1917321 11 FOLH1 1380 0.50 0.2 0.8 1.0 
rs7085104 10 AS3MT 1388 0.39 1.0 0.8 1.0 
rs1023159 21 SLC19A1 1386 0.42 0.4 0.8 1.0 
rs7279305 21 SLC19A1 1388 0.35 1.0 0.8 1.0 
rs7120743 11 FOLH1 1371 0.37 0.8 0.8 1.0 
rs13427202 2 DNMT3A 1387 0.47 0.6 0.8 1.0 
rs6058894 20 DNMT3B 1387 0.08 0.5 0.8 1.0 
rs4673981 2 ATIC 1388 0.39 0.8 0.8 1.0 
rs2116940 19 DNMT1 1387 0.08 0.6 0.8 1.0 
rs12987326 2 DNMT3A 1388 0.37 0.7 0.8 1.0 
rs4778721 15 MTHFS 1388 0.23 0.2 0.8 1.0 
rs9977111 21 SLC19A1 1355 0.33 0.07 0.8 1.0 
rs4804125 19 DNMT1 1387 0.08 0.6 0.8 1.0 
rs1473406 15 MTHFS 1386 0.15 0.9 0.8 1.0 
rs4778719 15 MTHFS 1388 0.23 0.2 0.8 1.0 
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dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs202700 11 FOLH1 1337 0.23 0.8 0.8 1.0 
rs6586282 21 CBS 1387 0.17 0.2 0.8 1.0 
rs4393531 15 MTHFS 1386 0.48 0.4 0.8 1.0 
rs1465825 2 DNMT3A 1387 0.27 0.3 0.8 1.0 
rs9305012 19 DNMT1 1387 0.08 0.6 0.8 1.0 
rs17751556 14 MTHFD1 1388 0.08 1.0 0.8 1.0 
rs6445606 3 CHDH 1388 0.29 0.2 0.9 1.0 
rs2301955 22 TCN2 1386 0.43 0.3 0.9 1.0 
rs12462004 19 DNMT1 1386 0.08 0.6 0.9 1.0 
rs2838977 21 SLC19A1 1386 0.39 0.9 0.9 1.0 
rs8112895 19 DNMT1 1388 0.08 0.6 0.9 1.0 
rs9621047 22 TCN2 1388 0.44 0.2 0.9 1.0 
rs2586182 15 MTHFS 1388 0.15 0.4 0.9 1.0 
rs17209637 15 MTHFS 1384 0.25 1.0 0.9 1.0 
rs767138 21 SLC19A1 1385 0.40 0.6 0.9 1.0 
rs13002567 2 DNMT3A 1388 0.28 0.5 0.9 1.0 
rs5753231 22 TCN2 1387 0.16 0.8 0.9 1.0 
rs4476347 2 ATIC 1387 0.25 0.4 0.9 1.0 
rs7586294 2 DNMT3A 1387 0.47 0.5 0.9 1.0 
rs5749135 22 TCN2 1388 0.43 0.3 0.9 1.0 
rs4779148 15 MTHFS 1388 0.11 0.2 0.9 1.0 
rs16971252 15 MTHFS 1388 0.06 0.3 0.9 1.0 
rs2877078 21 SLC19A1 1376 0.39 0.7 0.9 1.0 
rs2241807 3 CHDH 1388 0.43 0.7 0.9 1.0 
rs437302 20 DNMT3B 1388 0.09 1.0 0.9 1.0 
rs897453 17 PEMT 1384 0.49 0.6 0.9 1.0 
rs2586154 15 MTHFS 1388 0.15 0.5 0.9 1.0 
rs11629135 14 MTHFD1 1388 0.10 0.7 0.9 1.0 
rs2586153 15 MTHFS 1374 0.15 0.4 0.9 1.0 
rs11701960 21 SLC19A1 1387 0.17 1.0 0.9 1.0 
rs1604503 15 MTHFS 1388 0.14 0.4 0.9 1.0 
NA 1 MTHFR_02_OR 1285 0.39 0.4 0.9 1.0 
rs6518253 21 SLC19A1 1387 0.46 0.3 0.9 1.0 
rs12148881 15 MTHFS 1387 0.27 0.2 0.9 1.0 
rs4820888 22 TCN2 1387 0.47 0.1 0.9 1.0 
rs2424908 20 DNMT3B 1388 0.17 0.7 0.9 1.0 
rs7276295 21 SLC19A1 1388 0.06 0.3 0.9 1.0 
rs7219568 17 PEMT 1388 0.05 1.0 0.9 1.0 
rs2987981 14 MTHFD1 1388 0.25 0.9 0.9 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=496) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs582172 15 MTHFS 1388 0.41 0.6 0.9 1.0 
rs3785499 17 PEMT 1388 0.47 0.8 0.9 1.0 
rs2236222 14 MTHFD1 1388 0.10 0.5 0.9 1.0 
rs12627639 21 SLC19A1 1387 0.21 0.5 0.9 1.0 
rs8971 21 GART 1386 0.26 0.8 0.9 1.0 
rs16971231 15 MTHFS 1385 0.05 0.1 0.9 1.0 
rs4924922 17 PEMT 1388 0.36 0.3 0.9 1.0 
rs13036246 2 DNMT3A 1387 0.49 0.4 1.0 1.0 
rs3783728 14 MTHFD1 1388 0.08 1.0 1.0 1.0 
rs6485991 11 FOLH1 1382 0.16 0.6 1.0 1.0 
rs12453139 17 PEMT 1386 0.26 0.9 1.0 1.0 
rs4819138 21 SLC19A1 1388 0.39 0.8 1.0 1.0 
rs2733106 15 MTHFS 1383 0.15 0.5 1.0 1.0 
rs2834231 21 GART 1388 0.26 0.7 1.0 1.0 
rs1404774 2 ATIC 1380 0.21 0.4 1.0 1.0 
rs17279753 15 MTHFS 1388 0.20 0.5 1.0 1.0 
rs2834232 21 GART 1387 0.26 0.7 1.0 1.0 
rs17279885 15 MTHFS 1388 0.21 0.7 1.0 1.0 
rs12373907 21 SLC19A1 1387 0.38 0.4 1.0 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
SNPs modeled in codominant mode  of inheritance 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1256142 14 MTHFD1 1388 0.44 0.07 0.002 0.4 
rs2838965 21 SLC19A1 1384 0.42 0.05 0.004 0.6 
rs7124266 11 FOLH1 1388 0.30 0.6 0.01 0.9 
rs2236224 14 MTHFD1 1388 0.36 0.1 0.01 0.9 
rs8041943 15 MTHFS 1385 0.42 0.6 0.01 0.9 
rs2834235 21 GART 1388 0.38 0.7 0.01 0.9 
rs3821353 2 ATIC 1388 0.21 0.4 0.02 1.0 
rs6087990 20 DNMT3B 1388 0.33 0.6 0.02 1.0 
rs2865908 11 FOLH1 1388 0.19 0.9 0.02 1.0 
rs4094478 11 FOLH1 1365 0.20 0.7 0.02 1.0 
rs2236225 14 MTHFD1 1387 0.43 0.2 0.02 1.0 
rs10839210 11 FOLH1 1386 0.21 0.5 0.02 1.0 
rs3893384 15 MTHFS 1388 0.42 0.5 0.02 1.0 
rs3862342 11 FOLH1 1386 0.28 0.8 0.02 1.0 
rs10769558 11 FOLH1 1388 0.21 0.5 0.02 1.0 
rs16853782 2 ATIC 1388 0.21 0.7 0.03 1.0 
rs1847638 11 FOLH1 1335 0.21 1.0 0.03 1.0 
rs3772078 2 ATIC 1388 0.21 0.6 0.03 1.0 
rs11158542 14 MTHFD1 1388 0.29 0.8 0.03 1.0 
rs2305230 3 ALDH1L1 1387 0.19 0.7 0.03 1.0 
rs6058869 20 DNMT3B 1388 0.33 0.7 0.04 1.0 
rs2154583 21 GART 1384 0.39 0.7 0.04 1.0 
rs11191457 10 AS3MT 1385 0.23 0.4 0.04 1.0 
rs6517178 21 GART 1388 0.39 0.7 0.04 1.0 
rs4441015 11 FOLH1 1353 0.15 0.5 0.04 1.0 
rs282792 15 MTHFS 1388 0.39 0.6 0.04 1.0 
rs6573559 14 MTHFD1 1388 0.29 1.0 0.04 1.0 
rs11040198 11 FOLH1 1381 0.21 0.2 0.05 1.0 
rs12910340 15 MTHFS 1388 0.42 1.0 0.05 1.0 
rs2696923 11 FOLH1 1388 0.21 0.3 0.05 1.0 
rs7085854 10 AS3MT 1387 0.23 0.6 0.05 1.0 
rs6058893 20 DNMT3B 1388 0.33 0.2 0.05 1.0 
rs7111711 11 FOLH1 1388 0.25 0.9 0.05 1.0 
rs7107178 11 FOLH1 1387 0.25 1.0 0.06 1.0 
rs10839296 11 FOLH1 1371 0.25 0.8 0.06 1.0 
rs2696935 11 FOLH1 1388 0.21 0.4 0.06 1.0 
rs4817579 21 GART 1388 0.35 1.0 0.07 1.0 
rs1081235 15 MTHFS 1388 0.19 0.3 0.07 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4817577 21 GART 1388 0.34 0.9 0.07 1.0 
rs11627387 14 MTHFD1 1388 0.29 0.9 0.07 1.0 
rs4911107 20 DNMT3B 1388 0.32 0.6 0.08 1.0 
rs7283354 21 GART 1388 0.34 0.9 0.08 1.0 
rs2035027 15 MTHFS 1388 0.16 0.5 0.08 1.0 
rs11040421 11 FOLH1 1388 0.15 0.6 0.08 1.0 
rs6495441 15 MTHFS 1388 0.24 0.3 0.09 1.0 
rs4779140 15 MTHFS 1387 0.48 0.6 0.09 1.0 
rs6058897 20 DNMT3B 1388 0.43 0.2 0.09 1.0 
rs2281603 14 MTHFD1 1388 0.19 0.2 0.1 1.0 
rs16999714 19 DNMT1 1386 0.21 0.1 0.1 1.0 
rs12438477 15 MTHFS 1387 0.36 0.4 0.1 1.0 
rs473334 1 CTH 1388 0.31 0.9 0.1 1.0 
rs1880580 15 MTHFS 1388 0.30 0.09 0.1 1.0 
rs4779165 15 MTHFS 1387 0.16 0.4 0.1 1.0 
rs2838958 21 SLC19A1 1385 0.45 0.7 0.1 1.0 
rs372447 15 MTHFS 1388 0.38 0.9 0.1 1.0 
rs663649 1 CTH 1388 0.31 0.9 0.1 1.0 
rs865646 5 DHFR 1340 0.34 0.4 0.1 1.0 
rs3785499 17 PEMT 1388 0.47 0.8 0.1 1.0 
rs679470 11 FOLH1 1387 0.17 0.6 0.1 1.0 
rs7563206 2 ATIC 1387 0.47 0.6 0.1 1.0 
rs16971450 15 MTHFS 1387 0.16 0.4 0.1 1.0 
rs9974061 21 SLC19A1 1388 0.18 1.0 0.1 1.0 
rs648372 11 FOLH1 1370 0.17 0.5 0.1 1.0 
rs9835128 3 CHDH 1387 0.17 0.4 0.1 1.0 
rs7560488 2 DNMT3A 1333 0.47 0.2 0.1 1.0 
rs1880586 2 ATIC 1387 0.47 0.6 0.1 1.0 
rs2424932 20 DNMT3B 1387 0.43 0.5 0.1 1.0 
rs2424928 20 DNMT3B 1388 0.39 0.2 0.1 1.0 
rs4646404 17 PEMT 1383 0.36 0.3 0.1 1.0 
rs585800 5 BHMT 1388 0.26 0.05 0.1 1.0 
rs7951180 11 FOLH1 1369 0.17 0.4 0.2 1.0 
rs9323450 14 MTHFD1 1388 0.30 0.8 0.2 1.0 
rs2424921 20 DNMT3B 1388 0.39 0.3 0.2 1.0 
rs3783 17 SHMT1 1398 0.26 0.6 0.2 1.0 
rs4911263 20 DNMT3B 1388 0.32 1.0 0.2 1.0 
rs202676 11 FOLH1 1380 0.17 0.8 0.2 1.0 
rs2586154 15 MTHFS 1388 0.15 0.5 0.2 1.0 
rs6141813 20 DNMT3B 1388 0.13 0.8 0.2 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7587636 2 DNMT3A 1388 0.45 0.1 0.2 1.0 
rs12903985 15 MTHFS 1388 0.28 0.4 0.2 1.0 
rs6058891 20 DNMT3B 1386 0.39 0.2 0.2 1.0 
rs2424922 20 DNMT3B 1387 0.39 0.2 0.2 1.0 
rs9332 5 MTRR 1388 0.12 0.2 0.2 1.0 
rs7605753 2 DNMT3A 1388 0.47 0.6 0.2 1.0 
rs6087988 20 DNMT3B 1388 0.20 0.6 0.2 1.0 
rs6749992 2 DNMT3A 1388 0.47 0.8 0.2 1.0 
rs559062 1 CTH 1388 0.22 0.6 0.2 1.0 
rs12898642 15 MTHFS 1387 0.43 0.2 0.2 1.0 
rs7111215 11 FOLH1 1368 0.40 0.2 0.2 1.0 
rs13401241 2 DNMT3A 1388 0.45 0.1 0.2 1.0 
rs7220132 17 PEMT 1388 0.29 0.7 0.2 1.0 
rs10418 22 TCN2 1367 0.21 0.7 0.2 1.0 
rs1917311 11 FOLH1 1353 0.40 0.4 0.2 1.0 
rs1801131 1 MTHFR 1322 0.28 0.9 0.2 1.0 
rs7583409 2 DNMT3A 1387 0.35 0.4 0.2 1.0 
rs10163099 15 MTHFS 1385 0.26 0.1 0.2 1.0 
rs9306139 21 SLC19A1 1386 0.21 0.8 0.2 1.0 
rs2586182 15 MTHFS 1388 0.15 0.4 0.2 1.0 
rs910085 20 DNMT3B 1387 0.29 0.5 0.2 1.0 
rs2424914 20 DNMT3B 1388 0.39 0.4 0.2 1.0 
rs4479310 17 PEMT 1388 0.29 0.6 0.2 1.0 
rs1164685 11 FOLH1 1385 0.38 0.3 0.2 1.0 
rs6058883 20 DNMT3B 1387 0.39 0.3 0.2 1.0 
rs6495446 15 MTHFS 1387 0.26 0.1 0.2 1.0 
rs9976878 21 SLC19A1 1387 0.21 0.8 0.2 1.0 
rs663465 1 CTH 1387 0.41 0.4 0.2 1.0 
rs4987173 6 GNMT 1388 0.51 0.8 0.2 1.0 
rs2150460 21 SLC19A1 1388 0.21 0.9 0.2 1.0 
rs2183601 21 SLC19A1 1388 0.21 1.0 0.2 1.0 
rs1074390 15 MTHFS 1388 0.37 0.6 0.3 1.0 
rs2838973 21 SLC19A1 1388 0.21 1.0 0.3 1.0 
rs8074074 17 PEMT 1386 0.29 0.8 0.3 1.0 
rs4818789 21 SLC19A1 1388 0.25 0.5 0.3 1.0 
rs10420338 19 DNMT1 1388 0.47 0.6 0.3 1.0 
rs4646410 17 PEMT 1384 0.31 0.9 0.3 1.0 
rs2733103 15 MTHFS 1387 0.15 0.2 0.3 1.0 
rs8659 5 MTRR 1386 0.35 0.3 0.3 1.0 
rs4434082 21 SLC19A1 1387 0.21 0.9 0.3 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs914238 21 SLC19A1 1388 0.49 0.4 0.3 1.0 
rs7946 17 PEMT 1387 0.29 0.4 0.3 1.0 
rs759920 19 DNMT1 1388 0.47 0.7 0.3 1.0 
rs9890064 17 PEMT 1388 0.43 0.4 0.3 1.0 
rs2424913 20 DNMT3B 1387 0.37 0.2 0.3 1.0 
rs2424906 20 DNMT3B 1388 0.38 0.2 0.3 1.0 
rs12373907 21 SLC19A1 1387 0.38 0.4 0.3 1.0 
rs1801133 1 MTHFR 1388 0.40 0.5 0.3 1.0 
rs2586153 15 MTHFS 1374 0.15 0.4 0.3 1.0 
rs2838956 21 SLC19A1 1373 0.44 0.07 0.3 1.0 
rs2228611 19 DNMT1 1388 0.47 0.8 0.3 1.0 
NA 1 MTHFR_02_2_i 1388 0.40 0.5 0.3 1.0 
rs6706415 2 ATIC 1388 0.30 0.4 0.3 1.0 
rs4819128 21 SLC19A1 1388 0.44 0.2 0.3 1.0 
rs11085720 19 DNMT1 1388 0.42 0.5 0.3 1.0 
rs1846285 11 FOLH1 1385 0.17 0.2 0.3 1.0 
rs7581217 2 DNMT3A 1388 0.39 0.2 0.3 1.0 
rs1051266 21 SLC19A1 1388 0.45 0.2 0.3 1.0 
rs435689 15 MTHFS 1388 0.49 0.9 0.3 1.0 
rs4144700 11 FOLH1 1388 0.38 0.3 0.3 1.0 
rs3788200 21 SLC19A1 1388 0.45 0.3 0.3 1.0 
rs4924922 17 PEMT 1388 0.36 0.3 0.3 1.0 
rs588458 11 FOLH1 1367 0.38 0.3 0.3 1.0 
rs4672768 2 ATIC 1385 0.31 0.9 0.3 1.0 
rs3760188 17 PEMT 1388 0.46 0.6 0.3 1.0 
rs2733106 15 MTHFS 1383 0.15 0.5 0.3 1.0 
rs12614943 2 ATIC 1388 0.28 1.0 0.3 1.0 
rs1046778 10 AS3MT 1388 0.33 0.8 0.3 1.0 
rs10948059 6 GNMT 1370 0.48 0.8 0.3 1.0 
rs2866358 11 FOLH1 1372 0.38 0.2 0.3 1.0 
rs7174668 15 MTHFS 1388 0.20 0.2 0.3 1.0 
rs2290684 19 DNMT1 1388 0.47 0.8 0.3 1.0 
rs2115536 15 MTHFS 1388 0.50 0.05 0.4 1.0 
rs3755817 3 CHDH 1387 0.30 0.5 0.4 1.0 
rs4646344 17 PEMT 1388 0.47 0.7 0.4 1.0 
rs10498036 2 ATIC 1388 0.40 0.4 0.4 1.0 
rs1802059 5 MTRR 1387 0.37 0.4 0.4 1.0 
rs8074191 17 PEMT 1372 0.28 0.9 0.4 1.0 
rs11683424 2 DNMT3A 1388 0.12 0.5 0.4 1.0 
rs914232 21 SLC19A1 1387 0.44 0.2 0.4 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1380642 15 MTHFS 1388 0.18 0.3 0.4 1.0 
rs914231 21 SLC19A1 1383 0.44 0.2 0.4 1.0 
rs1127717 3 ALDH1L1 1388 0.24 0.6 0.4 1.0 
rs4673993 2 ATIC 1388 0.31 0.9 0.4 1.0 
rs282795 15 MTHFS 1387 0.32 0.7 0.4 1.0 
rs4673965 2 ATIC 1388 0.40 1.0 0.4 1.0 
rs7604984 2 ATIC 1388 0.40 0.4 0.4 1.0 
rs2267163 22 TCN2 1386 0.43 0.2 0.4 1.0 
rs204942 15 MTHFS 1388 0.20 0.1 0.4 1.0 
rs2409495 21 GART 1388 0.19 0.05 0.4 1.0 
rs897453 17 PEMT 1384 0.49 0.6 0.4 1.0 
rs4911108 20 DNMT3B 1384 0.29 0.7 0.4 1.0 
rs10519256 15 MTHFS 1388 0.11 0.1 0.4 1.0 
rs1979277 17 SHMT1 1398 0.27 0.8 0.4 1.0 
rs1888530 21 SLC19A1 1358 0.47 0.07 0.4 1.0 
NA 1 MTR_01_OR 1389 0.16 0.7 0.4 1.0 
rs11677670 2 DNMT3A 1382 0.17 0.5 0.4 1.0 
rs4673991 2 ATIC 1387 0.31 0.9 0.4 1.0 
rs1801198 22 TCN2 1387 0.43 0.3 0.4 1.0 
rs4646385 17 PEMT 1388 0.43 0.5 0.4 1.0 
rs10179873 2 ATIC 1388 0.30 0.4 0.4 1.0 
rs10460566 2 DNMT3A 1388 0.27 0.3 0.4 1.0 
rs770144 15 MTHFS 1388 0.20 0.3 0.4 1.0 
rs2115540 15 MTHFS 1387 0.50 0.05 0.4 1.0 
rs1983462 2 ATIC 1388 0.30 0.3 0.4 1.0 
rs12148881 15 MTHFS 1387 0.27 0.2 0.4 1.0 
rs7215833 17 PEMT 1388 0.35 0.5 0.4 1.0 
rs7177027 15 MTHFS 1388 0.24 0.08 0.4 1.0 
rs10197653 2 ATIC 1388 0.29 0.1 0.4 1.0 
rs1051298 21 SLC19A1 1387 0.46 0.3 0.4 1.0 
rs1979276 17 SHMT1 1395 0.30 1.0 0.4 1.0 
rs4646341 17 PEMT 1385 0.36 0.5 0.4 1.0 
rs8971 21 GART 1386 0.26 0.8 0.4 1.0 
rs7177659 15 MTHFS 1387 0.50 0.08 0.4 1.0 
rs6722613 2 DNMT3A 1388 0.40 1.0 0.4 1.0 
rs11871738 17 PEMT 1388 0.38 0.4 0.4 1.0 
rs17291414 19 DNMT1 1388 0.27 0.5 0.4 1.0 
rs17209637 15 MTHFS 1384 0.25 1.0 0.4 1.0 
rs4819130 21 SLC19A1 1384 0.45 0.2 0.4 1.0 
rs10197559 2 ATIC 1380 0.29 0.9 0.5 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11158540 14 MTHFD1 1388 0.34 0.9 0.5 1.0 
rs1950902 14 MTHFD1 1388 0.14 0.4 0.5 1.0 
rs3177999 21 SLC19A1 1380 0.45 0.2 0.5 1.0 
rs2330183 21 SLC19A1 1358 0.44 0.05 0.5 1.0 
rs2838961 21 SLC19A1 1388 0.34 1.0 0.5 1.0 
rs2834231 21 GART 1388 0.26 0.7 0.5 1.0 
rs12416687 10 AS3MT 1388 0.28 0.1 0.5 1.0 
rs2834232 21 GART 1387 0.26 0.7 0.5 1.0 
rs2424908 20 DNMT3B 1388 0.17 0.7 0.5 1.0 
rs11892429 2 ATIC 1388 0.29 0.7 0.5 1.0 
rs6711622 2 DNMT3A 1388 0.44 1.0 0.5 1.0 
rs3788190 21 SLC19A1 1387 0.47 0.1 0.5 1.0 
rs740234 22 TCN2 1388 0.23 0.8 0.5 1.0 
rs515064 1 CTH 1388 0.36 0.8 0.5 1.0 
rs4646359 17 PEMT 1388 0.45 0.3 0.5 1.0 
rs17745484 2 DNMT3A 1387 0.35 0.8 0.5 1.0 
rs1465825 2 DNMT3A 1387 0.27 0.3 0.5 1.0 
rs35020344 14 MTHFD1 1387 0.47 0.7 0.5 1.0 
NA 1 MTHFR_02_OR 1285 0.39 0.4 0.5 1.0 
rs1256107 14 MTHFD1 1387 0.48 0.7 0.5 1.0 
rs1805087 1 MTR 1388 0.17 0.7 0.5 1.0 
rs12591436 15 MTHFS 1388 0.35 0.6 0.5 1.0 
rs1081231 15 MTHFS 1387 0.18 0.8 0.5 1.0 
rs12482346 21 SLC19A1 1388 0.47 0.1 0.5 1.0 
rs2289093 2 DNMT3A 1388 0.28 0.2 0.5 1.0 
rs1051296 21 SLC19A1 1375 0.47 0.1 0.5 1.0 
rs282776 15 MTHFS 1388 0.36 1.0 0.5 1.0 
rs2275566 1 MTR 1388 0.42 0.1 0.5 1.0 
rs10165919 2 ATIC 1387 0.35 0.6 0.5 1.0 
rs1256095 14 MTHFD1 1377 0.48 0.8 0.5 1.0 
rs898436 15 MTHFS 1384 0.46 0.1 0.6 1.0 
rs3740392 10 AS3MT 1385 0.29 0.1 0.6 1.0 
rs600671 15 MTHFS 1387 0.46 0.1 0.6 1.0 
rs4646350 17 PEMT 1388 0.36 0.6 0.6 1.0 
rs12997662 2 ATIC 1387 0.33 0.7 0.6 1.0 
rs11869600 17 PEMT 1386 0.38 0.3 0.6 1.0 
rs4804122 19 DNMT1 1388 0.40 0.4 0.6 1.0 
rs8081810 17 PEMT 1387 0.21 0.9 0.6 1.0 
rs6485991 11 FOLH1 1382 0.16 0.6 0.6 1.0 
rs34048824 2 DNMT3A 1387 0.50 1.0 0.6 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12987326 2 DNMT3A 1388 0.37 0.7 0.6 1.0 
rs2987981 14 MTHFD1 1388 0.25 0.9 0.6 1.0 
rs567754 5 BHMT 1387 0.29 0.9 0.6 1.0 
rs443394 15 MTHFS 1388 0.41 0.3 0.6 1.0 
rs1667627 14 MTHFD2 1387 0.46 0.2 0.6 1.0 
rs12121543 1 MTHFR 1388 0.22 0.9 0.6 1.0 
rs4646340 17 PEMT 1388 0.36 0.5 0.6 1.0 
rs12999687 2 DNMT3A 1386 0.45 0.8 0.6 1.0 
rs7253062 19 DNMT1 1388 0.39 0.7 0.6 1.0 
rs11656215 17 PEMT 1388 0.45 0.4 0.6 1.0 
rs853858 20 DNMT3B 1386 0.37 0.2 0.6 1.0 
rs2275565 1 MTR 1388 0.20 0.6 0.6 1.0 
rs8011839 14 MTHFD1 1388 0.18 0.4 0.6 1.0 
rs12627639 21 SLC19A1 1387 0.21 0.5 0.6 1.0 
rs11681447 2 DNMT3A 1386 0.28 0.2 0.6 1.0 
NA 1 MTR_01_2_i 1388 0.17 0.7 0.6 1.0 
rs12905663 15 MTHFS 1381 0.27 0.2 0.6 1.0 
rs11687225 2 ATIC 1387 0.40 0.9 0.6 1.0 
rs11887120 2 DNMT3A 1388 0.42 0.5 0.6 1.0 
rs944422 21 SLC19A1 1384 0.35 0.9 0.6 1.0 
rs282778 15 MTHFS 1388 0.27 0.8 0.6 1.0 
rs2124344 17 PEMT 1387 0.36 0.7 0.6 1.0 
rs4779141 15 MTHFS 1386 0.34 0.8 0.6 1.0 
rs8101626 19 DNMT1 1388 0.39 0.7 0.6 1.0 
rs9977111 21 SLC19A1 1355 0.33 0.07 0.6 1.0 
rs7604425 2 ATIC 1388 0.35 0.7 0.6 1.0 
rs10748835 10 AS3MT 1388 0.44 0.3 0.6 1.0 
rs4532960 10 AS3MT 1387 0.44 0.3 0.6 1.0 
rs282814 15 MTHFS 1388 0.21 0.8 0.6 1.0 
rs202712 11 FOLH1 1387 0.23 0.7 0.6 1.0 
rs7575625 2 DNMT3A 1388 0.47 0.9 0.6 1.0 
rs8128676 21 SLC19A1 1350 0.22 1.0 0.6 1.0 
rs1808119 2 ATIC 1388 0.20 1.0 0.6 1.0 
rs6518253 21 SLC19A1 1387 0.46 0.3 0.7 1.0 
rs749130 2 DNMT3A 1388 0.44 0.6 0.7 1.0 
rs17285431 15 MTHFS 1388 0.17 0.1 0.7 1.0 
rs5749131 22 TCN2 1388 0.43 0.2 0.7 1.0 
rs16853834 2 ATIC 1388 0.16 1.0 0.7 1.0 
rs4244599 17 PEMT 1371 0.46 0.4 0.7 1.0 
rs6713377 2 DNMT3A 1387 0.47 0.9 0.7 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs685487 15 MTHFS 1388 0.37 0.09 0.7 1.0 
rs2987969 14 MTHFD1 1387 0.45 0.7 0.7 1.0 
rs12899781 15 MTHFS 1383 0.17 0.06 0.7 1.0 
rs734693 2 DNMT3A 1387 0.29 0.2 0.7 1.0 
rs2289195 2 DNMT3A 1387 0.44 0.2 0.7 1.0 
rs2983733 14 MTHFD1 1388 0.45 0.9 0.7 1.0 
rs1076991 14 MTHFD1 1388 0.45 1.0 0.7 1.0 
rs2983736 14 MTHFD1 1385 0.45 0.9 0.7 1.0 
rs1473406 15 MTHFS 1386 0.15 0.9 0.7 1.0 
rs1369703 2 DNMT3A 1388 0.45 0.2 0.7 1.0 
rs10498034 2 ATIC 1388 0.17 1.0 0.7 1.0 
rs8129350 21 SLC19A1 1387 0.35 0.9 0.7 1.0 
rs8018032 14 MTHFD1 1388 0.45 0.7 0.7 1.0 
rs1888533 21 SLC19A1 1388 0.48 0.3 0.7 1.0 
rs748196 17 PEMT 1385 0.42 0.9 0.7 1.0 
rs10839239 11 FOLH1 1386 0.23 0.6 0.7 1.0 
rs11158538 14 MTHFD1 1385 0.45 0.9 0.7 1.0 
rs1404774 2 ATIC 1380 0.21 0.4 0.7 1.0 
rs11040416 11 FOLH1 1388 0.42 0.4 0.7 1.0 
rs2288349 19 DNMT1 1387 0.39 0.5 0.7 1.0 
rs4531931 2 ATIC 1387 0.31 0.5 0.7 1.0 
rs6760069 2 ATIC 1387 0.14 0.5 0.7 1.0 
rs1109859 17 PEMT 1367 0.18 0.8 0.7 1.0 
rs617219 5 BHMT 1387 0.32 0.7 0.7 1.0 
rs445263 15 MTHFS 1388 0.30 0.9 0.7 1.0 
rs1809986 11 FOLH1 1388 0.37 1.0 0.7 1.0 
rs6445606 3 CHDH 1388 0.29 0.2 0.8 1.0 
rs376863 15 MTHFS 1366 0.50 0.9 0.8 1.0 
rs660439 11 FOLH1 1384 0.23 0.7 0.8 1.0 
rs750546 17 PEMT 1373 0.43 0.5 0.8 1.0 
rs8003379 14 MTHFD1 1387 0.24 0.4 0.8 1.0 
rs1801394 5 MTRTR 1398 0.49 0.8 0.8 1.0 
rs7120743 11 FOLH1 1371 0.37 0.8 0.8 1.0 
rs5753231 22 TCN2 1387 0.16 0.8 0.8 1.0 
rs9836592 3 CHDH 1388 0.31 0.3 0.8 1.0 
rs1464864 2 ATIC 1388 0.30 0.8 0.8 1.0 
rs699517 18 TYMS 1387 0.31 0.6 0.8 1.0 
rs1256112 14 MTHFD1 1388 0.40 0.4 0.8 1.0 
rs11040106 11 FOLH1 1379 0.36 0.6 0.8 1.0 
rs1059394 18 TYMS 1387 0.31 0.6 0.8 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1077965 15 MTHFS 1387 0.41 0.4 0.8 1.0 
rs731991 22 TCN2 1343 0.48 0.1 0.8 1.0 
rs7594432 2 DNMT3A 1388 0.45 0.3 0.8 1.0 
rs378057 15 MTHFS 1387 0.14 1.0 0.8 1.0 
rs12453139 17 PEMT 1386 0.26 0.9 0.8 1.0 
rs6511677 19 DNMT1 1387 0.39 0.6 0.8 1.0 
rs2790 18 TYMS 1384 0.20 0.7 0.8 1.0 
rs1650697 5 DHFR 1385 0.23 0.1 0.8 1.0 
rs1055345 21 SLC19A1 1387 0.29 0.3 0.8 1.0 
rs2162560 19 DNMT1 1387 0.39 0.6 0.8 1.0 
rs13427202 2 DNMT3A 1387 0.47 0.6 0.9 1.0 
rs11694842 2 DNMT3A 1387 0.28 0.4 0.9 1.0 
rs8128050 21 SLC19A1 1385 0.35 0.9 0.9 1.0 
rs17824591 14 MTHFD1 1386 0.23 0.2 0.9 1.0 
rs4393531 15 MTHFS 1386 0.48 0.4 0.9 1.0 
rs7085104 10 AS3MT 1388 0.39 1.0 0.9 1.0 
rs12898670 15 MTHFS 1387 0.32 0.9 0.9 1.0 
rs234706 21 CBS 1388 0.32 0.1 0.9 1.0 
rs4610054 2 ATIC 1383 0.38 1.0 0.9 1.0 
rs10839295 11 FOLH1 1387 0.39 0.5 0.9 1.0 
rs1917321 11 FOLH1 1380 0.50 0.2 0.9 1.0 
rs7586294 2 DNMT3A 1387 0.47 0.5 0.9 1.0 
rs4819138 21 SLC19A1 1388 0.39 0.8 0.9 1.0 
rs166868 15 MTHFS 1387 0.36 1.0 0.9 1.0 
rs11701960 21 SLC19A1 1387 0.17 1.0 0.9 1.0 
rs8129445 21 SLC19A1 1388 0.32 0.9 0.9 1.0 
rs6801605 3 CHDH 1388 0.38 0.6 0.9 1.0 
rs11855092 15 MTHFS 1388 0.23 0.07 0.9 1.0 
rs17284990 15 MTHFS 1388 0.22 0.5 0.9 1.0 
rs9789571 2 ATIC 1388 0.42 1.0 0.9 1.0 
rs282772 15 MTHFS 1388 0.13 0.3 0.9 1.0 
rs1814175 11 FOLH1 1384 0.39 0.4 0.9 1.0 
rs202700 11 FOLH1 1337 0.23 0.8 0.9 1.0 
rs4673981 2 ATIC 1388 0.39 0.8 0.9 1.0 
rs1023159 21 SLC19A1 1386 0.42 0.4 0.9 1.0 
rs3862350 11 FOLH1 1360 0.39 0.2 0.9 1.0 
rs2301955 22 TCN2 1386 0.43 0.3 0.9 1.0 
rs6586282 21 CBS 1387 0.17 0.2 0.9 1.0 
rs8128681 21 SLC19A1 1388 0.32 0.9 1.0 1.0 
rs5749135 22 TCN2 1388 0.43 0.3 1.0 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs9462856 6 GNMT 1388 0.41 0.9 1.0 1.0 
rs767138 21 SLC19A1 1385 0.40 0.6 1.0 1.0 
rs2838970 21 SLC19A1 1387 0.39 0.9 1.0 1.0 
rs13036246 2 DNMT3A 1387 0.49 0.4 1.0 1.0 
rs7279305 21 SLC19A1 1388 0.35 1.0 1.0 1.0 
rs4476347 2 ATIC 1387 0.25 0.4 1.0 1.0 
rs9621047 22 TCN2 1388 0.44 0.2 1.0 1.0 
rs13002567 2 DNMT3A 1388 0.28 0.5 1.0 1.0 
rs4778721 15 MTHFS 1388 0.23 0.2 1.0 1.0 
rs2877078 21 SLC19A1 1376 0.39 0.7 1.0 1.0 
rs2241807 3 CHDH 1388 0.43 0.7 1.0 1.0 
rs4820888 22 TCN2 1387 0.47 0.1 1.0 1.0 
rs582172 15 MTHFS 1388 0.41 0.6 1.0 1.0 
rs2838977 21 SLC19A1 1386 0.39 0.9 1.0 1.0 
rs4778719 15 MTHFS 1388 0.23 0.2 1.0 1.0 
rs17279885 15 MTHFS 1388 0.21 0.7 1.0 1.0 
rs17279753 15 MTHFS 1388 0.20 0.5 1.0 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
SNPs modeled in dominant mode of inheritance 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12098986 11 FOLH1 1386 0.09 0.2 0.0007 0.2 
rs12293923 11 FOLH1 1383 0.09 0.2 0.0007 0.2 
rs7358352 11 FOLH1 1387 0.09 0.4 0.0008 0.2 
rs650826 11 FOLH1 1386 0.09 0.2 0.0009 0.2 
rs11040261 11 FOLH1 1388 0.09 0.4 0.001 0.2 
rs598841 11 FOLH1 1383 0.09 0.2 0.001 0.2 
rs632220 11 FOLH1 1388 0.09 0.4 0.001 0.2 
rs1819409 11 FOLH1 1376 0.09 0.3 0.001 0.3 
rs683680 11 FOLH1 1387 0.09 0.2 0.001 0.3 
rs7926211 11 FOLH1 1385 0.09 0.2 0.001 0.3 
rs7117025 11 FOLH1 1388 0.09 0.4 0.002 0.3 
rs11040263 11 FOLH1 1385 0.09 0.2 0.002 0.4 
rs4495895 11 FOLH1 1353 0.09 0.4 0.004 0.6 
rs6087990 20 DNMT3B 1388 0.33 0.6 0.004 0.7 
rs6495449 15 MTHFS 1388 0.11 0.09 0.005 0.7 
rs2865908 11 FOLH1 1388 0.19 0.9 0.007 0.8 
rs4094478 11 FOLH1 1365 0.20 0.7 0.007 0.8 
rs10839210 11 FOLH1 1386 0.21 0.5 0.009 0.9 
rs2305230 3 ALDH1L1 1387 0.19 0.7 0.01 0.9 
rs10769558 11 FOLH1 1388 0.21 0.5 0.01 0.9 
rs1847638 11 FOLH1 1335 0.21 1.0 0.01 0.9 
rs11158542 14 MTHFD1 1388 0.29 0.8 0.01 0.9 
rs3821353 2 ATIC 1388 0.21 0.4 0.01 0.9 
rs6058869 20 DNMT3B 1388 0.33 0.7 0.01 1.0 
rs6573559 14 MTHFD1 1388 0.29 1.0 0.02 1.0 
rs11191457 10 AS3MT 1385 0.23 0.4 0.02 1.0 
rs11040198 11 FOLH1 1381 0.21 0.2 0.02 1.0 
rs2696923 11 FOLH1 1388 0.21 0.3 0.02 1.0 
rs3772078 2 ATIC 1388 0.21 0.6 0.02 1.0 
rs16853782 2 ATIC 1388 0.21 0.7 0.02 1.0 
rs6058893 20 DNMT3B 1388 0.33 0.2 0.02 1.0 
rs7929543 11 FOLH1 1388 0.08 1.0 0.02 1.0 
rs4441015 11 FOLH1 1353 0.15 0.5 0.02 1.0 
rs2696935 11 FOLH1 1388 0.21 0.4 0.02 1.0 
rs7085854 10 AS3MT 1387 0.23 0.6 0.02 1.0 
rs11627387 14 MTHFD1 1388 0.29 0.9 0.02 1.0 
rs4911107 20 DNMT3B 1388 0.32 0.6 0.03 1.0 
rs11607791 11 FOLH1 1387 0.07 1.0 0.03 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12438477 15 MTHFS 1387 0.36 0.4 0.03 1.0 
rs6058897 20 DNMT3B 1388 0.43 0.2 0.03 1.0 
rs12913164 15 MTHFS 1388 0.07 0.8 0.03 1.0 
rs2281603 14 MTHFD1 1388 0.19 0.2 0.04 1.0 
rs11040421 11 FOLH1 1388 0.15 0.6 0.04 1.0 
rs9974061 21 SLC19A1 1388 0.18 1.0 0.04 1.0 
rs2424928 20 DNMT3B 1388 0.39 0.2 0.04 1.0 
rs2838958 21 SLC19A1 1385 0.45 0.7 0.04 1.0 
rs2035027 15 MTHFS 1388 0.16 0.5 0.04 1.0 
rs9323450 14 MTHFD1 1388 0.30 0.8 0.05 1.0 
rs11634787 15 MTHFS 1388 0.09 0.3 0.05 1.0 
rs16853826 2 ATIC 1386 0.13 0.9 0.05 1.0 
rs2424921 20 DNMT3B 1388 0.39 0.3 0.05 1.0 
rs2424922 20 DNMT3B 1387 0.39 0.2 0.06 1.0 
rs7111711 11 FOLH1 1388 0.25 0.9 0.06 1.0 
rs12900076 15 MTHFS 1385 0.08 0.6 0.06 1.0 
rs16971450 15 MTHFS 1387 0.16 0.4 0.06 1.0 
rs865646 5 DHFR 1340 0.34 0.4 0.06 1.0 
rs2236224 14 MTHFD1 1388 0.36 0.1 0.06 1.0 
rs6058891 20 DNMT3B 1386 0.39 0.2 0.06 1.0 
rs4779165 15 MTHFS 1387 0.16 0.4 0.06 1.0 
rs10839229 11 FOLH1 1386 0.08 0.3 0.06 1.0 
rs4817577 21 GART 1388 0.34 0.9 0.06 1.0 
rs10839224 11 FOLH1 1388 0.08 0.3 0.06 1.0 
rs7107178 11 FOLH1 1387 0.25 1.0 0.07 1.0 
rs7605753 2 DNMT3A 1388 0.47 0.6 0.07 1.0 
rs6749992 2 DNMT3A 1388 0.47 0.8 0.07 1.0 
rs10839296 11 FOLH1 1371 0.25 0.8 0.07 1.0 
rs559062 1 CTH 1388 0.22 0.6 0.07 1.0 
rs12898642 15 MTHFS 1387 0.43 0.2 0.07 1.0 
rs585800 5 BHMT 1388 0.26 0.05 0.07 1.0 
rs6141813 20 DNMT3B 1388 0.13 0.8 0.07 1.0 
rs7283354 21 GART 1388 0.34 0.9 0.07 1.0 
rs4817579 21 GART 1388 0.35 1.0 0.08 1.0 
rs16906158 11 FOLH1 1387 0.08 0.6 0.08 1.0 
rs6087988 20 DNMT3B 1388 0.20 0.6 0.08 1.0 
rs910085 20 DNMT3B 1387 0.29 0.5 0.09 1.0 
rs6058883 20 DNMT3B 1387 0.39 0.3 0.09 1.0 
rs2424914 20 DNMT3B 1388 0.39 0.4 0.09 1.0 
rs4818789 21 SLC19A1 1388 0.25 0.5 0.1 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs2834233 21 GART 1387 0.08 0.5 0.1 1.0 
rs13317328 3 CHDH 1388 0.10 0.1 0.1 1.0 
rs1164681 11 FOLH1 1388 0.12 0.5 0.1 1.0 
rs4646410 17 PEMT 1384 0.31 0.9 0.1 1.0 
rs12592743 15 MTHFS 1388 0.09 0.5 0.1 1.0 
rs34033751 11 FOLH1 1371 0.11 0.4 0.1 1.0 
rs2424913 20 DNMT3B 1387 0.37 0.2 0.1 1.0 
rs2424906 20 DNMT3B 1388 0.38 0.2 0.1 1.0 
rs9890064 17 PEMT 1388 0.43 0.4 0.1 1.0 
rs202676 11 FOLH1 1380 0.17 0.8 0.1 1.0 
rs2838956 21 SLC19A1 1373 0.44 0.07 0.1 1.0 
rs372447 15 MTHFS 1388 0.38 0.9 0.1 1.0 
rs9606756 22 TCN2 1388 0.10 0.7 0.1 1.0 
rs11852515 15 MTHFS 1388 0.12 0.7 0.1 1.0 
rs679470 11 FOLH1 1387 0.17 0.6 0.1 1.0 
rs7583409 2 DNMT3A 1387 0.35 0.4 0.1 1.0 
rs3897953 15 MTHFS 1388 0.09 0.8 0.1 1.0 
rs4819128 21 SLC19A1 1388 0.44 0.2 0.1 1.0 
rs7587636 2 DNMT3A 1388 0.45 0.1 0.1 1.0 
rs1051266 21 SLC19A1 1388 0.45 0.2 0.1 1.0 
rs3788200 21 SLC19A1 1388 0.45 0.3 0.1 1.0 
rs9910747 17 PEMT 1388 0.07 0.4 0.1 1.0 
rs282792 15 MTHFS 1388 0.39 0.6 0.1 1.0 
rs10163099 15 MTHFS 1385 0.26 0.1 0.1 1.0 
rs6495446 15 MTHFS 1387 0.26 0.1 0.1 1.0 
rs13401241 2 DNMT3A 1388 0.45 0.1 0.1 1.0 
rs11040432 11 FOLH1 1387 0.08 1.0 0.1 1.0 
rs648372 11 FOLH1 1370 0.17 0.5 0.2 1.0 
rs1404772 2 ATIC 1388 0.08 0.4 0.2 1.0 
rs914232 21 SLC19A1 1387 0.44 0.2 0.2 1.0 
rs1846285 11 FOLH1 1385 0.17 0.2 0.2 1.0 
rs16988828 22 TCN2 1388 0.09 0.2 0.2 1.0 
rs12903985 15 MTHFS 1388 0.28 0.4 0.2 1.0 
rs4911108 20 DNMT3B 1384 0.29 0.7 0.2 1.0 
rs1380642 15 MTHFS 1388 0.18 0.3 0.2 1.0 
rs914231 21 SLC19A1 1383 0.44 0.2 0.2 1.0 
rs8659 5 MTRR 1386 0.35 0.3 0.2 1.0 
rs10418 22 TCN2 1367 0.21 0.7 0.2 1.0 
rs663649 1 CTH 1388 0.31 0.9 0.2 1.0 
rs7124266 11 FOLH1 1388 0.30 0.6 0.2 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs473334 1 CTH 1388 0.31 0.9 0.2 1.0 
rs6706415 2 ATIC 1388 0.30 0.4 0.2 1.0 
rs10948059 6 GNMT 1370 0.48 0.8 0.2 1.0 
rs4911263 20 DNMT3B 1388 0.32 1.0 0.2 1.0 
rs1046778 10 AS3MT 1388 0.33 0.8 0.2 1.0 
rs7102641 11 FOLH1 1385 0.08 0.4 0.2 1.0 
rs10197653 2 ATIC 1388 0.29 0.1 0.2 1.0 
rs4819130 21 SLC19A1 1384 0.45 0.2 0.2 1.0 
rs2838964 21 SLC19A1 1388 0.07 1.0 0.2 1.0 
rs7215833 17 PEMT 1388 0.35 0.5 0.2 1.0 
rs7951180 11 FOLH1 1369 0.17 0.4 0.2 1.0 
rs4646341 17 PEMT 1385 0.36 0.5 0.2 1.0 
rs8074074 17 PEMT 1386 0.29 0.8 0.2 1.0 
rs1802059 5 MTRR 1387 0.37 0.4 0.2 1.0 
rs3177999 21 SLC19A1 1380 0.45 0.2 0.2 1.0 
rs12614943 2 ATIC 1388 0.28 1.0 0.2 1.0 
rs10498036 2 ATIC 1388 0.40 0.4 0.2 1.0 
rs7934591 11 FOLH1 1388 0.08 0.8 0.2 1.0 
rs9897362 17 PEMT 1388 0.06 0.3 0.2 1.0 
rs10400277 11 FOLH1 1368 0.13 0.6 0.2 1.0 
rs2330183 21 SLC19A1 1358 0.44 0.05 0.2 1.0 
rs10197559 2 ATIC 1380 0.29 0.9 0.2 1.0 
rs914238 21 SLC19A1 1388 0.49 0.4 0.2 1.0 
rs7220132 17 PEMT 1388 0.29 0.7 0.2 1.0 
rs9282690 3 ALDH1L1 1388 0.07 0.8 0.2 1.0 
rs3783 17 SHMT1 1398 0.26 0.6 0.2 1.0 
rs11040390 11 FOLH1 1388 0.08 1.0 0.2 1.0 
NA 1 MTR_01_OR 1389 0.16 0.7 0.2 1.0 
rs2838961 21 SLC19A1 1388 0.34 1.0 0.2 1.0 
rs9835128 3 CHDH 1387 0.17 0.4 0.2 1.0 
rs12222221 11 FOLH1 1388 0.08 1.0 0.2 1.0 
rs4646385 17 PEMT 1388 0.43 0.5 0.2 1.0 
rs17279286 15 MTHFS 1387 0.05 0.7 0.2 1.0 
rs7117247 11 FOLH1 1388 0.07 0.1 0.2 1.0 
rs17745484 2 DNMT3A 1387 0.35 0.8 0.2 1.0 
rs7604984 2 ATIC 1388 0.40 0.4 0.2 1.0 
rs7560488 2 DNMT3A 1333 0.47 0.2 0.2 1.0 
rs4479310 17 PEMT 1388 0.29 0.6 0.3 1.0 
rs1256107 14 MTHFD1 1387 0.48 0.7 0.3 1.0 
rs1051298 21 SLC19A1 1387 0.46 0.3 0.3 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs10179873 2 ATIC 1388 0.30 0.4 0.3 1.0 
rs4646359 17 PEMT 1388 0.45 0.3 0.3 1.0 
rs7177659 15 MTHFS 1387 0.50 0.08 0.3 1.0 
rs1950902 14 MTHFD1 1388 0.14 0.4 0.3 1.0 
rs12416687 10 AS3MT 1388 0.28 0.06 0.3 1.0 
rs7113075 11 FOLH1 1387 0.08 0.8 0.3 1.0 
rs1256095 14 MTHFD1 1377 0.48 0.8 0.3 1.0 
rs740234 22 TCN2 1388 0.23 0.8 0.3 1.0 
rs16999714 19 DNMT1 1386 0.21 0.1 0.3 1.0 
rs3740392 10 AS3MT 1385 0.29 0.1 0.3 1.0 
rs6711622 2 DNMT3A 1388 0.44 1.0 0.3 1.0 
rs4673965 2 ATIC 1388 0.40 1.0 0.3 1.0 
rs3785499 17 PEMT 1388 0.47 0.8 0.3 1.0 
rs12591436 15 MTHFS 1388 0.35 0.6 0.3 1.0 
rs10380 5 MTRR 1388 0.10 0.4 0.3 1.0 
rs2834235 21 GART 1388 0.38 0.7 0.3 1.0 
rs11892429 2 ATIC 1388 0.29 0.7 0.3 1.0 
rs2066470 1 MTHFR 1384 0.09 0.2 0.3 1.0 
rs11040353 11 FOLH1 1387 0.08 0.8 0.3 1.0 
rs4804122 19 DNMT1 1388 0.40 0.4 0.3 1.0 
rs435689 15 MTHFS 1388 0.49 0.9 0.3 1.0 
rs7946 17 PEMT 1387 0.29 0.4 0.3 1.0 
rs600671 15 MTHFS 1387 0.46 0.1 0.3 1.0 
rs9332 5 MTRR 1388 0.12 0.2 0.3 1.0 
rs12613 21 CBS 1388 0.08 1.0 0.3 1.0 
rs7217764 17 PEMT 1388 0.05 1.0 0.3 1.0 
rs898436 15 MTHFS 1384 0.46 0.1 0.3 1.0 
rs1081231 15 MTHFS 1387 0.18 0.8 0.3 1.0 
rs4646350 17 PEMT 1388 0.36 0.6 0.3 1.0 
rs4779140 15 MTHFS 1387 0.48 0.6 0.3 1.0 
rs17291414 19 DNMT1 1388 0.27 0.5 0.3 1.0 
rs1667627 14 MTHFD2 1387 0.46 0.2 0.3 1.0 
rs770144 15 MTHFS 1388 0.20 0.3 0.3 1.0 
rs10501325 11 FOLH1 1388 0.07 0.1 0.3 1.0 
rs35020344 14 MTHFD1 1387 0.47 0.7 0.3 1.0 
rs4646340 17 PEMT 1388 0.36 0.5 0.3 1.0 
rs515064 1 CTH 1388 0.36 0.8 0.3 1.0 
rs2372535 2 ATIC 1388 0.15 1.0 0.3 1.0 
rs282778 15 MTHFS 1388 0.27 0.8 0.3 1.0 
rs1983462 2 ATIC 1388 0.30 0.3 0.3 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs7177027 15 MTHFS 1388 0.24 0.08 0.3 1.0 
rs3760188 17 PEMT 1388 0.46 0.6 0.3 1.0 
rs10165919 2 ATIC 1387 0.35 0.6 0.3 1.0 
rs2838965 21 SLC19A1 1384 0.42 0.05 0.3 1.0 
rs4646344 17 PEMT 1388 0.47 0.7 0.3 1.0 
rs12905663 15 MTHFS 1381 0.27 0.2 0.3 1.0 
rs2154583 21 GART 1384 0.39 0.7 0.3 1.0 
rs853858 20 DNMT3B 1386 0.37 0.2 0.3 1.0 
rs6517178 21 GART 1388 0.39 0.7 0.3 1.0 
rs8101626 19 DNMT1 1388 0.39 0.7 0.3 1.0 
rs2124344 17 PEMT 1387 0.36 0.7 0.3 1.0 
rs1956545 14 MTHFD1 1387 0.08 0.5 0.3 1.0 
rs3755817 3 CHDH 1387 0.30 0.5 0.3 1.0 
rs2275565 1 MTR 1388 0.20 0.6 0.3 1.0 
rs944422 21 SLC19A1 1384 0.35 0.9 0.3 1.0 
rs12999687 2 DNMT3A 1386 0.45 0.8 0.3 1.0 
rs12482346 21 SLC19A1 1388 0.47 0.1 0.3 1.0 
rs4820887 22 TCN2 1388 0.09 0.6 0.3 1.0 
rs3862342 11 FOLH1 1386 0.28 0.8 0.4 1.0 
rs8128676 21 SLC19A1 1350 0.22 1.0 0.4 1.0 
rs1460177 15 MTHFS 1388 0.09 0.4 0.4 1.0 
rs7759302 6 GNMT 1388 0.06 1.0 0.4 1.0 
rs3788190 21 SLC19A1 1387 0.47 0.1 0.4 1.0 
rs2424932 20 DNMT3B 1387 0.43 0.5 0.4 1.0 
rs1979276 17 SHMT1 1395 0.30 1.0 0.4 1.0 
NA 1 MTR_01_2_i 1388 0.17 0.7 0.4 1.0 
rs7575625 2 DNMT3A 1388 0.47 0.9 0.4 1.0 
rs1256142 14 MTHFD1 1388 0.44 0.07 0.4 1.0 
rs1805087 1 MTR 1388 0.17 0.7 0.4 1.0 
rs2236225 14 MTHFD1 1387 0.43 0.2 0.4 1.0 
rs11687225 2 ATIC 1387 0.40 0.9 0.4 1.0 
rs663465 1 CTH 1387 0.41 0.4 0.4 1.0 
rs7604425 2 ATIC 1388 0.35 0.7 0.4 1.0 
rs8034036 15 MTHFS 1386 0.11 0.09 0.4 1.0 
rs2289195 2 DNMT3A 1387 0.44 0.2 0.4 1.0 
rs202718 11 FOLH1 1388 0.15 0.9 0.4 1.0 
rs16971253 15 MTHFS 1387 0.10 1.0 0.4 1.0 
rs8015278 14 MTHFD1 1388 0.07 0.8 0.4 1.0 
rs8129350 21 SLC19A1 1387 0.35 0.9 0.4 1.0 
rs9621049 22 TCN2 1388 0.10 0.8 0.4 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1888533 21 SLC19A1 1388 0.48 0.3 0.4 1.0 
rs10460566 2 DNMT3A 1388 0.27 0.3 0.4 1.0 
rs11677670 2 DNMT3A 1382 0.17 0.5 0.4 1.0 
rs1074390 15 MTHFS 1388 0.37 0.6 0.4 1.0 
rs6495441 15 MTHFS 1388 0.24 0.3 0.4 1.0 
rs202712 11 FOLH1 1387 0.23 0.7 0.4 1.0 
rs6713377 2 DNMT3A 1387 0.47 0.9 0.4 1.0 
rs3740394 10 AS3MT 1387 0.12 0.3 0.4 1.0 
rs2289093 2 DNMT3A 1388 0.28 0.2 0.4 1.0 
rs7253062 19 DNMT1 1388 0.39 0.7 0.4 1.0 
rs10932605 2 ATIC 1388 0.14 0.3 0.4 1.0 
rs4531931 2 ATIC 1387 0.31 0.5 0.4 1.0 
rs16971249 15 MTHFS 1388 0.07 0.08 0.4 1.0 
rs1109859 17 PEMT 1367 0.18 0.8 0.4 1.0 
rs1979277 17 SHMT1 1398 0.27 0.8 0.4 1.0 
rs10509760 10 AS3MT 1388 0.12 0.3 0.4 1.0 
rs1888530 21 SLC19A1 1358 0.47 0.07 0.4 1.0 
rs9001 3 CHDH 1385 0.10 0.3 0.4 1.0 
rs4532960 10 AS3MT 1387 0.44 0.3 0.4 1.0 
rs11656215 17 PEMT 1388 0.45 0.4 0.4 1.0 
rs3893350 15 MTHFS 1388 0.13 0.1 0.4 1.0 
rs734693 2 DNMT3A 1387 0.29 0.2 0.4 1.0 
rs4924922 17 PEMT 1388 0.36 0.3 0.4 1.0 
rs8923 15 MTHFS 1388 0.08 0.1 0.4 1.0 
rs10748835 10 AS3MT 1388 0.44 0.3 0.4 1.0 
rs4244599 17 PEMT 1371 0.46 0.4 0.4 1.0 
rs12373907 21 SLC19A1 1387 0.38 0.4 0.5 1.0 
rs617219 5 BHMT 1387 0.32 0.7 0.5 1.0 
rs11683424 2 DNMT3A 1388 0.12 0.5 0.5 1.0 
rs4817580 21 GART 1387 0.10 0.5 0.5 1.0 
rs11681447 2 DNMT3A 1386 0.28 0.2 0.5 1.0 
rs749130 2 DNMT3A 1388 0.44 0.6 0.5 1.0 
rs8081810 17 PEMT 1387 0.21 0.9 0.5 1.0 
rs8074191 17 PEMT 1372 0.28 0.9 0.5 1.0 
rs2288350 19 DNMT1 1387 0.08 0.6 0.5 1.0 
rs2288349 19 DNMT1 1387 0.39 0.5 0.5 1.0 
rs10519256 15 MTHFS 1388 0.11 0.1 0.5 1.0 
rs10839239 11 FOLH1 1386 0.23 0.6 0.5 1.0 
rs12797843 11 FOLH1 1388 0.13 0.6 0.5 1.0 
rs1880580 15 MTHFS 1388 0.30 0.09 0.5 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs34048824 2 DNMT3A 1387 0.50 1.0 0.5 1.0 
rs750546 17 PEMT 1373 0.43 0.5 0.5 1.0 
rs12987326 2 DNMT3A 1388 0.37 0.7 0.5 1.0 
rs11191439 10 AS3MT 1387 0.12 0.2 0.5 1.0 
rs4902278 14 MTHFD1 1383 0.07 0.6 0.5 1.0 
rs567754 5 BHMT 1387 0.29 0.9 0.5 1.0 
rs1076991 14 MTHFD1 1388 0.45 1.0 0.5 1.0 
NA 1 MTHFR_02_OR 1285 0.39 0.4 0.5 1.0 
rs8068641 17 PEMT 1382 0.11 0.4 0.5 1.0 
rs4369857 2 ATIC 1388 0.05 0.7 0.5 1.0 
rs7563206 2 ATIC 1387 0.47 0.6 0.5 1.0 
rs282814 15 MTHFS 1388 0.21 0.8 0.5 1.0 
rs8111085 19 DNMT1 1387 0.08 0.6 0.5 1.0 
rs1256114 14 MTHFD1 1387 0.11 0.7 0.5 1.0 
rs11158538 14 MTHFD1 1385 0.45 0.9 0.5 1.0 
rs3800292 6 GNMT 1388 0.06 0.8 0.5 1.0 
rs8019804 14 MTHFD1 1388 0.07 1.0 0.5 1.0 
rs3893384 15 MTHFS 1388 0.42 0.5 0.5 1.0 
rs1051296 21 SLC19A1 1375 0.47 0.1 0.5 1.0 
rs6750194 2 ATIC 1375 0.08 0.4 0.5 1.0 
rs660439 11 FOLH1 1384 0.23 0.7 0.5 1.0 
rs897453 17 PEMT 1384 0.49 0.6 0.5 1.0 
rs17209637 15 MTHFS 1384 0.25 1.0 0.5 1.0 
rs11672909 19 DNMT1 1387 0.08 0.6 0.5 1.0 
rs11892646 2 DNMT3A 1387 0.12 0.6 0.5 1.0 
rs12148881 15 MTHFS 1387 0.27 0.2 0.5 1.0 
rs1465825 2 DNMT3A 1387 0.27 0.3 0.5 1.0 
rs9977111 21 SLC19A1 1355 0.33 0.07 0.5 1.0 
rs699517 18 TYMS 1387 0.31 0.6 0.5 1.0 
rs7144437 14 MTHFD1 1387 0.07 0.6 0.5 1.0 
rs1077965 15 MTHFS 1387 0.41 0.4 0.5 1.0 
rs4779141 15 MTHFS 1386 0.34 0.8 0.6 1.0 
rs6518253 21 SLC19A1 1387 0.46 0.3 0.6 1.0 
rs1256112 14 MTHFD1 1388 0.40 0.4 0.6 1.0 
rs378057 15 MTHFS 1387 0.14 1.0 0.6 1.0 
rs4925048 17 PEMT 1386 0.09 0.1 0.6 1.0 
rs12910340 15 MTHFS 1388 0.42 1.0 0.6 1.0 
rs10418707 19 DNMT1 1387 0.08 0.6 0.6 1.0 
rs2586153 15 MTHFS 1374 0.15 0.4 0.6 1.0 
rs17556442 11 FOLH1 1384 0.06 0.05 0.6 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1059394 18 TYMS 1387 0.31 0.6 0.6 1.0 
rs17211644 15 MTHFS 1388 0.10 0.7 0.6 1.0 
rs8128050 21 SLC19A1 1385 0.35 0.9 0.6 1.0 
rs4804494 19 DNMT1 1387 0.08 0.6 0.6 1.0 
rs2115536 15 MTHFS 1388 0.50 0.05 0.6 1.0 
rs10498034 2 ATIC 1388 0.17 1.0 0.6 1.0 
rs4804490 19 DNMT1 1386 0.08 0.6 0.6 1.0 
rs1055345 21 SLC19A1 1387 0.29 0.3 0.6 1.0 
rs8971 21 GART 1386 0.26 0.8 0.6 1.0 
rs5749131 22 TCN2 1388 0.43 0.2 0.6 1.0 
rs12899781 15 MTHFS 1383 0.17 0.06 0.6 1.0 
rs2790 18 TYMS 1384 0.20 0.7 0.6 1.0 
rs1020697 17 PEMT 1361 0.10 0.3 0.6 1.0 
rs2983733 14 MTHFD1 1388 0.45 0.9 0.6 1.0 
rs1650697 5 DHFR 1385 0.23 0.1 0.6 1.0 
rs2115540 15 MTHFS 1387 0.50 0.05 0.6 1.0 
rs8041943 15 MTHFS 1385 0.42 0.6 0.6 1.0 
rs1464864 2 ATIC 1388 0.30 0.8 0.6 1.0 
rs282795 15 MTHFS 1387 0.32 0.7 0.6 1.0 
rs2987981 14 MTHFD1 1388 0.25 0.9 0.6 1.0 
rs7594432 2 DNMT3A 1388 0.45 0.3 0.6 1.0 
rs17824591 14 MTHFD1 1386 0.23 0.2 0.6 1.0 
rs282776 15 MTHFS 1388 0.36 1.0 0.6 1.0 
rs6760069 2 ATIC 1387 0.14 0.5 0.6 1.0 
rs2983736 14 MTHFD1 1385 0.45 0.9 0.6 1.0 
rs17285431 15 MTHFS 1388 0.17 0.1 0.6 1.0 
rs437302 20 DNMT3B 1388 0.09 1.0 0.6 1.0 
rs2834231 21 GART 1388 0.26 0.7 0.6 1.0 
rs11158540 14 MTHFD1 1388 0.34 0.9 0.6 1.0 
rs2116940 19 DNMT1 1387 0.08 0.6 0.6 1.0 
rs4610054 2 ATIC 1383 0.38 1.0 0.6 1.0 
rs2834232 21 GART 1387 0.26 0.7 0.6 1.0 
rs4804125 19 DNMT1 1387 0.08 0.6 0.6 1.0 
rs7174668 15 MTHFS 1388 0.20 0.2 0.6 1.0 
rs11658944 17 PEMT 1387 0.05 0.7 0.6 1.0 
rs2733106 15 MTHFS 1383 0.15 0.5 0.6 1.0 
rs2586154 15 MTHFS 1388 0.15 0.5 0.6 1.0 
rs166868 15 MTHFS 1387 0.36 1.0 0.7 1.0 
rs6511677 19 DNMT1 1387 0.39 0.6 0.7 1.0 
rs7581217 2 DNMT3A 1388 0.39 0.2 0.7 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11869600 17 PEMT 1386 0.38 0.3 0.7 1.0 
rs9305012 19 DNMT1 1387 0.08 0.6 0.7 1.0 
rs12121543 1 MTHFR 1388 0.22 0.9 0.7 1.0 
rs1917321 11 FOLH1 1380 0.50 0.2 0.7 1.0 
rs2424908 20 DNMT3B 1388 0.17 0.7 0.7 1.0 
rs11855092 15 MTHFS 1388 0.23 0.1 0.7 1.0 
rs4393531 15 MTHFS 1386 0.48 0.4 0.7 1.0 
rs12627639 21 SLC19A1 1387 0.21 0.5 0.7 1.0 
rs2409495 21 GART 1388 0.19 0.05 0.7 1.0 
rs12462004 19 DNMT1 1386 0.08 0.6 0.7 1.0 
rs11040416 11 FOLH1 1388 0.42 0.4 0.7 1.0 
rs2289209 3 CHDH 1388 0.05 1.0 0.7 1.0 
rs685487 15 MTHFS 1388 0.37 0.1 0.7 1.0 
rs17728676 11 FOLH1 1387 0.07 0.1 0.7 1.0 
rs2162560 19 DNMT1 1387 0.39 0.6 0.7 1.0 
rs8112895 19 DNMT1 1388 0.08 0.6 0.7 1.0 
rs6801605 3 CHDH 1388 0.38 0.6 0.7 1.0 
rs2586182 15 MTHFS 1388 0.15 0.4 0.7 1.0 
rs4646404 17 PEMT 1383 0.36 0.3 0.7 1.0 
rs11694842 2 DNMT3A 1387 0.28 0.4 0.7 1.0 
rs17284990 15 MTHFS 1388 0.22 0.5 0.7 1.0 
rs204942 15 MTHFS 1388 0.20 0.1 0.7 1.0 
rs1880586 2 ATIC 1387 0.47 0.6 0.7 1.0 
rs234706 21 CBS 1388 0.32 0.1 0.7 1.0 
rs1917311 11 FOLH1 1353 0.40 0.4 0.7 1.0 
rs1369703 2 DNMT3A 1388 0.45 0.2 0.7 1.0 
rs1081235 15 MTHFS 1388 0.19 0.3 0.7 1.0 
rs2267163 22 TCN2 1386 0.43 0.2 0.7 1.0 
rs1404774 2 ATIC 1380 0.21 0.4 0.7 1.0 
rs8128681 21 SLC19A1 1388 0.32 0.9 0.7 1.0 
rs8011839 14 MTHFD1 1388 0.18 0.4 0.7 1.0 
rs1801133 1 MTHFR 1388 0.40 0.5 0.7 1.0 
NA 1 MTHFR_02_2_i 1388 0.40 0.5 0.7 1.0 
rs1801198 22 TCN2 1387 0.43 0.3 0.7 1.0 
rs282772 15 MTHFS 1388 0.13 0.3 0.8 1.0 
rs9789571 2 ATIC 1388 0.42 1.0 0.8 1.0 
rs2275566 1 MTR 1388 0.42 0.1 0.8 1.0 
rs588458 11 FOLH1 1367 0.38 0.3 0.8 1.0 
rs1814175 11 FOLH1 1384 0.39 0.4 0.8 1.0 
rs16853834 2 ATIC 1388 0.16 1.0 0.8 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs6485991 11 FOLH1 1382 0.16 0.6 0.8 1.0 
rs7111215 11 FOLH1 1368 0.40 0.2 0.8 1.0 
rs3774616 3 CHDH 1388 0.05 1.0 0.8 1.0 
rs3862350 11 FOLH1 1360 0.39 0.2 0.8 1.0 
rs2733103 15 MTHFS 1387 0.15 0.2 0.8 1.0 
rs12898670 15 MTHFS 1387 0.32 0.9 0.8 1.0 
rs4434082 21 SLC19A1 1387 0.21 0.9 0.8 1.0 
rs11085720 19 DNMT1 1388 0.42 0.5 0.8 1.0 
rs202700 11 FOLH1 1337 0.23 0.8 0.8 1.0 
rs445263 15 MTHFS 1388 0.30 0.9 0.8 1.0 
rs2838969 21 SLC19A1 1388 0.07 1.0 0.8 1.0 
rs748196 17 PEMT 1385 0.42 0.9 0.8 1.0 
rs12453139 17 PEMT 1386 0.26 0.9 0.8 1.0 
rs3818239 14 MTHFD1 1380 0.13 0.9 0.8 1.0 
rs9976878 21 SLC19A1 1387 0.21 0.8 0.8 1.0 
rs6586282 21 CBS 1387 0.17 0.2 0.8 1.0 
rs4819138 21 SLC19A1 1388 0.39 0.8 0.8 1.0 
rs2838973 21 SLC19A1 1388 0.21 1.0 0.8 1.0 
rs10839295 11 FOLH1 1387 0.39 0.5 0.8 1.0 
rs2290684 19 DNMT1 1388 0.47 0.8 0.8 1.0 
rs4672768 2 ATIC 1385 0.31 0.9 0.8 1.0 
rs9306139 21 SLC19A1 1386 0.21 0.8 0.8 1.0 
rs4144700 11 FOLH1 1388 0.38 0.3 0.8 1.0 
rs12797853 11 FOLH1 1385 0.13 0.7 0.8 1.0 
rs8003567 14 MTHFD1 1388 0.10 0.8 0.8 1.0 
rs11887120 2 DNMT3A 1388 0.42 0.5 0.8 1.0 
rs11627525 14 MTHFD1 1388 0.10 0.3 0.8 1.0 
rs2838970 21 SLC19A1 1387 0.39 0.9 0.8 1.0 
rs4673991 2 ATIC 1387 0.31 0.9 0.8 1.0 
rs4646383 17 PEMT 1387 0.09 0.5 0.8 1.0 
rs1801131 1 MTHFR 1322 0.28 0.9 0.8 1.0 
rs2183601 21 SLC19A1 1388 0.21 1.0 0.8 1.0 
rs10420338 19 DNMT1 1388 0.47 0.6 0.8 1.0 
rs4673993 2 ATIC 1388 0.31 0.9 0.8 1.0 
rs7279305 21 SLC19A1 1388 0.35 1.0 0.8 1.0 
rs9621047 22 TCN2 1388 0.44 0.2 0.8 1.0 
rs11701960 21 SLC19A1 1387 0.17 1.0 0.8 1.0 
rs1164685 11 FOLH1 1385 0.38 0.3 0.8 1.0 
rs443394 15 MTHFS 1388 0.41 0.3 0.9 1.0 
rs4476347 2 ATIC 1387 0.25 0.4 0.9 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs2150460 21 SLC19A1 1388 0.21 0.9 0.9 1.0 
rs2866358 11 FOLH1 1372 0.38 0.2 0.9 1.0 
rs6445606 3 CHDH 1388 0.29 0.2 0.9 1.0 
rs4987173 6 GNMT 1388 0.51 0.8 0.9 1.0 
rs4778721 15 MTHFS 1388 0.23 0.2 0.9 1.0 
rs2877078 21 SLC19A1 1376 0.39 0.7 0.9 1.0 
rs4778719 15 MTHFS 1388 0.23 0.2 0.9 1.0 
rs16971252 15 MTHFS 1388 0.06 0.3 0.9 1.0 
rs7219568 17 PEMT 1388 0.05 1.0 0.9 1.0 
rs582172 15 MTHFS 1388 0.41 0.6 0.9 1.0 
rs13002567 2 DNMT3A 1388 0.28 0.5 0.9 1.0 
rs9462856 6 GNMT 1388 0.41 0.9 0.9 1.0 
rs1473406 15 MTHFS 1386 0.15 0.9 0.9 1.0 
rs2838977 21 SLC19A1 1386 0.39 0.9 0.9 1.0 
rs1809986 11 FOLH1 1388 0.37 1.0 0.9 1.0 
rs2228611 19 DNMT1 1388 0.47 0.8 0.9 1.0 
rs7120743 11 FOLH1 1371 0.37 0.8 0.9 1.0 
rs731991 22 TCN2 1343 0.48 0.1 0.9 1.0 
rs8003379 14 MTHFD1 1387 0.24 0.4 0.9 1.0 
rs4820888 22 TCN2 1387 0.47 0.1 0.9 1.0 
rs376863 15 MTHFS 1366 0.50 0.9 0.9 1.0 
rs1023159 21 SLC19A1 1386 0.42 0.4 0.9 1.0 
rs7586294 2 DNMT3A 1387 0.47 0.5 0.9 1.0 
rs4779148 15 MTHFS 1388 0.11 0.2 0.9 1.0 
rs2241807 3 CHDH 1388 0.43 0.7 0.9 1.0 
rs13427202 2 DNMT3A 1387 0.47 0.6 0.9 1.0 
rs8129445 21 SLC19A1 1388 0.32 0.9 0.9 1.0 
rs1801394 5 MTRR 1398 0.49 0.8 0.9 1.0 
rs6722613 2 DNMT3A 1388 0.40 1.0 0.9 1.0 
rs1127717 3 ALDH1L1 1388 0.24 0.6 1.0 1.0 
rs2236222 14 MTHFD1 1388 0.10 0.5 1.0 1.0 
rs759920 19 DNMT1 1388 0.47 0.7 1.0 1.0 
rs5753231 22 TCN2 1387 0.16 0.8 1.0 1.0 
rs767138 21 SLC19A1 1385 0.40 0.6 1.0 1.0 
rs1604503 15 MTHFS 1388 0.14 0.4 1.0 1.0 
rs3783728 14 MTHFD1 1388 0.08 1.0 1.0 1.0 
rs4673981 2 ATIC 1388 0.39 0.8 1.0 1.0 
rs1808119 2 ATIC 1388 0.20 1.0 1.0 1.0 
rs11871738 17 PEMT 1388 0.38 0.4 1.0 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=495) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs12997662 2 ATIC 1387 0.33 0.7 1.0 1.0 
rs13036246 2 DNMT3A 1387 0.49 0.4 1.0 1.0 
rs6058894 20 DNMT3B 1387 0.08 0.5 1.0 1.0 
rs6058896 20 DNMT3B 1388 0.08 0.8 1.0 1.0 
rs16971231 15 MTHFS 1385 0.05 0.08 1.0 1.0 
rs11040106 11 FOLH1 1379 0.36 0.6 1.0 1.0 
rs9836592 3 CHDH 1388 0.31 0.3 1.0 1.0 
rs8018032 14 MTHFD1 1388 0.45 0.7 1.0 1.0 
rs7276295 21 SLC19A1 1388 0.06 0.3 1.0 1.0 
rs17279753 15 MTHFS 1388 0.20 0.5 1.0 1.0 
rs7085104 10 AS3MT 1388 0.39 1.0 1.0 1.0 
rs2301955 22 TCN2 1386 0.43 0.3 1.0 1.0 
rs2987969 14 MTHFD1 1387 0.45 0.7 1.0 1.0 
rs17751556 14 MTHFD1 1388 0.08 1.0 1.0 1.0 
rs1550117 2 DNMT3A 1387 0.08 1.0 1.0 1.0 
rs17279885 15 MTHFS 1388 0.21 0.7 1.0 1.0 
rs5749135 22 TCN2 1388 0.43 0.3 1.0 1.0 
rs11629135 14 MTHFD1 1388 0.10 0.7 1.0 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
SNPs modeled in recessive mode of inheritance 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1256142 14 MTHFD1 1388 0.44 0.07 0.0004 0.1 
rs7124266 11 FOLH1 1388 0.30 0.6 0.003 0.5 
rs2834235 21 GART 1388 0.38 0.7 0.003 0.5 
rs2236224 14 MTHFD1 1388 0.36 0.1 0.005 0.7 
rs2236225 14 MTHFD1 1387 0.43 0.2 0.006 0.8 
rs3862342 11 FOLH1 1386 0.28 0.8 0.007 0.8 
rs2838965 21 SLC19A1 1384 0.42 0.05 0.008 0.8 
rs8041943 15 MTHFS 1385 0.42 0.6 0.009 0.9 
rs2154583 21 GART 1384 0.39 0.7 0.01 0.9 
rs6517178 21 GART 1388 0.39 0.7 0.01 0.9 
rs3893384 15 MTHFS 1388 0.42 0.5 0.02 1.0 
rs6495441 15 MTHFS 1388 0.24 0.3 0.03 1.0 
rs1880580 15 MTHFS 1388 0.30 0.09 0.03 1.0 
rs4779140 15 MTHFS 1387 0.48 0.6 0.03 1.0 
rs1081235 15 MTHFS 1388 0.19 0.3 0.04 1.0 
rs7563206 2 ATIC 1387 0.47 0.6 0.04 1.0 
rs12910340 15 MTHFS 1388 0.42 1.0 0.04 1.0 
rs1880586 2 ATIC 1387 0.47 0.6 0.04 1.0 
rs2424932 20 DNMT3B 1387 0.43 0.5 0.04 1.0 
rs10839296 11 FOLH1 1371 0.25 0.8 0.04 1.0 
rs7107178 11 FOLH1 1387 0.25 1.0 0.04 1.0 
rs663649 1 CTH 1388 0.31 0.9 0.05 1.0 
rs4646404 17 PEMT 1383 0.36 0.3 0.05 1.0 
rs7560488 2 DNMT3A 1333 0.47 0.2 0.05 1.0 
rs4817579 21 GART 1388 0.35 1.0 0.05 1.0 
rs473334 1 CTH 1388 0.31 0.9 0.05 1.0 
rs7111711 11 FOLH1 1388 0.25 0.9 0.05 1.0 
rs4817577 21 GART 1388 0.34 0.9 0.06 1.0 
rs7283354 21 GART 1388 0.34 0.9 0.07 1.0 
rs7111215 11 FOLH1 1368 0.40 0.2 0.08 1.0 
rs1801131 1 MTHFR 1322 0.28 0.9 0.08 1.0 
rs3821353 2 ATIC 1388 0.21 0.4 0.08 1.0 
rs4911263 20 DNMT3B 1388 0.32 1.0 0.08 1.0 
rs1917311 11 FOLH1 1353 0.40 0.4 0.08 1.0 
rs9332 5 MTRR 1388 0.12 0.2 0.09 1.0 
rs663465 1 CTH 1387 0.41 0.4 0.09 1.0 
rs1164685 11 FOLH1 1385 0.38 0.3 0.1 1.0 
rs16853782 2 ATIC 1388 0.21 0.7 0.1 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs1074390 15 MTHFS 1388 0.37 0.6 0.1 1.0 
rs2733103 15 MTHFS 1387 0.15 0.2 0.1 1.0 
rs4987173 6 GNMT 1388 0.51 0.8 0.1 1.0 
rs2586154 15 MTHFS 1388 0.15 0.5 0.1 1.0 
rs12903985 15 MTHFS 1388 0.28 0.4 0.1 1.0 
rs6058869 20 DNMT3B 1388 0.33 0.7 0.1 1.0 
rs7220132 17 PEMT 1388 0.29 0.7 0.1 1.0 
rs2183601 21 SLC19A1 1388 0.21 1.0 0.1 1.0 
rs2150460 21 SLC19A1 1388 0.21 0.9 0.1 1.0 
rs9976878 21 SLC19A1 1387 0.21 0.8 0.1 1.0 
rs9306139 21 SLC19A1 1386 0.21 0.8 0.1 1.0 
rs11191457 10 AS3MT 1385 0.23 0.4 0.1 1.0 
rs7085854 10 AS3MT 1387 0.23 0.6 0.1 1.0 
rs4479310 17 PEMT 1388 0.29 0.6 0.1 1.0 
rs7587636 2 DNMT3A 1388 0.45 0.1 0.1 1.0 
rs11085720 19 DNMT1 1388 0.42 0.5 0.1 1.0 
rs10420338 19 DNMT1 1388 0.47 0.6 0.1 1.0 
rs2586182 15 MTHFS 1388 0.15 0.4 0.1 1.0 
rs759920 19 DNMT1 1388 0.47 0.7 0.1 1.0 
rs2838973 21 SLC19A1 1388 0.21 1.0 0.1 1.0 
rs585800 5 BHMT 1388 0.26 0.05 0.1 1.0 
rs4434082 21 SLC19A1 1387 0.21 0.9 0.1 1.0 
rs4441015 11 FOLH1 1353 0.15 0.5 0.1 1.0 
rs588458 11 FOLH1 1367 0.38 0.3 0.1 1.0 
rs16999714 19 DNMT1 1386 0.21 0.1 0.1 1.0 
rs2290684 19 DNMT1 1388 0.47 0.8 0.1 1.0 
rs4144700 11 FOLH1 1388 0.38 0.3 0.1 1.0 
rs7946 17 PEMT 1387 0.29 0.4 0.1 1.0 
rs865646 5 DHFR 1340 0.34 0.4 0.1 1.0 
rs7174668 15 MTHFS 1388 0.20 0.2 0.1 1.0 
rs13401241 2 DNMT3A 1388 0.45 0.1 0.2 1.0 
rs2228611 19 DNMT1 1388 0.47 0.8 0.2 1.0 
rs2115536 15 MTHFS 1388 0.50 0.05 0.2 1.0 
rs282792 15 MTHFS 1388 0.39 0.6 0.2 1.0 
rs2865908 11 FOLH1 1388 0.19 0.9 0.2 1.0 
rs2866358 11 FOLH1 1372 0.38 0.2 0.2 1.0 
rs3772078 2 ATIC 1388 0.21 0.6 0.2 1.0 
rs282795 15 MTHFS 1387 0.32 0.7 0.2 1.0 
rs10418 22 TCN2 1367 0.21 0.7 0.2 1.0 
rs8074074 17 PEMT 1386 0.29 0.8 0.2 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11040421 11 FOLH1 1388 0.15 0.6 0.2 1.0 
rs3760188 17 PEMT 1388 0.46 0.6 0.2 1.0 
rs2409495 21 GART 1388 0.19 0.05 0.2 1.0 
rs8074191 17 PEMT 1372 0.28 0.9 0.2 1.0 
rs204942 15 MTHFS 1388 0.20 0.1 0.2 1.0 
NA 1 MTHFR_02_2_i 1388 0.40 0.5 0.2 1.0 
rs1127717 3 ALDH1L1 1388 0.24 0.6 0.2 1.0 
rs1801133 1 MTHFR 1388 0.40 0.5 0.2 1.0 
rs10519256 15 MTHFS 1388 0.11 0.1 0.2 1.0 
rs1888530 21 SLC19A1 1358 0.47 0.07 0.2 1.0 
rs4672768 2 ATIC 1385 0.31 0.9 0.2 1.0 
rs2115540 15 MTHFS 1387 0.50 0.05 0.2 1.0 
rs3755817 3 CHDH 1387 0.30 0.5 0.2 1.0 
rs6058893 20 DNMT3B 1388 0.33 0.2 0.2 1.0 
rs4646344 17 PEMT 1388 0.47 0.7 0.2 1.0 
rs2838958 21 SLC19A1 1385 0.45 0.7 0.2 1.0 
rs8659 5 MTRR 1386 0.35 0.3 0.2 1.0 
rs3785499 17 PEMT 1388 0.47 0.8 0.2 1.0 
rs9835128 3 CHDH 1387 0.17 0.4 0.2 1.0 
rs1847638 11 FOLH1 1335 0.21 1.0 0.2 1.0 
rs10769558 11 FOLH1 1388 0.21 0.5 0.2 1.0 
rs4094478 11 FOLH1 1365 0.20 0.7 0.2 1.0 
rs4673993 2 ATIC 1388 0.31 0.9 0.2 1.0 
rs11158540 14 MTHFD1 1388 0.34 0.9 0.2 1.0 
rs11677670 2 DNMT3A 1382 0.17 0.5 0.2 1.0 
rs10839210 11 FOLH1 1386 0.21 0.5 0.2 1.0 
rs6706415 2 ATIC 1388 0.30 0.4 0.2 1.0 
rs2733106 15 MTHFS 1383 0.15 0.5 0.2 1.0 
rs2586153 15 MTHFS 1374 0.15 0.4 0.2 1.0 
rs7581217 2 DNMT3A 1388 0.39 0.2 0.2 1.0 
rs2696935 11 FOLH1 1388 0.21 0.4 0.2 1.0 
rs2696923 11 FOLH1 1388 0.21 0.3 0.2 1.0 
rs4673991 2 ATIC 1387 0.31 0.9 0.2 1.0 
rs6722613 2 DNMT3A 1388 0.40 1.0 0.2 1.0 
rs11871738 17 PEMT 1388 0.38 0.4 0.3 1.0 
rs2267163 22 TCN2 1386 0.43 0.2 0.3 1.0 
rs1983462 2 ATIC 1388 0.30 0.3 0.3 1.0 
rs1801198 22 TCN2 1387 0.43 0.3 0.3 1.0 
rs12373907 21 SLC19A1 1387 0.38 0.4 0.3 1.0 
rs3783 17 SHMT1 1398 0.26 0.6 0.3 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs11869600 17 PEMT 1386 0.38 0.3 0.3 1.0 
rs2275566 1 MTR 1388 0.42 0.1 0.3 1.0 
rs282776 15 MTHFS 1388 0.36 1.0 0.3 1.0 
rs7951180 11 FOLH1 1369 0.17 0.4 0.3 1.0 
rs443394 15 MTHFS 1388 0.41 0.3 0.3 1.0 
rs12121543 1 MTHFR 1388 0.22 0.9 0.3 1.0 
rs1046778 10 AS3MT 1388 0.33 0.8 0.3 1.0 
rs3788190 21 SLC19A1 1387 0.47 0.1 0.3 1.0 
rs1051296 21 SLC19A1 1375 0.47 0.1 0.3 1.0 
rs10179873 2 ATIC 1388 0.30 0.4 0.3 1.0 
rs12997662 2 ATIC 1387 0.33 0.7 0.3 1.0 
rs648372 11 FOLH1 1370 0.17 0.5 0.3 1.0 
rs8011839 14 MTHFD1 1388 0.18 0.4 0.3 1.0 
rs11887120 2 DNMT3A 1388 0.42 0.5 0.3 1.0 
rs2424908 20 DNMT3B 1388 0.17 0.7 0.3 1.0 
rs34048824 2 DNMT3A 1387 0.50 1.0 0.3 1.0 
rs8971 21 GART 1386 0.26 0.8 0.3 1.0 
rs1051298 21 SLC19A1 1387 0.46 0.3 0.3 1.0 
rs4924922 17 PEMT 1388 0.36 0.3 0.3 1.0 
rs4911107 20 DNMT3B 1388 0.32 0.6 0.3 1.0 
rs770144 15 MTHFS 1388 0.20 0.3 0.3 1.0 
rs2834231 21 GART 1388 0.26 0.7 0.3 1.0 
rs1846285 11 FOLH1 1385 0.17 0.2 0.3 1.0 
rs2834232 21 GART 1387 0.26 0.7 0.3 1.0 
rs11683424 2 DNMT3A 1388 0.12 0.5 0.3 1.0 
rs12482346 21 SLC19A1 1388 0.47 0.1 0.3 1.0 
rs6485991 11 FOLH1 1382 0.16 0.6 0.3 1.0 
rs897453 17 PEMT 1384 0.49 0.6 0.3 1.0 
rs4779141 15 MTHFS 1386 0.34 0.8 0.4 1.0 
rs1805087 1 MTR 1388 0.17 0.7 0.4 1.0 
rs4646410 17 PEMT 1384 0.31 0.9 0.4 1.0 
rs515064 1 CTH 1388 0.36 0.8 0.4 1.0 
rs16853834 2 ATIC 1388 0.16 1.0 0.4 1.0 
rs685487 15 MTHFS 1388 0.37 0.09 0.4 1.0 
rs372447 15 MTHFS 1388 0.38 0.9 0.4 1.0 
rs7253062 19 DNMT1 1388 0.39 0.7 0.4 1.0 
rs1808119 2 ATIC 1388 0.20 1.0 0.4 1.0 
rs11040198 11 FOLH1 1381 0.21 0.2 0.4 1.0 
rs17285431 15 MTHFS 1388 0.17 0.1 0.4 1.0 
rs5749131 22 TCN2 1388 0.43 0.2 0.4 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs2838956 21 SLC19A1 1373 0.44 0.1 0.4 1.0 
rs679470 11 FOLH1 1387 0.17 0.6 0.4 1.0 
rs12148881 15 MTHFS 1387 0.27 0.2 0.4 1.0 
rs1979277 17 SHMT1_01_OR 1398 0.27 0.8 0.4 1.0 
NA 1 MTR 1389 0.16 0.7 0.4 1.0 
rs12438477 15 MTHFS 1387 0.36 0.4 0.4 1.0 
rs35020344 14 MTHFD1 1387 0.47 0.7 0.4 1.0 
rs1369703 2 DNMT3A 1388 0.45 0.2 0.4 1.0 
rs2983733 14 MTHFD1 1388 0.45 0.9 0.4 1.0 
rs17209637 15 MTHFS 1384 0.25 1.0 0.4 1.0 
rs282814 15 MTHFS 1388 0.21 0.8 0.4 1.0 
rs748196 17 PEMT 1385 0.42 0.9 0.4 1.0 
rs6141813 20 DNMT3B 1388 0.13 0.8 0.4 1.0 
rs2983736 14 MTHFD1 1385 0.45 0.9 0.4 1.0 
rs6087990 20 DNMT3B 1388 0.33 0.6 0.4 1.0 
rs4532960 10 AS3MT 1387 0.44 0.3 0.4 1.0 
rs2987969 14 MTHFD1 1387 0.45 0.7 0.4 1.0 
rs12899781 15 MTHFS 1383 0.17 0.1 0.4 1.0 
rs10748835 10 AS3MT 1388 0.44 0.3 0.4 1.0 
rs11892429 2 ATIC 1388 0.29 0.7 0.4 1.0 
rs445263 15 MTHFS 1388 0.30 0.9 0.4 1.0 
rs8018032 14 MTHFD1 1388 0.45 0.7 0.4 1.0 
rs11040416 11 FOLH1 1388 0.42 0.4 0.4 1.0 
rs6711622 2 DNMT3A 1388 0.44 1.0 0.5 1.0 
rs10460566 2 DNMT3A 1388 0.27 0.3 0.5 1.0 
rs1465825 2 DNMT3A 1387 0.27 0.3 0.5 1.0 
rs2987981 14 MTHFD1 1388 0.25 0.9 0.5 1.0 
rs4819128 21 SLC19A1 1388 0.44 0.2 0.5 1.0 
rs12416687 10 AS3MT 1388 0.28 0.06 0.5 1.0 
rs10498034 2 ATIC 1388 0.17 1.0 0.5 1.0 
rs9890064 17 PEMT 1388 0.43 0.4 0.5 1.0 
rs12627639 21 SLC19A1 1387 0.21 0.5 0.5 1.0 
rs1473406 15 MTHFS 1386 0.15 0.9 0.5 1.0 
rs8003379 14 MTHFD1 1387 0.24 0.4 0.5 1.0 
rs6760069 2 ATIC 1387 0.14 0.5 0.5 1.0 
rs12999687 2 DNMT3A 1386 0.45 0.8 0.5 1.0 
rs9323450 14 MTHFD1 1388 0.30 0.8 0.5 1.0 
rs4646359 17 PEMT 1388 0.45 0.3 0.5 1.0 
rs1076991 14 MTHFD1 1388 0.45 1.0 0.5 1.0 
rs1801394 5 MTRR 1398 0.49 0.8 0.5 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
NA 1 MTHFR_02_OR 1285 0.39 0.4 0.5 1.0 
rs10197559 2 ATIC 1380 0.29 0.9 0.5 1.0 
rs1809986 11 FOLH1 1388 0.37 1.0 0.5 1.0 
rs5753231 22 TCN2 1387 0.16 0.8 0.5 1.0 
rs376863 15 MTHFS 1366 0.50 0.9 0.5 1.0 
NA 1 MTR_01_2_i 1388 0.17 0.7 0.5 1.0 
rs4244599 17 PEMT 1371 0.46 0.4 0.5 1.0 
rs6713377 2 DNMT3A 1387 0.47 0.9 0.5 1.0 
rs6058883 20 DNMT3B 1387 0.39 0.3 0.5 1.0 
rs11158538 14 MTHFD1 1385 0.45 0.9 0.5 1.0 
rs1950902 14 MTHFD1 1388 0.14 0.4 0.5 1.0 
rs731991 22 TCN2 1343 0.48 0.1 0.5 1.0 
rs7575625 2 DNMT3A 1388 0.47 0.9 0.5 1.0 
rs1979276 17 SHMT1 1395 0.30 1.0 0.5 1.0 
rs6058891 20 DNMT3B 1386 0.39 0.2 0.5 1.0 
rs6445606 3 CHDH 1388 0.29 0.2 0.5 1.0 
rs435689 15 MTHFS 1388 0.49 0.9 0.5 1.0 
rs2424921 20 DNMT3B 1388 0.39 0.3 0.5 1.0 
rs9836592 3 CHDH 1388 0.31 0.3 0.5 1.0 
rs7120743 11 FOLH1 1371 0.37 0.8 0.5 1.0 
rs2424914 20 DNMT3B 1388 0.39 0.4 0.5 1.0 
rs2288349 19 DNMT1 1387 0.39 0.5 0.6 1.0 
rs11040106 11 FOLH1 1379 0.36 0.6 0.6 1.0 
rs8081810 17 PEMT 1387 0.21 0.9 0.6 1.0 
rs914238 21 SLC19A1 1388 0.49 0.4 0.6 1.0 
rs910085 20 DNMT3B 1387 0.29 0.5 0.6 1.0 
rs567754 5 BHMT 1387 0.29 0.9 0.6 1.0 
rs2162560 19 DNMT1 1387 0.39 0.6 0.6 1.0 
rs6511677 19 DNMT1 1387 0.39 0.6 0.6 1.0 
rs2289093 2 DNMT3A 1388 0.28 0.2 0.6 1.0 
rs1404774 2 ATIC 1380 0.21 0.4 0.6 1.0 
rs12987326 2 DNMT3A 1388 0.37 0.7 0.6 1.0 
rs1667627 14 MTHFD2 1387 0.46 0.2 0.6 1.0 
rs9974061 21 SLC19A1 1388 0.18 1.0 0.6 1.0 
rs2330183 21 SLC19A1 1358 0.44 0.1 0.6 1.0 
rs914232 21 SLC19A1 1387 0.44 0.2 0.6 1.0 
rs7594432 2 DNMT3A 1388 0.45 0.3 0.6 1.0 
rs2424922 20 DNMT3B 1387 0.39 0.2 0.6 1.0 
rs7085104 10 AS3MT 1388 0.39 1.0 0.6 1.0 
rs12898670 15 MTHFS 1387 0.32 0.9 0.6 1.0 
278 
 
Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs13427202 2 DNMT3A 1387 0.47 0.6 0.6 1.0 
rs282778 15 MTHFS 1388 0.27 0.8 0.6 1.0 
rs202676 11 FOLH1 1380 0.17 0.8 0.6 1.0 
rs11694842 2 DNMT3A 1387 0.28 0.4 0.6 1.0 
rs1256112 14 MTHFD1 1388 0.40 0.4 0.6 1.0 
rs914231 21 SLC19A1 1383 0.44 0.2 0.6 1.0 
rs750546 17 PEMT 1373 0.43 0.5 0.6 1.0 
rs1464864 2 ATIC 1388 0.30 0.8 0.6 1.0 
rs10839295 11 FOLH1 1387 0.39 0.5 0.6 1.0 
rs10197653 2 ATIC 1388 0.29 0.1 0.6 1.0 
rs6518253 21 SLC19A1 1387 0.46 0.3 0.6 1.0 
rs4911108 20 DNMT3B 1384 0.29 0.7 0.7 1.0 
rs11681447 2 DNMT3A 1386 0.28 0.2 0.7 1.0 
rs12591436 15 MTHFS 1388 0.35 0.6 0.7 1.0 
rs17745484 2 DNMT3A 1387 0.35 0.8 0.7 1.0 
rs9977111 21 SLC19A1 1355 0.33 0.07 0.7 1.0 
rs8129445 21 SLC19A1 1388 0.32 0.9 0.7 1.0 
rs4804122 19 DNMT1 1388 0.40 0.4 0.7 1.0 
rs1059394 18 TYMS 1387 0.31 0.6 0.7 1.0 
rs234706 21 CBS 1388 0.32 0.1 0.7 1.0 
rs3788200 21 SLC19A1 1388 0.45 0.3 0.7 1.0 
rs2305230 3 ALDH1L1 1387 0.19 0.7 0.7 1.0 
rs699517 18 TYMS 1387 0.31 0.6 0.7 1.0 
rs1256095 14 MTHFD1 1377 0.48 0.8 0.7 1.0 
rs12453139 17 PEMT 1386 0.26 0.9 0.7 1.0 
rs1109859 17 PEMT 1367 0.18 0.8 0.7 1.0 
rs7605753 2 DNMT3A 1388 0.47 0.6 0.7 1.0 
rs617219 5 BHMT 1387 0.32 0.7 0.7 1.0 
rs1256107 14 MTHFD1 1387 0.48 0.7 0.7 1.0 
rs600671 15 MTHFS 1387 0.46 0.1 0.7 1.0 
rs4673965 2 ATIC 1388 0.40 1.0 0.7 1.0 
rs12905663 15 MTHFS 1381 0.27 0.2 0.7 1.0 
rs1077965 15 MTHFS 1387 0.41 0.4 0.7 1.0 
rs7586294 2 DNMT3A 1387 0.47 0.5 0.7 1.0 
rs740234 22 TCN2 1388 0.23 0.8 0.7 1.0 
rs6749992 2 DNMT3A 1388 0.47 0.8 0.7 1.0 
rs11656215 17 PEMT 1388 0.45 0.4 0.7 1.0 
rs8101626 19 DNMT1 1388 0.39 0.7 0.7 1.0 
rs12898642 15 MTHFS 1387 0.43 0.2 0.7 1.0 
rs7215833 17 PEMT 1388 0.35 0.5 0.7 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs4673981 2 ATIC 1388 0.39 0.8 0.7 1.0 
rs4819130 21 SLC19A1 1384 0.45 0.2 0.7 1.0 
rs898436 15 MTHFS 1384 0.46 0.1 0.7 1.0 
rs1888533 21 SLC19A1 1388 0.48 0.3 0.7 1.0 
rs3740392 10 AS3MT 1385 0.29 0.1 0.7 1.0 
rs17291414 19 DNMT1 1388 0.27 0.5 0.7 1.0 
rs282772 15 MTHFS 1388 0.13 0.3 0.7 1.0 
rs4818789 21 SLC19A1 1388 0.25 0.5 0.7 1.0 
rs11701960 21 SLC19A1 1387 0.17 1.0 0.7 1.0 
rs3177999 21 SLC19A1 1380 0.45 0.2 0.7 1.0 
rs10498036 2 ATIC 1388 0.40 0.4 0.7 1.0 
rs1023159 21 SLC19A1 1386 0.42 0.4 0.7 1.0 
rs378057 15 MTHFS 1387 0.14 1.0 0.7 1.0 
rs2424928 20 DNMT3B 1388 0.39 0.2 0.7 1.0 
rs2301955 22 TCN2 1386 0.43 0.3 0.7 1.0 
rs2424913 20 DNMT3B 1387 0.37 0.2 0.8 1.0 
rs1051266 21 SLC19A1 1388 0.45 0.2 0.8 1.0 
rs4531931 2 ATIC 1387 0.31 0.5 0.8 1.0 
rs9462856 6 GNMT 1388 0.41 0.9 0.8 1.0 
rs9789571 2 ATIC 1388 0.42 1.0 0.8 1.0 
rs7604984 2 ATIC 1388 0.40 0.4 0.8 1.0 
rs17824591 14 MTHFD1 1386 0.23 0.2 0.8 1.0 
rs749130 2 DNMT3A 1388 0.44 0.6 0.8 1.0 
rs5749135 22 TCN2 1388 0.43 0.3 0.8 1.0 
rs1814175 11 FOLH1 1384 0.39 0.4 0.8 1.0 
rs1802059 5 MTRR 1387 0.37 0.4 0.8 1.0 
rs2424906 20 DNMT3B 1388 0.38 0.2 0.8 1.0 
rs767138 21 SLC19A1 1385 0.40 0.6 0.8 1.0 
rs8129350 21 SLC19A1 1387 0.35 0.9 0.8 1.0 
rs166868 15 MTHFS 1387 0.36 1.0 0.8 1.0 
rs8128676 21 SLC19A1 1350 0.22 1.0 0.8 1.0 
rs3862350 11 FOLH1 1360 0.39 0.2 0.8 1.0 
rs12614943 2 ATIC 1388 0.28 1.0 0.8 1.0 
rs6058897 20 DNMT3B 1388 0.43 0.2 0.8 1.0 
rs7583409 2 DNMT3A 1387 0.35 0.4 0.8 1.0 
rs17284990 15 MTHFS 1388 0.22 0.5 0.8 1.0 
rs4819138 21 SLC19A1 1388 0.39 0.8 0.8 1.0 
rs4646385 17 PEMT 1388 0.43 0.5 0.8 1.0 
rs7177659 15 MTHFS 1387 0.50 0.08 0.8 1.0 
rs559062 1 CTH 1388 0.22 0.6 0.8 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs2124344 17 PEMT 1387 0.36 0.7 0.8 1.0 
rs202712 11 FOLH1 1387 0.23 0.7 0.8 1.0 
rs8128050 21 SLC19A1 1385 0.35 0.9 0.9 1.0 
rs734693 2 DNMT3A 1387 0.29 0.2 0.9 1.0 
rs2838970 21 SLC19A1 1387 0.39 0.9 0.9 1.0 
rs7279305 21 SLC19A1 1388 0.35 1.0 0.9 1.0 
rs1081231 15 MTHFS 1387 0.18 0.8 0.9 1.0 
rs16971450 15 MTHFS 1387 0.16 0.4 0.9 1.0 
rs13036246 2 DNMT3A 1387 0.49 0.4 0.9 1.0 
rs4779165 15 MTHFS 1387 0.16 0.4 0.9 1.0 
rs7177027 15 MTHFS 1388 0.24 0.08 0.9 1.0 
rs4646340 17 PEMT 1388 0.36 0.5 0.9 1.0 
rs6586282 21 CBS 1387 0.17 0.2 0.9 1.0 
rs2035027 15 MTHFS 1388 0.16 0.5 0.9 1.0 
rs1380642 15 MTHFS 1388 0.18 0.3 0.9 1.0 
rs2281603 14 MTHFD1 1388 0.19 0.2 0.9 1.0 
rs10163099 15 MTHFS 1385 0.26 0.1 0.9 1.0 
rs4393531 15 MTHFS 1386 0.48 0.4 0.9 1.0 
rs4778721 15 MTHFS 1388 0.23 0.2 0.9 1.0 
rs11687225 2 ATIC 1387 0.40 0.9 0.9 1.0 
rs2838961 21 SLC19A1 1388 0.34 1.0 0.9 1.0 
rs6801605 3 CHDH 1388 0.38 0.6 0.9 1.0 
rs4646341 17 PEMT 1385 0.36 0.5 0.9 1.0 
rs11855092 15 MTHFS 1388 0.23 0.07 0.9 1.0 
rs4778719 15 MTHFS 1388 0.23 0.2 0.9 1.0 
rs202700 11 FOLH1 1337 0.23 0.8 0.9 1.0 
rs4646350 17 PEMT 1388 0.36 0.6 0.9 1.0 
rs944422 21 SLC19A1 1384 0.35 0.9 0.9 1.0 
rs2241807 3 CHDH 1388 0.43 0.7 0.9 1.0 
rs2790 18 TYMS 1384 0.20 0.7 0.9 1.0 
rs10948059 6 GNMT 1370 0.48 0.8 0.9 1.0 
rs7604425 2 ATIC 1388 0.35 0.7 0.9 1.0 
rs11627387 14 MTHFD1 1388 0.29 0.9 0.9 1.0 
rs10165919 2 ATIC 1387 0.35 0.6 0.9 1.0 
rs6087988 20 DNMT3B 1388 0.20 0.6 0.9 1.0 
rs9621047 22 TCN2 1388 0.44 0.2 0.9 1.0 
rs2838977 21 SLC19A1 1386 0.39 0.9 0.9 1.0 
rs4610054 2 ATIC 1383 0.38 1.0 0.9 1.0 
rs853858 20 DNMT3B 1386 0.37 0.2 0.9 1.0 
rs10839239 11 FOLH1 1386 0.23 0.6 0.9 1.0 
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Supplementary Table S5-6 (cont.) Uncorrected and corrected p-values for the interaction between 
D4Z4 methylation levels and selected SNPs in the one-carbon metabolism pathway in the 
Spanish Bladder Cancer/EPICURO Study 
dbSNP ID (N=375) Chromosome Gene N MAF P HWE P LRT Corrected P LRT 
rs660439 11 FOLH1 1384 0.23 0.7 0.9 1.0 
rs17279753 15 MTHFS 1388 0.20 0.5 0.9 1.0 
rs4820888 22 TCN2 1387 0.47 0.1 1.0 1.0 
rs1917321 11 FOLH1 1380 0.50 0.2 1.0 1.0 
rs2289195 2 DNMT3A 1387 0.44 0.2 1.0 1.0 
rs1650697 5 DHFR 1385 0.23 0.1 1.0 1.0 
rs4476347 2 ATIC 1387 0.25 0.4 1.0 1.0 
rs2877078 21 SLC19A1 1376 0.39 0.7 1.0 1.0 
rs6495446 15 MTHFS 1387 0.26 0.1 1.0 1.0 
rs13002567 2 DNMT3A 1388 0.28 0.5 1.0 1.0 
rs8128681 21 SLC19A1 1388 0.32 0.9 1.0 1.0 
rs582172 15 MTHFS 1388 0.41 0.6 1.0 1.0 
rs17279885 15 MTHFS 1388 0.21 0.7 1.0 1.0 
rs2275565 1 MTR 1388 0.20 0.6 1.0 1.0 
rs11158542 14 MTHFD1 1388 0.29 0.8 1.0 1.0 
rs1055345 21 SLC19A1 1387 0.29 0.3 1.0 1.0 
rs6573559 14 MTHFD1 1388 0.29 1.0 1.0 1.0 
N, number of subjects; MAF, minor allele frequency; P HWE - Hardy-Weinberg Equilibrium chi-
square test p-value; P LRT, likelihood ratio test p-value for interaction; NA - dbSNP identifier not 
available. 
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Supplementary Table S5-7 Association between D4Z4 methylation level and urothelial 
carcinoma of the bladder risk stratified by FGFR3 expression and mutation status in the Spanish 
Bladder Cancer/EPICURO Study 
D4Z4 Methylation Cases Controls OR* 95% CI P-value 
Low FGFR3 expression† 
Low-grade NMIBC             
   M1, < 64.4% 42 358 1 Reference       
   M2, ≥ 64.4% 55 357 1.43 0.92 2.23 0.1 
High-grade NMIBC             
   M1, < 64.4% 21 358 1 Reference       
   M2, ≥ 64.4% 31 357 1.60 0.88 2.91 0.1 
MIBC             
   M1, < 64.4% 43 358 1 Reference       
   M2, ≥ 64.4% 37 357 0.92 0.57 1.49 0.7 
Wild type FGFR3‡             
Low-grade NMIBC             
   M1, < 64.4% 52 358 1 Reference       
   M2, ≥ 64.4% 65 357 1.28 0.85 1.92 0.2 
High-grade NMIBC             
   M1, < 64.4% 40 358 1 Reference       
   M2, ≥ 64.4% 47 357 1.29 0.81 2.04 0.3 
MIBC             
   M1, < 64.4% 54 358 1 Reference       
   M2, ≥ 64.4% 45 357 0.88 0.57 1.37 0.6 
Mutant FGFR3§             
Low-grade NMIBC             
   M1, < 64.4% 74 358 1 Reference       
   M2, ≥ 64.4% 92 357 1.35 0.95 1.93 0.09 
High-grade NMIBC             
   M1, < 64.4% 18 333 1 Reference       
   M2, ≥ 64.4% 15 329 0.90 0.44 1.86 0.8 
MIBC             
   M1, < 64.4% 4 358 1 Reference       
   M2, ≥ 64.40% 7 357 1.87 0.53 6.66 0.3 
M1, D4Z4 methylation level less than the median; M2, D4Z4 methylation level greater than or 
equal to the median. 
*Adjusted for age, gender, region and smoking status (never, occasional, former, and current). 
†P value for heterogeneity: low- vs high-grade NMIBC = 0.9; low-grade NMIBC vs MIBC = 0.1; 
high-grade NMIBC vs MIBC=0.2. 
‡P value for heterogeneity: low- vs high-grade NMIBC = 0.9; low-grade NMIBC vs MIBC = 0.1; 
high-grade NMIBC vs MIBC=0.2. 
§P value for heterogeneity: low- vs high-grade NMIBC = 0.3; low-grade NMIBC vs MIBC = 0.6; 
high-grade NMIBC vs MIBC=0.3. 
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Supplementary Table S5-8 Comparisons of controls and cases with and without D4Z4 methylation data by main characteristics in the 
Spanish Bladder Cancer/EPICURO Study 
Characteristic 
Controls   Cases 
With D4Z4 data Without D4Z4 data P-value*   With D4Z4 data Without D4Z4 data P-value* 
Age in years, median (IQR) 66 (13) 68 (13) 0.002   68 (13) 68 (13) 0.7 
Gender               
Male 642 (89.4) 463 (83.7) 0.003   617 (87.3) 450 (87.9) 0.7 
Female 76 (10.6) 90 (16.3)     90 (12.7) 62 (12.1)   
Region               
Barcelona 130 (18.1) 117 (21.2) 0.05   128 (18.1) 101 (19.7) 0.6 
Valles 117 (16.3) 73 (13.2)     113 (16.0) 75 (14.7)   
Elche 58 (8.1) 26 (4.7)     55 (7.8) 33 (6.5)   
Tenerife 122 (17.0) 104 (18.8)     120 (17.0) 99 (19.3)   
Asturias 291 (40.5) 233 (42.1)     291 (41.1) 204 (39.8)   
Smoking status†               
Never 206 (28.8) 161 (29.5) 0.4   102 (14.6) 64 (12.5) 0.8 
Occasional 53 (7.4) 44 (8.1)     30 (4.3) 22 (4.3)   
Former 261 (36.5) 214 (39.3)     266 (38.0) 204 (39.9)   
Current 195 (27.3) 126 (23.1)     303 (43.2) 221 (43.3)   
Total 718 553     707 512   
IQR, interquartile range. 
*Mann-Whitney test for age and D4Z4 methylation levels; Chi-square test for categorical variables. 
†Eleven controls and seven cases have missing information on smoking status. 
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Supplementary Table S6-1 Characteristics of non-muscle-invasive bladder cancer patients by LINE-1 and D4Z4 methylation in the 
Spanish Bladder Cancer/EPICURO study 
Characteristics 
LINE-1 methylation tertile   D4Z4 methylation median   
T1 T2 T3 P M1 M2 P 
N (%) N (%) N (%) Value N (%) N (%) Value 
Total 236 235 235   263 263   
Age in years               
Median (IQR) 66.5 (14.5) 68 (13.0) 69 (11.0) 0.01* 68 (14.0) 68 (12.0) 0.2* 
Sex               
Male 199 (84.3) 210 (89.4) 204 (86.8) 0.3 225 (85.6) 234 (89.0) 0.2 
Female 37 (15.7) 25 (10.6) 31 (13.2)   38 (14.4) 29 (11.0)   
Residential area               
Barcelona 40 (17.0) 49 (20.9) 38 (16.2) 0.3 46 (17.5) 57 (21.7) 0.1 
Valles 41 (17.3) 44 (18.7) 30 (12.7)   36 (13.7) 50 (19.0)   
Elche 13 (5.5) 21 (8.9) 15 (6.4)   19 (7.2) 22 (8.4)   
Tenerife 40 (17.0) 34 (14.5) 43 (18.3)   48 (18.3) 34 (12.9)   
Asturias 102 (43.2) 87 (37.0) 109 (46.4)   114 (43.4) 100 (38.0)   
Smoking status               
Never 39 (16.7) 24 (10.3) 33 (14.2) 0.2 43 (16.6) 31 (11.9) 0.4 
Occasional 8 (3.4) 11 (4.7) 7 (3.0)   12 (4.6) 12 (4.6)   
Former 86 (36.8) 99 (42.5) 106 (45.3)   96 (37.1) 109 (41.8)   
Current 101 (43.1) 99 (42.5) 87 (37.3)   108 (41.7) 109 (41.8)   
Missing 2 2 2   4 2   
Tobacco type               
Never 39 (17.1) 24 (10.8) 33 (14.5) 0.7 43 (17.2) 31 (12.4) 0.2 
Blond tobacco only 16 (7.0) 20 (9.0) 18 (7.9)   18 (7.6) 18 (7.2)   
Black tobacco only 82 (36.0) 76 (34.2) 83 (36.4)   77 (30.8) 101 (40.4)   
Both types 60 (26.3) 64 (28.8) 58 (25.4)   75 (30.0) 67 (26.8)   
Unknown 31 (13.6) 38 (17.1) 36 (15.8)   36 (14.4) 33 (13.2)   
Missing 8 13 7   13 13   
286 
 
Supplementary Table S6-1 (cont.) Characteristics of non-muscle-invasive bladder cancer patients by LINE-1 and D4Z4 methylation in 
the Spanish Bladder Cancer/EPICURO study 
Characteristics 
LINE-1 methylation tertile   D4Z4 methylation median   
T1 T2 T3 P- M1 M2 P- 
N (%) N (%) N (%) Value N (%) N (%) Value 
Combined stage and grade (T-G)               
Low-risk tumors               
TaGI† 100 (42.4) 103 (43.8) 87 (37.0) 0.4 99 (37.6) 109 (41.4) 0.3 
TaGII 77 (32.6) 66 (28.1) 90 (38.3)   81 (30.8) 93 (35.4)   
High-risk tumors               
TaGIII 20 (8.5) 25 (10.6) 22 (9.4)   31 (11.8) 28 (10.7)   
T1GII 5 (2.1) 3 (1.3) 7 (3.0)   6 (2.3) 5 (1.9)   
T1GIII 33 (14.0) 34 (14.5) 28 (11.9)   42 (16.0) 27 (10.3)   
Tis 1 (0.4) 4 (1.7) 1 (0.4)   4 (1.5) 1 (0.4)   
Tumor Multiplicity               
Solitary 165 (73.7) 144 (65.8) 158 (70.5) 0.2 166 (67.8) 173 (69.5) 0.7 
Multiple 59 (26.3) 75 (34.2) 66 (29.5)   79 (32.2) 76 (30.5)   
Missing 12 16 11   18 14   
Tumor Size               
≤ 3 cm  135 (57.2) 136 (57.9) 135 (57.5) 0.4 153 (58.2) 146 (55.5) 0.7 
> 3 cm 36 (15.3) 25 (10.6) 37 (15.7)   32 (12.2) 38 (14.5)   
Missing 65 (27.5) 74 (31.5) 63 (26.8)   78 (29.7) 79 (30.0)   
Treatment               
TURBT alone 95 (40.3) 101 (43.0) 95 (40.4) 0.5 96 (36.5) 120 (45.6) 0.1 
TURBT+BCG 71 (30.1) 73 (31.1) 65 (27.7)   86 (32.7) 81 (30.8)   
TURBT+Intravesical chemotherapy 60 (25.4) 49 (20.8) 57 (24.3)   66 (25.1) 52 (19.8)   
TURBT+BCG + Intravesical chemotherapy 3 (1.3) 3 (1.3) 9 (3.8)   3 (1.1) 5 (1.9)   
Others 7 (2.9) 9 (3.8) 9 (3.8)   12 (4.6) 5 (1.9)   
Follow-up                
Median (months) 76.1       76.2     
IQR, interquartile range; Tis, carcinoma in situ: “flat tumor”, TURBT, transurethral resection of the bladder tumor; BCG, bacillus Calmette-
Guérin.  
*P value from Kruskal-Wallis test. 
†TaGI includes papillary neoplasm of low malignant potential. 
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Supplementary Table S6-2 Characteristics of muscle-invasive bladder cancer patients by LINE-1 and D4Z4 methylation in the Spanish 
Bladder Cancer/EPICURO study 
Characteristics 
LINE-1 methylation tertile     D4Z4 methylation median   
T1 T2 T3 P-   M1 M2 P- 
N (%) N (%) N (%) Value   N (%) N (%) Value 
Total 63 63 63     70 69   
Age in years                 
Median (IQR) 68 (12.0) 68 (12.0) 69 (12.0) 1.0*   67.5 (9.0) 71 (12.0) 0.03* 
Sex                 
Male 57 (90.5) 56 (88.9) 54 (85.7) 0.7   58 (82.9) 65 (94.2) 0.04 
Female 6 (9.5) 7 (11.1) 9 (14.3)     12 (17.1) 4 (5.8)   
Residential area                 
Barcelona 16 (25.4) 5 (8.0) 7 (11.1) 0.06   12 (17.1) 8 (11.6) 0.3 
Valles 10 (15.9) 14 (22.2) 9 (14.3)     9 (12.9) 18 (26.1)   
Elche 3 (4.7) 8 (12.7) 3 (4.7)     4 (5.7) 6 (8.7)   
Tenerife 11 (17.5) 14 (22.2) 12 (19.1)     13 (18.6) 12 (17.4)   
Asturias 23 (36.5) 22 (34.9) 32 (50.8)     32 (45.7) 25 (36.2)   
Smoking status                 
Never 7 (11.1) 8 (12.7) 12 (19.5) 0.9   9 (12.9) 9 (13.0) 0.8 
Occasional 2 (3.2) 3 (4.8) 2 (3.2)     2 (2.8) 4 (5.8)   
Former 23 (36.5) 20 (31.8) 22 (34.9)     22 (31.4) 24 (34.8)   
Current 31 (49.2) 32 (50.8) 27 (42.9)     37 (52.9) 32 (46.4)   
Tobacco type                 
Never 7 (11.5) 8 (13.3) 12 (19.7) 0.1   9 (13.2) 9 (13.9) 0.9 
Blond tobacco only 2 (3.3) 8 (13.3) 2 (3.3)     6 (8.8) 4 (6.1)   
Black tobacco only 21 (34.4) 23 (38.3) 26 (42.6)     28 (41.2) 26 (40.0)   
Both types 16 (26.2) 14 (23.3) 11 (18.0)     15 (22.1) 14 (21.5)   
Unknown 15 (24.6) 7 (11.7) 10 (16.4)     10 (14.7) 12 (18.5)   
Missing 2 3 2     2 4   
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Supplementary Table S6-2 (cont.) Characteristics of muscle-invasive bladder cancer patients by LINE-1 and D4Z4 methylation in the 
Spanish Bladder Cancer/EPICURO study 
Characteristics 
LINE-1 methylation tertile     D4Z4 methylation median   
T1 T2 T3 P-   M1 M2 P- 
N (%) N (%) N (%) Value   N (%) N (%) Value 
Tumor stage (T)                 
T2 34 (54.0) 34 (54.0) 34 (54.0) 0.7   41 (58.6) 34 (49.3) 0.4 
T3 16 (25.4) 11 (17.4) 15 (23.8)     13 (18.6) 19 (27.5)   
T4 13 (20.6) 18 (28.6) 14 (22.2)     16 (22.8) 16 (23.2)   
Regional lymph node (N)                 
No lymph node metastases (N0) 39 (61.9) 48 (76.2) 39 (61.9) 0.4   52 (74.3) 43 (62.2) 0.2 
Lymph node metastases (N1-N3) 14 (22.2) 9 (14.3) 16 (25.4)     12 (17.1) 13 (18.8)   
Unknown nodal metastases (Nx) 10 (15.9) 6 (9.52) 8 (12.7)     6 (8.6) 13 (18.8)   
Metastasis (M)                 
No metastases (M0) 48 (76.2) 56 (88.9) 46 (73.0) 0.09   60 (85.7) 53 (76.8) 0.3 
Metastases (M1) 7 (11.1) 3 (4.8) 12 (19.1)     6 (8.6) 7 (10.1)   
Unknown (Mx) 8 (12.7) 4 (6.3) 5 (7.9)     4 (5.7) 9 (13.1)   
Treatment                 
Cystectomy 19 (30.2) 27 (42.8) 21 (33.3) 0.6   25 (35.7) 23 (33.3) 0.2 
Cystectomy + Systemic chemotherapy 10 (15.9) 9 (14.3) 7 (11.1)     9 (12.9) 10 (14.5)   
Systemic chemotherapy alone 7 (11.1) 5 (7.9) 6 (9.5)     8 (11.4) 3 (4.4)   
RdT+Systemic chemotherapy 5 (7.9) 7 (11.1) 6 (9.5)     4 (5.7) 12 (17.4)   
TURBT+BCG/intravesical chemotherapy 8 (12.7) 3 (4.8) 3 (4.8)     5 (7.1) 5 (7.3)   
Others 14 (22.2) 12 (19.1) 20 (31.8)     19 (27.2) 16 (23.2)   
Follow-up                  
Median (months) 23.3         25.5     
IQR, interquartile range; RdT, radiotherapy; TURBT, transurethral resection of the bladder tumor; BCG, bacillus Calmette-Guérin;    
*P value Kruskal-Wallis test                 
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ABSTRACT
BACKGROUND: Altered DNA methylation has been associated with various diseases.
OBJECTIVE: To evaluate the association between levels of methylation in leukocyte DNA at
long interspersed nuclear element 1 (LINE-1) and genetic and non-genetic characteristics of 892
control participants from the Spanish Bladder Cancer/EPICURO Study.
METHODS: We determined LINE-1 methylation levels by pyrosequencing. Individual data
included demographics, smoking status, nutrient intake, toenail concentrations of 12 trace
elements, xenobiotic metabolism gene variants, and 515 polymorphisms among 24 genes in the
one-carbon metabolism pathway. To assess the association between LINE-1 methylation levels
(percentage of methylated cytosines) and potential determinants, we estimated beta coefficients
(β) by robust linear regression.
RESULTS: Females had lower levels of LINE-1 methylation than males (β=-0.7, p-value=0.02).
Blond tobacco smokers showed lower methylation than non-smokers (β=-0.7, p-value=0.03).
Arsenic toenail concentration was inversely associated with LINE-1 methylation (β=-3.6, p­
value=0.003). By contrast, iron (β=0.002, p-value=0.009) and nickel (β=0.02, p-value=0.004)
were positively associated with LINE-1 methylation. SNPs in DNMT3A (rs7581217-per allele,
β=0.3, p-value=0.002), TCN2 (rs9606756-GG, β=1.9, p-value=0.008; rs4820887-AA, β=4.0, p­
value=4.8x10-7; rs9621049-TT, β=4.2, p-value=4.7x10-9), AS3MT (rs7085104-GG, β=0.7, p­
value=0.001), SLC19A1 (rs914238, TC vs. TT: β=0.5 and CC vs. TT: β=-0.3, global p­
value=0.0007) and MTHFS (rs1380642, CT vs. CC: β=0.3 and TT vs. CC; β=-0.8, global p­
value=0.05) were associated with LINE-1 methylation.
CONCLUSIONS: We identified several characteristics, environmental factors, and common
genetic variants that predicted DNA methylation among study participants.
4
  
 
            
          
             
          
             
               
               
             
                  
             
            
              
               
             
               
           
              
             
           
              
            
           
INTRODUCTION
DNA methylation plays a fundamental role in regulation of gene expression, genomic
imprinting, X-chromosome inactivation, and repression of transposable elements (Jones and
Liang 2009). Aberrant DNA methylation has been associated with various cancers, and with
developmental, autoimmune, and other chronic diseases (Robertson 2005). Global DNA
methylation can be directly quantified by measuring 5-methylcytosine content of the genome, or
can be estimated based on methylation of repetitive sequences such as Alu elements or long
interspersed nuclear element 1 (LINE-1) (Yang et al. 2004). Age, sex, smoking, and arsenic and
lead exposures have been associated with DNA methylation, but findings have been inconsistent
among studies (Breitling et al. 2011; El-Maarri et al. 2007; Fraga et al. 2005a; Fuke et al. 2004;
Terry et al. 2011). The folate and methionine-dependent one-carbon metabolism pathway could
modulate DNA methylation by altering the level of S-adenosylmethionine (SAM), the principal
source of methyl groups (Ulrey et al. 2005). Genetic variants might also influence the
methylation of CpG loci locally, or might have a global influence on methylation throughout the
genome. For example, a single nucleotide polymorphism (SNP) in TRPC3-isoform 2 has been
reported to regulate the methylation status of its own promoter (Martin-Trujillo et al. 2011), and
variants of the methylenetetrahydrofolate reductase gene (MTHFR) have been associated with
global DNA hypomethylation (Castro et al. 2004; Friso et al. 2002). However, although the
determinants of global and site-specific methylation are widely assumed to be likely contributors
to health and disease, they are poorly defined at this time.
Assessing the impact of both genetic and non-genetic factors on global DNA methylation may
improve our understanding of the molecular pathogenesis of many common diseases. Therefore,
we investigated associations of global DNA methylation in LINE-1 from bisulfite-modified
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granulocyte DNA with genetic variants and personal, demographic, lifestyle, and environmental
characteristics.
METHODS
Study population: The study population, design, and data collection have been previously
described (Garcia-Closas et al. 2005). Briefly, participating individuals were controls from the
Spanish Bladder Cancer/EPICURO Study who were admitted to hospitals in five regions of
Spain for a range of conditions including hernia, fractures, and other non-cancer diseases, and
were 20–81 years of age. We collected demographic and exposure information at the hospitals
using computer-assisted personal interviews. From a total of 1,271 controls that agreed to
participate in the study and were interviewed, 1,056 provided blood for DNA extraction. We
excluded twenty-three subjects because of inadequate or poor quality DNA (N=15) or missing
smoking status data (N=8). Three subjects with missing data on smoking status were included
because they had data on other variables including age, gender, region, and body mass index
(BMI). To ensure homogeneity, we also excluded one non-Caucasian individual, leaving 925
individuals with granulocyte DNA for bisulfite modification and pyrosequencing.
Pyrosequencing failed in 33 individuals; thus, the final study population for the present analysis
included 892 participants. We obtained written informed consent from all participants, and the
study was approved by the local Spanish institutional review boards and US National Cancer
Institute.
Quantification of LINE-1 methylation: We extracted granulocyte DNA using standard
methods (Garcia-Closas et al. 2005). We carried out bisulfite conversion of DNA using the EZ­
96 DNA METHYLATION-GOLDTM KIT (Zymo Research, Irvine, CA, USA) according to the
6
  
          
                
                 
            
             
                
             
              
             
                 
            
           
           
            
             
               
             
            
                
 
               
               
             
 
manufacturer’s recommendations. We carried out PCR amplification of bisulfite-modified DNA
using a set of forward and reverse primers reported previously (Estecio et al. 2007). To quantify
the methylation level of each of the first four CpG sites next to the pyrosequencing primer, we
performed sequencing of the PCR product by pyrosequencing, using the PyroMarkTM Q24
System (QIAGEN, Valencia, CA, USA) as recommended by the manufacturer. The first four
were the CpGs from which we could obtain methylation values of all samples. We extracted the
methylation level at each CpG site using the PyroMarkTM Application Software version 2.0.6
(QIAGEN, Valencia, CA, USA), and we expressed the value as the percentage of methylated
cytosines over the sum of methylated and unmethylated cytosines. We used the average
methylation level of the first four LINE-1 CpG sites as a surrogate marker of the global DNA
methylation level. To determine whether changes in blood cell populations affect LINE-1
methylation levels, we analyzed LINE-1 methylation in independently purified granulocyte and
lymphocyte samples. The results showed no significant difference in LINE-1 methylation
between granulocyte and lymphocyte samples, thus suggesting that variation in the distribution
of peripheral blood cell populations among participants would not contribute to variation in
global DNA methylation (data not shown). For the present study, we used DNA extracted from
granulocyte to quantify DNA methylation. As a quality control measure, we measured LINE-1
methylation in 129 randomly selected duplicate samples and the within-sample coefficient of
variation (CV) was 4.0%. In the analysis, we used the average of the duplicates for those
samples.
Nutritional assessment: We estimated the usual intake of vitamins B1, B2, B3, B6, and B12,
folate, protein, alcohol, fruit and vegetable over the five years before interview using a validated
food frequency questionnaire of 127 items (R Garcia-Closas et al. 2007). Micronutrients and
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macronutrients included in the present analysis have been suggested as important co-factors and
methyl donors in one-carbon metabolism (Stover 2009). We calculated nutrient density variables
by dividing the total estimated mass of daily food consumed by the total estimated daily energy
intake (µg/day/kcal).
Trace elements: We collected toenail clippings to estimate chronic exposure to trace elements.
Sample collection and experimental methods used to measure trace elements level have been
reported (Amaral et al. 2012). Briefly, after cleaning and washing the toenails to remove external
contaminants, we quantified elements at the Trace Element Analysis Core (Dartmouth College,
NH, USA), using inductively coupled plasma-mass spectrometry (Hopkins et al. 2004). We
digested the samples with Optima HNO3 (Fisher Scientific, St. Louis, MO) at 105 °C followed
by addition of H2O2 and further heating the dilution with deionized water. We recorded
gravimetrically all sample preparation steps. As a quality control, each batch of analyses
included six standard reference material samples with known trace element content (SRM; GBW
07601, powdered human hair) and six analytic blanks, along with the study samples. In total, we
determined concentrations (µg/g) of 12 trace elements (aluminum, arsenic, cadmium, chromium,
copper, iron, lead, manganese, nickel, selenium, vanadium, and zinc).
Genotyping: For genotype assays, we extracted DNA from leukocytes as described previously
(Garcia-Closas et al. 2005). We determined genotypes at the Core Genotyping Facility of the
Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, USA. We
selected for the analysis a total of 515 SNPs in 24 genes involved in the one-carbon metabolism
pathway, including DNA methylation and arsenic metabolism (see Supplemental Material, Table
S1 for a list of the 24 genes evaluated). We selected these genes because they are critical for the
one-carbon metabolism pathway (Lee et al. 2009; Ulrey et al. 2005). Previously, we described in
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detail methods of the genotyping process (Garcia-Closas et al. 2005; M Garcia-Closas et al.
2007; Rothman et al. 2010). We genotyped SNPs using Illumina Infinium® Human1M-Duo,
Illumina GoldenGate® and TaqMan® assays (see Supplemental Material, Table S2 for a
complete list of SNPs according to assay). In addition, we estimated associations between LINE­
1 methylation and GSTM1, GSTT1, and NAT2 variants because of their relevance to bladder
cancer (Cash et al. 2012). These variants were determined as described in (Garcia-Closas et al.
2005). All genotypes included in the study were in Hardy-Weinberg Equilibrium in the study
population (p-value > 0.05) (data not shown).
Statistical analysis: The distribution of LINE-1 methylation levels was slightly bimodal and
positively skewed (Supplemental Material, Figure S1). To estimate associations between LINE-1
methylation levels and each of the variables considered, we fitted bivariate robust linear
regression models and calculated the corresponding beta coefficients and 95% confidence
intervals (95%CI). Characteristics analyzed as continuous variables were age, micronutrient
intakes, fruit and vegetable intakes, and toenail concentrations of trace elements. Characteristics
analyzed as categorical variables were BMI (<25.0, 25.0-26.99, 27.0-29.99, ≥30.0), smoking
status (non-, occasional, former, current smoker), and tobacco type (non-smoker, blond only,
black only, blond and black, unknown).
To identify SNPs for detailed assessment we first used the Fisher’s exact test to screen SNPs that
were significantly associated (p<0.05) with LINE-1 methylation categorized according to tertiles
(<56.7%, 56.7–58.6%, and >58.6%) according to codominant mode of inheritance. The 22 SNPs
identified for further analyses (listed in Supplemental Material, Table S3) were subsequently
modeled according to all modes of inheritance (additive, codominant, dominant and recessive).
The mode of inheritance that best predicted LINE-1 methylation is reported in Table 2.
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In addition to age and gender, adjusted robust linear regression models for each potential
predictor included region, which may be related to diet, micronutrients (Gabriel et al. 2006), and
environmental pollution, and smoking status, which may be related to trace elements (Moerman
and Potts 2011). We also did a sensitivity analysis without adjusting for smoking status to see if
there was a change in the beta estimates. We included all the 515 SNPs in the analysis regardless
of linkage disequilibrium. The association between LINE-1 methylation and potential predictors
was assessed in the multivariable adjusted model stratifying by gender. Because arsenic and
rs7085104 in arsenic (+3 oxidation state) methyltransferase (AS3MT), which is involved in
arsenic metabolism, were individually associated with LINE-1 methylation, we assessed the
presence of effect modification by including a multiplicative interaction term in a model adjusted
for age, gender, region and smoking status. Wald test was used to calculate the interaction p-
value. We corrected for multiple testing using the Bonferroni’s method. We conducted a
sensitivity analysis, excluding 42 individuals with CV >4% for LINE-1 methylation in duplicate
samples. This exclusion did not result in substantial differences in the beta coefficients; therefore
these individuals remained in the analyses (data not shown). All statistical tests were two-sided,
and a p-value ≤ 0.05 was considered significant. We carried all data analyses out using
STATA/SE version 10.1 (StataCorp, College Station, TX, USA).
RESULTS
The characteristics of the 892 participants in the present study and median and mean LINE-1
methylation levels according to each variable of interest are provided in Supplemental Material,
Table S4. The majority of the study participants were males (89%) and regular smokers (63.9%),
with median age of 66 years [interquartile range (IQR)=13]. The mean LINE-1 methylation level
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was 58.9% (SD=5.3%) with minimum and maximum value of 37.9% and 85.7%, respectively.
Table 1 shows the association between LINE-1 methylation levels and characteristics of study
subjects. In the bivariable robust linear regression analysis, only toenail arsenic and nickel
concentrations were significantly associated with LINE-1 methylation. However, in
multivariable robust linear regression models adjusted for age, gender, region, and smoking
status, the levels of LINE-1 methylation were significantly lower in females than in males
(adjusted β = -0.7; 95%CI: -1.2, -0.1, p-value=0.02) and in smokers of blond tobacco only
(adjusted β = -0.7; 95%CI: -1.3, -0.08, p-value=0.03) and of both blond and black tobacco
(adjusted β = -0.6; 95%CI: -1.1, -0.07, p-value=0.03) compared with nonsmokers. Toenail
arsenic concentration also was negatively associated with LINE-1 methylation (adjusted β for a
1-µg/g increase = -3.6; 95%CI: -5.9, -1.2, p-value=0.003). In contrast, LINE-1 levels were
positively associated with 1-µg/g increases in toenail concentrations of iron (adjusted β = 0.002;
95%CI: 0.001, 0.004, p-value=0.009) and nickel (adjusted β = 0.02; 95%CI: 0.005, 0.03, p­
value=0.004). BMI, B vitamins, folate, total protein, alcohol, fruit and vegetable intake were not
significantly associated with LINE-1 methylation regardless of adjustment for covariates (Table
1). Results from the multivariable analyses without adjusting for smoking status done as a
sensitivity analysis were not different from the associations above (Supplemental Material, Table
S5). If we were to correct for multiple comparisons by Bonferroni’s method none of the above
would be significant.
Out of the 515 genetic variants assessed, 22 passed a first screening using Fisher’s exact test (p­
value≤0.05 according to codominant mode of inheritance) (Supplemental Material, Table S3). Of
these, seven SNPs in five genes were significantly associated with LINE-1 methylation based on
multivariable models adjusted for age, gender, region, and smoking status (Table 2; model-based
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estimates for the 15 SNPs that were not significantly associated with LINE-1 methylation are
reported in Supplemental Material, Table S6.) Significant positive associations were estimated
for DNMT3A-rs7581217 (per allele: adjusted β = 0.3; 95%CI: 0.1, 0.6, p-value=0.002); TCN2­
rs9621049 (recessive: adjusted β = 4.2; 95%CI: 2.8, 5.7, p-value=4.7x10-9), TCN2-rs4820887
(recessive: adjusted β = 4.0; 95%CI: 2.5, 5.6, p-value=4.8x10-7) and TCN2-rs9606756 (recessive:
adjusted β = 1.9; 95%CI: 0.5, 3.3, p-value=0.008); and AS3MT-rs7085104 (recessive: adjusted β
= 0.7; 95%CI: 0.3, 1.2, p-value=0.001). In addition, significant associations under the
codominant mode of inheritance (based on global p-values) were estimated for SLC19A1­
rs914238 (TC vs. TT, β = 0.5; 95%CI: 0.08, 0.8; CC vs. TT, β = -0.3; 95%CI: -0.7, 0.2; global
p-value=0.0007) and MTHFS-rs1380642 (CT vs. CC, β = 0.3; 95%CI: -0.08, 0.6; TT vs. CC, β =
-0.8; 95%CI: -1.6, 0.09; global p-value=0.05). After correcting for multiple testing using the
Bonferroni’s method, TCN2-rs9621049 and TCN2-rs4820887 remained significant (p<0.05).
A significant interaction (p-value=0.01) was observed between arsenic and AS3MT-rs7085104
on LINE-1 methylation (adjusted β for 1-µg/g increase in As = -4.1; 95%CI: -6.6, -1.7, p­
value=0.001 for genotype AA/AG; and adjusted β for 1-µg/g increase in As = 10.2; 95%CI: -3.2,
23.7, p-value=0.1 for genotype GG).
After simultaneously adjusting for age, geographic region, and all factors that were significant
predictors of LINE-1 methylation (sex; tobacco type; toenail arsenic, iron and nickel; and the 5
SNPs noted above), associations with sex, arsenic, nickel, iron, DNMT3A-rs7581217, TCN2­
rs9621049, and MTHFS-rs1380642 remained significant. The association with blond tobacco
was nonsignificant although the direction of the point estimate remained unchanged. The
association between rs9606756, rs4820887 and LINE-1 methylation become nonsignifcant
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(Supplemental Material, Table S7). This might be due to reduced sample size in the
simultaneously adjusted model due to missing data.
DISCUSSION
In the present study, we took a comprehensive approach to assess associations of genetic and
non-genetic factors with LINE-1 methylation in a group of individuals aged 20-81 years. Lower
levels of LINE-1 methylation were found among females compared with males, and among
smokers of blond tobacco compared with non-smokers. In addition, toenail concentrations of
arsenic were also negatively associated with LINE-1 methylation. On the other hand, LINE-1
methylation levels were positively associated with toenail concentrations of iron and nickel, and
with seven variants in DNMT3A, TCN2, AS3MT, SLC19A1, and MTHFS genes.
Our findings support previous results showing that females have significantly lower levels of
LINE-1 methylation (El-Maarri et al. 2007; El-Maarri et al. 2011; Wilhelm et al. 2010; Zhu et al.
2012). DNA methylation is important for X-chromosome inactivation in females (Jones and
Liang 2009), and although LINE-1 sequences do not seem to be the major mechanism involved
in this process, they may be involved in spreading the X-inactivation signal across the
chromosome (Bailey et al. 2000). In support of this, a recent study showed that LINE-1
sequences were hypomethylated in the inactive X-chromosome (Singer et al. 2012). A small
study of 33 men and 33 women reported lower levels of blood SAM in women (Poirier et al.
2001). Hormonal factors may also contribute to the difference in methylation levels between
genders. However, a recent in vitro study assessing the role of estrogen, progesterone and
dihydrotestosterone on DNA methylation in four cell lines found no detectable effect of these
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hormones on methylation levels at the LINE-1 and Alu repeats (El-Maarri et al. 2011). Further
studies are needed to decipher the relationship between gender and LINE-1 methylation.
Because tobacco smoking is an important contributor to disease and is a modifiable behavioral
factor, there has been much interest in the relationship between smoking and DNA methylation.
Our findings are in line with other studies that reported no association between LINE-1
methylation and smoking status (Terry et al. 2011). In the present study, we found that subjects
who smoked blond tobacco had lower levels of global DNA methylation than nonsmokers. An
experimental study has shown that cigarette smoke condensates can induce DNA demethylation
in repeat elements, such as LINE-1 and D4Z4 (Liu et al. 2010). Both black and blond tobacco
cause disease although the former is more mutagenic, reflective of the higher levels of N-
nitrosamines and aromatic amines in smoke produced by black tobacco (Malaveille et al. 1989).
Our findings suggest that the toxic effects of blond tobacco could be mediated by modulating the
epigenetic landscape. This may have a public health implication given epigenetic alterations are
reversible.
We also provide evidence that arsenic levels were inversely associated with LINE-1 methylation,
and that arsenic may have a strong effect on LINE-1 methylation. For each µg/g increase in
arsenic there was a 3.6% decrease in DNA methylation level. This inverse association is in
agreement with that from a population-based study that used a similar assay to assess LINE-1
methylation levels and toenail concentrations of arsenic (Wilhelm et al. 2010), as well as with
several other experimental studies (Reichard and Puga 2010; Ren et al. 2011). The mechanisms
through which arsenic exposure influences DNA methylation are not fully understood. Studies in
cell lines and mouse models exposed to arsenic for up to 22 and 48 weeks, respectively have
shown that prolonged exposure to sodium arsenite resulted in decreased global DNA
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methylation, and inhibition of DNMT1, DNMT3A, and DNMT3B gene expression (Reichard and
Puga 2010; Ren et al. 2011). It is likely that through the combined effect of depleting the cellular
pool of SAM and inhibiting the activity of DNMTs, both inorganic and organic arsenic may lead
to decreased global DNA methylation.
We are not aware of any human studies associating iron and nickel levels and global DNA
methylation. In the present study, iron and nickel showed a small but significant positive
association with LINE-1 methylation level. Genes involved in hepatocellular carcinoma (HCC)
have been found to be hypermethylated in hereditary hemochromatosis, a disease characterized
by chronic iron overload that is a risk factor for HCC (Lehmann et al. 2007). Iron, together with
2-oxoglutarate and oxygen, is an essential cofactor for the ten-eleven translocation (TET) family
of proteins that hydroxylate 5-methylcytosine to 5-hydroxymethylcytosine and further oxidize to
5-carboxylcytosine and 5-formylcytosine, which have all been suggested to be precursors for
both active and passive DNA demethylation (Bhutani et al. 2011). Experimental studies
conducted in Chinese hamster cell lines (G12) treated with nickel chloride for up to 3 weeks
have shown that nickel chloride leads to both promoter hypermethylation and elevated total
genomic DNA methylation (Lee et al. 1995; Lee et al. 1998). How nickel induces DNA
methylation is not yet understood, but it has been proposed that nickel first induces chromatin
condensation followed by de novo methylation of heterochromatic DNA (Lee et al. 1995).
The three SNPs with the strongest associations with LINE-1 methylation were all in TCN2,
including two exonic SNPs that result in missense substitutions (rs9606756 and rs9621049) and
one intronic SNP (rs4820887). SNPs rs9621049 and rs4820887 have a linkage disequilibrium r2 
value of 0.8 implying that the observed effect in LINE-1 methylation may eventually be
attributed to either of them. TCN2 encodes for transcobalamin II which binds and transports
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vitamin B12 into the cell (Regec et al. 1995), which suggests that variations in TCN2 could
potentially impair the one-carbon metabolism pathway by altering the cytoplasmic concentration
of vitamin B12. TCN2-rs9606756 leads to an I23V substitution located at a NAGNAG tandem
acceptor site that is a target of alternative splicing (Hiller et al. 2006). TCN2-rs9621049 leads to
a S348F and may also play a role in the availability of vitamin B12 in the cell thereby affecting
LINE-1 methylation levels.
Four SNPs in other genes (DNMT3A-rs7581217; AS3MT-rs7085104; MTHFS-rs1380642;
SLC19A1-rs914238) involved in the one-carbon metabolism were also associated with global
DNA methylation in our study population. DNMT3A, a de novo DNA methyltransferase,
establishes the patterns of methylation in early embryonic development, along with DNMT3B,
and cooperates with DNMT1 to maintain the methylation of repetitive sequences, such as LINE-1
and Alu elements (Jones and Liang 2009). Recurrent mutations in DNMT3A have been associated
with adult hematologic malignancies (Ley et al. 2010; Yan et al. 2011), and mice lacking
Dnmt3a die in the first weeks of postnatal life (Robertson 2005). The product of AS3MT
catalyzes the conversion of trivalent arsenic by addition of a methyl group to monomethylarsonic
acid and dimethylarsonic acid (Ren et al. 2011); monomethylarsonic acid being the most toxic
metabolite (Engstrom et al. 2011). rs7085104, located in the promoter region of AS3MT, has
been associated with arsenic metabolism, as evidenced by differences in urinary concentration of
arsenic metabolites (Engstrom et al. 2011; Valenzuela et al. 2009). We also observed a
significant interaction of this SNP with levels of arsenic on LINE-1 methylation levels. While
subjects with at least one copy of the major allele had a 4.1% decrease in methylation level for 1­
µg/g increase in arsenic, which is comparable to the overall population (-3.6%), those
homozygous for the variant allele had a 10% increase in LINE-1 methylation. These findings
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support the putative functionality of the association. The product of MTHFS catalyzes the
conversion of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate and a genome-wide
association study reported an association between a variant in this gene and chronic kidney
disease (Kottgen et al. 2008). SLC19A1 is a ubiquitously expressed major transporter of folate
and antifolates and regulator of the intracellular concentrations of folate (Matherly et al. 2007).
Common variants in this gene have been associated with plasma folate levels, various types of
cancer (esophageal, gastric and acute lymphoblastic leukemia), and altered methotrexate
transport and adverse effects of methotrexate (Matherly et al. 2007).
Among the limitations of the study is the majority of individuals were of advanced age (mean
age 64 years, SD=10 years) and men. This may explain the lack of association between DNA
methylation and age in our study population, in contrast with other studies that included subjects
with a broader age range (Fraga et al. 2005b). Thus, our findings refer to an adult population of
mostly men. Results were consistent with estimates for the population as a whole when stratified
by gender, with the exception of nickel, tobacco type, and MTHFS-rs1380642 which become
nonsignificant while the point estimates were in the same direction (data not shown). These
differences may reflect reduced power to estimate associations among women due to the small
sample size. The presence of missing data for some of the variables might have resulted in
decreased power but even with the available sample size we were able to reproduce previous
results and identify novel predictors of LINE-1 methylation. Furthermore, while the study
subjects were recruited from hospitals, none of reasons for hospitalization were significantly
associated with LINE-1 methylation.
Strengths of the study include its size, the availability and quality of individual data on
demographics, lifestyle, environmental exposures, and genetics. Additionally, we assessed
17
 
  
             
            
               
               
                  
              
             
               
   
             
              
                
              
            
              
            
             
            
 
  
LINE-1 methylation levels, which are considered a good marker of global DNA methylation
(Yang et al. 2004), using pyrosequencing, which gives accurate and reproducible measurements
(Estecio et al. 2007; Laird 2010; Tost and Gut 2007). Furthermore, this assessment was made
using DNA from granulocytes, avoiding a possible effect of cell blood count in our study.
To the best of our knowledge, this is the first study to identify seven SNPs in association to
changes in LINE-1 methylation and to integrate different types of information to assess the
determinants of global methylation in blood DNA. Integration of both internal and external
exposure data in this study is a step forward in understanding how the exposome modulates
DNA methylation patterns.
In conclusion, the current study provides further evidence that DNA methylation levels are
influenced by variants in genes involved in the one-carbon metabolism pathway, and exposure to
trace elements and tobacco smoke. Given the fact that smoking and some of the genetic variants
and trace elements associated with LINE-1 methylation in the present study have also been
associated with adverse health outcomes including cancer, our results provide additional insight
into the potential mechanism through which these agents participate in the development of those
diseases. Furthermore, these factors should be considered as potential confounders in etiologic
and interventional studies analyzing the role of DNA methylation in disease. Nevertheless, future
studies are required to replicate and extend our findings in different populations.
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Appendix 1. Spanish Bladder Cancer / EPICURO Study investigators
Institut Municipal d’Investigació Mèdica, Universitat Pompeu Fabra, Barcelona – Coordinating
Center (M. Kogevinas, N. Malats, F.X. Real, M. Sala, G. Castaño, M. Torà, D. Puente, C.
Villanueva, C. Murta-Nascimento, J. Fortuny, E. López, S. Hernández, R. Jaramillo, G. Vellalta,
L. Palencia, F. Fermández, A. Amorós, A. Alfaro, G. Carretero); Hospital del Mar, Universitat
Autònoma de Barcelona, Barcelona (J. Lloreta, S. Serrano, L. Ferrer, A. Gelabert, J. Carles, O.
Bielsa, K. Villadiego), Hospital Germans Trias i Pujol, Badalona, Barcelona (L. Cecchini, J.M.
Saladié, L. Ibarz); Hospital de Sant Boi, Sant Boi de Llobregat, Barcelona (M. Céspedes);
Consorci Hospitalari Parc Taulí, Sabadell (C. Serra, D. García, J. Pujadas, R. Hernando, A.
Cabezuelo, C. Abad, A. Prera, J. Prat); Centre Hospitalari i Cardiològic, Manresa, Barcelona (M.
Domènech, J. Badal, J. Malet); Hospital Universitario de Canarias, La Laguna, Tenerife (R.
García-Closas, J. Rodríguez de Vera, A.I. Martín); Hospital Universitario Nuestra Señora de la
Candelaria, Tenerife (J. Taño, F. Cáceres); Hospital General Universitario de Elche, Universidad
Miguel Hernández, Elche, Alicante (A. Carrato, F. García-López, M. Ull, A. Teruel, E. Andrada,
A. Bustos, A. Castillejo, J.L. Soto); Universidad de Oviedo, Oviedo, Asturias (A. Tardón);
Hospital San Agustín, Avilés, Asturias (J.L. Guate, J.M. Lanzas, J. Velasco); Hospital Central
Covadonga, Oviedo, Asturias (J.M. Fernández, J.J. Rodríguez, A. Herrero), Hospital Central
General, Oviedo, Asturias (R. Abascal, C. Manzano, T. Miralles); Hospital de Cabueñes, Gijón,
Asturias (M. Rivas, M. Arguelles); Hospital de Jove, Gijón, Asturias (M. Díaz, J. Sánchez, O.
González); Hospital de Cruz Roja, Gijón, Asturias (A. Mateos, V. Frade); Hospital Alvarez-
Buylla (Mieres, Asturias): P. Muntañola, C. Pravia; Hospital Jarrio, Coaña, Asturias (A.M.
Huescar, F. Huergo); Hospital Carmen y Severo Ochoa, Cangas, Asturias (J. Mosquera). 
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Table 1. Association between LINE-1 methylation level and individual characteristics of study subjects in the SBC/EPICURO
Study
Variables N LINE-1 methylationMean (95% CI)
Unadjusted β (95% CI) P-value N Adjusted β (95% CI)a,b P-value
Age (years) 892 ─ -0.004 (-0.02, 0.01) 0.6 889 -0.006 (-0.02, 0.01) 0.5
Gender
Male 792 59.0 (58.6, 59.4) Ref 789 Ref
Female 100 58.0 (57.1, 58.8) -0.4 (-0.9, 0.05) 0.08 100 -0.7 (-1.2, -0.1) 0.02
Region
Barcelona 168 59.3 (58.5, 60.2) Ref 168 Ref
Vallès 135 58.3 (57.5, 59.0) -0.2 (-0.7, 0.4) 0.5 135 -0.2 (-0.7, 0.3) 0.5
Elche 73 58.2 (57.1, 59.3) -0.4 (-1.1, 0.2) 0.2 73 -0.5 (-1.1, 0.2) 0.1
Tenerife 145 58.6 (57.8, 59.4) -0.1 (-0.7, 0.4) 0.7 144 -0.1 (-0.6, 0.4) 0.7
Asturias 371 59.2 (58.6, 59.8) 0.2 (-0.3, 0.6) 0.5 369 0.1 (-0.3, 0.6) 0.6
Body mass index (kg/m²)
<25.0 372 58.8 (58.3, 59.3) Ref 370 Ref
25.0-26.99 148 58.9 (57.9, 59.9) -0.2 (-0.6, 0.3) 0.5 148 -0.2 (-0.6, 0.3) 0.4
27.0-29.99 120 59.0 (58.1, 59.8) 0.1 (-0.3, 0.6) 0.6 120 0.2 (-0.3, 0.7) 0.4
≥30.0 57 58.8 (57.5, 60.2) -0.08 (-0.7, 0.6) 0.8 57 -0.03 (-0.7, 0.6) 0.9
Missing data 195
Smoking status
Non-smoker 255 58.2 (57.7, 58.7) Ref 255 Ref
Occasional smoker 66 60.0 (58.4, 61.5) 0.4 (-0.2, 1.1) 0.2 66 0.3 (-0.3, 1.0) 0.3
Former smoker 329 58.9 (58.3, 59.5) -0.2 (-0.5, 0.3) 0.6 329 -0.3 (-0.7, 0.1) 0.2
Current smoker 239 59.4 (58.6, 60.2) -0.2 (-0.6, 0.2) 0.4 239 -0.4 (-0.9, 0.07) 0.1
Missing data 3
Tobacco type
Non-smoker 255 58.2 (57.7, 58.7) Ref 255 Ref
Blond only 99 58.5 (57.6, 59.5) -0.5 (-1.0, 0.09) 0.1 99 -0.7 (-1.3, -0.08) 0.03
Black only 219 59.6 (58.8, 60.4) 0.06 (-0.4, 0.5) 0.8 218 -0.2 (-0.6, 0.3) 0.5
Blond and black 154 58.7 (57.8, 59.6) -0.3 (-0.8, 0.2) 0.2 154 -0.6 (-1.1, -0.07) 0.03
Unknown 97 59.3 (58.2, 60.5) -0.01 (-0.6, 0.6) 0.9 97 -0.12 (-0.7, 0.5) 0.7
  
 
   
   
          
 
   
     
 
  
        
           
                
              
                
               
  
        
              
              
              
              
              
             
             
             
             
             
               
   
        
             
             
             
             
             
             
             
             
             
             
             
Variables N LINE-1 methylationMean (95% CI)
Unadjusted β (95% CI) P-value N Adjusted β (95% CI)a,b P-value
Missing data 68
Controls' diagnosis
Hernia 332 58.8 (58.2, 59.4) Ref 330 Ref
Fracture & Trauma 263 59.3 (58.6, 60.0) -0.2 (-0.5, 0.2) 0.4 262 -0.02 (-0.4, 0.4) 0.9
Hydrocele 122 58.7 (57.8, 59.6) 0.2 (-0.3, 0.7) 0.4 122 0.2 (-0.3, 0.7) 0.5
Other Abdominal Surgery 99 58.3 (57.4, 59.2) -0.2 (-0.7, 0.3) 0.4 99 -0.09 (-0.6, 0.5) 0.7
Other Diseases 76 59.2 (57.9, 60.5) 0.01 (-0.9, 0.6) 0.9 76 0.2 (-0.4, 0.8) 0.5
Dietary intakec 
Vitamin B1 (µg/day/kcal) 645 ─ 0.5 (-0.6, 1.6) 0.3 644 0.6 (-0.6, 1.7) 0.3
Vitamin B2 (µg/day/kcal) 645 ─ 0.1 (-0.5, 0.8) 0.7 644 0.2 (-0.5, 0.8) 0.6
Vitamin B3 (µg/day/kcal) 645 ─ 0.01 (-0.05, 0.08) 0.7 644 0.02 (-0.05, 0.09) 0.5
Vitamin B6 (µg/day/kcal) 645 ─ 0.6 (-0.2, 1.4) 0.1 644 0.8 (-0.05, 1.6) 0.07
Vitamin B12 (µg/day/kcal) 645 ─ -0.04 (-0.09, 0.01) 0.1 644 -0.03 (-0.08, 0.02) 0.3
Folate (µg/day/kcal) 645 ─ 0.001 (-0.002, 0.004) 0.4 644 0.003 (-0.001, 0.01) 0.1
Protein (µg/day/kcal) 645 ─ 0.01 (-0.01, 0.03) 0.4 644 0.01 (-0.01, 0.03) 0.4
Alcohol (µg/day/kcal) 645 ─ -0.002 (-0.02, 0.02) 0.8 644 -0.01 (-0.03, 0.02) 0.5
Fruit (g/day/kcal) 639 ─ 0.0001 (-0.001, 0.002) 0.9 638 0.0001 (-0.001, 0.002) 0.9
Vegetable (g/day/kcal) 640 ─ 0.001 (-0.001, 0.003) 0.3 639 0.002 (-0.001, 0.004) 0.1
Fruit and vegetable (g/day/kcal) 639 ─ 0.0003 (-0.0008, 0.001) 0.6 638 0.0005 (-0.0007, 0.002) 0.4
Toenail trace elementsd 
Aluminum (µg/g) 658 ─ -0.003 (-0.008, 0.002) 0.2 658 -0.003 (-0.008, 0.002) 0.2
Arsenic (µg/g) 659 ─ -2.9 (-5.2, -0.6) 0.02 659 -3.6 (-5.9, -1.2) 0.003
Cadmium (µg/g) 659 ─ 0.08 (-0.4, 0.5) 0.7 659 0.1 (-0.3, 0.6) 0.6
Chromium (µg/g) 658 ─ 0.06 (-0.01, 0.1) 0.09 659 -0.01 (-0.05, 0.03) 0.6
Copper (µg/g) 659 ─ -0.002 (-0.06, 0.05) 0.95 659 -0.01 (-0.07, 0.04) 0.6
Iron (µg/g) 657 ─ -0.002 (-0.006, 0.002) 0.4 658 0.002 (0.001, 0.004) 0.009
Lead (µg/g) 659 ─ -0.05 (-0.1, 0.03) 0.2 659 -0.06 (-0.1, 0.02) 0.2
Manganese (µg/g) 659 ─ -0.03 (-0.1, 0.09) 0.7 659 -0.05 (-0.2, 0.06) 0.4
Nickel (µg/g) 659 ─ 0.02 (0.006, 0.03) 0.002 659 0.02 (0.005, 0.03) 0.004
Selenium (µg/g) 659 ─ 0.1 (-0.8, 1.0) 0.8 659 0.2 (-0.7 1.2) 0.6
Vanadium (µg/g) 651 ─ -0.7 (-2.7, 1.3) 0.5 651 -0.9 (-2.8, 1.2) 0.4
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Variables N LINE-1 methylationMean (95% CI)
Unadjusted β (95% CI) P-value N Adjusted β (95% CI)a,b P-value
Zinc (µg/g) 659 ─ -0.002 (-0.004, 0.001) 0.2 659 -0.001 (-0.004, 0.002) 0.4
NAT2 phenotype
Rapid/Intermediate acetylator 389 59.0 (58.4, 59.6) Ref 388 Ref
Slow acetylator 498 58.8 (58.4, 59.2) 0.2 (-0.1, 0.5) 0.3 496 0.2 (-0.1, 0.5) 0.2
Missing data 5
GSTM1 genotype
(+/+, +/-) 421 58.9 (58.3, 59.4) Ref 419 Ref
(-/-) 462 59.0 (58.5, 59.4) 0.04 (-0.3, 0.4) 0.8 461 0.01 (-0.3, 0.3) 0.9
Missing data 9
GSTT1 genotype
(+/+, +/-) 688 59.0 (58.6, 59.4) Ref 685 Ref
(-/-) 198 58.5 (57.9, 59.2) -0.2 (-0.6, 0.2) 0.3 198 -0.2 (-0.6, 0.2) 0.4
Missing data 6
aAdjusted for age, gender, region, and smoking status (non-, occasional, former, current smoker). Tobacco type's β is not adjusted for smoking
 
status.
 
bThe number of observations are reduced by three because of missing data on smoking status.
 
cData available for those who completed food frequency questionnaire.
 
dData available for those who provided toenail for trace element assessment.
 
Note: the exposure contrast for trace elements is 1-µg/g and for dietary variables is 1-µg/day/kcal.
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Table 2. Association between LINE-1 methylation levels and single nucleotide polymorphisms in genes involved in the one-carbon metabolism pathway 
 
Gene dbSNP [Chromosome, position in the gene, locationa] MAF N MOI Genotype Unadjusted β (95% CI) P-value Adjusted β
b (95% CI) P-value 
DNMT3A rs7581217 [2, intron, 25378448] 0.39 875 Additive per allele T 0.3 (0.1, 0.6) 0.003 0.3 (0.1, 0.6) 0.002 
AS3MT rs7085104 [10, flanking 5'UTR, 
104618863]  
0.38 751 Recessive AA/AG Ref  Ref  
   124  GG 0.8 (0.3, 1.2) 0.0008 0.7 (0.3, 1.2) 0.001 
MTHFSc 
rs1380642 [15, flanking 3'UTR, 
77883926]  
0.18 585 Codominant CC Ref 0.03 Ref 0.05 
   258  CT 0.3 (-0.05, 0.6)  0.3 (-0.08, 0.6)  
   32  TT -0.8 (-1.6, 0.07)  -0.8 (-1.6, 0.09)  
SLC19A1c 
rs914238 [21, flanking 5'UTR, 
45840089] 
0.49 231 Codominant TT Ref 0.0008 Ref 0.0007 
   435  TC 0.5 (0.09, 0.8)  0.5 (0.08, 0.8)  
   209  CC -0.2 (-0.7, 0.2)  -0.3 (-0.7, 0.2)  
TCN2d rs9621049 [22, exon, 29343419] 0.11 864 Recessive CC/CT Ref  Ref  
     11  TT 4.5 (3.1, 5.9) 4.3 x 10-10 4.2 (2.8, 5.7) 4.7 x 10-9 
  rs9606756 [22, exon, 29336860]  0.12 864 Recessive AA/AG Ref  Ref  
     11  GG 2.2 (0.8, 3.6) 0.003 1.9 (0.5, 3.3) 0.008 
  rs4820887 [22, intron, 29346914]  0.10 866 Recessive GG/GA Ref  Ref  
     9  AA 4.6 (3.0, 6.2) 9.3 x 10-9 4.0 (2.5, 5.6) 4.8 x 10-7 
MAF, minor allele frequency; MOI, mode of inheritance. 
aHuman Genome Build 36.3 location. 
bAdjusted for age, gender, region, and smoking status. 
cGlobal p-value for rs1380642 and rs914238 was estimated by using a two-degrees of freedom likelihood-ratio test. 
dLinkage disequilibrium (rs4820887 vs. rs9621049) r2 = 0.8.  
 
